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Introduction 
This work investigated in a UK prospective cohort study, firstly, the aetiology of 
gallstone disease, and secondly, that of pancreatic cancer, with a focus on physical 
activity and diet. The epidemiological studies benefitted from the accuracy of 
measurement tools, namely a validated physical activity questionnaire and a seven-
day food diary (7-DFD). These novel methods aided the improved definition of 
risk factors thus highlighting biological mechanisms leading to disease and 
methods of prevention. The third investigation was a clinical survey evaluating 
benefits for patients of a Pancreatic Support Service (PASS), which screened and 
treated nutritional and depressive symptoms in patients with pancreatic cancer. 
 
Methods 
The European Prospective Investigation into Cancer-Norfolk enrolled 25 639 men 
and women, aged 45-74 years, between 1993-1997, measuring anthropometrics, 
lifestyle factors, diet with 7-DFDs, physical activity and collecting serum samples 
at baseline. The cohort was followed up until 2010, with multi-variate hazard ratios 
calculated for incident symptomatic gallstones and pancreatic cancer according to 
risk factors. The clinical survey, compared survival, doses of chemotherapy and 
clinical parameters in a retrospective group of 16 patients and then in a prospective 
group of 19 patients who were also reviewed by PASS. 
 
Results 
For gallstone disease, positive associations were found for obesity, serum 
triglycerides, dietary calcium and trans fatty acids, with inverse associations for 
serum HDL, physical activity, alcohol, caffeinated coffee and dietary niacin, 
cholesterol and iron intake. Pancreatic cancer had inverse associations detected for 
physical activity, dietary docosahexaenoic acid, dietary vitamin E and selenium, 
and serum vitamin C. The survey found those reviewed by PASS had fewer and 
shorter hospital admissions with no effects on survival or doses of chemotherapy. 
 
Conclusion 
This work found associations between various dietary factors and physical activity 
for both symptomatic gallstones and pancreatic cancer. These findings have 
implications in understanding biological mechanisms and could lead to 
preventative public health measures for both diseases. The survey reported the 
introduction of PASS was associated with a reduced number and duration of 
hospital admissions and the reasons for this should be explored in future work. 
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Abstract 
Obesity, physical activity, alcohol, serum lipids and dietary nutrients in the 
aetiology of gallstones - a UK prospective cohort study. 
INTRODUCTION: Gallstones are a common gastroenterological disease with 
their formation involving cholesterol saturation, aggregation of crystals and 
gallbladder stasis. These mechanisms are influenced by obesity, physical activity, 
alcohol and diet, all of which were evaluated in a UK prospective study using 
novel methods of assessing exposures. Data from serum lipids was also analysed to 
clarify the potential mechanisms for how lifestyle factors may affect gallstone 
formation. 
METHODS: A total of 25 639 men and women, aged 45-74 years were recruited 
between 1993-1997 into the European Prospective Investigation into Cancer-
Norfolk. Participants attended a health check at enrolment which recorded their 
anthropometrics, alcohol intake, serum lipids with a physical activity questionnaire 
which had been previously validated against detailed physiological measures. A 
seven-day food diary (7-DFD), the most accurate pragmatic form of measuring diet 
in large scale epidemiological studies, was completed recording all food eaten, 
detailing brands and portion sizes. Nutrient intakes were calculated in those 
diagnosed with gallstone disease and in a random sample of 3 970 controls, using a 
computer program with information on 55 000 foods. Sex specific hazard ratios 
(HR) were calculated of developing incident symptomatic gallstone disease after 
14 years for body mass index, waist circumference, serum lipids and alcohol 
intake. To minimise a regression dilution effect, physical activity was analysed 
after 5 years and nutrient intakes after 10 years follow-up. Analyses were adjusted 
for age, gender, body mass index, alcohol intake and total energy intake. 
RESULTS: In men and women, each unit in body mass index and each inch in 
waist circumference were associated with an 8% increased risk of gallstones. 
Increased serum triglycerides were positively associated (men, highest vs lowest 
quartile HR=2.02, 95% CI=1.03-3.98; women HR=2.43 95% CI=1.52-3.90), with 
negative associations for physical activity (“active” vs “inactive” category >65% 
reduction) and HDL (men, highest vs lowest quartile of HDL, HR=0.22, 95% 
CI=0.09-0.52; women, HR=0.55, 95% CI=0.36-0.85). In men only, increased 
dietary calcium intake was associated with disease (highest vs lowest quintile of 
intake, HR=2.31, 95% CI=1.00-5.35), with inverse associations for alcohol (3% 
reduction per unit/week. 95% CI=1%-5%) and caffeinated coffee (23% reduction 
per cup/day, 95% CI=5%-38%). In women only, increased dietary trans fatty acids 
were positively associated (HR=1.94, 95% CI=1.06-3.54), with inverse effects 
dietary cholesterol (highest vs lowest quintile HR=0.59 95% CI=0.35-0.99), iron 
(highest vs lowest quintile HR=0.35 95% CI=0.19-0.66) and niacin (HR=0.54 95% 
CI=0.32-0.90). 
CONCLUSION: This is the first large European prospective study to investigate 
gallstones and has confirmed and defined the effects of BMI, waist circumference, 
physical activity, alcohol and coffee. The use of detailed 7-DFDs has provided 
novel inverse associations in women for dietary iron, niacin and cholesterol. 
Positive association with disease were reported for dietary trans fatty acids in 
women and calcium intake and in men with all findings supported by plausible 
biological mechanisms. If future aetiological work confirms causal associations, 
then population-based dietary and lifestyle recommendations may help prevent a 
significant proportion of symptomatic gallstones. 
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Introduction 
 
Gallstone disease represents a major health problem worldwide. In the 
United Kingdom, 49 000 cholecystectomies are performed annually1 with 700 000 
in the United States, where the treatment of such patients costs $6.2 billion.2 In 
England, data collected from Hospital Episode Statistics for admissions from the 
Department of Health between 1989/1990 and 1999/2000, showed the age-
standardised annual hospital admission rates for cholelithiasis increased by 30% for 
males and 64% for females (figure 1).3 
Asymptomatic gallstones are present in up to 20% of the European adult 
population4-6 and of these an estimated 2% develop symptoms each year.7 The 
commonest symptoms are abdominal pain but complications such as pancreatitis 
and cholangitis can be fatal. This chapter reviews the descriptive epidemiology of 
gallstone disease, biological mechanisms leading to gallstone formation, clinical 
presentations, and aetiological factors. To identify the relevant literature, searches 
of Medline (OVID and PubMed) were performed identifying English language 
articles using terms related to each section in this thesis and the keywords 
“gallstones” and “gallstones disease”. Papers were identified between 1950 and 
March 2011. The bibliographies of retrieved articles were reviewed to identify 
additional relevant references. 
 
Definition of gallstone disease 
 Gallstones are calculi formed in the gallbladder or less commonly in the 
biliary tree. The term cholelithiasis (derived from the Greek: chol-, "bile" + lith-, 
"stone" + iasis-, "process") describes the presence of gallstones, whilst 
cholecystolithiasis describes the presence of stones in the gallbladder and 
choledocholithiasis is stones in the bile ducts. Gallstones may cause symptoms, and 
hence gallstone disease, either within the gallbladder, or if they migrate, the biliary 
tree or small bowel. 
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Figure 1. The age-standardised hospital admission rates for cholelithiasis per 
100,000 population, by sex, in England between 1989/1990 and 1999/2000 
(source; Kang et al, Aliment Pharmacol Ther 20033). 
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1. Descriptive Epidemiology 
 
Prevalence 
 The prevalence of gallstones has been assessed in epidemiological studies 
using either trans-abdominal ultrasonography (USS) in live subjects and necropsy 
studies in the deceased. The burden of gallstone disease is similar in the Western 
countries, with the median prevalence in large population, as detected by trans-
abdominal ultrasonography, ranging between 5.9% to 21.9%.8 In the UK, the 
prevalence of gallstones in a stratified random sample of 1 896 British adults using 
ultrasonography was 6.8% in male and 8.0% in females.9 Although there has been 
an increase in the age-standardised hospital admission rates for gallstone disease, a 
study of the prevalence of gallstones at necropsy in England reported between 1998 
and 2008, gallstones in men fell slightly from 20.2% to 19.1% (p=0.022), and in 
women fell from 30.4% to 29.0% (p=0.03), with a gallstone related mortality of 
0.7%.10 Prevalence studies using necropsy should be interpreted with caution, as 
the population are mostly elderly or have died prematurely and are more likely to 
have co-morbidities than the general population which could predispose to 
gallstone disease.  
 
Age 
 Gallstone disease is rare in children with the frequency of disease rising 
markedly after the age of 40 years. A cross-sectional survey of 15 910 men and 13 
674 women showed that age is a strong risk factor in both sexes for both prevalent 
asymptomatic gallstones and gallstone disease.11 Compared to men aged 30-39 
years, those aged 60-69 had an odds ratio (OR) for gallstones of 4.48 (95% 
CI=3.59-5.59) and for gallstone disease OR=5.63 (95% CI=4.65-6.83) and in 
women, OR 3.07 (95% CI=2.58-3.65) for gallstones and OR=3.95 (95% CI=3.43-
4.54) for gallstone disease. Increasing age predisposes to gallstone formation due 
to declining activity of cholesterol 7α-hydroxylase, the rate limiting enzyme for 
bile acid synthesis, a process which leads to increased biliary cholesterol 
saturation.6 The elderly are also more likely to have lifestyle risk factors, such as 
decreasing physical activity, which may promote gallstone formation. 
 
Ethnicity 
Ethnicity influences gallstone prevalence with the highest rates been 
described in Pima Indians, who are native to Arizona, in the United States. Female 
Pima Indians have a prevalence of gallstones of 64.1% and for men it is 29.5%.12 
Similar rates occur in native South Americans, particularly in Chile with rates of 
16 
 
49.4% in women and 12.6% in men.13 A prevalence study in the United States 
using ultrasonography in a population over 14 000, found white Americans have 
prevalence rates of 16.6% in women and 8.6% in men, black Americans have 
prevalence rates of 13.9% in women and 5.3% in men, and Mexican Americans 
have rates of 26.7% in women and 8.9% in men.14 The lowest rates of gallstone 
prevalence and disease occur in Africa and Asia with necropsy rates of 3%.6 
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2. Clinical presentations of gallstone disease 
 
 Gallstones can produce a variety of symptoms and syndromes, dependent 
on their anatomical site, with approximately 2% becoming symptomatic each year.7 
However, most patients with gallstones remain symptom free, with the risk of 
symptoms and complications receding 15 to 20 years after developing of prevalent 
stones. 15-16 In a Swedish population of 739 men and women aged 35-85 years, 
during the first 5 years after detection of asymptomatic gallstones the cumulative 
risk of requiring treatment was 7.6%.17 A Cochrane Review in 2010 concluded that 
only patients with symptomatic gallstones should undergo surgery as complications 
of elective cholecystectomy are high, at approximately 17% for surgury.18 These 
complications are usually mild, although can occasionally be serious including 
biliary leakage, peritonitis, fistula formation and the inherent risks of a general 
anaesthetic. 
 
Biliary colic 
 Up to three-quarters of patients presenting with gallstone disease 
experience episodes of severe abdominal pain due to biliary colic. Biliary colic 
most commonly occurs when a gallstone becomes lodged in the cystic duct, 
although can rarely occur in the absence of gallstones in patients with gallbladder 
polyps or cholesterolosis of the gallbladder.15 Biliary colic typically produces 
moderate to severe right-upper quadrant pain, around 15 minutes after a meal, 
although the attacks can also occur at random. The pain can be associated with 
nausea and vomiting and the symptoms rarely last longer than 3 to 4 hours, which 
corresponds with the time for the gallstone to pass through the biliary tree or 
become dislodged from the cystic duct. Prolonged symptoms raise the possibility 
of a complication of gallstone disease or an alternative diagnosis. Mild 
inflammatory change of the gallbladder wall can occur with biliary colic, with 
recurrent episodes leading to chronic cholecystitis.15 Biliary colic usually responds 
promptly to analgesics, in particular non-steroidal anti-inflammatory drugs. 
Recurrent biliary colic is usually treated by removal of the gallbladder 
(cholecystectomy), performed by a laparoscopic approach, although open 
procedures are occasionally required for more complex cases. Non-surgical 
approaches to treat gallstones are limited in patients unfit for surgery but include 
oral litholysis (dissolution of gallstones) with ursodeoxycholic acid but 50% of 
gallstones recur. Extracorporeal shockwave lithotripsy has been abandoned due to 
the success of laparoscopic surgery.19 
18 
 
Acute cholecystitis 
 Acute cholecystitis is acute inflammation of the gallbladder wall, which in 
95% of cases is due to complete obstruction of the cystic duct by a gallstone with 
the remainder due to acalculous cholecystitis. The resulting inflammation causes 
oedema, infection, vascular compromise with serious cases complicated by 
gallbladder empyema (a pus filled gallbladder). Here, gallbladder wall necrosis 
occurs with perforation and abscess formation and peritonitis. Acute cholecystitis 
is initially treated with intravenous fluids and antibiotics which leads to a 
resolution of the acute inflammation in 70-80% of patients.15 The timing of when 
to offer laproscopic cholecystectomy in patients with acute cholecystitis remains 
controversial, with early surgery within 48 hours of onset of symptoms associated 
with reduced complications and lower conversion rates to open procedures than 
delayed (>5 days) or interval (>6 weeks) surgery.15 In those patients with 
significant co-morbidities, conservative treatment with intravenous antibiotics and 
fluids is often the preferred treatment whilst monitoring for complications which 
can be treated with percutaneous cholecystostomy if a gallbladder empyema 
develops. 
 
Ascending cholangitis 
 Ascending cholangitis is inflammation of the bile ducts due to bacterial 
infection, characterised by Charcot’s triad of fever, jaundice and right upper 
abdominal pain. This is caused by obstruction of biliary drainage due to a migrated 
gallstone occluding the common bile duct. This potentially life-threatening 
complication requires urgent supportive care, antibiotics and drainage of the biliary 
tree, usually by endoscopic retrograde cholangiopancreatogram (ERCP) with either 
removal of the stone or placement of a stent. 
 
Acute biliary pancreatitis  
Gallstones are the commonest cause of acute pancreatitis, accounting for 
approximately 65% of cases,20 where the stone occludes the pancreatic duct 
preventing the outflow of pancreatic enzymes. Autodigestion occurs, in which the 
pancreatic enzymes cause pancreatic damage with both local and systemic 
inflammatory response. Acute gallstone pancreatitis usually presents with rapid 
onset upper abdominal pain and vomiting. Gallstone pancreatitis can be a life-
threatening disease and requires correction of hypovolaemia, antibiotics and the 
early consideration of endoscopic sphincterotomy via ERCP in severe cases.20 
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Gallbladder cancer 
Cancer of the gallbladder is rare, with around 620 cases diagnosed each 
year in the UK.21 Gallbladder cancer usually arises in the setting of chronic 
inflammation, with most patients (75%) having pre-existing gallstones and 
cholecystitis. The presence of gallstones increases the risk of gallbladder cancer by 
4 to 5 fold.22 Although gallstone disease is associated with a significantly increased 
risk of developing gallbladder cancer, the aetiology is likely to be multi-factorial. 
Other risk factors for gallbladder cancer include inflammatory diseases such as 
primary sclerosing cholangitis, ulcerative colits and helicobacter infection. 
Medications (methyldopa, oral contraceptives), chemical exposures (pesticides, 
vinyl chloride) heavy metals and radiation have also been implicated in disease.22 
 
Rare presentations of gallstone disease 
Impaction of gallstones in the gallbladder neck (Hartmann’s pouch) can 
lead to compression of the common hepatic duct producing jaundice, which is 
termed Mirizzi’s syndrome. This presentation can be further complicated by fistula 
formation (cholecystocholedochal fistula) which usually requires surgical repair. 
Gallstones can rarely erode through the gallbladder wall and into the stomach 
(cholecystogastric fistula) or small bowel (cholecystoenteric fistula). Gallstone 
impaction in the stomach or duodenum leads to gastric outlet obstruction, known as 
Bouveret’s syndrome, while stone impaction in the small bowel causes gallstone 
ileus. 
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3. The pathogenesis of gallstones 
 
Bile and cholesterol 
The formation of gallstones is a complex biochemical process, involving 
the interaction of bile contents, cholesterol concentration and gallbladder motility. 
Bile is a complex aqueous colloidal fluid which has several physiological 
functions, including the excretion of lipids and facilitating intestinal fat absorption. 
Bile is formed in the hepatic canaliculi (spaces between the tight junctions of 
hepatocytes) before being transported into the bile ducts. Bile consists of water, 
electrolytes and lipid solutes dispersed in mixed micelles (aggregates of surfactants 
in a colloid) and vesicles which can emulsify other fats. The lipid solutes consist of 
bile salts, phospholipids (96% phospatidylcholines), cholesterol, proteins and 
bilirubin conjugates. Phospholipids and bile salts are essential for removal of 
insoluble cholesterol molecules.23 
In health, half of the secreted bile is stored, concentrated and slightly 
acidified in the gallbladder in between meals. The gallbladder mucosa concentrates 
the bile by active absorption of water and electrolytes in exchange for hydrogen 
and bicarbonate which acidify the bile. The mucosa also secretes proteins and 
mucus glycoproteins which influence the composition of bile and play a role in 
gallstone pathogenesis. In the gallbladder water is reabsorbed leading to increased 
cholesterol saturation and explains why most stones form in the gallbladder rather 
than the biliary tree.24 Bile remains in the gallbladder for several hours until it is 
excreted into the intestine. Several hormones influence gallbladder function, the 
primary hormone being cholecystokinin (CKK) as well as secretin, gastrin and 
pancreatic polypeptide.25 Vagotomy and inflammation disrupt neural input into the 
gallbladder which promotes gallbladder hypotonia and biliary stasis leading to 
gallstone formation. 
Cholesterol is a sterol, also classified as a steroid alcohol, which is a 
subgroup of steroids. The overall molecule is flat with a polar hydroxyl group at 
the 3-position of the A-ring. Cholesterol is synthesized from one molecule of acetyl 
CoA (also known as acetyl-coenzyme A) and one molecule of acetoacetyl-CoA via 
the mevalonate pathway, which includes the enzyme 3-hydroxy-3-methyl-glutaryl-
CoA reductase (HMG-CoA). Cholesterol is solubilised in bile within the micelles, 
and in particular by bile salts and phospholipids (i.e. phosphatidylcholine), with 
their concentration determining the degree of cholesterol saturation within the 
bile.19 
 
21 
 
Bile salts 
Bile salts, also termed bile acids, are one constituent of bile, and are 
anionic detergents synthesized from cholesterol in the liver and represent a major 
pathway for the excretion of cholesterol and other waste products. Bile salts serve 
several other biological functions including the emulsification of lipids and 
activation of digestive lipases. They are largely (95%-99%) reabsorbed in the distal 
small bowel, taken up by the liver, and re-secreted into the bile, a process known as 
enterohepatic circulation.26 
The rate-determining enzyme of bile salt formation is cholesterol-7α-
hydroxylase (CYP7A1), which is highly regulated. It is a member of the 
cytochrome P450 superfamily, which is a large and diverse group of enzymes. 
CYP7A1 catalyzes the formation of 7-alpha-hydroxycholesterol from cholesterol, 
with low activity of CYP7A1 causing increased cholesterol secretion and decreased 
bile salt excretion in humans which predisposes to gallstone formation.27 CYP7A1 
is down-regulated by Sterol Regulatory Element Binding Proteins (SREBP) when 
plasma cholesterol levels are low and is up-regulated by the nuclear receptor LXR 
(liver X receptor) when cholesterol (specifically oxysterol) levels are high.28 Gene 
expression of CYP7A1 is strongly repressed by insulin, and results in low levels of 
CYP7A1 expression in the human liver and increases the risk of gallstone 
disease.29 
The primary bile salts, cholate and chenodeoxycholate, are hydrophilic bile 
salts which solubilise cholesterol in the bile and prevent gallstone formation. The 
pharmacological use of hydrophilic bile salts such as ursodeoxycholate can 
dissolve stones and prevent cholesterol crystallization. However, secondary bile 
salts (i.e. deoxycholate) formed from the deconjugation of primary bile salts in the 
intestine by bacterial CYP7A1 activity are hydrophobic and strongly promote 
cholesterol crystallization. Humans have the most hydrophobic bile salt 
composition of all animals.30 Some gallstone patients have more bacteria with 
CYP7A1 activity. Administering antibiotics and suppressing these bacteria reduces 
biliary deoxycholate concentration and normalises biliary cholesterol saturation 
which prevents of the formation of gallstones.31 Prolonged small and large bowel 
transit times promote absorption of deoxycholate into the enteropathic circulation. 
Slow intestinal transit increases secondary biliary acid formation (deoxycholic 
acid) which leads to increased gallstone disease.32  
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Gallstone formation and genetics 
Gallstones are formed from the precipitation of bile and a mixture of 
particulate matter within the gallbladder. Gallstones are broadly categorised into 
four groups; cholesterol gallstones; mixed type, brown pigment stones and black 
pigment stones with a considerable overlap existing between these groups.33 In 
western societies, 80-90% gallstones are cholesterol gallstones with the remainder 
being brown or black pigment stones.19, 34-35 Cholesterol gallstones are composed 
mainly of cholesterol crystals (70%) held together by a matrix of glycoproteins, 
calcium salts and bile pigments.19  
Genetic factors are involved in the development of gallstones. Gallstone 
susceptibility is a “complex trait” with genetic factors estimated to contribute to 
25% of the risk of disease.36 Studies in both human and mouse models have 
identified multiple cholesterol gallstone susceptibility genes (Lith genes) and 
contributed to the understanding of the pathophysiological mechanisms of 
cholesterol gallstone formation.37 The genetic predisposition to gallstones can 
either arises from a monogenic defect though more commonly polymorphisms in 
multiple genes, with each one contributing to the risk of subsequent disease. The 
mechanisms involve either gene-gene interactions, or interactions with the 
environment including diet, obesity, drugs and pregnancy. This has lead to a new 
view that hepatic hypersecretion of biliary cholesterol could be induced by multiple 
Lith genes and insulin resistance in the metabolic syndrome, which interact with 
environmental factors to produce the disease phenotype.37 
Inbred mice have been used to identify over 80 cholesterol gallstone 
susceptibility (Lith) genes using the technique of quantitative trait locus (QTL) 
analysis.37 These genes exert their effects either in the liver, gallbladder or small 
intestine. An example of the gene effects include altered hormone receptors 
function (i.e. oestrogen receptor, cholecystokinin), lipid membrane transporters, 
lipid regulatory enzymes and altered mucin production.37 By evaluating the effects 
of lith genes, the pathogenic model of cholesterol gallstone formation suggests the 
primary factor is the hepatic hypersecretion of cholesterol into the bile which may 
be accompanied by further alterations in the hepatic secretion of bile salts or 
phospholipids leading to cholesterol supersaturation of the bile. Alterations in the 
proportions of constituents in bile can lead to “phase separation” of cholesterol 
from solution in bile. All the following changes in bile composition promote 
cholesterol crystallization; 1) increased cholesterol concentration; 2) increased bile 
salt hydrophobicity; 3) increased phospholipids containing unsaturated acyl chains. 
Preventative factors are 1) dilute cholesterol saturation; 2) hydrophilic bile salts; 3) 
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saturated phospholid acyl chains.30 With phase separation there is formation of 
unilamellar vesicles which aggregate to form multilamellar vesicles and eventually 
micro-crystals. These micro-crystals aggregate within the gallbladder where 
cholesterol monohydrate crystals are able to nucleate in the mucin gel glycoprotein 
scaffolding enabling stone formation.23 Excess mucin secretion, which aids 
accelerated phase transitions of cholesterol and dysfunctional gallbladder motility 
both promote gallstone formation.38 Occasionally monogenic defects lead to 
gallstone disease, such defects of ABCB11  (adenosine triposphate-binding cassette 
transporter B11) which controls bile salt export and underlies benign recurrent 
intrahepatic cholestasis (BRIC), 65% of BRIC patients developing gallstones.39 
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4. The study cohort population  
 
EPIC 
The baseline study population used to investigate the aetiology of gallstone 
disease and pancreatic cancer was the European Prospective Investigation into 
Cancer and Nutrition – Norfolk (EPIC-Norfolk). EPIC was conceived in the 1980’s 
to principally define more clearly the relationship between nutrition and the 
aetiology of common cancers and chronic diseases. EPIC-Norfolk is part of a wider 
prospective cohort investigation in 10 European countries collecting data on diet, 
lifestyle and environmental factors in approximately 520 000 middle-aged 
European adults.40 These subjects are being followed up to investigate the 
incidence of illnesses in relation to both epidemiological data and biochemical 
markers recorded at baseline. EPIC-Europe recruited participants at 26 centres in 
the European countries of Denmark, France, Germany, Greece, Italy, The 
Netherlands, Norway, Spain, Sweden and the United Kingdom (Figure 2). In the 
UK there are two sub-cohorts, one co-ordinated from Oxford of a nationwide 
population of around 57 500 men and women over the age of 35 years, with a high 
proportion of vegetarians. The second sub-cohort, EPIC-Norfolk, is co-ordinated 
from Cambridge, with a population of 30 447 men and women living in Norfolk, 
East Anglia. 
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Figure 2. Countries collaborating in the European Prospective Investigation into 
Cancer and Nutrition (EPIC) (source; EPIC-Norfolk website). 
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EPIC-Norfolk 
EPIC-Norfolk was designed with the intention of recruiting a cohort of 
approximately 25 000 men and women from the general population, aged 45-74 
years. Norfolk is a geographically distinct area with little outward population 
migration and served by three hospitals. The stability of the Norfolk population 
was an advantage as this would facilitate more complete case ascertainment of 
future disease end-points. The initial estimate of the cohort size was chosen as a 
balance, to firstly generate a sufficient number of clinical end-points and secondly 
to aid the practicality of using accurate methods for measuring exposures, 
including biological assays.41 The city of Norwich and the surrounding area were 
chosen as this population was derived from a mix of city, suburban and rural 
lifestyles (Figure 3). In total, 77 630 individuals were identified between 1993 and 
1997 who were registered with 35 general practices and were sent invitations to 
participate. Of these, 30 447 (39.2%) gave signed consent for participation and 
completed a baseline health and lifestyle questionnaire. All those who returned the 
health and lifestyle questionnaire were sent an appointment to attend a health 
check, to which 25 639 (84.2%) participants attended with most completing a 
seven-day food diary (Figure 4). The Norwich District Health Authority Ethics 
Committee approved the study and all volunteers gave signed consent for their 
medical notes to be reviewed if they developed illnesses. 
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Figure 3. Location of study population EPIC-Norfolk. 
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Figure 4. The number of participants involved in different phases of recruitment for 
EPIC-Norfolk and the data collection methods used. 
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5. Measurement of lifestyle and diet 
 
At recruitment the following characteristics and exposures were recorded; 
i. Basic demography 
ii. Anthropometrics 
iii. Physical activity  
iv. Alcohol consumption 
v. Dietary intake 
vi. Blood and urine analysis 
Each of these is now described in greater detail. 
 
Basic demography 
The health and lifestyle questionnaire recorded information on age, gender, 
social class as determined by occupation,42 family history of illness, previous 
medical history, medication, parity, alcohol, consumption, cigarette smoking and 
physical activity. Smoking status was classed as “never smoker”, “previous 
smoker” or “current smoker”. Type 2 diabetes status, was classified either as 
present or absent at baseline. 
 
Anthropometry 
At the baseline health check, a nurse recorded anthropometric assessments 
including height (nearest millimetre without shoes using a free-standing 
stadiometer) and weight (nearest 0.2kg without shoes in light clothing using digital 
scales) from which body mass index (BMI, kg/m2) was calculated. Hip and chest 
circumferences were measured using a D-loop non-stretch fibreglass tape (to the 
nearest millimetre) 41. 
 
Physical activity 
Physical activity was assessed within the health and lifestyle questionnaire 
sent to participants at the initial enrolment. The questionnaire recorded 
participants’ physical activity at work (one of four categories), home and during 
recreation (including the intensity and duration) and finally the number of flights of 
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stairs they climbed per day (appendix 1). The EPIC physical activity questionnaire 
had been previously validated by comparing it to a 3-day activity diary.43 However, 
using a validating measure of the same fundamental type as the one to be validated 
increases the risk of correlated error.44 Therefore, a second validation study of the 
EPIC physical activity questionnaire used objectively measured energy expenditure 
as the validating measure.45 In this work, conducted over one year, 173 volunteers 
completed four separate assessments of cardiorespiratory fitness (as measured by 
sub-maximal oxygen consumption whilst cycling) and secondly 4-day energy 
expenditure (as determined by heart rate monitoring). Concurrently, participants 
completed the EPIC physical activity questionnaire which recorded their activities 
over the past year. In the analysis, the only questions on physical activity that 
correlated with energy expenditure related to occupational activity (p for trend 
<0.001) and certain recreational activities (a combination of cycling and other 
physical activity i.e. keep fit, aerobics, swimming and jogging).45 Questions on 
low-intensity activities (i.e. gardening, walking and housework) and stair climbing 
did not significantly correlate with energy expenditure and hence were not used in 
the derivation of a four-level physical activity index, which combined physical 
activity at work with the time taken performing recreational activity. These four 
categories were “inactive”, “moderately inactive”, “moderately active” and 
“active” (Table 1). Within each individual category, the summations of different 
amounts of occupational and recreational physical activity levels were similar. 
There were positive associations between the 4-level physical activity index, 
derived from the physical activity questionnaire and the measures of the ratio of 
daytime energy expenditure to resting metabolic rate (p=0.003) and 
cardiorespiratory fitness (p=0.001). The repeatability of the questionnaire was high 
(weighted kappa=0.6, p<0.001) when evaluated in 2 271 participants who 
completed the questionnaire on two occasions, 18-21 months apart 45. Therefore, 
the relevant information on physical activity was extracted from the baseline 
questionnaire. 
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Table 1. The 4-level physical activity index (Source; Wareham 
et al, Public Health Nutr 200345). 
 
Category of Physical Activity Description of activity 
Inactive  Sedentary job and no recreational activity. 
Moderately Inactive Sedentary job with <0.5h recreational activity per day 
or Standing job with no recreational activity. 
Moderately Active Sedentary job with 0.5 to 1.0 hr recreational activity per 
day 
or Standing job with 0.5 hr recreational activity per day 
or Physical job with no recreational activity. 
Active Sedentary job with > 1.0 hr recreational activity per day 
or Standing job with >0.5 hr recreational activity per day 
or Physical job with at least some recreational activity 
or Heavy Manual Job. 
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Dietary assessments 
EPIC-Norfolk was unique amongst EPIC centres, as 7-day food diaries 
were used to assess dietary intake in its participants. However, similar to other 
EPIC centres, a food frequency questionnaire (FFQ) and a 24-hour recall record 
were also completed. The 7-day food diary (7-DFD) allowed finer between-
individual discrimination with validation studies demonstrating improved 
correlations with dietary intakes compared to FFQs.46-47 This reduces regression 
dilution that may otherwise prevent the detection of true associations between diet 
and disease. Therefore, EPIC-Norfolk has unique advantage compared to other 
large prospective cohort studies by virtue of the use of 7-day food diaries.  
A total of 23 658 participants completed seven-day food diaries (7-DFDs) 
in the week after the baseline health check (response rate of 92.2%). A nurse 
explained how to complete the diary, the first day of which was filled in with the 
nurse, as a 24 hour recall of their previous day’s dietary intake. The remaining six 
days were completed by the participants themselves at home. They recorded their 
entire dietary intake, including portion sizes, brands and cooking methods in eight 
separate meal times daily. The names of commercially prepared foods or packaging 
from products were included in the diary to allow more accurate nutritional 
assessments. Homemade foods were described in detail using recipes supplied by 
the participants. Portion sizes were estimated by either weighing the food or 
comparing each item with photographs supplied of different foods of varying 
quantities. At the end of the week’s record, supplementary questions were asked on 
important contributions to nutrient intake, including cooking oils and milk 
consumption. 
After completion, the diaries were returned to the research centre where 
they were interpreted and coded by trained nutritionists with the data inputted into 
a specially designed computer programme called DINER (Data Into Nutrients for 
Epidemiological Research). Each data enterer worked according to an extensive 
data entry reference manual (DINER_derm) to ensure consistency between coders. 
Each item in the food record is entered by making references to a series of 
windows of nutritional options to produce the final line of data. A food item, 
portion size and number of portions are entered for all reported foods (Figure 5). 
The program was designed to ask for the information necessary for each specific 
food list item, such as fat used in cooking or brand name. Food diaries were 
entered according to each individual meal slot. Reasons for missing meals were 
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documented, and factors affecting usual intake such as illness or special diet were 
recorded. Every entry in the diary was allocated to one of both 11 000 food items 
and 55 000 portion sizes within DINER, by selecting the food item which best 
described it. Where a description of the food was lacking, the item was assigned 
the average composition for that food type. DINER facilitated the translation from 
participant reported free text of food into lines of structured data (Figure 5) which 
was then converted into nutrient values or food groups.48 Each line of data in each 
food diary was converted into a weight of that food and then the nutrient database 
in DINER calculated the nutrients contained in the weight of food. Intake for each 
day was summated to give the total intake over 7 days and then each nutrient was 
then divided by 7 to provide the average daily intake. The nutrient database in 
DINER is based on foods in the United Kingdom Food Composition Database, the 
nutrient database of the Royal Society of Chemistry and from food manufacturer’s 
databases. Each 7-DFD took a nutritionist approximately 4 hours to code with an 
average of 220 food and drink items reported in each diary. An example of the 
accuracy of their nutrient assessment was that 337 specific types and brands of 
breakfast cereals were included in DINER. The computer program was checked for 
potential errors in the coded diaries such as unexpectedly large portion sizes or 
duplication of entries. If any anomalies were detected they were further assessed by 
the nutritionist. As most, but not all, of the returned 23 658 diaries are coded in 
EPIC-Norfolk, a random sample of 3 970 (16.8%) have been coded to use in the 
gallstone study in a case-cohort analysis. The size and nature of this subset of the 3 
970 subjects was derived by the EPIC-Norfolk co-ordinating centre and was not 
specific to this study. It was considered to be a large enough sample to allow 
statistically significant comparisons to be a calculated against relatively common 
diseases. The subset was designed to have similar characteristics and demographics 
as the whole EPIC-Norfolk population. Although not used in this study, repeated 7-
DFDs were completed by 21 000 participants 18 months after enrolment, 16 000 
participants at 3 years and 10 000 participants at 13 years. These food diaries will 
be coded by nutritionists in the future. 
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Figure 5.  An example of data entry using DINER 
 
A participant has recorded eating a homemade apple pie, size coded as 3B. 
 
The data coder enters apple pie into DINER using a drop down menu which details 
the type of pastry used. 
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Figure 5 continued. The portion size can be selected from a large number of 
options. In this example participant has used picture references to code the portion 
size as “3b”. 
 
 
Figure 5 continued. An example of the lines of data produced with each diary 
entry. 
 
Each food item in the 7-DFD is represented by one line of data in the final 
structure. A sandwich is entered as bread, spread and filling, a cup of tea is entered 
as black tea and milk (and sugar where taken). After a coder has made the initial 
entry for a food diary, they run a checking program. The program checks that the 
correct number of days and meal slots have been entered (or noted as empty) and 
identifies potentially unreasonable amounts of foods and that the right portion 
types have been used for different food items (source; EPIC-Norfolk website). 
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Supplement use 
The use of vitamin and mineral supplements was also recorded in the 7-
DFD by participants. A label-based database was developed containing information 
on 2 066 supplements, with 16 586 ingredients. This vitamin and mineral 
supplements (ViMiS) database contained manufacturers’ information to allow 
calculation of each micronutrient intake.49 To simplify the analysis, a binary 
variable of “user” or “non-user” for each vitamin or mineral was classed by 
whether the dose exceeded 5% of food-sourced intake as defined by the cohorts 
completed 7-DFD’s. For example, the average daily intake of vitamin C from the 
diet was 89mg, with 5% of daily intake 4.45mg; therefore a participant 
supplementing with 60mg of vitamin C a week (average 8.6mg/day) would be 
classified a vitamin C supplement user whereas a supplement of 30mg vitamin C a 
week would be recorded as a non-user.49  
 
Alcohol consumption 
Alcohol intake was assessed from the food frequency questionnaire (FFQ) 
as data was collected all the participants who completed the baseline questionnaire 
and average alcohol intake is the only dietary variable that is recalled with greater 
accuracy using FFQs than 7-DFD 50-51. The FFQ recorded how many drinks were 
consumed each week of: i) beer, cider or lager, ii) wine, iii) sherry or fortified wine 
and iv) spirits and from this alcohol was estimated in UK units. An example of the 
estimates used are that an average pint of beer will have 2.2 units of alcohol and 
one glass of small wine has 1.5 units (1 UK unit = 7.9 grams or 10 millilitres). 
 
Blood and urine samples 
At baseline, non-fasting blood samples were taken and immediately 
transported to the laboratory to measure full blood count, serum triglycerides, total 
cholesterol, HDL cholesterol, LDL cholesterol, glycosylated haemoglobin A1c 
(HbA1c), Thyroid-Stimulating Hormone (TSH), free Thyroxine (T4) and serum 
vitamin C. The remainder of the serum was stored for potential analyses in the 
future. Urinalysis was performed using Multistix 8SG testing for blood, leucocytes, 
nitrite, specific gravity, glucose, protein, ketone, and pH with a specimen kept for 
storage. 
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6. Risk factors for gallstone disease 
 
The rise in the prevalence of gallstone disease in the last century suggests 
life-style factors are of paramount importance in the aetiology of gallstones. The 
potential risk factors that are involved will be discussed in this chapter.  
 
Gender and female sex hormones 
Gallstone disease is commoner in women who are twice as likely to form 
gallstones.8 However, the prevalence in males rises towards that in females with 
increasing age so that the ratio changes from 1:2 in subjects under 50 years, to 
1:1.2 in those over 70 years.10  The mechanism for the increased risk of gallstone 
disease in women is probably related to female sex hormones as parity, oral 
contraceptive use and hormone replacement therapy (HRT) all increase the risk of 
gallstone disease.52-53 There are biological mechanisms to explain these 
associations with Lith gene studies demonstrating that oestrogen enhances 
cholesterol cholelithogenesis by augmenting functions of the hepatic estrogen 
receptor-α (ER-α). In the liver, the ER-α receptor stimulates the SREBP-2 (sterol 
regulatory element binding proteins pathway) promoting cholesterol biosynthesis 
and hepatic secretion of biliary cholesterol.54 Furthermore, progesterone and 
oestrogen receptors have been identified in human gallbladder tissue with 3 months 
of oestrogen therapy increasing residual gallbladder volumes and reduce 
gallbladder emptying both of which promote stone formation.55 
There is robust aetiological epidemiological data confirming female sex 
hormones are a risk factor for gallstone disease. Compared to being nulliparous, 
each additional pregnancy increases the risk of gallstone disease by approximately 
10%,11 whilst HRT use for greater than 1 year has been associated with a 4x greater 
risk of gallstone disease (OR = 4.05, 95% CI = 1.12-14.76).52 Randomised placebo 
controlled trials of oestrogen use designed initially to assess the secondary 
prevention of coronary heart disease in post-menopausal women, showed that 
oestrogen supplementation increased the risk of gallstone disease with results of 
OR=1.38 (95% CI=1.00-1.92)56 and OR=1.59 (95% CI=1.28-1.97) 53. The 
consistency of the experimental, epidemiological and trial evidence implies 
oestrogen is a causal risk factor for gallstone disease. 
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Underlying chronic diseases and medical conditions 
Liver Cirrhosis 
 Liver cirrhosis is a well-established risk factor for gallstone disease with 
the prevalence of gallstone disease 25-30% higher than the general population.57 
Most stones in cirrhotic patients are composed of black pigment type the 
mechanism of formation related to altered pigment secretion, abnormal gallbladder 
motility and increased oestrogen levels.8 There may be confounding with non-
alcoholic fatty liver disease which is associated with obesity and dyslipidaemia. As 
cirrhosis is uncommon, it only contributes to a small proportion of all gallstone 
disease. 
 
Terminal ileal disease and Crohn’s disease 
 Terminal ileal disease, usually caused by small bowel Crohn’s disease, 
leads to a 2 to 3 fold increased risk of mostly pigment gallstones.58 Here normal 
reabsorption of bile salts in the terminal ileum is prevented, allowing bile salts to 
enter the colon where they solubilise unconjugated bilirubin, which is  passively 
absorped in the colon, reconjugated, and resecreted into bile. This process leads to 
excess bilirubin secretion and predisposes to black pigment gallstone formation.59 
Again, as Crohn’s disease is uncommon, it has little effect on the total burden of 
disease, although the increased risk of gallstone disease is an important 
consideration when evaluating a patient with Crohn’s disease and abdominal 
symptoms. 
 
Rapid weight loss 
 Weight loss exceeding 1.5kg per week from dieting predisposes to 
gallstone formation.60-62 Patients undergoing bariatric surgery are particularly prone 
to gallstone formation (prevalence pre-operatively of 21.6% vs 1 year post-
operative incidence of 52.8%) which is believed to be induced by a lack of 
gallbladder stimulation and hence biliary stasis. Decreased calorie intake and rapid 
bowel transit alter gut hormone secretion, with reduced cholecystokinin release, 
leading to gallbladder hypomotility.63 Prophylactic cholecystectomy at the time of 
bariatric surgery is sometimes considered or the routine use of ursodeoxycholic 
acid post-operatively.64 
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Obesity 
 Increasing obesity is a risk factor for gallstone disease although the 
mechanism is unknown and data from European studies is minimal. The World 
Health Organisation defines obesity as “abnormal or excessive fat accumulation 
that may impair health”.65 Body mass index (BMI; expressed in kg/m2) is often 
used as a measure of obesity and gives an estimate of relative weight for height. 
The World Health Organisation categories BMI as follows; BMI 20-25 kg/m2 
“normal”, 25-<30 kg/m2 “overweight”, 30-<35 kg/m2 “obese class I”, 35-<40 
kg/m2 “obese class II”, >40 kg/m2 “obese class III”.65 However, BMI is not an 
accurate measure of total body fat or the distribution of body fat.66 Waist 
circumference gives a better estimation of central adiposity, particularly in 
advancing age when there is attrition of muscle volume67 and a tendency for fat to 
accumulate intra-abdominally.68 Abdominal obesity is associated with 
hyperinsulinaemia and insulin resistance which leads to dyslipidaemia, namely 
elevated serum triglycerides and reduced HDL.69-72 These lipid alterations raise 
biliary cholesterol saturation73-74 and increase mucin production, both of which 
enhance the aggregation of cholesterol into microcrystals.75 Obesity and 
hyperinsulinaemia also contribute to gallstone formation by causing gallbladder 
hypomotility which promotes cholesterol crystal aggregation.76-78 
 Epidemiological studies have confirmed the association between 
obesity and gallstones. Cohort studies have methodological advantages over case-
control studies, in that the anthropometry recorded is prior to the development of 
disease and more likely to be related to aetiology. In case-control work patients 
may have difficulty accurately recalling their pre-symptomatic weight and use of 
their current weight may have altered due to disease. Large prospective cohort 
studies in the US have found BMI, waist circumference or waist-hip-ratio increase 
the risk of symptomatic gallstones in both genders,79-80 with smaller European 
prospective studies confirming the association in both incident asymptomatic and 
symptomatic gallstones.81-82 Further work is needed to clarify the association in a 
large European study and to assess biological mechanism. 
  
Type 2 Diabetes 
 Type 2 diabetes is positively associated with gallstone disease although 
the association is complex as it may be confounded by obesity, dyslipidaemia, and 
a family history of gallstones. Type 2 diabetes is characterised by insulin resistance 
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which increases the risk of gallstone formation.83-84 Supportive epidemiological 
data includes a large case control study where men with diabetes had OR=1.54 
(95% CI=1.24-1.91) and women OR=1.92 (95% CI=1.60-2.31).11 The same 
population was then followed up prospectively for 10 years to identify those 
developing incident gallstone disease, and failed to show that diabetes was an 
independent risk factor for gallstones in women (men OR=2.72, 95% CI 0.89-8.33, 
women OR=1.00 95% CI 0.22-4.49).81 Further studies that have adjusted for the 
presence of obesity also did not find diabetes an independent risk factor for 
gallstone disease.85-87 Therefore, it appears that diabetes is unlikely to be an 
independent risk factor for gallstone disease though is related to anthropometric 
risk factors. 
 
Dyslipidaemia 
Although most gallstones consist of cholesterol, no definite association has 
been shown between serum hypercholesterolaemia and gallstone disease.85, 88-89 
However, there is evidence that the dyslipidaemia associated with obesity, diabetes 
and the metabolic syndrome, i.e. low serum high-density lipoprotein-cholesterol 
(HDL) and raised serum triglycerides increase risk.88-89 Patients with 
hypertriglyceridaemia are known to have both cholesterol supersaturation of the 
bile and decreased gallbladder motility with an increased risk of gallstone 
formation.90 Increased serum HDL may be important in preventing stone 
formation. HDL plays a critical role in the reverse cholesterol transport by 
removing cholesterol from the peripheral tissues and delivering it to hepatocytes 
for excretion into the bile. HDL also accepts a significant amount of excess 
cholesterol from the liver and plays an important role maintaining cellular 
cholesterol homeostasis.91 In rodents and humans, cholesterol from plasma HDL is 
a key source of cholesterol for biliary secretion either as unesterified cholesterol or 
after transformation into primary bile acids.92 In human studies, using radiolabelled 
cholesterol, HDL cholesterol rather than LDL cholesterol represents the main 
source of biliary lipid cholesterol secretion93 with a much larger fraction of 
cholesterol carried by HDL secreted in the form of bile acids compared to that of 
LDL.94 These findings may explain why raised serum HDL has an inverse 
relationship with biliary cholesterol saturation74 and gallstone disease although the 
exact pathophysiological mechanisms are not defined. Mouse models deficient of 
the binding proteins apoA-I (apolipoprotein A-I) or ABCA1 (ATP-binding cassette 
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transporter A1), which control HDL levels do not change biliary cholesterol 
secretion.95-96 However, a particular polymorphism (TaqBI) of cholesteryl transfer 
protein (CETP) which transfers HDL to non-HDL lipoproteins for further uptake 
by the LDL pathway in the liver, lowers plasma HDL levels and is associated with 
gallstone disease.97-98 Raised triglycerides could influence gallstone formation by 
increasing biliary cholesterol saturation73 and bile viscosity via enhanced mucin 
production promoting aggregation of cholesterol into microcrystals, the precursor 
of stones.75  
The biological hypotheses described above need to be supported by 
epidemiological work. These would need to show that serum lipids measured 
before the development of disease influence the risk of gallstones. Cohort studies 
are the preferred methodology for studying serum markers of disease as they are 
measured before diagnosis, while case-control studies could lead to bias if lipid 
levels are altered by the disease itself. There are two previous prospective cohort 
studies which investigated serum lipids and their association with gallstone disease. 
A US study found that increased serum HDL and decreased triglycerides were 
associated with a decreased risk of gallstones in men and women.88 An Italian 
prospective study (MICOL) evaluated the presence of gallstones using 
ultrasonography at enrolment and again 10 years later and found that men, but not 
women, had a negative association with HDL and total cholesterol and a positive 
association with triglycerides. These prospective studies suggest that serum lipids 
are predictive of the risk of developing gallstone disease, although there are 
inconsistencies particularly in females, and whether total cholesterol is associated. 
Lipid profile data from case-control99-101 and cross-sectional work11, 89, 102-103 also 
showed inconsistent associations and have less validity as it is unknown if 
alterations in the lipid profile precede the development of disease. A consistent 
effect of decreased HDL and increased triglycerides leading to gallstone disease 
would suggest that obesity and the metabolic syndrome may in part lead to 
gallstone disease by inducing this pattern of dyslipidaemia. More data is required 
from European populations to help clarify the inconsistencies. Data from the same 
population measuring both lipid biomarkers and anthropometry is needed. 
 
Physical activity 
There are several plausible biological mechanisms for how physical 
activity may prevent gallstone formation. Exercise reduces plasma triglycerides104 
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and insulin levels105, both of which lead to a lower cholesterol saturation of the 
bile74, 106. Triglycerides also increase bile viscosity by stimulating mucin secretion 
from gallbladder mucosal cells which promotes the aggregation of cholesterol into 
microcrystals75. Regular exercise raises High-Density Lipoprotein–Cholesterol 
(HDL-C) levels107-108 which are inversely associated with gallstone prevalence.89 
HDL-C is a precursor of bile acids94 which reduce its lithogenicity. Exercise, by 
increasing cholecystokinin levels, has a prokinetic effect on the gut109 which 
stimulates gallbladder contractility and prevents bile stasis.110 To support the 
experimental data for a protective effect of exercise, large population based 
epidemiological studies are required showing that those who exercise are at a lower 
risk of developing gallstones. Both case-control and prospective cohort studies can 
be used to investigate this potential association. However, prospective 
investigations provide more accurate information on pre-symptomatic physical 
activity, as this is measured before the development of disease and consequently is 
not subject to the recall biases inherent in case-control studies. The published 
cohort studies have reported that higher levels of physical activity reduced the risk 
of symptomatic gallstones by approximately a third.111-115 However, a limitation of 
all these investigations was that the method for measuring physical activity, namely 
questionnaires had not been validated against detailed physiological measures of 
physical activity, including energy expenditure and cardiorespiratory fitness. 
Similar data on exercise is also needed in European populations to clarify the 
association and define the magnitude of effect. To address these limitations, 
physical activity questionnaires assessed against energy expenditure (repeated 4-
day heart monitoring) and cardiorespiratory fitness (repeated measures of sub-
maximal oxygen uptake)45 are important since they allow the accurate 
categorisation of physical activity levels. Demonstrating an association of physical 
activity with gallstones should lead to it being accurately measured and included in 
aetiological models of gallstone formation. It would also be important as 
encouraging increased physical activity levels may help to reduce the numbers 
developing symptomatic gallstones. 
 
Alcohol 
Alcohol may prevent the development of gallstones by several biological 
mechanisms. Alcohol stimulates cholecystokinin release116 and therefore gut 
motility117 which prevents biliary stasis and cholesterol crystal aggregation.32 
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Alcohol intake also increases HDL levels118-120 by reducing cholesteryl ester 
transfer protein (CETP) activity which prevents the conversion of HDL into 
LDL.121 HDL is then metabolised to primary bile acids which help to solubilise 
biliary cholesterol. Alcohol may also increase lecithin cholesterol acyl transferase 
(LCAT) activity (an enzyme that converts free cholesterol into cholesteryl ester), 
which further increases HDL.122 
The role of alcohol is best investigated by prospective cohort 
investigations. Cohort studies which record alcohol intake before the development 
of symptoms have methodological advantages over case-control work and avoid 
protopathic bias which occurs if alcohol intake is reduced following the 
development of symptoms.123 Prospective cohort studies of health professional 
from the United States reported inverse associations between alcohol intake and 
gallstones in both men 124 and women.125 A further prospective US study of 12 773 
people reported an inverse association in women, although none in men.88 Smaller 
case-control studies using ultrasonography to assess outcome for prevalent silent 
stones also found an inverse association with alcohol.126-127 However, prospective 
data in a European population is required investigating alcohol in this population, 
describe the effect size, and assess if the effects are in both males and females. 
Alcohol intake is more reliably recalled than other dietary intakes, and as such, it is 
one of the few dietary factors that is evaluated with greater accuracy using a food 
frequency questionnaire, rather than a food diary.47 Hence, in EPIC-Norfolk, 
alcohol intake is the only dietary value derived from the FFQ rather than the 7-
DFD. 
 
Drug and medical treatments 
Statins 
Statins inhibit 3-hydroxy 3 methylglutaryl (HMG) coenzyme A (CoA) 
reductase which diminishes cholesterol synthesis in the liver, resulting in reduced 
biliary cholesterol saturation in humans.128  Statins also increase plasma HDL 
levels and decrease plasma triglycerides129 which are associated with a decreased 
risk of gallstone disease. Data on statin use may be obtained from both prospective 
and retrospective work as potential recall bias for medication use should be 
minimal in retrospective work. The largest prospective cohort study in this field 
used the UK General Practice Research Database (GPRD) and identified 27 035 
patients with a history of cholecystectomy who were matched against 106 531 
controls. The adjusted odds ratio for requiring cholecystectomy after 20 or more 
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prescriptions of statins was 0.64 (95% CI 0.59-0.70).130 Another large prospective 
study was the US Nurses’ Health study which identified 2 479 incident case of 
cholecystectomy after 8 years follow-up from the baseline population of 90 302 
women aged 34-59 years. Users of statins, compared to non-users, had a 
multivariate relative risk of disease of 0.82 (95% CI=0.70-0.96).131 The results 
from these two large epidemiological studies suggest that statins do prevent 
gallstone disease, although there is a risk of residual confounding. People 
prescribed statins are often advised by their doctors to make alterations to their diet 
and lifestyle, leading to changes in their behaviour that could reduce the risk of 
developing gallstones. Future work needs to include all potential aetiological 
agents in the models investigating statins. 
 
Fibrates 
Fibrates may potentially alter the risk of developing gallstone disease due 
to their effects on biliary cholesterol secretion. Fibrates are the first choice drug to 
treat hypertriglycerdiaemia and reduce the risk of cardiovascular disease and can 
also be used in the therapy for hypercholesterolaemia if statins are not tolerated.132 
Fibrates are hypolipidemic drugs that lower the progression of atherosclerotic 
lesions mainly through activation of the nuclear receptor peroxisome-proliferator 
activated receptor-alpha (PPAR-α) which is a subgroup of a nuclear receptor gene 
family. PPAR-α activation mediates changes in lipoprotein metabolism leading to 
an increased hepatic uptake and esterification of free fatty acids, as well as 
increasing mitochondrial free fatty acid uptake promoting free fatty acid 
oxidation.133 Fibrates also significantly reduce cholesterol-7-alpha-hydroxylase 
(CYP7A1) activity.27, 134 CYP7A1 is the rate limiting enzyme for bile acid 
biosynthesis and hence cholesterol elimination, with low activity of CYP7A1 
causing increased cholesterol secretion in humans.27 Fibrates increase biliary 
cholesterol secretion 135 and in a randomised controlled trial to evaluate the effects 
of clofibrate in cardiovascular disease, 1 103 participants were treated with 
clofibrate vs 2 789 with placebo. The rate of any gallbladder disease was higher in 
the treatment group (3.3% vs 2.0%, p=0.018).136 This finding was confirmed in a 
case-control study which reported an increased risk for the presence of gallstones 
(diagnosed with ultrasonography) with a history of fibrate use (multivariate 
RR=1.7, 95% CI 1.0-2.7).137 Since there is strong biological data relating fibrate 
use to increased gallstone formation with supporting data from RCTs and case-
control studies, fibrates are regarded as causal agents for the development of 
gallstone disease.  
45 
 
Aspirin 
Aspirin could prevent gallstone formation by reducing the volume of 
mucin secreted into the gallbladder. Mucin release is partly mediated by 
prostaglandins formed from arachidonic acid via the cyclo-oxygenase pathway, 
which aspirin inhibits. Animal models have demonstrated that aspirin inhibits 
mucin secretion 138 with human studies in obese participants confirming this effect 
139
. Although some clinical investigations and one observational study have 
reported that aspirin use is associated with reduced gallstone formation 11, 140 these 
findings are not supported by other investigations. A RCT of 4 524 patients who 
received either 1 000mg of aspirin a day or placebo found no difference in the rate 
of hospitalization for gallstone disease.141 A case-control study assessed gallstone 
prevalence between users and non-users of aspirin or NSAIDs and again reported 
no differences.142 However, aspirin has been effective in preventing gallstone 
formation in the obese undergoing rapid weight loss143 and future prospective 
studies examining the timing and dose of aspirin use with respect to gallstone 
diagnosis are needed to clarify if it has an effect. 
 
 Total parenteral nutrition, octreotide and ceftriaxone 
  Total parenteral nutrition and the drug, octreotide, both suppress the 
release of cholecystokinin leading to gallbladder stasis and stone formation. 
Octreotride also predisposes to gallstones by slowing colonic transit times which 
increases the absorption of the hydrophobic secondary bile salt, deoxycholate, 
which is re-secreted into the bile and promotes cholesterol precipitation.144 More 
than 50% of patients treated with octreotide will develop cholelithiasis 145 with the 
same proportion forming biliary sludge after 6 weeks of TPN treatment.8 As the 
number of people receiving these two therapies is relatively small, they have a 
minimal significance on the total burden of gallbladder disease. Ceftriaxone is a 
third generation cephalosporin which is secreted unmetabolised into the bile and is 
associated with the production of biliary sludge.146 However, its short term use 
rarely leads to gallstone disease. 
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7. Diet and gallstones disease 
 
 The geographical variation in gallstone disease prevalence, with increased 
disease in Westernised countries, suggests that environmental factors, and in 
particular diet, are likely to be involved in the pathogenesis of gallstone disease. 
Over the past 40 years, within the same population group in the UK, there has been 
a dramatic increases in both gallstone prevalence147 and disease requiring 
hospitalisation.3 To assess diet and the risk of developing incident gallstones or 
gallstone disease extensive epidemiological and experimental work has been 
performed. There are a multitude of nutrients which could either increase or 
decrease the risk including macronutrients, vitamins and minerals. Prospective 
epidemiological studies which evaluate diet prior to the development of symptoms 
are methodologically superior to case-control studies and cross-sectional surveys of 
gallstone disease, as they eliminate protopathic and recall biases. Studies that use 
ultrasonography to detect silent gallstones in case-control studies should also 
eliminate protopathic bias. 
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Measuring dietary intake 
Diet is a plausible environmental factor to investigate in the aetiology of 
gallstone disease, although nutritional epidemiology has many methodological 
limitations. If the aim is to measure current dietary habits, the Heisenberg 
uncertainty principle may occur, namely, by stopping something to measure it, its 
behaviour changes, which in practice means when people are asked to record 
current dietary intake they may be inclined to alter their eating habits.148 If the aim 
is to measure past dietary intake, then difficulties in recalling food intake and 
conceptual abilities lead to measurement error. Even if the diet is accurately 
recorded, further error will be introduced by the use of food composition tables 
which convert dietary data to nutrient values. Food composition tables and nutrient 
databases give average values of a limited number of samples of each food type. 
Food composition table are subject to sampling errors, missing values, nutrient 
losses and gains during processing, and altered bioavailability which all contribute 
to error and variation in findings from nutritional studies. To minimise the error 
from measuring diet an appropriate assessment method should be selected which 
has been thoroughly validated.  
The ideal DAM would be quick and easy to complete and cheap but both 
accurate and reproducible. There is no single best DAM which can be applied as a 
standard in all epidemiological studies and all the available options have 
advantages and disadvantages. Various dietary assessment methods (DAMs) are 
available with varying degrees of accuracy and cost. These range from (cheapest 
and least accurate first) national food supply data, household surveys, 24-hour 
recall to food frequency questionnaires, food diaries, weighed records and 
laboratory assessments such as urinary nitrogen as a biomarker of protein intake, 
and doubly labelled water to evaluate energy expenditure. 
 
Dietary assessments in populations 
 Diet can be assessed in either populations or individuals. This section will 
discuss methods of measuring dietary intake in groups, by national food supply 
data and 24-hour recalls obtaining national dietary data and the use of the food 
account method in household surveys. Estimating a nation’s dietary intake can be 
made from national food supply data which is usually collected commercially and 
can be used in ecological studies. One example is the Food and Agricultural 
Organization of the United Nations (FAO) which calculates the quantity of food 
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produced in a country. This is added to the food imported, and then a subtraction of 
the food exported, lost in storage, fed to animals, and used for non-dietary purposes 
to calculate a measure of consumption. This gives an estimate of the per capita 
consumption of dietary intake, by dividing by the size of the total population.149 
The data collected can be used to compare differences between the incidence of 
disease and diet in different countries to generate hypotheses on aetiology. There 
are errors inherent in this approach which makes interpretation difficult, principally 
as there is no correction for co-variates associated with disease risk. National 
population surveys have been used to collect more detailed dietary information on 
subgroups of this population. Commonly, in the population setting 24-hour recall 
diaries are used to investigate the associations between diet and disease and can 
provide a reasonable estimate of the diet in a given group. Household surveys 
provide information on the average dietary consumption and are most often 
undertaken using the “food account method” where all the food entering the 
household is recorded, usually in the form of shopping purchases. The longest 
running household survey using this method is the British Household Food 
Consumption and Expenditure Survey (The National Food Survey), which is 
conducted annually.148 Household surveys allow comparisons of different sub-
groups within a population, for example the geographical variation of dietary fibre 
intake and colon cancer mortality within the UK.150 Such work is hypotheses 
generating rather than hypothesis testing and for more detailed assessments 
evaluations of diet in individuals is required. There are three principle methods of 
assessing diet in individuals, namely food frequency questionnaires, 24-hour recall 
and food diaries. 
 
Food frequency questionnaires (FFQs) 
 Food frequency questionnaires are the most frequently used dietary 
assessment methods (DAM) in case-control studies and cohort studies.148 They are 
designed to measure usual eating habits over a defined period of time and consist 
of lists of food types and items, together with options on the frequency of 
consumption, ranging from never to many times per day (Figure 6). FFQs can 
either be self or interviewer administered and benefit from being quick, easy to 
undertake and cheap. They have advantages if the sample is geographically 
dispersed, when they can be posted. They are suitable for certain nutrients which 
are readily recalled e.g. alcohol, particularly if the aim is to rank participants into 
broad groups of intake rather than precise qualitative amounts. Considerable work 
is required to develop and validate FFQs against recognised standards. 
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Figure 6. An example of a completed food frequency questionnaire (source;  EPIC-
Norfolk website). 
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24-hour food recall 
 The 24-hour food recall method records the previous day’s intake, and is 
commonly used in cross-sectional investigations, although they may also be 
employed in case-control and cohort studies. The participant is asked to report all 
their food and drink consumed in the 24-hours prior to the interview by a 
researcher or by self-completing the questionnaire. Subjects should not be given 
prior warning of the interview to prevent alteration of their behaviour.  The actual 
foods consumed are described together with estimated or the known weights or 
portion sizes. 24-hour recalls are quick and easy to administer with good 
compliance as the information is relatively easy to recall. This method was used in 
the US National Health and Nutrition Examinations Survey (NHANES) III.151 The 
limitations are that they only provide a snap-shot of dietary intake and no estimate 
of the day-to-day variation of an individual’s diet. When used in epidemiological 
studies to rank individuals into categories of nutrient intake, this inherent 
measurement error will reduce the ability to describe significant associations 
between diet and disease, as many will be misclassified.148 There is also a tendency 
for subjects with a high intake to under-report and those with a very low intake to 
over-report leading to a “flat-slope” syndrome.152 Hence, the use of 24-hour recalls 
in large scale nutritional epidemiological research may result in no significant 
differences being detected between dietary intakes of a nutrient and disease, 
although one may actually exist (type II error). For differences to be detected then 
large variations in diet between cases and control would need to exist. 
 
Food diaries 
Food diaries require an individual to accurately record, over a set time 
period, usually 3 to 7 days, all food and drink consumed. The individuals are taught 
how to describe and estimate the type and weight of food to be eaten, including 
brands, individual recipes and to record any leftover. Detail regarding the volume 
of food consumed can be improved by asking participants to weigh the food, use 
the packaging, or compare the product to pictures or photos of portion sizes. The 
text recorded in the diary is interpreted by a nutritionist and entered into a 
computer program to produce average daily nutrient values of intake. Historically, 
food diaries have been used to validate FFQ and 24-hour recalls. They have not 
been used as methods to record dietary intake in large cohort studies due the length 
of time and tuition required to complete and interpret them successfully. 
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Validity of dietary assessment methods 
All dietary assessments methods (DAMs) incur measurement error, so 
validation of DAMs enables an understanding of the relationship between what is 
measured and the truest measures of intake. To establish the validity of a DAM it 
needs to be compared against the best standard or reference measure, even though 
this may itself have inherent errors.153 Therefore, it is only possible to evaluate 
DAMs relative to a previously established “best” reference measure. The latter 
should ideally have an error independent of that which might be recorded in the 
DAM. Ideally, a valid external measure, such as a biochemical marker of intake, 
should be used rather than an internal measure, such as a detailed diary, which 
could lead to a bias in one aspect of measurement being carried over to another.148 
Biomarkers of dietary intake are an unbiased reference measure in nutritional 
validation studies because their measurement error is independent of those of 
DAMs.51 Examples of biomarkers used in validation studies include doubly 
labelled water (measure of energy expenditure), urinary nitrogen excretion (protein 
intake) and serum concentrations (e.g. vitamin C and carotenoids).51 However, not 
all biomarkers reliably reflect dietary intake (i.e. serum iron levels and dietary iron 
intake) and they do not exist for most nutrients, so other reference methods are 
required such as weighed records. 
Dietary assessment and validation in EPIC-Norfolk 
The EPIC cohort in Norfolk is unique amongst EPIC centres, as 7-day food 
diaries were used to assess dietary intake in its participants. However, as in other 
EPIC centres, a food frequency questionnaire (FFQ) and a 24-hour recall record 
were also used. The 7-day food diary used in the Norfolk cohort allows finer 
between-individual discrimination and validation studies, against weighed records, 
have demonstrated improved correlations with dietary intakes.51 Extensive work 
was carried out to select the validation methods to be used in EPIC-Norfolk. 
Studies conducted in a metabolic suite, established a validation protocol to provide 
the most feasible accurate measure of usual dietary intake over a one year period. 
This protocol was a minimum of 16 days of weighed records (4x4 days over one 
year) and eight 24-hour urinary  collections for nitrogen and potassium (4x2 days 
over one year).51 Validation studies for daily intakes of nutrient compared to 16-
day weighed records were conducted on 24-hour recalls, FFQs and 7-day food 
diaries. These reported that 7-day food diaries had better correlation coefficients 
for nearly all nutrients (17 of 18) than FFQ and 24-hour recall when using weighed 
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records as the standard (Table 2). Compared to 16-day weighed records, examples 
of correlations achieved for 7-DFDs, 24-hr recall and FFQs were;  
  7-DFD  24-hr recall FFQ 
energy intake  r=0.59   r=0.42   r=0.52  
sugars intake  r=0.77   r=0.63   r=0.51 
iron intake r=0.83  r=0.53  r=0.43 
vit C intake  r=0.70   r=0.54  r=0.54 
alcohol  intake r=0.88  r=0.60  r=0.90 
 
The only dietary variable which had a higher correlation when measured with the 
FFQ compared to the 7-DFD was alcohol. This was partly due to alcohol intake 
often being zero and alcohol is readily recalled.51  
The validity of the different dietary methods has also been compared with 
24-hour urine biomarkers for nitrogen and potassium excretion which are used to 
estimate dietary protein and potassium intake, respectively.46, 51 Participants were 
classed into quintiles of dietary intake to allow comparisons with the urinary 
measurements. 7-day food diaries achieved a correlation for protein intake of 
r=0.65, compared to FFQs r=0.24, and 24-hour recall r=0.10. Similar findings were 
reported for potassium consumption. The results from validation studies using 
external measures of 16-day weighed records and 24-hour urine excretion studies, 
highlight that 7-DFD give the most accurate measure of dietary intake when 
compared to FFQs and 24-hour recall. Nutritional epidemiological studies will only 
detect diet-disease relationships, particularly small effects, if the DAMs are 
sufficiently accurate. Inaccuracies in DAMs may explain the difficulties in defining 
associations when using FFQ and 24-hour recall data which has been used in all 
previous epidemiological studies. Aetiological studies of diet and disease risk are 
therefore need using data from food diaries. 
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Table 2. Means, standard deviations and Spearman correlation coefficients for 
daily intakes of nutrients compared between 16-day weighed record and three 
different dietary methods (source; Bingham SA et al Int J Epidemiol 200151).  
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Reproducibility of dietary assessments 
 Reproducibility is a measure of the ability of the dietary assessment 
method to obtain the same result at repeated testing. The terms reproducibility, 
reliability and repeatability have been used synonymously, although they define 
subtly different aspects. Repeatability is the ability to repeat the method in the 
same manner and reliability is the accuracy of a measure. Reproducibility is the 
ability of a dietary assessment method to obtain the same result again.153 Potential 
variations in dietary observations in individuals may be due to the normal variation 
in diet or due error in the DAM used. To reduce the variability due to dietary 
variation, a study can be undertaken over a longer period of time, with repeated 
measures and in large populations to balance out normal or seasonal variations. 
Inaccuracy can also be incurred by the assessment tool used (measurement error), 
which can be reduced by using robust and simple assessment tools, which are not 
dependent upon observer reporting. 
To investigate whether dietary intake from a single measurement was 
representative of longer term dietary habits, a Dutch study used food frequency 
questionnaires in a cohort of 400 participants to record dietary intake at baseline 
with repeat assessment each year for five years. The single baseline FFQ ranked 
subjects according to into quintiles of nutrient intake, and there was little variation 
over 5 years, with an average decline in the correlation coefficient for a nutrient 
over this time of r=0.07.154 These results indicate that a single baseline measure of 
dietary intake places most participants in the appropriate quintile for at least 5 
years, although there is a lack of data to clarify how long a single baseline measure 
remains reliable. 
 
Overview of nutritional assessment methods 
Nutritional epidemiology is a complex discipline which can involve 
several different types of study design and dietary assessment methods. Although 
randomised controlled trials would be the ideal methodology they are not practical 
and therefore cohort studies are used. These are preferable to case-control work as 
there are less recall and selection biases. To measure diet, the most accurate and 
pragmatic method is required. 7-day food diaries are the most accurate pragmatic 
measure to use if there is the infrastructure and finance to support their use, 
although there are no published reports using these in the investigation of 
gallstones and pancreatic cancer. 
55 
 
8. Diet as a risk factor for gallstone disease 
 
Total energy intake 
Total energy intake may lead to gallstone disease by contributing to weight 
gain and obesity, although it is unclear if total energy intake leads to weight gain, 
with previous prospective epidemiological studies reporting no effect of total 
energy intake on the risk of weight gain of a population.155-156 157 The causes for 
obesity are complex and not yet fully understood, with excess energy intake and a 
sedentary lifestyle probably being important factors with host genetics, colonic 
flora, and environmental conditions also involved.158 Epidemiological studies 
assessing total energy intake in gallstone disease have reported mixed results. 
Prospective studies of symptomatic gallstone disease have found both a positive 159 
and inverse association with total energy intake 160 with cross-sectional and case-
control studies reporting similar results, though these studies are limited by study 
numbers and their inherent biases. Further prospective studies in different 
populations are required to clarify if total energy intake is involved in the aetiology 
of gallstone disease. 
 
Dietary fat and fatty acid groups 
Dietary fat consists of fatty acids, cholesterol or sterols. Naturally 
occurring fatty acids are by far the largest component of the dietary fat, and they 
are grouped depending on the presence of double bonds on the carbon chain, being 
either saturated (no double bonds), monounsaturated (one double bond) or 
polyunsaturated fatty acids (more than one double bond)(Figure 7).161 Another 
group of fatty acids are the trans fatty acids (or trans-fats) that are polyunsaturated 
fatty acids formed by the partial hydrogenation of unsaturated oils. During this 
process, hydrogen binds to some of the double bonded carbons, changing them into 
single bonds, which solidifies the oil which can be a useful property in the 
commercial preparation of foods. They are found in small concentrations in dairy 
products but nearly all dietary trans fatty acids produced industrially. 
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Figure 7. Diagrams and examples of the three main fatty acid classes. 
 
 
A saturated fatty acid, stearic acid (18:0); A monounsaturated fatty acid, oleic acid 
(18:1n-9 cis); The polyunsaturated fatty acids, linoleic acid (18:2n-6,9 all cis) and 
arachidonic acid (20:4n-6,9,12,15 all cis) (source; 
http://web.virginia.edu/Heidi/chapter8/Images/8883n08_01.jpg). 
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Total fat intake 
Total dietary fat could contribute to gallstone disease by promoting weight 
gain which stimulates several pathogenic mechanisms. However, prospective 
cohort studies including the Nurses' Health Study of over 90 000 women 162 and the 
Health Professionals Follow-up Study of 50 000 men 163 found no association 
between the overall percentage of calories derived from fat and weight gain. There 
were similar findings for other important health outcomes, including cancer, heart 
disease, and weight gain. Supporting these findings, a large randomised trial of 49 
000 post-menopausal women from the US found that those on a low-fat diet didn’t 
lose or gain weight any more weight than women who followed their normal diet 
164
 and there was no effect on cardiovascular outcomes.165 However, these same 
studies did report that the composition of dietary fat consumed did alter outcomes 
with a strong positive association with weight gain with the percentage of energy 
derived from animal fat, saturated fat, and trans fat.166 The manner in which 
different fatty acids are metabolised may lead to differing contributions to weight 
gain with monounsaturated, and polyunsaturated fatty acids more likely to be 
oxidised, rather than stored as is the case with saturated fatty acids.167 
Epidemiological studies have reported mixed findings for total fat intake 
and the development of gallstones. Three prospective studies of symptomatic 
gallstone disease did not find any associations with total dietary fat.159-160, 168 
Studies using ultrasonography to detect silent stones found an inverse association 
in an Italian population 169 and a positive though non-significant association with 
total fat in a Danish population.170 The mixed results for total dietary fat probably 
reflect the mixed biological effect of fatty acid groups and it is possible that total 
dietary fat is not associated with gallstone disease. Further inconsistencies in the 
data may be due to errors in the methodology for recording dietary fat intake. 
However, no previous study has used 7-day food diaries to evaluate dietary intake 
which gives a higher correlation for fat intake compared to FFQs (correlation using 
16-day weighed records of fat intake against FFQ=0.55 and 7-DFD=0.6351). 
Therefore, clarification of the role of total fat in can be achieved in the EPIC-
Norfolk cohort using 7-DFDs to estimate dietary fat intake with the prospective 
design a further methodological advantage. 
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Saturated fatty acids  
Long chain saturated fatty acids are known to contribute to raised serum 
triglycerides,171-172 and increase insulin secretion and decrease insulin sensitivity173-
176
 which are mechanisms which promote gallstone disease. Both epidemiological 
and intervention studies of fatty acid classes suggest that saturated fat worsens 
insulin sensitivity, while monounsaturated and ω-6 polyunsaturated fats improve 
it.174 Raised insulin levels cause gallbladder hypomotility and dyslipidaemia 
leading to increased biliary cholesterol saturation and mucin production, all of 
which promote stone formation. In studies on hamsters, saturated fatty acids, and 
in-particular long chain ones, have been shown to increase cholesterol gallstone 
formation.177-178 A prospective cohort study in the US Health Professionals study 
found that short and medium chain saturated fatty acids were not associated with 
gallstone risk although long-chain saturated fatty acids did increase the risk of 
disease (highest quinitle vs lowest relative risk=1.24, 95% CI=1.02-1.50).179 
Further confirmatory prospective cohort studies are required to clarify if total 
saturated fatty acid intake or individual fatty acids increase the risk of gallstone 
disease. 
 
Monounsaturated and Polyunsaturated fatty acids 
 Monounsaturated and polyunsaturated fatty acids could reduce the 
formation of gallstones via their effects on insulin sensitivity.174 In hamster models 
of gallstone disease, diets rich in mono and polyunsaturated fatty acids prevented 
the formation of gallstones.180-181 There is limited epidemiological data in this area. 
A study using US Health Professionals cohort reported the highest intake of 
monounsaturated fatty acids had a relative risk of disease of 0.83 (95% CI=0.70-
1.00, p for trend=0.01) whilst for polyunsaturated fatty acids RR=0.84 (95% CI 
0.73-0.96, p for trend=0.01).182 Further aetiological studies in this area are required 
to clarify if there is an association with mono and poly-unsaturated fatty acid intake 
and the use of 7-day food diaries will provide a more accurate assessment of the 
dietary intake. 
 
Trans fatty acids 
Trans fatty acids (TFAs) are formed during the process of partial 
hydrogenation of mono- or polyunsaturated fatty acids. They occur naturally in the 
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milk and the animal fat of ruminants such as sheep and cows in the form of 
conjugated linoleic acid and vaccenic acid, although they only contribute to around 
0.5% of total energy intake.183 However, after the industrial hydrogenation of oils 
was developed to produce trans fatty acids in the early 20th century, industrially 
produced TFAs became the largest contributor to dietary trans fatty acids and a 
significant part of the Western diet providing 2 to 5% of total energy intake and 
approximately 5% of total fat in the United States.184 Trans-fatty acids solidify and 
preserve foods and are mostly consumed in fast food, snack food and baked 
foods.185 During the 1990’s studies began to report the potential negative health 
outcomes associated with trans-fatty acids consumption. In randomised trials, TFA 
consumption lowered HDL-cholesterol and raised LDL-cholesterol, triglycerides 
and total cholesterol,186 with these lipid changes known to be associated with 
gallstone disease.88, 187 TFAs act via several biological mechanisms to cause 
cardiovascular disease and potentially gallstones, namely by promoting systemic 
inflammation, insulin resistance and visceral adiposity.185, 188 Trans fatty acid 
consumption is associated with a greater risk of cardiovascular disease than any 
other nutrient per calorie consumed.189 Due to these negative cardiovascular 
outcomes associated with TFAs, measures were taken to reduce industrially made 
TFAs in the diet. In the UK, major advances have been made with all major 
supermarkets ceasing the use of TFAs in their own branded food in 2007. In 2010, 
an editorial in the British Medical Jounal183 and a statement from the National 
Institute for Health and Clinical Excellence (NICE)190 called for the complete 
removal of industrial trans-fatty acids from the diet. 
There is currently limited experimental and epidemiological work 
evaluating TFAs and gallstone disease. The main mechanism by which TFAs may 
cause gallstone disease is via serum lipid changes. A dietary intervention study in 
healthy subjects demonstrated that a diet with 10% of energy derived from TFAs 
lead to raised LDL-cholesterol and decreased HDL-chloesterol 191. TFAs increase 
in plasma trigylcerides.186, 192 These lipid changes are known to be associated with 
increased biliary cholesterol saturation and an increased gallstone disease 
incidence.88, 187 Only one epidemiological study has evaluated trans fatty acids and 
symptomatic gallstone disease namely the Health Professionals Follow-up Study in 
men which found a small increased risk with increased TFA intake (higest vs 
lowest quintile HR=1.23, 95% CI=1.04-1.44).193 These results need to be 
confirmed in further epidemiological studies, particularly in women and in a 
European population.  
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Dietary cholesterol 
 Since the majority of gallstones are mostly composed of cholesterol, it has 
been hypothesized that dietary cholesterol predisposes to gallstone formation, with 
many reviews on aetiology listing increased dietary cholesterol as a risk factor.8, 19, 
194
 This has been supported by studies in some, but not all animal models. 
Increased dietary cholesterol lead to gallstones in the prairie dog, 195 squirrel 
monkey196 and hamster197 although, in chickens, rabbits and rats, a month of a high 
cholesterol diet had no effect on the biliary composition.198  
Human intervention studies evaluating the effects of dietary cholesterol 
have given mixed results. A study of 10 men fed a high cholesterol diet 
(750mg/day) for 3 weeks reported the mean biliary cholesterol saturation 
increased.199 Another study fed 12 patients with asymptomatic gallstones and 7 
healthy women, 500mg, 750mg and 1000mg of dietary cholesterol for 3 weeks. In 
both groups the cholesterol saturation increased with increased dietary cholesterol 
intake, with those with prevalent gallstones having increased biliary cholesterol 
secretion compared to the healthy controls.200 A Danish study of nine healthy 
female students assessed their biliary compostion before and after the addition egg 
yolk to the diet (1-2g cholesterol daily) while keeping macronutrients unchanged. 
They found no increase in biliary cholesterol concentration, with some individuals 
actually decreasing their levels.201 These findings were replicated in another study 
of six normolipidemic and six hypertriglyceridaemic subjects, where high dietary 
cholesterol feeding had no consistent effects on the molar cholesterol concentration 
in duodenal bile.202 However, they did find that in normolipidemic subjects, a high 
dietary intake of cholesterol lead to changes in bile acid composition with an 
increased production of chenodeoxycholic acid. This caused a reduced cholic acid 
to chenodeoxycholic acid ratio which reduces cholesterol saturation of the bile. 
Chenodeoxycholic acid can be used to treat gallstones as it solubilises the bile. 
However, cholic acid increases cholesterol super-saturation by down-regulating 
cholesterol-7-α-hydroxylase (the rate-limiting step in bile acid synthesis).202 Hence, 
it appears in experimental human studies that dietary cholesterol may alter the 
biliary composition, although clarification is needed. The inconsistencies may be 
due to cholesterol metabolism varying between different populations, with short-
term dietary cholesterol supplementation leading to increased cholesterol saturation 
of the bile in some groups. In others there may be an increase of chenodeoxycholic 
acid secretion which could prevent gallstones. However, long-term increased 
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dietary cholesterol may lead to further adaptive responses not evaluated in these 
interventional studies. 
The epidemiological evidence for the role of dietary cholesterol has largely 
taken place in case-control and cross-sectional studies which are vulnerable to bias 
and in particular protopathic bias. The results varied between an increased risk of 
gallstones with increased dietary cholesterol203-204 to a decreased risk127, 205 with the 
only large prospective cohort study, which used food frequency questionnaires to 
assess dietary cholesterol, not finding any association (highest vs lowest quintile 
RR=1.0 95% CI=0.8-1.3).206 Hence, to clarify the role of long term dietary 
cholesterol in the risk of gallstone disease prospective studies are required using an 
accurate measure of dietary intake which can be achieved with 7-day food diaries. 
 
Protein 
 A high protein diet affects the lipid profile with an increased HDL and 
decreased triglycerides as well as improved insulin sensitivity,207-208 which decrease 
the risk of gallstone diease.88 Hamster models have supported the role of a high 
protein diet in protecting against gallstone disease.209-210 In epidemiological work, 
the US Nurses’ Health study examined the effect of protein in 121 700 women with 
7 831 cases of cholecystectomy over a 20 year follow-up period. Total dietary 
protein was not associated with cholecystectomy (highest quintile of intake vs the 
lowest RR=1.00, 95%=0.93-1.08), although vegetable protein was associated with 
a decreased risk with a RR= 0.79 (95% CI=0.71-0.88). These results suggest that 
vegetable based proteins may reduce the risk of gallstones although there could be 
a residual confounding effect from other dietary components of a high vegetable 
diet. However, overall there is no compelling evidence of a direct effect of protein 
intake on gallstone risk, and hence it is not included as a covariant in the analysis. 
 
Carbohydrates 
 Carbohydrates have varying physical forms, chemical structures and 
particle sizes that produce different physiological responses, including on glucose 
homeostasis and insulin action. A simple classification separates the smallest 
carbohydrates into monosaccharides and disaccharides, which are commonly 
referred to as sugars, with the larger polysaccharides and oligosaccharides referred 
to as complex carbohydrates. The glycaemic index is used as a measure of how 
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quickly food glucose is absorbed, while glycaemic load is a measure of the total 
absorbable glucose in foods. High measures of each, correspond with increased 
insulin demands and insulin resistance.211 A high intake of carbohydrates has been 
associated with the dyslipidaemia found in gallstone disease,212 and the substitution 
of unsaturated fatty acids for carbohydrates can improve the lipid profile 213 The 
effects of carbohydrates on insulin and lipids may be a mechanism though which 
they could cause gallstone. 
 Epidemiological studies have found that dietary sugars are associated with 
an increased risk of gallstone disease in both case-control 204 and prospective 
studies.168 Dietary carbohydrates and gallstone disease have been assessed 
prospectively in both the US Health Professionals Study (men) and the Nurses’ 
Health Study (women). In men, after adjusting for known risk factors, the highest 
vs the lowest quintile of total carbohydrate had relative risk of 1.59 (95% CI 1.25-
2.02; p for trend=0.002) with positive associations for glycaemic load and 
glycaemic index.214 Similar results were reported in women, with total 
carbohydrate intake showing a positive association (highest vs lowest quintile, 
RR=1.35, 95% CI=1.17-1.55; p for trend<0.0001) as did glycaemic load and 
glycaemic index.215 These finding suggest that carbohydrates are associated with 
gallstone disease although they need to be investigated prospectively in a European 
population using an accurate measure of diet and do not yet justify the inclusion of 
carbohydrates as a covariant of gallstone disease. 
 
Iron 
The availability of iron affects the function of several enzyme systems 
which could alter the risk of developing gallstones via several different 
mechanisms. Perhaps the most important in gallstone formation is cholesterol-7α-
hydroxylase (CYP7A1) which regulates bile salt excretion and maintains 
cholesterol in solution. CYP7A1 requires a reducing agent (electron donor) for 
effective functioning, which is a role fulfilled by iron.28 Animal studies of the 
effects of iron deficiency have been carried out in 40 male prairie dogs, with no 
previous evidence of anaemia or iron deficiency, who were fed either a iron 
supplemented or iron deficient diet for 8 wks.216 The bile of dogs on an iron 
deficient diet had more cholesterol crystals (80% vs 20%, p<0.05) and a higher 
cholesterol saturation index (1.27 vs 0.91, p<0.05). The measured CYP7A1 levels 
were lower in dogs fed an iron deficient diet, suggesting that iron deficiency 
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promotes cholesterol gallstone formation due to alterations in the activity of this 
hepatic enzyme. Another mechanism involving iron deficiency inducing gallstone 
formation is through raised biliary transferrin levels, which have been found in the 
gallbladder of iron deficient prairie dogs. Transferrin acts as a powerful 
pronucleating agent promoting stone formation 216. Iron also alters gallbladder 
motility and bile flow since it is a co-factor for nitric oxide synthase (NOS) which 
plays a key role in bile flow regulation and the normal relaxation of the 
gallbladder. This was demonstrated in 24 female prairie dogs fed either a normal or 
iron deficient diet for 8 weeks 217. Fasting gallbladder volumes were measured and 
gallbladder muscle strips were harvested to measure NOS. They found that dogs 
fed an iron deficient diet had greater gallbladder volumes and diminished NOS 
levels both of which contribute to gallbladder stasis and gallstone formation. A 
similar study also evaluated sphincter of oddi function and found that after 8 weeks 
of an iron deficient diet dogs had reduced NOS concentration in the sphincter of 
oddi and increased cholesterol crystal formation.218 However, conversely iron may 
also promote the formation of gallstones via the oxidisation of proteins which then 
become less soluble and precipitate.  Pigment stones are rich in iron and excess 
iron easily forms aggregates to promote both cholesterol and pigment stones.219  
It is possible that both iron deficiency and iron excess may contribute to 
gallstone formation with men more susceptible to iron overload and women to iron 
deficiency due to menstruation and pregnancy. Epidemiological studies in humans 
evaluating the role of iron in gallstone disease are limited with the only prospective 
study conducted in male in the US Health Professionals study which found a higher 
intake of dietary iron was associated with an increased risk of disease.220 A Turkish 
case-control study of 111 cases (80% female) and 81 controls (84% female) found 
that iron deficiency was associated with a higher prevalence of gallstones disease 
and impaired gallbladder motility.221 An Indian study of male and female patients 
admitted with gallstone disease found iron deficient patients had increased biliary 
cholesterol compared to those with normal serum iron levels222 with a similar study 
in both men and women finding gallbladder cholesterol concentrations were higher 
in patients with a low serum iron.223 Therefore the available evidence suggests that 
excess dietary iron is a risk factor for men although in men and women iron 
deficiency is a risk factor for gallstones. Despite the potential biological effects of 
iron in the formation of gallstones there is a lack of studies investigating the role of 
dietary iron intake in gallstone disease. No previous cohort studies have 
investigated the effect of dietary intake in women and only one in males. For these 
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reasons, this study in the EPIC-Norfolk cohort will evaluate whether dietary iron 
alters the risk of gallstone disease. 
 
Niacin 
Niacin is a B vitamin found in a large variety of foods though particularly 
in cereals, meat, vegetables and mushrooms. Niacin could reduce gallstone disease 
by altering cholesterol metabolism. Niacin was originally shown to alter the serum 
lipid profile in 1955,224  firstly lowering total cholesterol, serum triglycerides, very-
low-density lipoprotein (VLDL) and low density lipoprotein (LDL) and secondly, 
increasing high-density lipoprotein (HDL) levels.225-226 Niacin exerts these effects 
by inhibiting the enzyme hepatocyte diacylglycerol acyltransferase-2 which is 
important in triglyceride synthesis. The inhibition of triglyceride synthesis results 
in accelerated degradation of apolipoprotein B (a protein that forms, and binds to 
LDL) decreased VLDL, LDL secretion.227 Niacin is the most potent agent at 
increasing HDL levels, which it achieves by increasing the half-life of HDL via 
inhibition of the expression of a surface protein on the hepatocyte, thus preventing 
hepatic uptake of HDL.227 
 The serum lipid changes that niacin achieves at pharmacological doses are 
associated with a decreased risk of gallstone disease, particularly raised HDL and 
lowered triglycerides 88 Few studies have evaluated the effects of niacin on 
gallstone disease. Experimental models in animals showed that rabbits and quails 
fed a diet rich in niacin had reduced plasma and biliary cholesterol levels.228-229 
However, niacin supplementation in rats lead to an increased biliary cholesterol 
saturation though this did not lead to an aggregation of cholesterol crystals, 
increased bile acid secretion protected against gallstone formation.230 No 
epidemiological studies have assessed the impact of dietary niacin on the risk of 
developing gallstones in humans, which is merited in view of the biological actions 
of this nutrient. 
 
Fibre 
A high fibre diet may prevent gallstone disease by shortening intestinal 
transit times which reduces the formation of secondary bile salts. Secondary bile 
salts are hydrophobic and promote cholesterol precipitation and gallstone 
formation231-232. Fibre may also have an effect on serum lipids, by reducing serum 
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cholesterol, although it may not alter serum HDL and triglyceride levels.233-234 
Studies in the prairie dog, found that fibre supplementation of a lithogenic diet 
reduced biliary cholesterol concentration.235 Two prospective cohort studies have 
evaluated the association between dietary fibre and gallstone disease in women 
with both reporting an inverse association.160, 236 Further case-control and cross-
sectional studies have also found an inverse association of dietary fibre intake.169-
170, 203-204
 However, of the current work only one study was a large cohort,236 and 
the effect of fibre in men is unknown. The Italian MICOL study used 
ultrasonography to detect silent gallstones reported no association of fibre to 
gallstone disease in 14 272 men with 787 cases of disease 169. To clarify if there is 
an association between fibre and gallstone disease we have reported a prospective 
cohort study for the first time using 7-day food diaries to assess dietary intake 
which has better correlations for dietary fibre intake than FFQs which were used in 
previous studies (correlation using 16-day weighed records of fat intake against 
FFQ=0.55 vs 7-DFD=0.74 51). 
 
Calcium 
Calcium is the major chemical constituent of gallstones and is found in 
both “pure” cholesterol gallstones at low concentrations and in brown and black 
pigment stones at high concentrations.33 Calcium salts (either bilirubinates, 
carbonates, fatty acylates and bile salts) play a fundamental role in the formation of 
gallstones and it has been proposed that gallstone formation requires both 
cholesterol and calcium salt precipitation.237 Microscopic examination of gallstones 
reveal that cholesterol crystal and calcium salt precipitates are organised in a 
structured manor, often with alternating rings of cholesterol and pigment 
deposits,238. This is similar to the biomineralization process of structures including 
bone and teeth.33 Patients with gallstones of any type tend to have gallbladder bile 
containing a higher calcium concentration than those without gallstones.239-240 
Patients with a history of primary hyperparathyroidism which causes 
hypercalcaemia, have increased prevalence rates of cholelithiasis in some 241-242 but 
not all surveys.243 
The effect of dietary calcium on gallstone disease has not been extensively 
investigated in epidemiological or human intervention studies. Biliary calcium has 
also been recognized to play a central role in the formation of pigment gallstones. 
Calcium supplementation in the prairie dog has been shown to increase biliary 
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calcium and long term supplementation promotes gallbladder sludge and pigment 
gallstone formation in the prairie dog.244 Epidemiological studies in a small 
prospective study in men 168 and a case-control study reported calcium was 
associated with a reduced risk of gallstone disease.203 However, large prospective 
trial data is lacking to clearly define the relationship between calcium and gallstone 
disease. 
 
Coffee 
Both caffeinated coffee and decaffeinated coffee have biological affects 
which alter hepatobiliary processes involved in cholesterol lithogenesis. 
Gallbladder function was assessed in a study of six healthy volunteers after the 
consumption of either caffeinated, decaffeinated coffee or sodium chloride. 
Caffeinated coffee lead to increased cholecystokinin (CCK) release and gallbladder 
contraction in a dose dependent fashion.245  Decaffeinated coffee compared to 
isosmotic and isothermic sodium chloride solution also increased CCK release and 
gallbladder contraction. These results suggest caffeinated coffee, and to a lesser 
degree, decaffeinated coffee, stimulate gallbladder function which could prevent 
gallstones. These findings were supported by a RCT of caffeine added to the diet of 
sixteen prairie dogs. None of those fed caffeine developed gallstones whilst all 
dogs not given caffeine did form stones, with gallbladder function tests reporting 
increased bile flow, improved GB motility and reduced gallbladder bile protein 
levels.246 Caffeine may also have effects on inhibiting gallbladder fluid 
absorption.247 Apart from caffeine, coffee also contains cafestol and kahweol which 
are derived from the lipid fraction and are members of the diterpene family. These 
two compounds can alter lipid metabolism down regulate 3-HMG-CoA reductase 
activity which diminishes cholesterol synthesis in the liver,248 with these action 
leading to reduced biliary cholesterol saturation in humans.128 
Epidemiological studies investigating the effects of coffee intake and 
gallstone disease have been undertaken in the US Nurses’ Health Study and the US 
Health Professionals’ Study which both reported inverse associations for increased 
caffeinated coffee intake, although no effects were found for either tea or 
decaffeinated coffee intake. Not all studies have reported a negative association of 
coffee with gallstone. A US cross-sectional survey used ultrasonography to screen 
13 938 US citizens for prevalent gallstones, with dietary information collected in 
the Third National Health and Nutrition Survey, and did not report an association 
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with either men and women with coffee consumption.249 A Danish and German 
cross-sectional survey,250-251 also reported no effect of coffee intake. However, 
neither of these European studies was prospective and coffee avoidance may occur 
in patients with symptomatic upper gastrointestinal disease. Therefore, further 
studies, particularly in European populations, are required to confirm that coffee 
and caffeine intake is inversely associated with gallstone disease. 
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9. Summary of introduction 
 
Gallstones are a common clinical problem and their formation is complex 
involving many pathophysiological and biochemical mechanisms. These include 
cholesterol saturation, aggregation of crystals and stasis of the gallbladder. Many 
factors can affect these processes including the well established risk factors of 
gender, obesity, physical activity, parity and hormone replacement therapy. The 
epidemiological data is consistent for obesity but there is little information from 
European populations and the precise biological mechanisms are unknown. The 
effect of exercise also needs to be investigated in a European population using 
validated instruments for recording physical activity. Many nutrients including 
food groups, vitamins and minerals may impact upon stone formation, although the 
current epidemiological literature is either limited prospective cohort work or uses 
less accurate measures of dietary intake. This is the first cohort study to use 7-day 
food diaries to evaluate dietary exposures, which are the most accurate pragmatic 
dietary assessment method in large scale epidemiological work. The aim of this 
study was to assess in a large European prospective study the effects of lifestyle 
factors including obesity, physical activity, diet and alcohol on the risk of 
developing symptomatic gallstone disease in both genders. Data from serum lipids 
was also analysed to clarify the potential biological mechanisms for how lifestyle 
factors may affect gallstone formation. The prospective design of the study is 
essential to reduce the selection and measurement biases associated with previous 
case-control studies. Confirmation and quantification of potential risk factors 
associated with symptomatic gallstones will further our understanding of gallstone 
aetiology and could influence public health policy to help prevent biliary stone 
disease. 
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Methods 
1. Selection of epidemiological study evidence 
 
To investigate potential risk factors of disease, there are several clinical 
and epidemiological study designs available, each with inherent advantages and 
disadvantages. Studies are either observational, where the investigator does not 
assign the subjects their exposure, or interventional (experimental), where the 
exposure is assigned. Observational studies are sub-divided again into either 
descriptive investigations, including ecological, cross-sectional and case series, or 
to analytical studies, namely case-control or cohort studies (Figure 8). Each of 
these methodological designs is relevant to investigating the aetiology of a disease. 
The selection of the study design is dependent on the stage of development 
of the hypothesis, logistics and the exposure being studied. Descriptive studies are 
often the initial investigations used to develop hypotheses, as they are relatively 
quick and inexpensive to conduct. The findings can then be developed in more 
complex study designs comparing different levels of exposures or interventions. 
Since the allocation of a nutritional intervention to an individual can be both 
pragmatically and ethically difficult, cohort studies are often employed to provide 
robust information. Prospective cohort investigations remove both recall and 
selection biases associated with case-control studies. The degree of recall bias for 
an exposure varies according to the one being studied. Recalling past diet is 
difficult, whereas exposures such as smoking and parity are readily recalled with 
accuracy. The following section describes study design in greater detail. 
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Figure 8. Overview of study designs. 
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Ecological and cross-sectional studies 
Both ecological and cross-sectional studies are descriptive studies which 
generate hypotheses and benefit from being less expensive and time-consuming to 
perform and can utilise routinely collected data. However, they cannot assess a 
temporal relationship and may not be generalisable to other populations and hence 
other study designs are required to more accurately assess the aetiology of disease. 
Ecological studies are conducted at a population level, rather than in individuals, 
and allow comparison between populations or changes in their characteristics over 
time. An example would be the decline in smoking prevalence and the decreased 
rates of lung cancer in a given population over a period of time. Ecological 
investigations identify potential risk factors for further investigation in other types 
of study, although they are unable to explore causality. Cross-sectional 
(prevalence) studies measure the frequency of an exposure and outcome, at a given 
point in time. This measures the number of individuals with a disease in that 
population and the proportion who are exposed to that risk factor. Cross-sectional 
studies identify prevalent rather than incident disease which can lead to 
associations being made with factors that prolong survival or occur as a result of 
the disease rather than associations with aetiology.  
 
Case-control studies 
Ecological and cross-sectional investigations generate hypotheses which 
can be investigated in analytical work, which includes case-control studies. Case-
control studies identify people with a disease (cases) who are then compared with 
those who do not have the disease (controls). They are used to study a wide variety 
of diseases and exposures and benefit from being able to use accurate measurement 
tools as the numbers studied are often relatively small. Case-control studies have 
advantages when studying rare diseases and exposures as they can recruit from 
many sites and require relatively small sample sizes compared to cohort studies. 
However, a major problem they have is recall bias where it is difficult to ensure the 
information collected truly represents that before the onset of symptoms i.e. that 
involved in aetiology of the disease. If patients have had symptoms for long 
periods recalling the pre-symptomatic exposure is difficult. Consequently cases 
tend to report their current exposure in the symptomatic period which is not 
reflective of that involved in the aetiology. This recall bias is of particular 
relevance when recording dietary intake. Another limitation of case-control studies 
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is that there can be substantial selection biases, particularly if control groups are 
selected which are unrepresentative of the general population. Ideally both cases 
and controls should be drawn from the same population and are therefore 
comparable. However, the relative simplicity of case-control studies means that 
they are often the first study design used to compare differences in risk factors 
between groups, although more complex study designs may be utilised to advance 
the hypothesis. 
 
Prospective cohort studies 
The second method of analytical study design is the prospective cohort 
study which recruits a defined group of well people who are subsequently 
followed-up, of whom a small number are diagnosed with the disease under 
investigation. Cohort studies allow a comparison of baseline risk factors between 
people who subsequently develop disease, with those who do not. Their strength is 
that the exposure data is collected before the onset of symptoms and disease and 
hence truly representative of that which may be involved in aetiology. Recall bias 
is eliminated with this study design which can be high in case-control work, 
particularly for exposures such as diet. Also there is less selection bias as both 
those who develop the disease and those who remain well are drawn from the same 
base-line population. Furthermore, advantages of cohort studies are that they both 
allow study of many diseases developing in the baseline population and the 
calculation of incidence. However, due to their large size which is required to 
acquire sufficient cases for analysis, they are expensive to set up and manage, 
requiring a large amount of logistical support. There is also a time lag between 
creating a cohort for study and having the data available for analysis. Finally, the 
representativeness of the cohort compared to the general population needs to be 
considered in terms of the population demographics, level of exposure and nature 
of the disease.  
 
Randomised control trials 
A limitation of all observation work is that there may be unknown factors 
associated with aetiology which exist in different proportions between case and 
controls. This methodological problem can be overcome in randomised controlled 
trial (RCTs). In RCTs, the study subjects are allocated by random to receive the 
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treatments under study or no treatment, which should ideally be a placebo or sham 
treatment. Following randomisation, the two or more groups of subjects are 
followed up in exactly the same way, and therefore the only differences between 
them are the intervention being assessed. Randomisation minimises selection 
biases which should ensure that the characteristics between the study groups are 
very similar. Also it allows an equal distribution of confounders in that both known 
and unknown prognostic factors should occur at the same rate in both groups. 
RCTs are usually performed to assess clinical treatments, such as new drugs, 
although they can also provide evidence on aetiology. For example, studies 
initiated in the 1980s to investigate aspirin in the prevention of cardiovascular 
disease are now providing additional data regarding aspirin lowering the risk of 
developing cancer.40-41 However, not all exposures can be assessed in RCTs; for 
example it is not possible or ethical to randomise participants to an intervention 
which may be harmful i.e. smoking or high trans-fatty acid diet. Furthermore, it is 
also difficult and unethical to assess factors which cannot be excluded from the 
control group i.e. an intervention trial of vitamin C supplementation as both 
controls and cases will consume vitamin C in their diet. 
 
Hierarchy of study design 
In evaluating the evidence for risk factors in the review of pancreatic 
cancer, priority has been given to interventional work, namely randomised 
controlled studies which minimises both bias and confounding. However, 
interventional trials of diets do not exist for many nutrients as they are both 
impractical to conduct and unethical. Information from observational 
epidemiological studies is therefore required. Although both case-control and 
cohort studies can be used to investigate aetiology, cohort studies provide stronger 
evidence of associations than case-control studies, as the former have decreased 
recall and selection biases. For diet, recalling past diet prior to the onset of disease 
can be difficult, hence cohort studies are preferred for nutritional studies and have 
been utilised within this study. However, for variables such as smoking, parity and 
medication use, recall bias is lower and case-control work is valid and 
pragmatically easier to conduct. The order of hierarchy used when reviewing study 
evidence is RCTs, cohort studies which provider stronger evidence of associations 
than case-control studies and finally descriptive investigations (Figure 9). 
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However, all study types are important in the process of developing and 
investigating hypotheses. 
 
Choice of study design 
This study has used the cohort design to investigate the aetiology of both 
gallstone disease and pancreatic cancer to minimise recall and selection bias. This 
is particularly important in dietary enquiries as diet is liable to change over time 
and it is unrealistic to expect people to remember their dietary pattern several years 
previously. Both gallstone disease and pancreatic cancer may affect the subject’s 
diet and hence introduce protopathic bias if the dietary history is measured after the 
onset of symptoms. A cohort design allows the detection of unexpected effects 
factors in the aetiology of disease rather than restriction to selected factors defined 
when designing a case-control study or RCT. Difficulties undertaking a cohort 
study are the inherent time-lag between initiation of the study and derivation of 
study findings and the expense of conducting a cohort study. However, with EPIC-
Norfolk the study has already been ongoing for over 17 years and the considerable 
expense in designing, coordinating and managing the cohort has also already been 
borne by funders, the Medical Research Council, UK, and Cancer Research, UK. 
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Figure 9. The hierarchy of study design in determining causality. 
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2. Case ascertainment 
 
After recruitment and completion of questionnaires, the cohort was 
monitored to identify those participants who developed new incident gallstone 
disease up to June 2007, i.e. a maximum follow-up time of 14 years after 
recruitment. The definition of incident symptomatic gallstones was made if the 
participant developed clinical evidence of new symptoms suggesting gallstone 
disease at least 18 months after recruitment, along with either radiological and/or 
surgical evidence of gallstones. Participants with symptomatic gallstone disease 
were identified by matching the EPIC database with the Norfolk Health Authority 
computer records of hospital admissions and procedures. The International 
Classification of Diseases-10 (ICD-10) codes used were K80.0 (biliary colic, 
cholecystitis, cholangitis and pancreatitis secondary to gallstones)(table 2).252 The 
notes of all potential cases were retrieved by requesting them from Norfolk and 
Norwich University Hospital records. The clinical notes were reviewed by a 
medical gastroenterologist to ensure that the symptoms recorded were suggestive 
of gallstone disease and reports were sought confirming the presence of gallstones 
on ultrasonography, CT scan, surgical and pathological specimens. Cases were 
excluded if participants recorded a history of gallstone disease or cholecystectomy 
at recruitment in the health and lifestyle questionnaire (figure 8). Cases were also 
excluded if they developed symptoms within 18 months of recruitment into EPIC-
Norfolk to ensure the baseline data were truly representative of that prior to 
symptoms. The presence of “silent” (asymptomatic) gallstones at recruitment was 
not assessed as to do this, abdominal ultrasonography of the whole cohort would be 
required which was unfeasible. Therefore all confirmed cases of new gallstone 
disease, diagnosed after at least 18 months after entry into EPIC-Norfolk were 
identified with their case notes reviewed before being determined suitable for 
inclusion in the study. 
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Table 3. The ICD-10 codes of used to identify clinical cases which could be 
attributable to gallstone disease. 
ICD-10 code  
K80   
K80.0   
K80.1   
K80.2   
 
K80.3   
K80.4   
K80.5   
K80.8   
K85  
K86.1 
Clinical diagnosis 
Cholelithiasis 
Calculus of gall bladder with acute cholecystitis 
Calculus of gallbladder with other cholecystitis 
Calculus of gall bladder without cholecystitis 
(e.g. biliary colic, gallstone (impacted) of cystic duct) 
Calculus of bile duct with cholangitis 
Calculus of bile duct with cholecystitis 
Calculus of bile duct without cholangitis of cholecystitis 
Other cholelithiasis 
Acute pancreatitis 
Chronic pancreatitis 
 
 
 
 
 
Figure 10. Recruitment questions to define gallstone and gallbladder status 
 
 
 
Gallstones     Yes  ____ 
 
Age first diagnosed?     ____ 
 
Have you had your gallbladder removed? Yes  ____ 
 
If yes, please state at what age   Age  ____ 
 
78 
 
3. Statistical analyses 
 
The statistical analysis was performed using the computer program 
STATA Version 10 (Stata, College Station, Texas, USA). The data for men and 
women were analysed separately, as the current known covariates differ between 
the genders. Baseline characteristics and risk factors were compared between those 
with and without incident gallstone disease using a t-test for normally distributed 
continuous variables, a Mann-Whitney U test for non-parametric continuous 
variables, and a chi-squared test for categorical variables. Known risk factors for 
gallstone disease and study exposures were defined and divided into categories 
(table 3). Cox proportional hazards regression models estimated the hazard ratios 
(with 95% confidence intervals) of developing incident gallstone disease according 
to each category of exposure, using the lowest level of exposure as the baseline 
value, with further analyses of the trends across categories.  
Hazard ratios are used to allow hypothesis testing and reflect the analysis 
of time survived to an event such as development of a disease, death or cure. A 
hazard is the rate at which an event happens, so that the probability of an event 
happening in a short time interval is the length of time multiplied by the hazard. 
Although the hazard may vary with time, the assumption in proportional hazard 
models for survival analysis is that the hazard in one group is a constant proportion 
of the hazard in the other group with this proportion the hazard ratio. Hazard ratios 
differ from relative risk ratios in that the latter are cumulative over an entire study, 
using a defined endpoint, while the former represent instantaneous risk over the 
study time period. Hazard ratios are less prone to selection bias with respect to the 
endpoints chosen, and can indicate risks that happen before the endpoint. 
A cohort analysis was made for variables available in the whole cohort, 
namely BMI, waist circumference, serum lipids, physical activity and alcohol 
intake derived from the FFQ. For alcohol, the FFQ was used rather than the 7-DFD 
as it is one of very nutrients that the FFQ can measure with equal accuracy to the 7-
DFD51 and also the data was complete for the whole cohort. The cohort analyses 
were made after 14 years follow-up, except physical activity where the primary 
analysis was made after 5 years to minimise the effects of regression dilution bias. 
For dietary variables a case-cohort analysis was performed (see dietary analysis 
section below), as all food diaries are yet to be coded, with a follow-up period of 
10 years to minimise regression dilution bias. 
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Table 4. Characteristics and exposures used in analysis, with units and cut-points. 
Characteristic Units Cut-points 
    Men Women 
Age at recruitment Years continuous Continuous 
  
  
  
Parity number of children -- 0 
  
 
-- 1-2 
  
 
-- ≥3 
  
  
  
Hormone 
 
-- never used 
replacement 
 
-- previous use 
therapy 
 
-- current use 
  
  
  
Body mass index kilograms/metre
2
 <25 (normal) <25 
  
 
25-<30 (overweight) 25-<30 
  
 
30-<35 (obese class I) 30-<35 
  
 
≥35 (obese class II & III) ≥35 
  
  
  
Waist  inches <34 <28 
 circumference 
 
34-<36 28-<30 
  
 
36-<38 30-<32 
  
 
38-<40 32-<34 
  
 
40-<42 34-<36 
  
 
≥42 ≥36 
  
  
  
Serum lipids Mmol/litre Quartiles Quartiles 
  
  
  
Alcohol intake units per week 0 0 
  (1 UK unit = >0-<7 >0-<7 
  7.9 grams or 7-<14 7-<14 
  10 mls) 14-<21 14-<21 
  
 
≥21 ≥21 
  
  
  
 Physical activity Derived from  Inactive Inactive 
  physical Moderately inactive Moderately inactive 
  activity index  Moderately active Moderately active 
  (table 2) Active Active 
  
  
  
Dietary nutrients Variable Quintiles Quintiles 
        
Coffee and Tea Cups per day 0, 1, 2, ≥3 0, 1, 2, ≥3 
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Obesity analysis 
 Two different measures of obesity were analysed; body mass index and 
waist circumference with the categories for each shown in table 3. In the 
multivariate analysis, each was corrected for known risk factors for gallstone 
disease which in men were age at recruitment253, alcohol124 and physical activity254 
with the addition of parity and HRT use in women.52 A further analysis assessed 
the effect of each additional unit of BMI and inch of waist circumference on the 
risk of disease. 
 
Serum lipid analysis 
Serum lipids were analysed in sex-specific quartiles of triglycerides, total 
cholesterol, HDL and LDL and adjusted only for age at recruitment. These HRs 
were not adjusted for other factors such as obesity and alcohol, as previous studies 
suggest that obesity69-72 and alcohol118-120 modify the lipid profile and hence could 
be on the same causal pathway as lipids and are therefore not true confounders. 
However, where significant associations with gallstone disease have been found, a 
further analysis has been performed with stratification of body mass index and 
alcohol intake categories. 
 
Alcohol analysis 
Alcohol was analysed both as a categorical variable (table 3) as well as a 
continuous variable to estimate its unit effect. These analyses were adjusted for age 
at recruitment, BMI and physical activity, with the addition of parity and HRT use 
in women. 
 
Physical activity analysis 
Physical activity was analysed using the four levels of physical activity 
(table 2). The hazard ratios were adjusted for age at recruitment, BMI and alcohol 
in men with the addition of parity and HRT use in women. An analysis was 
performed of a binary variable comparing the highest level of physical activity 
against a combination of the lowest three. The primary outcome was the risk of 
developing symptomatic gallstones after 5 years of follow-up. Five years was 
considered the time over which a single measure of baseline physical activity 
would be representative of that in the future, therefore minimising regression 
dilution bias. The secondary outcome was the risk of gallstones at the full follow 
up time of up to 14 years after recruitment. The combined population attributable 
risk (PAR) of increasing physical activity by one level was calculated using the 
formula; Combined PAR = 1 – (1–PAR1)x(1–PAR2)x(1–PAR3), where PAR1 = 
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the reduction in incidence that would be observed (after five years) if “inactive” 
participants increased their activity by one level. PAR2 and PAR3 are similar 
calculations for the “moderately inactive” and “moderately active” groups, if the 
activity level is increased by one category. 
 
Dietary analysis 
For dietary variables, a case-cohort analysis was performed using a 
representative subset of 3 970 randomly selected participants from the cohort who 
did not develop gallstones. This approach was required as not all of the completed 
diaries had been coded. Each nutrient was divided into gender specific fifths of 
intake across the distribution of the whole cohort. Multi-variate analyses adjusted 
for age at recruitment, physical activity, total energy intake, alcohol intake and 
BMI, as well as parity and HRT in women. The primary analysis was performed 
after 10 years of follow-up. Ten years was considered the time during which a 
single measure of dietary intake at recruitment from the 7-DFD would be 
representative of long-term nutritional intake. This approach would reduce 
regression dilution bias potentially caused by a proportion of the cohort altering 
their diet during follow up. 
Energy adjustment of intakes was made for dietary nutrients as it helps to 
control for several factors including body size, metabolic rate and physical activity. 
For example, a positive association with a food type may not be a true aetiological 
factor, just that it is related to larger body sizes or greater physical activity (and 
hence energy expenditure). Adjusting for energy intake may also reduce the errors 
from estimating dietary intake of nutrients.255 Energy intake will also have 
measurement error, which is highly correlated to the intake of nutrients. By 
adjusting for energy intake the errors of nutrient intake are partially corrected, 
which has been demonstrated for protein.255 There are significant differences in 
absolute macronutrient intake between individuals who give valid records, and 
those who do not, and these differences are reduced after adjusting for energy 
expenditure.148 
 
Coffee and tea analysis 
Caffeinated coffee and tea data was derived from the 7-DFD and was 
analysed by the number of cups consumed a day, where one cup was the equivalent 
of 250ml. There were four categories, namely zero intake, up to one cup a day 
(<250mls), 2 cups (250-500mls) or ≥3cupsable. The hazard ratios were adjusted for 
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age at recruitment, BMI and physical activity, with the addition of parity and HRT 
use in women. 
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Results 
 
1. Obesity, physical activity, alcohol use and serum lipids 
 
Baseline characteristics of the cohort used in the analysis of obesity, 
alcohol, physical activity and serum lipids. 
From the initial cohort of 25 639 participants, 1 376 (5.4%) were excluded 
from the analysis who reported a cholecystectomy (1 000 participants) or a medical 
diagnosis of gallstones (376) at recruitment, which left a cohort of 24 263 
participants (13 075 women and 11 188 men). During the 14 years of follow-up 
(279 504 person-years), a total of 201 women (1.56% of women) and 95 men 
(0.86% of men) developed incident symptomatic gallstones. The incidence of 
symptomatic gallstones in women was nearly double that of men (1.34 per 1 000 P-
Y vs 0.74 per 1 000 P-Y, p<0.0001). In women, the mean age at diagnosis was 
65.9 yrs (SD=9.4yrs) with the interval between enrolment to diagnosis of 6.0 yrs 
(SD=2.9yrs). In men, the mean age at diagnosis was 69.1 yrs (SD=9.2yrs) with the 
interval to diagnosis of 5.9 yrs (SD=3.0yrs). The baseline characteristics of the 
cohort by gallstone status are shown in Table 5. In women, cases had more children 
and greater HRT use than controls. The clinical diagnoses were: biliary colic 
(53.7%), cholecystitis (23.6%), obstructive jaundice (10.2%), acute pancreatitis 
(10.1%), empyema (1.4%) and ascending cholangitis (1.0%). The baseline data 
were 100% complete for the whole cohort for physical activity, alcohol intake, 
BMI and waist circumference. Data on serum cholesterol and triglycerides were 
available on 93.2% of the cohort and 90.1% for HDL and LDL, with similar 
proportions for both cases and controls. 
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Table 5. Baseline characteristics of the study population according to incident 
gallstone disease status after 14 years of follow-up. 
   
Men 
  
Women 
 
  
Incident 
Non-
incident p value Incident 
Non-
incident p value 
    disease disease   disease disease   
        Number 86 11 188 
 
201 12 874 
 
        Age at recruitment 63.2 59.4 <0.0001 60.0 58.7 0.050 
 
(years, mean (SD)) (9.1) (9.3) 
 
(8.8) (9.3) 
 
        Body mass index  27.5 26.5 0.0036 28.0 26.1 <0.0001 
 
(kg/m2, mean (SD)) (2.9) (3.3) 
 
(4.8) (4.3) 
 
        Alcohol intake, median  5.0 6.0 0.037 2.0 2.5 0.16 
 
(units/wk, (IQR)) (1.5-10.5) (2-14.5) 
 
(0.5-6.0) (0.5-6.5) 
 
        Physical activity index score 
 
0.095 
  
0.079 
 
Inactive 40.0% 30.5% 
 
31.3% 29.8% 
 
 
Moderately inactive 27.4% 24.5% 
 
37.3% 32.2% 
 
 
Moderately active 16.8% 23.1% 
 
21.9% 22.3% 
 
 
Active 15.8% 21.9% 
 
9.5% 15.7% 
 
        Parity category 0.038 
 
0 children - - 
 
9.0% 14.2% 
 
 
1-2 children - - 
 
54.7% 55.8% 
 
 
≥3 children - - 
 
36.3% 30.0% 
 
        Hormone Replacement Therapy use 
    
0.011 
 
Never taken - - 
 
58.7% 68.6% 
 
 
Former user - - 
 
14.9% 11.2% 
 
 
Current used - - 
 
26.4% 20.2% 
 
                
SD=standard deviation, IQR=inter-quartile range,  
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Obesity 
The mean BMI at recruitment was significantly higher in cases than 
control for both genders (Table 5). Increased body mass index significantly 
increased the risk of developing gallstones in both genders (Table 6). For each 
additional unit increase of BMI in men, the adjusted hazard ratio (HR)=1.08 (95% 
CI=1.02-1.14, p=0.005) and in women, the HR=1.08 (95% CI=1.06-1.11, p<0.001) 
i.e. an 8% increased risk of developing gallstone disease in both genders. Higher 
categories of BMI were also positively associated with disease, for men a BMI 25-
<30 vs BMI <25 the adjusted HR=2.31 (95% CI=1.35-3.97) and in women 
HR=1.60 (95% CI=1.14-2.24) with significant trends across categories. The 
population attributable fraction of incident gallstone disease with a BMI greater 
than 25kg/m2 was 38% in the whole population (46% in men and 35% in women). 
Waist circumference was positively associated with the risk of developing 
gallstone disease in both genders (Table 7). In men, for each one inch increase in 
waist circumference the HR=1.08 (95% CI=1.03-1.14, p=0.002) and in women the 
HR=1.08 (95% CI=1.05-1.12, p<0.001). Most categories of waist circumference 
were found to at least double the risk of incident gallstone disease. In men, for a 
waist circumference of 40-<42 inches vs <34 inches the HR=3.94 (95% CI=1.45-
10.68). In women, for a waist circumference of 34-<36 vs <28 inches the HR=2.88 
(95% CI=1.59-5.21). Waist circumference measurements correlated strongly with 
BMI in both men (r=0.85) and in women (r=0.85). 
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Table 6. The effect of body mass index (BMI) on the risk of developing 
symptomatic gallstones. 
 
  Category of Body Mass Index (kg/m2)   p for 
Men <25 25-<30 30-<35 ≥35  trend 
Number of participants  3 764      5 920 1 302 177 
% of cohort 33.7 53.0 11.7 1.6 
Number of P-Y 43 649      68 175 15 052 2 019 
Number of cases 17 63 13 2 
Cases per 1000 P-Y 0.39 0.92 0.86 0.99 
Hazard ratio1 1.00 2.29 2.08 2.53 0.012 
(95% CI) (1.34-3.92) (1.01-4.30) (0.59-11.00) 
Hazard ratio2 1.00 2.31 2.12 2.62 0.010 
(95% CI) (1.35-3.97) (1.03-4.37) (0.60-11.42) 
Women <25 25-<30 30-<35 ≥35   
Number of participants 5 941 5 020 1 589 499 
% of cohort 45.5 38.5 12.2 3.8 
Number of PY 68 295 57 847 18 221 5 656 
Number of cases 58 83 41 18 
Cases per 1000 P-Y 0.85 1.43 2.25 3.18 
Hazard ratio1 1.00 1.64 2.59 3.70 <0.001 
(95% CI) (1.17-2.30)  (1.73-3.86) (2.18-6.28) 
Hazard ratio3 1.00 1.60 2.57 3.60 <0.001 
(95% CI)   (1.14-2.24)  (1.73-3.89) (2.11-6.14)   
1
 Adjusted for age at recruitment. 
2
 Adjusted for age and categories of physical activity & alcohol intake. 
3
 Model as 2 with hormone replacement therapy use & parity. 
P-Y = person-years 
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Table 7. The effect of waist circumference on the risk of developing symptomatic 
gallstones. 
             p for 
Men <34 inches 34'' - <36'' 36'' - <38'' 38'' - <40'' 40'' - <42'' ≥42'' trend 
Participants, n 1 760 2 007 2 547 2 120 1 340 1 395 
% of cohort 15.8% 18.0% 22.8% 19.0% 12.0% 12.4% 
Number of P-Y 20 438 23 299 29 398 24 530 15 357 15 940 
Number of cases 5 12 26 18 18 16 
Cases per 1000 P-Y 0.24 0.52 0.88 0.73 1.17 1.00 
Hazard ratio1 1.00 1.96 3.28 2.63 3.92 3.35 0.008 
(95% CI) (0.69-5.57) (1.26-8.57) (0.98-7.13) (1.45-10.63) (1.22-9.19) 
Hazard ratio2 1.00 1.95 3.31 2.66 3.94 3.40 0.008 
(95% CI) (0.69-5.55) (1.27-8.84) (0.99-7.21) (1.45-10.68) (1.23-9.37) 
Women < 28'' 28'' - <30'' 30'' - <32'' 32'' - <34'' 34'' - <36'' ≥36''   
Participants, n 1 980 2 401 2 680 2 194 1 540 2 251 
% of cohort 15.2% 18.4% 20.5% 16.8% 11.8% 17.3% 
Number of P-Y 22 711 27 638 30 896 25 318  17 648 25 771 
Number of cases 16 19 37 37 38 54 
Cases per 1000 P-Y 0.70 0.69 1.20 1.46 2.15 2.06 
Hazard ratio1 1.00 0.97 1.68 2.04 2.99 2.91 
 
<0.001 
(95% CI) (0.50-1.87)  (0.93-3.03) (1.13-3.70) (1.65-5.42)  (1.65-5.13) 
Hazard ratio3 1.00 0.94 1.60 1.94 2.88 2.77 <0.001 
(95% CI)   (0.49-1.84)  (0.89-2.88) (1.07-3.52) (1.59-5.21) (1.56-4.89)   
1
 Adjusted for age at recruitment. 
2
 Adjusted for age and physical activity & alcohol intake 
3
 Model as 2 with adjustment for hormone replacement therapy & parity. 
P-Y = person years 
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Physical activity 
 Physical activity was analysed after 5 years of follow-up to reduce 
regression dilution error, with increased level of physical activity associated with a 
reduced risk of gallstone disease in both men and women (Table 8). In men, the 
“active” category vs the “inactive” category the HR=0.18 (95% CI=0.04-0.80) with 
a significant trend across categories (p=0.008). After 14 years of follow-up, the 
results in men were not significant (active vs inactive HR=0.73, 95% CI=0.40-
1.35, p for trend=0.20). In women after 5 years, the “active” vs “inactive” category 
HR=0.34 (95% CI=0.14-0.83) with a trend across categories p=0.041. In women 
after 14 years of follow-up the results were not significant (“active” vs “inactive” 
HR=0.66, 95% CI=0.39-1.12, a p for trend of 0.24). 
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Table 8. Physical activity and the risk of developing symptomatic gallstones. 
 
  Categories of physical activity   p for 
Men Inactive Moderate inactive Moderate active Active trend 
Participants, n 3 416 2 740 2 581 2 450 
% of cohort 30.5% 24.5% 23.1% 21.9% 
5 years follow-up 
Number of P-Y 17 037 13 675 12 888 12 246 
Number of cases 22 12 6 2 
Cases per 1000 P-Y 1.29 0.88 0.47 0.16 
Hazard ratio1 1.00 0.79 0.46 0.17 0.005 
(95% CI) (0.39-1.61) (0.18-1.14) (0.4-0.74) 
Hazard ratio2 1.00 0.82 0.49 0.18 0.008 
(95% CI)  (0.40-1.68)  (0.20-1.22)  (0.04-0.80) 
14 years follow-up 
Number of P-Y 39 181 31 701 29 918 28 374 
Number of cases 38 26 16 15 
Cases per 1000 P-Y 0.97 0.82 0.53 0.53 
Hazard ratio1 1.00 0.96 0.67 0.70 0.14 
(95% CI) (0.58-1.59) (0.37-1.22) (0.38-1.29) 
Hazard ratio2 1.00 0.99 0.70 0.73 0.20 
(95% CI)   (0.60-1.64) (0.39-1.27) (0.40-1.35)   
  
Women Inactive Moderate inactive Moderate active Active 
Participants, n 3 902 4 215 2 915 2 043 
% of cohort 29.8% 32.2% 22.3% 15.6% 
5 years follow up 
Number of P-Y 19 447 21 014 14 537 10 203 
Number of cases 35 33 22 6 
Cases per 1000 P-Y 1.80 1.57 1.51 0.59 
Hazard ratio1 1.00 0.89 0.86 0.34 0.033 
(95% CI) (0.55-1.45) (0.50-1.50) (0.14-0.81) 
Hazard ratio3 1.00 0.87 0.89 0.34 0.041 
(95% CI) (0.53-1.43) (0.51-1.54)  (0.14-0.83) 
14 years follow up 
Number of P-Y 44 677 48 401 33 560 23 676 
Number of cases 63 75 44 19 
Cases per 1000 P-Y 1.41 1.55 1.31 0.80 
Hazard ratio1 1.00 1.16 1.00 0.62 0.13 
(95% CI) (0.82-1.63)  (0.68-1.49)  (0.37-1.06) 
Hazard ratio3 1.00 1.19 1.07 0.66 0.24 
(95% CI)   (0.84-1.68) (0.72-1.60)  (0.39-1.12)   
1Adjusted for age at recruitment. 
2
 Adjusted for age and categories of body mass index and alcohol intake. 
3
 Model as 2 with adjustment for hormone replacement therapy & parity. 
P-Y = person-years 
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Alcohol 
In men after 14 years of follow-up, alcohol had an inverse association for 
each extra unit consumed per week with a HR=0.97 (95% CI=0.95-0.99, p=0.016) 
i.e. a 3% reduction in the risk of gallstone disease for each extra unit of alcohol per 
week. In women, there was no unit effect (HR=0.99, 95% CI=0.97-1.02). There 
were no associations between the individual categories of alcohol intake and the 
risk of developing gallstones in either gender (Table 9), although in men the trend 
across categories was significant (HR=0.82, 95% CI=0.68-1.00, p=0.044). 
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Table 9. Alcohol intake and the risk of developing symptomatic gallstones. 
Alcohol category (units* per week) p for 
Men 0 0.1-<7 7-<14 14-<21 ≥21 trend 
Participants, n 1 098 4 911 2 375 1 236 1 568 
% of cohort 9.8% 43.9% 21.2% 11.1% 14.0% 
Number of P-Y 12 740 57 071 27 263 14 135 17 969 
Number of cases 11 48 24 6 6 
Cases per 1000 P-Y 0.86 0.84 0.88 0.42 0.33 
Hazard ratio1 1.00 1.09 1.18 0.59 0.47 0.056 
(95% CI) (0.56-2.10) (0.58-2.42) (0.22-1.61)  (0.17-1.29) 
Hazard ratio2 1.00 1.10 1.20 0.58 0.46 0.044 
(95% CI)    (0.58-2.14) (0.58-2.46) (0.21-1.58) (0.17-1.25)   
Women 0 0.1-<7 7-<14 14-<21 ≥21   
Participants, n 2 277 7 995 1 935 611 257 
% of cohort 17.4% 61.1% 14.8% 4.7% 2.0% 
Number of P-Y 26 468 91 965 22 049 6 979 2 854 
Number of cases 38 128 22 9 4 
Cases per 1000 P-Y 1.44 1.39 1.00 1.29 1.40 
Hazard ratio1 1.00 1.01 0.73 0.94 1.04 0.49 
(95% CI)  (0.70-1.45)  (0.43-1.23) (0.45-1.94) (0.37-2.92) 
Hazard ratio3 1.00 1.01 0.72 0.99 1.10 0.57 
(95% CI)    (0.70-1.46) (0.42-1.24) (0.48-2.05)  (0.39-3.11)   
* one unit = 10 mls or 7.9 grams of alcohol 
1
 Adjusted for age at recruitment. 
2
 Adjusted for age and categories of physical activity & BMI. 
3
 Model as 2 with adjustment for hormone replacement therapy & parity. 
P-Y =person-years 
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Lipids 
After 14 years follow-up, increased serum triglycerides were associated 
with a higher risk of symptomatic gallstones in both genders (Table 10). In men, 
the highest vs the lowest quarter HR=2.02 (95% CI=1.03-3.98) with the trend 
across quarters HR=1.29 (95% CI=1.05-1.57, p=0.009). Similarly, in women, the 
highest vs lowest quarter HR=2.43 (95% CI=1.52-3.90) and the trend across 
quarters HR=1.30 (95% CI=1.13-1.48, p<0.001). An increasing serum HDL was 
inversely associated with symptomatic gallstones in both genders (Table 10). In 
men, comparing the highest vs the lowest quarter of HDL, the HR=0.22 (95% 
CI=0.09-0.52) and the trend across quarters HR=0.62 (95% CI=0.49-0.77 
p<0.001). In women, comparing the highest vs the lowest quarter of HDL, the 
HR=0.55 (95% CI=0.36-0.85), and the trend across quarters HR=0.84 (95% 
CI=0.74-0.96 p=0.010). Total cholesterol and LDL cholesterol levels were not 
associated with the risk of developing gallstone disease in either sex. 
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Table 10. Serum lipids and the risk of developing symptomatic gallstones. 
  Quarter of the distribution   p for 
Men 1 2 3 4 trend 
Triglycerides 
Cutpoints (mmol/l) 0.30-1.20 1.28-1.80 1.90-2.50 2.60-18.90 
Hazard ratio 1.00 1.37 2.18 2.02 0.013 
(95% CI) - (0.70-2.68) (1.14-4.15) (1.03-3.98) 
Total cholesterol 
Cutpoints (mmol/l) 2.05-5.30 5.35-6.0 6.05-6.70 6.75-15.10 
Hazard ratio 1.00 0.92 0.70 0.68 0.145 
(95% CI) - (0.55-1.62) (0.38-1.30) (0.36-1.25) 
HDL-cholesterol 
Cutpoints (mmol/l) 0.20-1.00 1.10-1.20 1.30-1.40 1.49-3.20 
Hazard ratio 1.00 0.87 0.35 0.22 <0.001 
(95% CI) - (0.54-1.40) (0.17-0.72) (0.09-0.52) 
LDL-cholesterol 
Cutpoints (mmol/l) 0.50-3.28 3.29-3.87 3.88-4.51 4.52-8.66 
Hazard ratio 1.00 1.47 0.89 1.05 0.686 
(95% CI) - (0.81-2.63) (0.64-1.72) (0.56-1.95)   
Women 1 2 3 4 
Triglycerides 
Cutpoints (mmol/l) 0.19-1.00 1.09-1.40 1.50-2.00 2.05-26.00 
Hazard ratio 1.00 1.97 2.40 2.43 <0.001 
(95% CI) - (1.24-3.15) (1.52-3.80) (1.52-3.90) 
Total cholesterol 
Cutpoints (mmol/l) 2.60-5.40 5.5-6.20 6.30-7.0 7.10-18.00 
Hazard ratio 1.00 1.13 1.29 1.14 0.483 
(95% CI) - (0.72-1.69) (0.81-1.91) (0.70-1.72) 
HDL-cholesterol 
Cutpoints (mmol/l) 0.50-1.10 1.15-1.40 1.50-1.70 1.90-5.90 
Hazard ratio 1.00 0.85 0.82 0.55 0.010 
(95% CI) - (0.57-1.26) (0.56-1.20) (0.36-0.85) 
LDL-cholesterol 
Cutpoints (mmol/l) 0.44-3.24 3.25-3.90 3.91-4.69 4.70-10.30 
Hazard ratio 1.00 1.11 1.43 1.13 0.419 
(95% CI) - (0.72-1.74) (0.93-2.18) (0.72-1.77)   
Hazard ratios were adjusted for age. 
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 Since serum triglycerides and HDL were both found to have significant 
effects upon the risk of gallstone disease, a further analysis was made stratifying 
categories of body mass index (BMI). In Table 11, the trend across category hazard 
ratio has been calculated for increased quarters of serum triglycerides for each 
category of body mass index. In men, only in those with a BMI <25kg/m2 was 
there a significant effect (trend HR=1.71, p for trend=0.030). In women no 
significant effects were found in any BMI category. A similar analysis was 
performed for HDL and BMI, detailed in Table 12. In men significant trend hazard 
ratios were found in all categories except in those with a BMI >35 and in women, 
no significant effects were found. 
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Table 11. Stratified analysis of serum triglycerides by body mass index category 
and the trend hazard ratio of developing symptomatic gallstones. 
 Quarter of triglycerides distribution Trend  p for 
Men 1 2 3 4 HR Trend 
BMI category  
<25 kg/m2  
Number of cases 
(controls) 3 (1351) 3 (1086) 4 (628) 4 (399) 1.71 0.030 
 
25 to <30 kg/m2  
Number of cases 
(controls) 9 (1200) 16 (1546) 19 (1287) 13 (1175) 1.16 0.22 
 
30 to <35 kg/m2  
Number of cases 
(controls) 1 (139) 2 (282) 4 (306) 4 (367) 1.19 0.57 
 
> 35 kg/m2  
Number of cases 
(controls) 1 (12) 1 (27) 0 (36) 0 (50) 0.27 0.17 
 
Quarter of triglycerides distribution Trend p for 
Women 1 2 3 4 HR Trend 
BMI category  
<25 kg/m2  
Number of cases 
(controls) 16 (2304) 13 (1435) 17 (1102) 6 (646) 1.11 0.63 
 
25 to <30 kg/m2  
Number of cases 
(controls) 9 (1042) 22 (1092) 22 (1137) 26 (1174) 1.19 0.19 
 
30 to <35 kg/m2  
Number of cases 
(controls) 4 (198) 8 (272) 11 (374) 14 (489) 1.03 0.89 
 
> 35 kg/m2  
Number of cases 
(controls) 0 (35) 4 (70) 4 (115) 5 (163) 1.07 0.82 
 
Hazard ratios were adjusted for age.  
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Table 12. Stratified analysis of serum HDL by body mass index category and the 
trend hazard ratio of developing symptomatic gallstones. 
  Quarter of HDL distribution   Trend  p for 
Men 1 2 3 4 HR trend 
BMI category  
<25 kg/m2  
Number of cases 
(controls) 4 (766) 9 (848) 1 (800) 0 (1050) 0.50 0.011 
 
25 to <30 kg/m2  
Number of cases 
(controls) 27 (1801) 16 (1422) 8 (1058) 6 (946) 0.74 0.020 
 
30 to <35 kg/m2  
Number of cases 
(controls) 7 (500) 4 (308) 0 (158) 0 (128) 0.47 0.092 
 
> 35 kg/m2  
Number of cases 
(controls) 2 (65) 0 (33) 0 (10) 0 (17) N/A N/A 
 
Quarter of HDL distribution Trend p for 
Women 1 2 3 4 HR trend 
BMI category  
<25 kg/m2  
Number of cases 
(controls) 12 (1289) 12 (1024) 14 (1431) 14 (1743) 0.95 0.66 
 
25 to <30 kg/m2  
Number of cases 
(controls) 31 (1643) 18 (938) 18 (1010) 12 (854) 0.93 0.44 
 
30 to <35 kg/m2  
Number of cases 
(controls) 21 (590) 5 (299) 9 (281) 2 (163) 0.81 0.21 
 
> 35 kg/m2  
Number of cases 
(controls) 7 (226) 3 (79) 2 (48) 1 (30) 1.13 0.65 
 
N/A = not able to calculate  
Hazard ratios were adjusted for age.  
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 Further analysis was made for serum triglycerides and HDL stratified for 
categories of alcohol intake. Due to the small numbers in the highest category of 
alcohol (>21 units per week) this category was combined with those consuming >7 
units per week. In Table 13, the trend across category hazard ratio has been 
calculated for increased quarters of serum triglycerides for categories of alcohol 
intake. In men, those with an alcohol intake >7 units per week, the trend effect of 
increased triglycerides was significant (trend HR=1.58, p for trend=0.006) with a 
greater magnitude of effect in those with zero intake although the result was only 
of borderline significance (trend HR=1.81, p for trend=0.053). In women no 
significant effects were found in any of the alcohol categories for serum 
triglycerides. 
A similar analysis was performed for HDL and alcohol, detailed in Table 
14. In men, a similar magnitude of effect was found for both 0 to <7 units of 
alcohol per week (trend HR=0.63, p for trend =0.008) and for >7units per week 
(trend HR=0.64, p for trend=0.006). In women, only found in those consuming 0 to 
<7 units per week had a significant effect (HR=0.82, p for trend=0.016).  
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Table 13. Stratified analysis of serum triglycerides by alcohol category and the 
trend hazard ratio of developing symptomatic gallstones. 
  Quarter of triglyceride distribution   Trend  p for 
Men 1 2 3 4 HR trend 
Alcohol category  
0 units/week  
Number of cases 
(controls) 2 (234) 1 (267) 2 (203) 6 (215) 1.81 0.053 
 
> 0 to <7 units/wk  
Number of cases 
(controls) 10 (1183) 11 (1301) 13 (983) 6 (912) 1.00 0.99 
 
≥ 7 units/wk  
Number of cases 
(controls) 2 (1298) 10 (1398) 12 (1073) 9 (867) 1.58 0.006 
 
Quarter of triglyceride distribution Trend p for 
Women 1 2 3 4 HR trend 
Alcohol category  
0 units/week  
Number of cases 
(controls) 5 (449) 7 (437) 8 (508) 10 (580) 1.20 0.28 
 
> 0 to <7 units/wk  
Number of cases 
(controls) 15 (2233) 32 (1756) 36 (1665) 34 (1491) 1.36 0.24 
 
≥ 7 units/wk  
Number of cases 
(controls) 7 (609) 5 (470) 6 (399) 4 (294) 1.04 0.86 
 
Hazard ratios were adjusted for age.  
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Table 14. Stratified analysis of serum HDL by alcohol category and the trend 
hazard ratio of developing symptomatic gallstones. 
  Quarter of HDL distribution   Trend  p for 
Men 1 2 3 4 HR Trend 
Alcohol category  
0 units/week  
Number of cases 
(controls) 8 (390) 1 (252) 2 (161) 0 (116) 0.48 0.073 
 
> 0 to <7 units/wk  
Number of cases 
(controls) 20 (1621) 15 (1226) 3 (801) 2 (722) 0.63 0.008 
 
≥ 7 units/wk  
Number of cases 
(controls) 12 (1126) 13 (1140) 4 (1064) 4 (1306) 0.64 0.006 
 
Quarter of HDL distribution Trend p for 
Women 1 2 3 4 HR Trend 
Alcohol category  
0 units/week  
Number of cases 
(controls) 13 (760) 5 (411) 10 (474) 2 (329) 0.88 0.46 
 
> 0 to <7 units/wk  
Number of cases 
(controls) 50 (2442) 28 (1475) 21 (1670) 18 (1558) 0.82 0.016 
 
≥ 7 units/wk  
Number of cases 
(controls) 6 (419) 1 (342) 8 (435) 7 (576) 1.05 0.80 
 
Hazard ratios were adjusted for age.  
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2. Dietary outcomes using 7-day food diaries 
 
Baseline characteristics of the cohort used in the analysis of dietary 
nutrients 
All dietary analyses were made after 10 years of follow-up to reduce the 
effects of regression dilution bias. From the initial cohort 23 658 (92.3%) who 
completed the 7-day food diary (7-DFD), after excluding those with a previous 
history of cholecystectomy or gallstone, 166 women and 82 men developed 
incident gallstone disease. Not all food diaries from the cohort are currently coded, 
so a random sample 2 066 women and 1 660 men were used as the comparison 
population. The total length of exposure over 10 years, was 21 555 person-years 
for women and 17 050 for men. The baseline characteristics were compared 
between participants with and without incident gallstone disease and are listed in 
Table 15 which shows in both genders BMI was higher in cases and controls. In 
men, cases had a lower alcohol intake. In women, cases were more likely to use 
HRT. 
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Table 15. Baseline characteristics of the study population, after 10 years of follow-
up, according to incident gallstone disease status. 
 
Men 
  
Women 
 
 
 
 
Incident Non-incident p value Incident Non-incident p value 
    
Disease disease   disease disease   
      
Number 82 1 660 
 
164 2 066 
 
      
Age at recruitment 64.0 59.5 <0.0001 60.0 58.7 0.006 
(years, mean (SD)) (8.4) (9.3) 
 
(8.9) (9.4) 
 
      
Body mass index  27.7 26.5 0.0011 27.9 26.1 <0.0001 
(kg/m2, mean (SD)) (2.9) (3.3) 
 
(4.5) (4.2) 
 
      
Alcohol intake  5.0 6.0 0.044 2.0 2.5 0.11 
(units/wk, median (IQR)) (1.5-10.5) (2-14.0) (0.5-5.8) (0.5-7.0) 
 
      
Physical activity index score 
  
0.055 
  
0.094 
Inactive 40.2% 30.4% 
 
35.4% 29.0% 
 
Moderately inactive 26.8% 23.2% 
 
34.8% 32.9% 
 
Moderately active 19.5% 23.3% 
 
21.3% 22.5% 
 
Active 13.4% 23.2% 
 
8.5% 15.6% 
 
      
Parity category 
     
0.11 
0 children - - 
 
7.9% 14.0% 
 
1-2 children - - 
 
56.7% 54.7% 
 
≥3 children - - 
 
35.4% 31.3% 
 
      
Hormone Replacement Therapy use 
    
0.028 
Never taken - - 
 
59.9% 68.9% 
 
Former user - - 
 
15.9% 12.2% 
 
Current used - - 
 
26.2% 18.9% 
 
    
            
SD=standard deviation, IQR=interquartile range 
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Total energy intake and macronutrient 
Quintiles of total energy intake and the dietary macronutrients, fat, protein 
and carbohydrate, had no association with symptomatic gallstone disease after 10 
years in either men or women (Table 16 and Table 17). 
 
Fatty acid classes 
None of the naturally occurring fatty acid classes (saturated, 
monounsaturated and polyunsaturated fatty acids) were associated with gallstone 
disease in men (Table 18), or women (Table 19) after 10 years of follow up.  
However, trans-fats were associated with an increased risk of gallstones in women, 
but not in men. In women, the highest quintile of trans-fat intake compared to the 
lowest intake had a HR of 1.94 (95% CI=1.06-3.54) with the trend across fifths, 
HR=1.16 95% CI=1.00-1.33, p=0.051) (Table 19). 
 
Cholesterol 
In women, increased dietary cholesterol was associated with a reduced risk 
of gallstone disease after 10 years of follow-up. The highest quintile of cholesterol 
intake compared to the lowest had a HR of 0.56 (95% CI=0.35-0.99) with a 
significant trend across fifths (HR=0.86 95% CI=0.76-0.97, p=0.015) (Table 19). 
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Table 16. Total energy and macronutrient intake and the risk of developing 
symptomatic gallstones in men. 
    Quintile     
Men 1 2 3 4 5 
Number of participants 350 350 350 350 350 
Total energy intake 
Cut points (kcal/day) 322 to 1813 1814 to2111 2112 to 2337 2339 to 2640 2643 to 6050 
Cases 22 19 14 12 15 
HR (95% CI)1 1.00 0.86 (0.47-1.62) 0.71 (0.36-1.39) 0.64 (0.31-1.29) 0.97 (0.49-1.91) 
HR (95% CI)2 1.00 0.93 (0.50-1.73) 0.81 (0.41-1.60) 0.75 (0.37-1.53) 1.19 (0.60-2.39) 
Total fat intake 
Cut points (grams/day) 16 to 65 65 to 77 78 to 90 91 to 107 107 to 340 
Cases 22 18 12 16 14 
HR (95% CI)1 1.00 0.80 (0.43-1.49) 0.58 (0.29-1.17) 0.81 (0.43-1.55) 0.81 (0.41-1.61) 
HR (95% CI)2 1.00 0.75 (0.37-1.53) 0.58 (0.23-1.42) 0.79 (0.30-2.07) 0.61 (0.19-1.98) 
Total carbohydrate 
Cut points (grams/day) 20 to 215 216 to 253 254 to 286 287 to 330 330 to 647 
Cases 21 15 16 18 12 
HR (95% CI)1 1.00 0.68 (0.35-1.31) 0.80 (0.42-1.53) 1.00 (0.53-1.89) 0.69 (0.34-1.42) 
HR (95% CI)2 1.00 0.74 (0.35-1.55) 0.91 (0.39-2.13) 1.08 (0.41-2.83) 0.62 (0.19-2.00) 
Total protein 
Cut points (grams/day) 26 to 67 67 to 77 77 to 85 85 to 95 96 to 175 
Cases 17 24 8 15 18 
HR (95% CI)1 1.00 0.68 (0.35-1.31) 0.80 (0.42-1.53) 1.00 (0.53-1.89) 0.69 (0.34-1.42) 
HR (95% CI)2 1.00 1.50 (0.77-2.90) 0.59 (0.24-1.48) 1.17 (0.51-2.73) 1.56 (0.63-3.87) 
            
HR=hazard ratio, CI=confidence interval. 
1 Adjusted for age at recruitment. 
2 Adjusted for age and categories of BMI, physical activity, alcohol and quintiles of total energy intake. 
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Table 17. Total energy and macronutrient intake and the risk of developing 
symptomatic gallstones in women. 
    Quintile     
Women 1 2 3 4 5 
Number of participants 449 449 449 449 449 
Total energy intake 
Cut points (kcal/day) 588 to 1373 1373 to 1598 1598 to 1782 1782 to 2020 2020 to 3527 
Cases 37 33 31 26 37 
HR (95% CI)1 1.00 0.90 (0.57-1.44) 0.84 (0.52-1.36) 0.75 (0.46-1.23) 1.09 (0.69-1.72) 
HR (95% CI)2 1.00 1.02 (0.63-1.64) 0.94 (0.58-1.51) 0.86 (0.52-1.44) 1.31 (0.82-2.09) 
Total fat intake 
Cut points (grams/day) 13 to 48 49 to 59 59 to 68 69 to 80 80 to 176 
Cases 42 23 29 29 41 
HR (95% CI)1 1.00 0.53 (0.32-0.88) 0.69 (0.43-1.10) 0.70 (0.43-1.11) 1.06 (0.69-1.63) 
HR (95% CI)2 1.00 0.54 (0.31-0.95) 0.78 (0.42-1.44) 0.88 (0.43-1.80) 1.35 (0.60-3.04) 
Total carbohydrate 
Cut points (grams/day) 58 to 168 168 to 199 199 to 224 224 to 257 258 to 418 
Cases 39 25 36 35 29 
HR (95% CI)1 1.00 0.65 (0.40-1.08) 0.97 (0.61-1.52) 0.92 (0.59-1.46) 0.78 (0.48-1.26) 
HR (95% CI)2 1.00 0.67 (0.38-1.18) 1.02 (0.55-1.92) 0.91 (0.45-1.86) 0.62 (0.27-1.42) 
Total protein 
Cut points (grams/day) 24-54 54-61 61-68 69-76 77-145 
Cases 32 49 22 30 31 
HR (95% CI)1 1.00 0.68 (0.35-1.31) 0.80 (0.42-1.53) 1.00 (0.53-1.89) 0.69 (0.34-1.42) 
HR (95% CI)2 1.00 1.50 (0.94-2.41) 0.64 (0.36-1.15) 0.79 (0.44-1.41) 0.73 (0.39-1.37) 
            
HR=hazard ratio, CI=confidence interval. 
1 Adjusted for age. 
2 Adjusted for age and categories of BMI , alcohol, physical activity,  HRT use, parity and quintiles of total energy intake. 
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Table 18. Fatty acid class and cholesterol intake and the risk of developing 
symptomatic gallstones in men. 
    Quintile     
Men 1 2 3 4 5 
Number of participants 350 350 350 350 350 
Total energy intake 
Cut points (kcal/day) 322 to 1813 1814 to 2111 2112 to 2337 2339 to 2640 2643 to 6050 
Cases 22 19 14 12 15 
HR (95% CI)1 1.00 0.86 (0.47-1.62) 0.71 (0.36-1.39) 0.64 (0.31-1.29) 0.97 (0.49-1.91) 
HR (95% CI)2 1.00 0.93 (0.50-1.73) 0.81 (0.41-1.60) 0.75 (0.37-1.53) 1.19 (0.60-2.39) 
Total fat intake 
Cut points (grams/day) 16 to 65 65 to 77 78 to 90 91 to 107 107 to 340 
Cases 22 18 12 16 14 
HR (95% CI)1 1.00 0.80 (0.43-1.49) 0.58 (0.29-1.17) 0.81 (0.43-1.55) 0.81 (0.41-1.61) 
HR (95% CI)2 1.00 0.75 (0.37-1.53) 0.58 (0.23-1.42) 0.79 (0.30-2.07) 0.61 (0.19-1.98) 
Total carbohydrate 
Cut points (grams/day) 20 to215 216 to 253 254 to 286 287 to 330 330 to 647 
Cases 21 15 16 18 12 
HR (95% CI)1 1.00 0.68 (0.35-1.31) 0.80 (0.42-1.53) 1.00 (0.53-1.89) 0.69 (0.34-1.42) 
HR (95% CI)2 1.00 0.74 (0.35-1.55) 0.91 (0.39-2.13) 1.08 (0.41-2.83) 0.62 (0.19-2.00) 
Total protein 
Cut points (grams/day) 26 to 67 67 to 77 77 to 85 85 to 95 96 to 175 
Cases 17 24 8 15 18 
HR (95% CI)1 1.00 0.68 (0.35-1.31) 0.80 (0.42-1.53) 1.00 (0.53-1.89) 0.69 (0.34-1.42) 
HR (95% CI)2 1.00 1.50 (0.77-2.90) 0.59 (0.24-1.48) 1.17 (0.51-2.73) 1.56 (0.63-3.87) 
            
HR=hazard ratio, CI=confidence interval. 
1 Adjusted for age. 
2 Adjusted for age and categories of BMI, physical activity and alcohol. 
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Table 19. Fatty acid class and cholesterol intake and the risk of developing 
symptomatic gallstones in women. 
    Quintile     
Women 1 2 3 4 5 
Number of participants 449 449 449 449 449 
Saturated fats 
Cut points (grams/day) 3.6 to 17.3 17.4 to 21.5 21.6 to 25.8 25.9 to 31.7 31.7 to 84.4 
Cases 41 28 24 34 37 
HR (95% CI)1 1.00 0.66 (0.42-1.05) 0.52 (0.31-0.85) 0.84 (0.55-1.30) 0.92 (0.60-1.40) 
HR (95% CI)2 1.00 0.62 (0.38-1.04) 0.57 (0.28-0.92) 0.84 (0.46-1.47) 0.87 (0.44-1.63) 
Monounsaturated fats 
Cut points (grams/day) 3.7 to 16.5 16.5 to 20.3 20.3 to 23.9 23.9 to 27.9 27.9 to 59.4 
Cases 41 18 40 23 42 
HR (95% CI)1 1.00 0.44 (0.26-0.74) 0.94 (0.62-1.43) 0.52 (0.31-0.86) 1.16 (0.77-1.74) 
HR (95% CI)2 1.00 0.46 (0.26-0.82) 1.18 (0.64-1.92) 0.68 (0.31-1.22) 1.31 (0.69-2.74) 
Polyunsaturated fats 
Cut points (grams/day) 1.9 to 8.7 8.7 to 10.7 10.8 to 12.8 12.9 to 15.8 15.9 to 39.6 
Cases 42 26 26 31 39 
HR (95% CI)1 1.00 0.61 (0.38-0.97) 0.64 (0.40-1.02) 0.74 (0.47-1.16) 1.02 (0.67-1.56) 
HR (95% CI)2 1.00 0.60 (0.37-0.99) 0.64 (0.39-1.10) 0.82 (0.44-1.32) 1.05 (0.59-1.90) 
Trans fats 
Cut points (grams/day) 0.2 to 1.6 1.6 to 2.1 2.1 to 2.6 2.6 to 3.3 3.3 to 9.6 
Cases 33 28 31 27 45 
HR (95% CI)1 1.00 0.84 (0.51-1.38) 0.96 (0.59-1.56) 0.81 (0.49-1.34) 1.40 (0.49-2.19) 
HR (95% CI)2 1.00 0.96 (0.58-1.61) 1.17 (0.68-2.00) 1.07 (0.60-1.91) 1.94 (1.06-3.54) * 
Dietary cholesterol 
Cut points (mg/day) 2.1 to 119 120 to 153 154 to 188 189 to 233 233 to 684 
Cases 40 36 34 24 30 
HR (95% CI)1 1.00 0.90 (0.57-1.41) 0.84 (0.53-1.32) 0.57 (0.35-0.95) 0.76 (0.47-1.21) 
HR (95% CI)2 1.00 0.82 (0.52-1.30) 0.73 (0.46-1.18) 0.54 (0.32-0.91) 0.59 (0.35-0.99) ** 
            
HR=hazard ratio, CI=confidence interval, mg=milligram. 
*p for trend=0.05, **p for trend=0.015 
1 Adjusted for age. 
2 Adjusted for age, BMI category, physical activity category, alcohol category, HRT use, parity and quintiles of total energy 
intake. 
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Iron 
In women, after 10 years of follow-up, increased dietary iron was 
associated with a reduced risk of developing symptomatic gallstones with the 
highest quintile of intake vs the lowest HR=0.35 (95% CI=0.19-0.66) with a 
significant trend across fifths (HR=0.82, 95% CI=0.71-0.94, p=0.004) (Table 21). 
No effect was found for dietary iron intake in men (Table 20). 
 
Niacin 
 Increased dietary niacin was associated with a reduced risk of gallstone 
disease in women, for each of the four higher quintiles of niacin intake (p<0.05) 
(Table 21). The highest quintile of niacin intake compared to the lowest, had a 
hazard ratio of 0.54 (95% CI=0.32-0.90) with a significant trend across fifths 
(HR=0.86, 95% CI=0.76-0.97, p=0.004). Since the effect sizes were similar for 
each of the four higher intake of niacin, this could suggest that there could be a 
threshold effect for dietary niacin, with women in the lowest fifth of intake at a 
higher risk of disease. In men, there were negative associations with each of the 
four higher quintiles of dietary niacin intake, though none were statistically 
significant (Table 20) and no effect across quintiles HR=0.97( 95% CI=0.81-1.16, 
p=0.70). 
 
Fibre 
 In women, after 10 years of follow-up, there was a negative association 
between the four higher quintiles of dietary fibre and symptomatic gallstone 
disease, however, none of the quintiles reached statistical significance (Table 21) 
and the trend across categories was also non-significant (HR=0.91, 95% CI=0.81-
1.03, p=0.14). In men, there was no association between fibre intake and disease 
(Table 20). 
Dietary calcium 
 Dietary calcium was associated with an increased risk of gallstone disease 
in men after 10 years of follow-up, with the highest quintile of intake vs the lowest 
HR=2.31 (95% CI=1.00-5.35) and the trend across categories HR=1.25 (95% 
CI=1.03-1.52, p=0.023) (Table 20). In women, no effects were found for dietary 
calcium intake (Table 21). 
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Table 20. Dietary iron, niacin, fibre and calcium intake and the risk of developing 
symptomatic gallstones in men. 
    Quintile     
Men 1 2 3 4 5 
Number of participants 350 350 350 350 350 
Dietary iron 
Cut points (mg/day) 3.4 to 10.2 10.2 to 11.9 11.8 to 13.8 13.8 to 16.1 16.1 to 42.2 
Cases 22 21 15 16 16 
HR (95% CI)1 1.00 0.90 (0.48-1.69) 0.67 (0.33-1.33) 0.87 (0.45-1.70) 0.86 (0.44-1.67) 
HR (95% CI)2 1.00 0.98 (0.50-1.90) 0.70 (0.33-1.51) 1.00 (0.46-2.17) 0.97 (0.44-2.15) 
Dietary niacin 
Cut points (mg/day) 5.6 to 15.9 15.9 to 19.1 19.2 to 22.2 22.2 to 26.1 26.1 to 60.1 
Cases 25 16 19 17 13 
HR (95% CI)1 1.00 0.69 (0.36-1.32) 0.94 (0.50-1.76) 0.80 (0.41-1.55) 0.72 (0.35-1.48) 
HR (95% CI)2 1.00 0.75 (0.37-1.53) 0.58 (0.23-1.42) 0.79 (0.30-2.07) 0.61 (0.19-1.98) 
Dietary fibre 
Cut points (grams/day) 3.6 to 11.4 11.4 to 13.8 13.9 to 16.5 16.5 to 20.0 20.1 to 61.2 
Cases 20 16 19 20 15 
HR (95% CI)1 1.00 0.64 (0.31-1.32) 1.03 (0.54-1.97) 1.08 (0.57-2.07) 0.91 (0.46-1.80) 
HR (95% CI)2 1.00 0.64 (0.31-1.35) 1.11 (0.55-2.22) 1.16 (0.58-2.31) 1.01 (0.48-2.13) 
Dietary calcium 
Cut points (mg/day) 152 to 677 677 to 816 817 to 963 963 to 1152 1153 to 2788 
Cases 18 18 11 22 21 
HR (95% CI)1 1.00 1.08 (0.54-2.16) 0.71 (0.32-1.57) 1.48 (0.75-2.88) 1.63 (0.83-3.20) * 
HR (95% CI)2 1.00 1.29 (0.62-2.67) 0.92 (0.39-2.15) 2.12 (0.97-4.61) 2.31 (1.00-5.35) ** 
            
HR=hazard ratio, CI=confidence interval, mg=milligram. 
*p for trend=0.089, **p for trend=0.023 
1Adjusted for age. 
2Adjusted for age and categories of BMI, physical activity, alcohol intake and quintiles of energy intake. 
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Table 21. Dietary iron, niacin, fibre and calcium intake and the risk of developing 
symptomatic gallstones in women. 
    Quintile     p for 
Women 1 2 3 4 5 trend 
Number of 
participants 350 350 350 350 350 
Dietary iron 
Cut points (mg/day) 1.9 to 8.3 8.3 to 9.7 9.7 to 11.2 11.2 to 13.2 13.2 to 39.5 
Cases 47 38 32 40 21 
HR (95% CI)1 1.00 0.81 (0.52-1.26) 0.69 (0.43-1.10) 0.85 (0.55-1.32) 0.44 (0.25-0.76) 0.012 
HR (95% CI)2 *虵*虵*0.7 0.72 (0.45-1.16) 0.59 (0.35-1.00) 0.68 (0.46-1.14) 0.35 (0.19-0.66) 0.004 
Dietary niacin 
Cut points (mg/day) 1.8 to 12.9 12.9 to 15.5 15.5 to 17.9 17.9 to 21.0 21.1 to 44.8 
Cases 51 35 29 34 29 
HR (95% CI)1 1.00 0.81 (0.52-1.26) 0.69 (0.43-1.10) 0.85 (0.55-1.32) 0.44 (0.25-0.76) 0.033 
HR (95% CI)2 1.00 0.72 (0.45-1.16) 0.59 (0.35-1.00) 0.68 (0.46-1.14) 0.35 (0.19-0.66) 0.014 
Dietary fibre 
Cut points 
(grams/day) 1.3 to 10.3 10.2 to 12.5 12.5 to 14.7 14.7 to 17.6 17.6 to 51.4 
Cases 49 31 39 26 33 
HR (95% CI)1 1.00 0.71 (0.45-1.13) 0.85 (0.54-1.32) 0.62 (0.38-1.00) 0.71 (0.45-1.14) 0.12 
HR (95% CI)2 1.00 0.70 (0.44-1.13) 0.83 (0.52-1.31) 0.63 (0.37-1.05) 0.68 (0.41-1.13) 0.14 
Dietary calcium 
Cut points (mg/day) 120 to 588 558 to 680 681 to 800 800 to 943 943 to 2871 
Cases 32 45 38 32 31 
HR (95% CI)1 1.00 1.35 (0.84-2.14) 1.13 (0.70-1.84) 0.91 (0.55-1.52) 1.00 (0.61-1.66) 0.47 
HR (95% CI)2 1.00 1.40 (0.85-2.29) 1.21 (0.71-2.06) 0.92 (0.52-1.66) 0.97 (0.53-1.77) 0.44 
            
HR=hazard ratio, CI=confidence interval, mg=milligram. 
1Adjusted for age. 
2Adjusted for age and categories of BMI, physical activity, alcohol intake and quintiles of energy intake. 
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Coffee and tea 
 Caffeinated coffee was associated with a decreased risk of gallstone 
disease in men with three or more cups a day compared to zero intake associated 
with a 57% reduced risk (HR=0.43, 95% CI=0.22-0.83) (Table 22). There was a 
significant effect for each additional cup drank per day (HR=0.77 95% CI=0.62-
0.95, p=0.013). No effects were found for caffeinated tea, decaffeinated coffee in 
men and women and also no effect was found for caffeinated coffee in women 
(Table 23). 
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Table 22. Caffeinated and decaffeinated coffee and caffeinated tea and the risk of 
symptomatic gallstones in men. 
    Cups per day   
Men 0 (none) 1 (<250mls/day) 2 (250-500mls/day) 3+ (>500mls/day) 
Caffeinated coffee 
Number of participants 438 518 342 453 
% of cohort 25.0% 29.5% 19.5% 26.0% 
Number of P-Y 4 809 5 864 3 902 5 242 
Number of cases 34 25 16 15 
HR (95% CI)1 1.00 0.61 (0.35-1.04) 0.63 (0.34-1.17) 0.44 (0.23-0.85) * 
HR (95% CI)2 1.00 0.60 (0.35-1.04) 0.61 (0.33-1.14) 0.43 (0.22-0.83) ** 
Caffeinated tea 
Number of participants 176 138 245 1 196 
% of cohort 10.0% 7.9% 14.0% 68.1% 
Number of P-Y 1 982 1 544 2 767 13 524 
Number of cases 5 8 11 66 
HR (95% CI)1 1.00 1.78 (0.56-5.60) 1.18 (0.39-3.51) 1.58 (0.64-3.95) 
HR (95% CI)2 1.00 1.75 (0.55-5.51) 1.15 (0.38-3.44) 1.58 (0.63-3.96) 
Decaffeinated coffee >30mls/day 
Number of participants 1 511 244 
% of cohort 86.1% 13.9% 
Number of P-Y 17 056 2 761 
Number of cases 79 11 
HR (95% CI)1 1.00 1.02 (0.54-1.93) 
HR (95% CI)2 1.00 1.03 (0.54-1.94) 
          
P-Y=person years, HR=hazard ratio, CI=confidence interval. 
*p for trend=0.015, **p for trend=0.013 
1Adjusted for age. 
2Adjusted for age, BMI category, physical activity, alcohol category and quintiles of total energy intake. 
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Table 23. Caffeinated and decaffeinated coffee and caffeinated tea and the risk of 
symptomatic gallstones in women. 
    Cups per day   
Women 0 (none) 1 (<250mls/day) 2 (250-500mls/day) 3+ (>500mls/day) 
Caffeinated coffee 
Number of participants 545 681 438 583 
% of cohort 24.3% 30.3% 19.5% 25.9% 
Number of P-Y 5 998 7 583 4 887 6 555 
Number of cases 51 46 40 41 
HR (95% CI)1 1.00 0.72 (0.47-1.08) 0.98 (0.64-1.51) 0.79 (0.51-1.21) 
HR (95% CI)2 1.00 0.78 (0.52-1.19) 1.06 (0.68-1.65) 0.85 (0.55-1.31) 
Caffeinated tea 
Number of participants 262 210 309 1 466 
% of cohort 11.5% 9.5% 13.8% 65.2% 
Number of P-Y 2 885 2 318 3 463 16 357 
Number of cases 20 18 21 119 
HR (95% CI)1 1.00 1.15 (0.60-2.19) 0.82 (0.44-1.55) 0.94 (0.57-1.53) 
HR (95% CI)2 1.00 1.18 (0.62-2.26) 0.86 (0.46-1.63) 0.95 (0.58-1.57) 
Decaffeinated coffee 0   >30mls/day   
Number of participants 1 828 419 
% of cohort 81.4% 18.6% 
Number of P-Y 20 280 4 744 
Number of cases 389 30 
HR (95% CI)1 1.00 0.92 (0.62-1.38) 
HR (95% CI)2 1.00 0.98 (0.65-1.46) 
          
P-Y=person years, HR=hazard ratio, CI=confidence interval. 
*p for trend=0.015, **p for trend=0.013 
1Adjusted for age. 
2Adjusted for age, BMI category, physical activity category, alcohol category, HRT use, parity and quintiles of 
total energy intake. 
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Discussion 
 
The epidemiological study of anthropometry, diet, physical activity and 
lipid biomarkers found that in both men and women, body mass index, waist 
circumference and serum triglycerides were positively associated with the 
development of symptomatic gallstone disease, with physical activity and HDL 
negatively associated. Additionally, in men only, alcohol and caffeinated coffee 
consumption were negatively associated with the development of disease with 
increased dietary calcium positively associated. In women only, dietary trans-fatty 
acids were positively associated with disease, with dietary cholesterol, iron and 
niacin negatively associated. Each of these risk factors will now be discussed. 
 
1. Obesity, physical activity, alcohol use and serum lipids 
 
Obesity 
In both men and women, increasing obesity was positively associated with 
the development of gallstones, with each extra unit of BMI, or additional inch of 
waist circumference, significantly increasing the risk by 8%. A BMI greater than 
25kg/m2 (overweight or obese) was associated with at least a doubling in risk 
compared to one less than 25kg/m2 (normal BMI) with 38% of incident gallstone 
disease attributable to a BMI greater than 25kg/m2. There was a trend across 
categories with both an increased BMI and waist circumference associated with a 
greater risk of disease. The epidemiological data supports experimental data as 
obesity has several biological mechanisms contributing to gallstone disease 
predominantly by promoting hyperinsulinaemia, insulin resistance and 
dyslipidaemia. These pathophysiological changes lead to increased biliary 
cholesterol concentration, greater mucin secretion and gallbladder hypomotility, all 
of which are important processes in gallstone formation. 
Our results support the findings from many other studies that obesity 
increases the risk of gallstone disease, including the largest prospective studies 
conducted in US cohorts. The Nurses’ Health study initially evaluated the effect of 
BMI on the risk of newly diagnosed symptomatic gallstone disease in 90 302 
women aged 34-59 years.60 After 8 years of follow-up, 2 122 cases were diagnosed 
and the multivariate analysis, a BMI≥35 compared to a BMI<24 had a RR of 
gallstone disease of 4.64 (95% CI=3.86-5.57). In EPIC-Norfolk, our results were 
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similar, with a BMI≥35 vs <25 associated with a HR of 3.60 (95% CI=2.11-6.11). 
The Nurses’ Health later reported the effect of waist circumference on the risk of 
cholecystectomy in 42 312 women, followed-up for 14 years, in which 3 197 cases 
were identified. A waist circumference of ≥36 inches vs <26 inches had a 
multivariable RR of 3.40 (95% CI 2.84-4.07)80, a result of similar magnitude to that 
obtained in women this study (≥36 inches vs <28 inches, HR=2.77 95% CI 1.56-
4.89). However, the rate of gallstone disease in Nurses’ Health study was 6.2 
cholecystectomies per 1000 person years (PYs) compared to 1.3 cases of 
symptomatic gallstone disease per 1000 PYs in females in EPIC-Norfolk, which 
highlights the potential differences in the populations studied, and the importance 
of verifying that waist circumference is also significant risk factor in a UK 
population. In studies of men, the US Health Professional Follow-up Study 
identified 1 117 incident cases of gallstone disease, in a cohort of 51 529 
participants, and assessed the effects of both BMI and waist circumference.79 Those 
with a BMI≥28.5 compared to a BMI<22.2 had a multivariate RR=2.30 (95% 
CI=1.76-3.00) which are similar results from men in EPIC-Norfolk (BMI≥35 vs 
BMI<25 HR=2.62 95% CI=0.60-11.42). The Health Professional Follow-up Study 
analysis of waist circumference reported a waist circumference of >40.4 inches 
compared to <34 inches had a multivariate RR=2.45 (95% CI=1.94-3.11) which 
again was of similar magnitude to that found in men in EPIC-Norfolk (≥42 inches 
vs <34 inches, HR=3.40 95% CI 1.23-9.37). 
This is the first UK prospective study to quantify the effect of obesity on 
the risk of developing gallstone disease. By demonstrating that each unit of BMI, 
or additional inch of waist circumference, increases the risk of gallstone disease by 
8%, it provides a simple and concise measure to enable public health planning to 
prevent the burden of disease. The calculated population attributable fraction from 
EPIC-Norfolk, estimates that 38% of symptomatic gallstone disease are due to a 
BMI over 25. The evidence supports a causal role for obesity in gallstone disease, 
since experimental evidence and aetiological work consistently report large effect 
sizes, with a dose effect. 
 
Physical activity 
This study reported after 5 years of follow-up and adjusting for covariates, 
the highest level of physical activity was associated with a 82% reduced risk of 
developing symptomatic gallstones in men, with a 66% reduced risk in women. 
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After 14 years of follow-up the negative association remained, but of smaller 
magnitude and not statistically significant. The amount of physical activity in the 
highest category is equivalent to either exercising for one hour a day if employed in 
a sedentary job, exercising for 30 minutes a day if working in a standing job, or 
finally a heavy manual job without any additional activity (Table 1). There are 
plausible biological mechanisms to explain the protective effect found with regular 
exercise increasing HDL and reducing plasma triglycerides.104, 256 Both these lipid 
changes are inversely associated with the prevalence of gallstones.88 Exercise also 
decreases biliary cholesterol,74, mucus secretion,75 and improves gallbladder 
motility,110 all of which prevent gallstone formation. 
The finding of a significant reduction in risk after five years of follow-up, 
but not after the full follow-up period, may be attributable to regression dilution 
bias. The study used a single measure of physical activity, taken at recruitment, 
although repeated assessments to account for variation over time would give more 
accurate data. Prospective studies which analyse disease rates from just one initial 
baseline survey of a risk factor generally underestimate the real associations of 
disease after longer periods of follow up 257. This random measurement error 
occurs as some of the population will change their level of physical activity over 
time. If this happens in both those who may become cases or non-cases there is an 
under-estimate of the true association. Physical activity is likely to vary over time, 
particularly as a population ages. Hence, it is likely that the analysis after five 
years, rather than fourteen years of follow-up, gives a more accurate assessment 
between physical activity and incident gallstone disease from baseline data. 
The protective effect of physical activity is supported by work from five 
other aetiological prospective cohort studies which demonstrated an inverse 
association with gallstones 111-115. However, none of these used a physical activity 
questionnaire validated against physiological parameters which is a more accurate 
assessment of physical activity. A study of 7 831 American men of Japanese 
ancestry 111, reported a relative risk (RR) between the highest and lowest quartiles 
of physical activity of 0.7 (95% CI=0.6-1.0). In the US Health Professionals 
Follow-Up Study of 45 813 men 112, the RR of gallstone disease between the 
highest and lowest quintiles of physical activity was 0.63 (95% CI=0.51-0.79).  
Similarly, in the US Nurses’ Health Study of 60 290 women 113, those in the 
highest quintile of activity had a RR of cholecystectomy of 0.69 (95% CI=0.61-
0.78). A US study of 8 010 postmenopausal women 114 reported participants in the 
two lowest quartiles of physical activity had an odds ratio (OR) of 1.59 (95% 
CI=1.11-2.29) and 1.57 (95% CI=1.11-2.23) of developing gallstones compared 
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with the highest quartile. The same study randomised 182 women to a walking 
intervention programme with follow up for 14 years. Women in the lowest tertile 
of physical activity had a 13% higher risk of developing gallstones (OR=1.13, 95% 
CI=1.01-1.28). Two other prospective studies failed to demonstrate associations, 
although they had significant methodological weaknesses including the use of an 
unvalidated method of recording physical activity and a prolonged follow-up 
period of up to 50 years.85, 258 
The results from EPIC-Norfolk and previous studies demonstrate that 
physical activity reduces the risk of developing symptomatic stones. A prospective 
study using trans-abdominal ultrasonography helped to clarify whether physical 
activity exerted this effect by reducing symptoms or by preventing stone 
formation.115 A cohort of 2 130 American Indian men and women, a population 
with a high risk of developing gallstones, underwent ultrasonography examination 
at baseline to exclude prevalent gallstones and then repeated the ultrasonography 
after four years of follow-up. Physical activity was recorded at baseline using an 
questionnaire assessing leisure and occupational activity.The authors found that 
650 participants developed gallstones which were either silent or symptomatic. The 
median baseline physical activity levels were lower in both women (p<0.01) and 
men (p<0.10) with new gallstone formation. These results suggest that exercise 
reduces gallstone formation rather than reducing symptoms from existing stones. In 
summary, data from experimental and aetiological work suggests that increased 
physical activity reduces gallstones by a causal mechanism. The results in 
epidemiological studies are consistent and with large effect sizes with a dose 
response. 
 
Alcohol 
We detected inverse association between increased alcohol intake and 
symptomatic gallstone disease in men, but not women. In men, each additional unit 
of alcohol (10mls or 7.9grams) significantly reduced the risk of symptomatic 
gallstones by 3% and there was a significant trend across categories (HR=0.82 95% 
CI 0.68-1.00, p=0.044) although no individual categories reached statistical 
significance. Larger numbers of cases and controls in each category may have 
allowed detection of a small effect. There are several biological mechanisms which 
could account for the protective effect of alcohol. Alcohol stimulates 
cholecystokinin release116 and gut motility117 which prevents biliary stasis and 
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cholesterol crystal aggregation.32 Alcohol also increases serum HDL levels 118-120 
by reducing cholesteryl ester transfer protein (CETP) activity which prevents the 
conversion of HDL into LDL,121 with increased HDL leading to reduced 
cholesterol concentration in the bile.74 
 Prospective cohort studies from the United States have reported inverse 
associations between alcohol intake and gallstones in the Health Professional 
Follow-Up Study of men (1.9-3.8 units/day alcohol vs no intake RR=0.75, 95% 
CI=0.60-0.93)124 and the Nurses’ Health Study in women (1.9-3.8 units/day alcohol 
vs no intake RR=0.80, 95% CI=0.72-0.89).125 The Atherosclerosis Risk in 
Communities (ARIC) Study involving 12 773 men and women from four different 
US states (North Carolina, Minnesota, Mississippi and Maryland) who were either 
white (9478 participants) or African American (3295) reported a negative 
association in women (>7 drinks/week RR=0.53, 95% CI=0.3-0.9), although no 
effect in men.88 The Italian MICOL study used ultrasonography in 14 272 men and 
identified 787 participants with asymptomatic gallstones (hence avoiding 
protopathic bias) which found a protective effect of alcohol in men (chi-
square=10.9, p=0.001). However, in 11 850 females of which 1 014 had silent 
gallstones, alcohol was not significantly protective (chi-square=1.4, p=0.24).169  
Our study also failed to detect an effect of alcohol in women which is a finding 
replicated in two other case-control studies.103, 205 The lack of effect in women in 
this study could be due to the lower rates of alcohol consumption in women with 
only 21.5% drinking more than 7 units (56g) of alcohol a week compared to 46.4% 
of men. Therefore, a lack of subjects and hence power may cause a small inverse 
association to be undetected.  Also, we used a single food-frequency questionnaire 
at recruitment to estimate alcohol intake, unlike the US Nurses’ Health Study 
which used repeated assessments of alcohol intake during follow-up. A single 
recording of alcohol intake will lead to measurement error and an underestimation 
of any effects, if one is present, which may explain the lack of effect found in 
women.  
There is accumulating evidence to support a causal role for alcohol 
preventing gallstones, including biochemical and experimental data, although its 
effect size is likely to be modest. However, before it can be deemed a causal factor, 
the inconsistency of reports needs to be clarified. This could be achieved by using 
more accurate assessments of alcohol intake in future aetiological work to reduce 
measurement error, as well as the larger cohort sizes. 
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Lipids 
The three risk factors previously discussed, namely obesity, physical 
activity and alcohol may all exert their effects through alteration of the lipid 
profile. Raised triglycerides could influence gallstone formation by increasing 
biliary cholesterol saturation73 and mucin production75 and decreasing gallbladder 
motility90 all of which increase the risk of gallstone formation. Increased serum 
HDL may prevent gallstone formation as it is the major source of cholesterol for 
biliary secretion with a much larger fraction secreted in the form of bile acids 
compared to that of LDL94 leading to  reduced biliary cholesterol saturation.74 This 
study is the largest prospective study evaluating serum lipids and the risk of 
gallstone disease and reported that raised serum high density lipoprotein-
cholesterol (HDL) and decreased triglycerides were associated with a reduced risk 
of symptomatic gallstone disease.  
In the stratified analysis, an elevated serum triglyceride increased the risk 
of gallstones only in men with a BMI <25kg/m2, with no effects in women, 
suggesting an increased BMI may not exert its effects via elevation of triglycerides. 
The stratified analysis of BMI and HDL showed a decreased risk of gallstone 
disease with increased serum HDL in all BMI categories for both men and women 
which neither supports nor contradicts the theory that obesity increases gallstone 
risk by suppressing serum HDL. In the stratified analysis of alcohol intake and 
triglycerides, men consuming the most alcohol (>7 units/week) with high 
triglycerides had the greatest risk of gallstone disease suggesting that alcohol may 
predispose some the gallstone disease by elevating serum triglycerides. In the 
stratified analysis of alcohol intake and HDL, in men, a similar protective effect of 
increased HDL was found in those consuming alcohol, suggesting that alcohol 
could protect against gallstone disease by increasing HDL.   
There are two previous prospective cohort studies that have evaluated the 
relationship between gallstone disease and serum lipids, the largest being the 
Atherosclerosis Risk in Communities (ARIC) Study in the US of 12 773 men and 
women88 which is similar to our work in Norfolk and found the same trends and 
magnitudes of associations. Elevated HDL was negatively associated with 
gallstone disease in men (highest vs lowest quarter HDL, RR=0.42, 95% CI=0.3-
0.7) and in women (highest vs lowest quarter HDL, RR=0.64, 95% CI=0.5-0.9). 
Raised triglycerides were positively associated with disease in men (highest vs 
lowest quartile RR=1.65, 95% CI=1.0-2.7) and in women (highest vs lowest 
quartile RR=2.57, 95% CI=1.7-3.9). An Italian study evaluated the gallbladder 
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with ultrasonography at enrolment and repeated it 10 years later to assess for new 
gallstone formation.81 Here 232 men and 253 women were identified with new 
incident gallstone disease. In men there was a negative association with HDL 
cholesterol (regression coefficient (RE)= -0.0118, p<0.040) and total cholesterol 
(RE= -0.0034, p<0.030) and a positive association with triglycerides (RE= 0.0004, 
p<0.007). In women no associations were found with any of the serum lipids. A 
limitation of the lipids data was the use of non-fasting blood sample to measure 
serum lipids. Serum HDL and total cholesterol are not significantly different in the 
fasting and non-fasting state.259 However, serum triglycerides remain elevated for 
several hours after eating and the calculation of serum LDL is dependent on serum 
triglycerides and hence for accurate measurement of these two lipids a 12-hour fast 
is recommended.259 The lack of fasting samples in EPIC-Norfolk would cause 
measurement error in serum triglyceride and LDL level with an underestimate of 
the magnitude of effects found. Overall, consistent findings from the previous 
American and Italian studies, and now the largest prospective study to be 
conducted, helps to support a role for the dyslipidaemia found in obesity and 
metabolic syndrome in the aetiology of gallstones. These findings are consistent 
with the epidemiological associations we found with obesity, physical activity and 
alcohol and may explain the route through which they act. 
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2. Diet 
 
The results from this study are the first to be reported in a prospective 
investigation using 7-day food diaries to measure dietary intake in a large cohort. 
Diet is a plausible environmental factor to investigate in the aetiology of gallstone 
disease cancer, with different nutrients having effects on mechanism involved in 
gallstone formation. When assessing the role of diet in disease there are limitations 
to an epidemiological studies. Measurement of diet lacks precision and specificity, 
causing small effect sizes to be difficult to detect. Further measurement error is 
incurred if the physical attributes of a food are not taken into consideration i.e. 
cooking style and preparation, freshness etc. which can affect nutrient values. 
Finally, nutrient intakes are highly correlated, and therefore attribution of causation 
to one nutrient considered to be acting on its own may be misleading. 260 Each of 
these limitations should be considered when drawing conclusions from results 
obtained. 
 
Total energy intake                                               
There was no effect of total energy intake after either age adjustment or in 
the multi-variate model. There is a lack of plausible biological mechanisms to 
explain how total energy intake may contribute to gallstone disease beyond a 
possible contribution to obesity. Our findings are consistent with previous 
prospective studies which reported mixed findings. Results from the US Nurses’ 
Health study revealed that among the 59 306 women whose BMI was less than 25 
kg/m2, a high energy intake (>8200 J per day), as compared those with a low 
energy intake (<4730 J per day), was associated with an increased incidence of 
symptomatic gallstones (RR=2.1; 95% CI=1.4-3.3).159 However, in those with a 
BMI>25 energy intake did not increase the risk of developing gallstones. The 
results were only adjusted for age and alcohol intake with none for physical 
activity, parity or HRT use and BMI was only defined into two categories. Hence, 
although this prospective study has been conducted using appropriate 
methodology, the failure to adjust for many confounders and to find an association 
in those with a BMI> 25 suggests that the importance of total energy intake is 
uncertain. A smaller US prospective study of 4 730 women used data recorded in 
the National Health and Nutrition Examination Survey collected between the year 
1971-75, who were then followed-up for 10 years. The authors reported that in 
women below 50 years of age there was a decreased risk of developing hospitalised 
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gallstone disease with an increased energy intake (HR 75th percentile vs 25th 
percentile =0.69 95% CI=0.53-0.88), although no adjustment was made for 
physical activity.160 The Italian MICOL study using ultrasonography to assess for 
asymptomatic gallstone disease found that in men an increased total energy intake 
was associated with a reduced risk of gallstones (highest vs lowest quintile of 
intake RR=0.79, 95% CI=0.63-0.99, p for trend =0.004) although no effect was 
seen in women.169 The study design of MICOL negated recall and protopathic bias 
but not adjust was made for physical activity. A variety of cross-sectional and case-
control studies have found positive, negative and no associations, although they are 
limited by study numbers and design.127, 203-204, 261 Results from this study suggest 
that total energy intake is not directly associated with the development of gallstone 
disease after adjusting for known co-variates including obesity and physical 
activity. This revives the hypothesis that the composition of the diet, rather than the 
absolute intake of energy, could determine gallstone risk. 
 
Total fat  
This work found that total dietary fat was not associated with gallstone disease in 
either men or women. Previously total dietary fat was thought to contribute to 
weight gain and hence promote gallstone formation, although it is now recognised 
that total dietary fat is not a risk factor for weight gain.162-164 The lack of a plausible 
biological mechanism for total dietary fat is supported by the epidemiological data 
which has failed to find a consistent association between this macronutrient and 
gallstone disease. The largest prospective cohort to assess dietary fat was the 
Nurses’ Health study of 88 837 women, followed-up for 4 years and identified 433 
participants undergoing cholecystectomy. The highest vs lowest quintile of fat 
intake had a RR of cholecystectomy = 0.9 (95% CI=0.7-1.1, p for trend=0.8).206 
Data from other epidemiological studies has also not supported an effect of total 
dietary fat on gallstone disease. The data from this study, previous epidemiological 
studies and the lack of supporting experimental evidence suggests that total fat 
intake is not associated with gallstone disease. However, fat composition and 
individual fatty acids, rather total dietary fat, need to be considered when reaching 
conclusions about dietary fat and the risk of developing gallstone disease. 
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Trans-fatty acids 
This study found that an increased dietary intake of trans-fatty acids 
(TFAs) were associated with an increased risk of gallstone disease in women, but 
not in men. TFAs are known to alter the serum lipid profile, causing raised 
triglycerides and decreased HDL191, both of which are associated with an increased 
risk of gallstone disease. TFAs also increase insulin resistance 185, 188 which is also 
associated with gallstone disease. Only one previous epidemiological study has 
been published which has evaluated the association of trans-fatty acids and 
symptomatic gallstone disease. The US Health Professionals Follow-up Study of 
45 912 men monitored for 14 years identified 2 356 new cases of symptomatic 
gallstone disease.193 After adjusting for co-variates, men in the highest compared to 
the lowest quintile had a RR of disease of 1.23 (95% CI=1.04-1.44, p for 
trend=0.03). The results reported from EPIC-Norfolk for women after 10 years 
follow-up are of a higher magnitude (HR=1.95, 95% CI 1.06-3.54, p for 
trend=0.051). The greater effect size in EPIC-Norfolk could be due to the use of 7-
day food diaries rather than food frequency questionnaires which were used in the 
Health Professional study. FFQs have greater measurement error for nutrient intake 
causing an underestimation of the true effect size. EPIC-Norfolk failed to detect an 
effect for men, although this might be due to the small number of cases in men. 
There are consistent results from this work, the Health Professionals Study and 
experimental investigations that suggest trans-fatty acids promote gallstone 
disease. Measures already undertaken to reduce TFAs consumption in the diet over 
the past decade could therefore lead to a fall in gallstone incidence and the 
industrial eradication of TFAs from the diet should be encouraged. Further research 
into this area is may be difficult to undertake due to lower levels of TFA in the diet 
and ethical issues concerning the introduction of TFAs into the diet. 
 
Dietary cholesterol 
 This study found that the highest quintile of dietary cholesterol intake, after 
10 years of follow-up in women, was associated with a 41% (HR=0.59 95% 
CI=0.35-0.99) reduction in symptomatic gallstone disease (p for trend=0.015). No 
associations were found in men. Dietary cholesterol may influence gallstone 
formation through complex regulatory affects in the liver. The conversion of 
cholesterol into bile salts is a major pathway for its elimination from the body, 
along with direct hepatic excretion.262 The exact serum lipid source of the 
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cholesterol excreted into the bile is unclear, although it is likely to be derived from 
an increased uptake of HDL and LDL as well as the decreased conversion of 
cholesterol into bile salts.37 Cholesterol is involved in two negative feedback 
mechanisms which could influence gallstone formation. The first involves the rate 
determining enzyme in bile salt synthesis, cholesterol 7-alpha hydroxylase 
(CYP7A). Dietary cholesterol is known to up-regulate CYP7A which leads to 
increased bile salt production, with less cholesterol available for excretion in the 
bile, both of which reduce the risk of gallstone formation.26  Lith gene analysis has 
identified a further cholesterol negative feedback mechanism.  A family of 
transcription factors called sterol regulatory element binding proteins (SREBP) 
regulate the synthesis of cholesterol, especially SREBP-2. When cholesterol levels 
are low, SREBP-2 is released and activates genes for HMG-CoA reductase, as well 
as other enzymes involved in cholesterol synthesis.263 In summary, raised dietary 
cholesterol intake could lead to a reduced risk of gallstone formation by up-
regulating CYP7A which increases bile salt excretion, and also by inhibiting the 
release of SREBP-2, which down-regulates hepatic cholesterol synthesis, with both 
these effects reducing biliary cholesterol concentration. Therefore, the previous 
hypothesis that dietary cholesterol could lead to stone formation may have been too 
simplistic. 
Previous epidemiological studies evaluating the role of dietary cholesterol 
have shown inconsistent results. The only large prospective cohort study, which 
used food frequency questionnaires to assess dietary cholesterol intake in 88 837 
women, did not find any association (highest vs lowest quintile RR=1.0, 95% 
CI=0.8-1.3).206 The results from case-control and cross-sectional work include an 
increased risk of gallstones with increased dietary cholesterol203-204 and a decreased 
risk.127, 205 However, a randomised control trial in men from Los Angeles of a diet 
designed to lower plasma cholesterol (high in unsaturated fat, low in saturated fat, 
low in cholesterol, and high in plant sterol) reported that those receiving the 
experimental diet versus those on a normal diet had a higher rate of gallstone 
prevalence (34% vs 14%, p<0.01).264 Furthermore, in those on the experimental 
diet, the prevalence of gallstones correlated with the number of trial meals eaten 
(p<0.05). 264 These study findings lead to an editorial in the New England Journal 
of Medicine suggesting that a diet designed to lower plasma cholesterol may 
promote gallstone formation,265 although it is unclear which element of the diet 
may have lead to the increased gallstone prevalence. 
There are several cautions to interpreting the findings for dietary 
cholesterol in women, particularly since these findings were not replicated in men. 
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Dietary cholesterol intake could also be correlated with an altered lifestyle or 
dietary behaviour. For example, those who are overweight may have been told to 
reduce total fat and cholesterol in their diet and hence have a low cholesterol 
intake, although in the analysis adjustment was made for BMI. Alternatively, 
participants with high serum cholesterol may have been following a low 
cholesterol diet and may also have been treated with a fibrate or statin. However, 
serum cholesterol is not associated with gallstone disease,88 and although fibrates 
promote stone formation, current evidence suggest that statins reduce the risk of 
gallstones. Overall, the finding that dietary cholesterol protects against gallstone 
disease is supported by a plausible mechanism and the previous similar finding in 
the study of men from Los Angeles.264 However, further epidemiological research 
into the association is needed to look for a consistent effect before increased 
dietary cholesterol could be regarded as reducing the risk of gallstone disease. 
 
Iron 
 Dietary iron was associated with a highly significant decreased risk of 
gallstone disease in women, but not men, after 10 years of follow-up. The highest 
quintile of intake had a HR of 0.35 (95% CI=0.71-0.94) with an 18% reduction for 
each increased fifth of intake (p for trend=0.004). The lack of effect in men may be 
due to the low rates of iron deficiency in men. Iron has several biological effects 
which could account for a reduced risk of gallstone disease. Iron is required for the 
effective function of the enzyme CYP7A1, enabling cholesterol conversion into 
bile salts which maintains biliary cholesterol in solution.28 Iron is also required for 
nitric oxide synthase function, with iron deficiency associated with decreased 
gallbladder motility 217 and impaired sphincter of Oddi dysfunction 218 which both 
promote gallstone formation. Furthermore, there is a pro-nucleating effect of raised 
biliary transferrin levels found in iron deficiency.216 
Only one previous prospective study has evaluated dietary iron intake, and 
this was conducted solely in men. The US Health Professionals study followed-up 
44 758 men for six years with 2 468 developing symptomatic gallstones. Those 
with a higher intake of haem iron were at an increased risk of developing gallstones 
(highest quintile vs lowest RR=1.21, 95% CI=1.03-1.42), although non-haem iron 
intake was not associated (highest quintile vs lowest RR=1.14, 95% CI=0.99-
1.31).220 This study was in men aged 40-75 years, which is a group vulnerable to 
iron overload, since iron stores accumulate in linear fashion in men with increasing 
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age 266 with excess iron stores possibly contributing to stone formation. The authors 
suggested that elevated iron stores can induce lipid peroxidation, generating 
hydroxyl radicals that stimulate mucus glycoprotein secretion into the gallbladder 
and promote cholesterol crystal formation. They commented that a diet with a high 
iron content may be correlated with increased meat intake and hence increased 
dietary saturated fat and triglyceride intake, which could promote gallstone 
formation, although the study did correct for saturated fat intake.  
Several small aetiological studies have been published suggesting that iron 
deficiency promotes gallstone formation. A Turkish case-control study compared 
gallstone prevalence in 111 iron deficient patients against 81 controls using 
ultrasonography.221 The prevalence of gallstones or previous cholecystectomy was 
higher in the iron deficient patients ( 13.5% vs 6.2%, p=0.048). They also assessed 
gallbladder motility in both groups using gallbladder emptying studies, and 
reported a higher residual volume of the gallbladder in those with iron deficiency 
(4mls vs 2.8ml, p=0.035) indicating impaired gallbladder motility. An Indian study 
of 100 patients admitted with gallstone disease measured serum iron and biliary 
cholesterol concentrations. Patients with iron deficiency had increased biliary 
cholesterol compared to those with normal serum iron levels (biliary cholesterol 
375mg/dl vs 214mg/dl, p<0.0001).222. A similar study of 50 patients with gallstone 
disease divided patients into two groups dependent on whether they had normal or 
low serum iron levels and reported gallbladder cholesterol concentrations were 
significantly higher in the low serum iron group (0.7g/dl vs 1.2g/dl, p<0.0001).223 
 In this work from EPIC-Norfolk, increased dietary iron was associated 
with a decreased risk of gallstones in women with the magnitude and dose-effect 
supportive of a causal effect suggesting this is a true association. This novel finding 
could partly account for the increased rates of gallstone disease seen in women of 
child bearing age who are prone to iron deficiency and gallstone disease. Further 
epidemiological studies are needed to confirm this association and imply causation, 
although it may be possible to use data collected from randomised controlled trials 
of iron supplementation in women to assess if such therapy is associated with 
lower rates of gallstone disease. 
 
Niacin 
 I believe this is the first epidemiological study to evaluate the effect of 
dietary niacin intake on the risk of developing gallstone disease. The study found 
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that in women, after 10 years of follow-up, dietary niacin significantly reduced the 
risk of disease, with those in the top quintile 46% less likely to develop gallstones 
compared to those in the bottom one. Furthermore, there was a 14% reduced risk 
for each increased quintile of intake (p for trend=0.004). No effects were found in 
men, although all four higher quintiles had a non-significant inverse association 
with gallstone disease. Niacin could prevent gallstone disease by its known 
biological effects on lipid metabolism and is already used by cardiologists to 
prevent vascular disease.267 Niacin increases serum HDL and lowers serum 
triglycerides, with these lipid changes associated with a reduced risk of gallstone 
disease. However, cardiologists prescribe niacin at doses of 1 to 2 grams a day 
whereas the average dietary intake in EPIC-Norfolk was 17 mg per day in women 
and 21 mg per day in men. 
 There are no human studies which have directly investigated the effects of 
dietary niacin on gallstone disease or biliary composition. However, in the 1970’s a 
large randomised controlled trial in 8 341 men with a previous myocardial infarct, 
assigned participants to one of several treatments, including either niacin 
3grams/day (1 110 participants), clofibrate 1.8 grams per day (1 103) or placebo (2 
789). The primary end-points were vascular events with secondary end-points 
including incident gallbladder disease (either cholecystectomy or symptomatic 
gallstones). In those treated with niacin the five year rate of new gallbladder 
disease was 2.7% vs 2.0% (p=0.18) in the placebo group. This placebo controlled 
trial suggests that niacin supplementation may not prevent gallstone disease in 
men, although similar studies have not taken place in women who had an inverse 
association with niacin in this study. Further epidemiological and clinical studies 
on the effect of dietary niacin, particularly in women, would need to be undertaken 
before advocating that niacin has a direct effect in preventing gallstone disease. 
 
Fibre 
Dietary fibre was not associated with symptomatic gallstone disease in 
either gender after 10 years of follow-up which was defined as the primary end-
point. Women did have negative associations for each higher quintile of intake, 
although none reached statistical significance (highest vs lowest HR=0.68, 95% 
CI=0.41-1.13). There are biological mechanisms to account for fibre preventing 
gallstone formation. These include shortening intestinal transit times which reduces 
the formation of hydrophobic secondary bile salts which may otherwise promote 
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gallstone formation. Fibre also has some modest effects on serum lipid, although 
these appear to mostly be to decrease serum total cholesterol and LDL-cholesterol 
rather than raising HDL or decreasing triglycerides.234 
Dietary fibre has been assessed in the US Nurses’ Health Study which 
followed-up 69 778 women for 16 years identifying 5 771 cases of 
cholecystectomy. Women in the highest quintile compared to the lowest intake of 
fibre, had a relative risk of cholecystectomy of 0.87 (95% CI=0.78-0.96, p for 
trend=0.005) with the effect maintained for insoluble fibre, but not soluble fibre. In 
the analysis, adjustments were made for many lifestyle habits which could be 
correlated with increased fibre intake (i.e. smoking, physical activity and alcohol) 
which lead to a strengthening of the association. However, the authors also 
adjusted for factors not proven to be risk factors for gallstone disease including 
dietary protein and saturated fat.236 The modest inverse effect reported in the 
Nurses’ Health Study may concur with the borderline results found in EPIC-
Norfolk. If EPIC-Norfolk had had more cases of disease, an significant effect may 
have been identified. Although EPIC-Norfolk had the benefit of using 7-DFDs to 
measure diet, detecting a statistically significant small effect size with only 201 
cases identified would be difficult. The only other prospective cohort study of 
women found an inverse association between fibre and gallstone disease.160 No 
studies have reported an effect of fibre in men169 which reflects the findings in this 
study. 
 
Calcium 
 In men, dietary calcium was associated with a significant increased risk of 
gallstone disease after 10 years of follow-up (highest quintile of intake vs the 
lowest HR=2.31, 95% CI 1.00-5.35, trend across categories HR=1.25, 95% CI 
1.03-1.52, p=0.023). In women, no effects were found for dietary calcium intake. 
There are biological mechanisms by which calcium intake could both increase and 
decrease the risk of gallstone disease. Calcium salt precipitation plays a 
fundamental role in the formation of all types of gallstones,237 with the bile of 
patients with gallstones containing a higher concentration of calcium then those 
without gallstones.239-240 Patients with a history of primary hyperparathyroidism, 
which causes hypercalcaemia, have been found in some but not all surveys to have 
an increased prevalence rate of cholelithiasis.241-243 Through these mechanisms 
increased dietary calcium could raise the risk of gallstone disease, as reported in 
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this study. However, the previous but sparse epidemiological data suggested a 
protective role for calcium, possibly due to the ability of this mineral to bind to 
secondary bile salts in the gut lumen which prevents their re-absorption. The 
prospective Dutch Zupten study of 860 men identified 54 cases of symptomatic 
gallstone disease and reported that the top tertile of calcium intake was associated 
with a reduced risk of gallstones (HR=0.3, 95% CI 0.1-0.7).168 A case-control study 
of only 54 cases and 46 controls also reported calcium was associated with a 
reduced risk of gallstone disease in women, but not in men.203 However, until this 
investigation in Norfolk there was a lack of a large prospective study. The results 
from EPIC-Norfolk indicate that dietary calcium intake needs to be investigated 
further as a potential risk factor for gallstone disease. There are limitations to our 
study, which include the null finding in women, which increases the likelihood that 
the increased risk found in men was a chance finding. The study does not include 
an assessment of calcium supplementation, which could explain the null effect in 
females who are more likely to use calcium supplements. Future research could use 
the populations studied in previous randomised controlled trials of oral calcium 
supplementation undertaken in the fields of osteoporosis and hypertension, to 
evaluate if calcium supplementation lead to increased rates of gallstone disease. 
 
Coffee 
In men, but not women, caffeinated coffee had a strong inverse association 
with symptomatic gallstone disease, with each cup drank per day reducing the risk 
by 23%. No effects were found for tea or decaffeinated coffee, for men or women. 
Caffeinated coffee has metabolic effect that influence gallstone formation 
including, increased CCK release and gallbladder contraction,245 increased bile 
flow and reduced gallbladder bile protein levels,246 and reduced gallbladder fluid 
absorption.247  
The results from EPIC-Norfolk are supported by the US Health 
Professionals study of 51 529 men. Over a  10 year period, 1 081 participants were 
identified with symptomatic gallstone disease.268 The consumption of caffeinated 
coffee was associated with a dose dependent negative association with ≥4 cups a 
day RR=0.67 95% CI=0.53-0.84. No effect was reported for tea or decaffeinated 
coffee., although the Nurses’ Health study did report an inverse association. In over 
80 000 women, 7 811 cases of cholecystectomy were reported during 20 years of 
follow-up. In those who consumed caffeinated coffee there was a statistical inverse 
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association with a dose effect for 1, 2-3 or ≥4 cups a day compared to no intake (≥4 
vs 0, multivariate RR=0.77, 95% CI=0.71-0.83, p for trend<0.001).269 Caffeinated 
drinks of any type were also found to have an inverse association, although 
decaffeinated coffee was not associated with risk. EPIC-Norfolk did not find an 
association in women, which could either be due to a reduced effect of coffee in 
women or that over risk factors i.e. parity, HRT use, override the effects of coffee.  
Several studies have reported no effect of coffee intake,249-251 but they are 
limited by being cross-sectional surveys of prevalent disease which may incur bias 
due to the avoidance of coffee, particularly since it stimulates gallbladder 
contraction which could provoke biliary colic. EPIC-Norfolk is the first European 
study to report a protective effect of caffeine in men but no effects of decaffeinated 
coffee. This is likely to be a true association, as there is a large dose-dependent 
effect, it has been replicated in previous cohort studies and there are supporting 
biological mechanisms and experimental work. 
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3. Strengths and limitations of the study design 
 
There are several strengths and limitations to the study which need to be 
considered when interpreting the findings. A large population cohort was used in 
EPIC-Norfolk which reduces the possibility of chance findings in our results. 
However, with only 86 cases of incident gallstone disease after 10 years of follow-
up available for analysis in the male population, chance findings become more 
likely. However, for all the associations found in this study there are plausible 
biological mechanisms to support their role and usually either supporting animal or 
human intervention studies. 
 
Internal validity 
Chance 
The internal validity of a study is dependent on chance, bias, confounding 
and measurement error. There are several advantages and limitations to this study 
which need to be considered when interpreting the findings. A relatively large 
population cohort was used in EPIC-Norfolk, of over 25 000, with 166 female & 
82 male incident cases of gallstone after 10 years and 201 women and 95 men after 
14 years which is of sufficient magnitude to minimise chance findings, although 
this was more likely to occur for men. For all the associations found in this study 
there are plausible biological mechanisms to explain their action, with either 
supporting animal or human intervention studies.  
Chance finding are minimised in larger studies such as the US Nurses’ 
Health Study which included >60 000 women, with >1 000 000 person-years 
follow-up and identified over 6 000 cases of cholecystectomy,131, 270-271 and the US 
Health Professionals Study which included >40 000 participants, with >500 000 P-
Ys follow-up identifying >2 000 incident cases of symptomatic gallstones.193, 220, 272 
However, these large cohort studies did not benefit from utilising the more accurate 
methods of measuring risk exposures used in EPIC-Norfolk, such as the 7-day food 
diaries. The size of the US studies will have compensated for some of the 
inaccuracies of measurements, but they may still be unable to detect the effect of 
specific nutrients if the dietary assessment method was not of sufficiently detailed. 
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Selection bias 
A major advantage was the prospective design of this study which 
minimises several potential sources of bias. The anthropometric, serum lipid, 
physical activity and dietary data were collected at baseline prior to the 
development of known gallstone disease. The prospective study design also 
reduced selection bias as cases and non-cases are drawn from the same population. 
If cases and non-cases are compared at the time disease is identified, there is the 
potential for differential reporting of exposures, particularly dietary intakes, which 
is a limitation of the case-control design. Also, symptoms may alter behaviour in 
those with gallstone disease, in particular they may alter their diet by decreasing 
foods which precipitate symptoms causing a “protopathic” bias123 and leading to  
type 1 error. To minimise bias introduced by a disease altering behaviour prior to 
its diagnosis, no cases were included if they were diagnosed within 18 months of 
enrolment into EPIC-Norfolk. 
 
Regression dilution bias 
All the analyses relied on a single baseline measurement, which after 
prolonged follow-up, can lead to regression dilution bias due to participants 
altering their diet. Prospective studies which analyse disease risk from just one 
initial baseline survey of an exposure, may underestimate the magnitude of risk of 
disease after longer periods of follow-up. This effect is amplified if the analysis 
includes many co-variates, all of which become less accurate over time.257 This 
random measurement error occurs as some of the population will change their 
magnitude of exposure to the risk over time. In EPIC-Norfolk, we considered that 
physical activity and dietary intake were particularly vulnerable to variation over 
time. Ideally, the analysis should be made after the shortest period possible prior to 
the development of symptoms to minimise the effects of regression dilution bias, 
whilst allowing an appropriate follow-up period to acquire a significant number of 
incident cases of disease. For physical activity, the primary analysis was performed 
after five years to allow the accumulation of a significant number of incident cases, 
and the secondary analysis after fourteen years of follow-up to give a more 
accurate assessment between physical activity and incident gallstone disease from 
baseline data, and indeed a stronger association was seen at 5 years than 14 years. 
In dietary analysis, the analysis was performed after 10 years follow-up and in 
future work we intend to include data from diaries completed by participants after 
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18 months and 5 years of follow-up which will help to minimise regression dilution 
bias. 
 
Follow-up bias 
Follow-up bias could occur if those with a specific characteristic were 
more likely to move away from the catchment area of the local hospital where 
incident cases of gallstone disease were identified. For example; if more 
participants with a high level of physical activity moved outside the catchment area 
of the local hospital compared to inactive participants, then our study would 
conclude a higher level of physical is associated with a lower risk of disease. 
However, this is unlikely to occur on a large scale as the study population chosen 
had little outward migration.41 Follow-up bias could also occur due to a limitation 
in the method of identifying cases of potential gallstone disease. All patients were 
identified at the Norfolk and Norwich University Hospital (NNUH) using the 
hospital database records, although EPIC-Norfolk participants treated at 
surrounding NHS hospital such as James Paget Hospital in Great Yarmouth or 
local private hospitals would not be identified. It is unlikely that participants 
treated at NHS hospitals would have different characteristics or behaviour to those 
treated at the NNUH. Follow-up bias may occur by not identifying patients treated 
in the private sector, as they are likely to have different lifestyle and diet 
characteristics. However, we suspect that numbers solely treated in the private 
sector are small and would not significantly alter results. 
 
Lack of asymptomatic stones and stone type 
A limitation of this study was that no evaluation was made of prevalent 
asymptomatic stones either at recruitment or during the follow-up period. Previous 
studies have used ultrasonography to evaluate the presence of “silent” gallstones at 
both enrolment and follow-up which provides information on whether both 
asymptomatic and symptomatic stones have similar risk factors, which they do.81-82, 
126
 However, this study was not originally designed to evaluate prevalent gallstone 
disease and screening a cohort of over 25 000 people with ultrasonography would 
be costly and unfeasible. From the outset, this study did not attempt to estimate the 
incidence of gallstone formation but rather the incidence and risk factors for new 
symptomatic gallstones, which are of direct clinical and public health importance. 
No analysis was made of whether the cases of gallstone disease were due to 
cholesterol stones, brown, black or mixed pigment stones. This would have been 
particularly useful in clarifying which biological mechanism may be involved and 
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is probably of particular relevance to the findings for dietary iron and calcium since 
they are more likely to be involved in the pathogenesis of pigment stones. 
However, the majority of gallstones in the Western population are cholesterol 
stones. 
 
Adjustment for known risk factors 
Importantly, in the analysis we adjusted for the majority of known risk 
factors for gallstones, although there was no information on family history of 
gallstones, rapid weight loss and prolonged fasting which can affect stone 
formation.60-61,160, 169 A family history of gallstones and associated genes are 
estimated to contribute around 25% of the total gallstone risk.36 However, this 
deficiency may be less important as the genes need to interact with environmental 
factors to cause disease. The genetic predisposition to gallstones arises from 
polymorphisms in multiple genes with each making a small contribution to the risk 
of developing disease.37 Genes can lead to disease via either gene-gene interactions 
or interactions with the environment including diet, obesity, drugs or pregnancy. It 
would have been useful to assess if those with a family history of disease had an 
interaction with any of risk factors in this study. 
 
External validity 
The study is generalisable to a UK population aged between 45-74 years of 
age who are most susceptible to gallstones. However these results cannot be 
extrapolated to younger adults and children as they are not included in the study 
population and may have different risk factors. The disease presentation in this 
study was representative of that seen clinically, being predominantly biliary colic. 
The previous justification for the role of several nutrients in gallstone disease have 
been based upon animal models or on the acute feeding of human subjects with the 
volumes or doses of the nutrient given much higher than that achieve normally in 
the diet. However, both of these models are likely to be unreliable when 
interpreting the chronic effects lower levels of dietary intake. For this reason, the 
evidence collected from EPIC-Norfolk will have much greater validity, as it has 
been demonstrated in a large, diverse UK population.  
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Concluding remarks of the discussion 
This large UK prospective cohort study investigating the aetiology of 
gallstone disease has for the first time reported significant effects of dietary trans-
fatty acids, cholesterol, iron and niacin in women and calcium in men. The 
discovery of these novel risk factors was aided by the use 7-day food diaries which 
provided the most accurate measure of dietary intake undertaken in a large scale 
study. These new findings are supported by biological mechanisms but need to be 
explored in future studies to look for consistent effects, and if confirmed, could 
provide information to modify the diet or behaviour to reduce the risk of 
developing gallstone disease or the recurrence of symptoms. These novels findings 
may have clinical implications such as identifying high risk populations which may 
benefit from the use of appropriate preventative measures. One such population is 
pregnant females who are susceptible to iron deficiency as well as gallstone disease 
and may benefit from iron supplements at an early stage of pregnancy to prevent 
gallstones. Another high risk population are patients with a history of gallstone 
disease who are currently recommended to follow a low fat/low cholesterol diet 
which may actually be contributing to the future development of gallstones or bile 
duct calculi rather than consuming a cholesterol containing diet which may help 
prevent stone recurrence. This scenario is analogous to those who suffer from 
calcium oxalate renal stones who require an appropriate calcium intake to prevent 
recurrent renal stones. Hence the new understanding of the dietary nutrients which 
alter the risk of developing gallstone disease will lead to an improved 
understanding of the biological mechanisms involved in the pathogenesis of 
gallstone disease as well as improved management of those susceptible to stone 
formation. 
This study has also defined the precise effect of previously defined risk 
factors for gallstone disease. The lifestyle risk factors obesity and physical activity 
were estimated for the first time in a UK population, with a supportive mechanism 
of effect from the serum lipids data. Our results confirmed a protective effect for 
alcohol and caffeine intake that in men, but not women. Evidence from EPIC-
Norfolk and other studies will allow a predictive model of gallstone disease to be 
devised, which could lead to public health measures to prevent this common 
gastrointestinal disease. 
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CHAPTER TWO 
 
THE AETIOLOGY OF PANCREATIC 
CANCER 
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Abstract 
 
Pancreatic cancer: physical activity, dietary nutrients and serum vitamin C in 
the aetiology of disease: data from a UK prospective cohort study using 
information from detailed and validated questionnaires. 
 
INTRODUCTION: The aetiology of pancreatic cancer is largely unknown, 
although physical activity and dietary nutrients may prevent carcinogenesis via 
improved insulin sensitivity and prevention of DNA damage. The aim of this 
prospective study was to investigate physical activity and dietary nutrients, 
particularly fatty acids and anti-oxidants, and the risk of developing pancreatic 
cancer. The study benefitted from accurate methods of measuring exposures, 
namely, a physical activity questionnaire, validated against detailed physiological 
measures, and a seven-day food diary (7-DFD), the most accurate pragmatic form 
of measuring diet in large scale epidemiological studies. 
METHODS: A total of 25 639 men and women, aged 45-74 years were recruited 
between 1993-1997 into the European Prospective Investigation into Cancer-
Norfolk. Participants attended a health check at enrolment which recorded their 
anthropometrics, alcohol intake, serum lipids with a questionnaire recording 
occupational and recreational physical activity. A 7-DFD was completed recording 
all food eaten, detailing brands and portion sizes. Nutrient intakes were calculated 
in those diagnosed with pancreatic cancer and a random sample of 3 970 controls, 
using a computer program with information on 55 000 foods. Hazard ratios (HR) 
were calculated, using Cox regression, for developing pancreatic cancer for 
categories of physical activity, nutrient intakes and serum vitamin C, adjusted for 
age, gender, smoking status, body mass index and diabetes, with the addition of 
total energy intake for dietary nutrients. The primary analysis was made after 10 
years follow-up, with a total follow-up period of 17 years. 
RESULTS: During the 10 year follow-up period, 53 participants (41.5% women) 
developed pancreatic cancer (69.7 years (SD=8.6 years). The main findings in the 
primary analysis were statistically significant inverse associations for increased 
physical activity in participants younger than 65 years (“active” vs “inactive” 
HR=0.11 95% CI=0.01-0.88), increased dietary DHA intake (trend across quintiles 
HR=0.80 95% CI=0.65-0.98), a threshold effect for dietary vitamin E and selenium 
and increased serum vitamin C levels (highest vs lowest quintile HR=0.16, 95% 
CI=0.04-0.73, p for trend=0.008). Borderline statistically significant negative 
associations were found for total n-3 fatty acid intake (highest vs lowest quintile 
HR=0.30, 95% CI=0.07-1.21) and the threshold effect of dietary vitamin C.  
CONCLUSION: There were inverse associations for physical activity, serum 
vitamin C and dietary antioxidants and n-3 fatty acids. They are all supported by 
plausible biological mechanisms and justify measuring these factors in future 
aetiological work. If consistent associations are confirmed in future 
epidemiological studies, implying causality, then population-based dietary and 
physical activity recommendations may help prevent a significant proportion of 
pancreatic cancer cases. 
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Introduction 
 
Exocrine pancreatic cancer is a devastating disease causing approximately 
230 000 deaths annually worldwide, representing approximately 2% of cancers 
overall, but 6% of cancer deaths.273 The cancer has a very poor prognosis, with 
only 16% of patients surviving beyond 1 year and just 0.2-3.0% longer than 5 
years.274-275 The poor survival times highlight the need to identify modifiable risk 
factors to prevent the incidence of this lethal disease and to guide developments for 
future treatments. 
The study of the epidemiology of pancreatic cancer has three aims i) to 
describe the distribution and burden of the disease; ii) to elucidate the aetiology; 
iii) to provide information necessary to prevent the disease as well as to help 
understand the biology to aid treatment.276 So far only a few risk factors for 
pancreatic cancer have been clearly defined which hinders the prevention of this 
tumour. The recognised environmental risk factors are tobacco smoking,277 
diabetes 278 and obesity.279-280  Diet is a possible risk factor for pancreatic cancer, 
although not yet confirmed, and could account for some of the differences in 
incidence between countries with different diets and the increased prevalence in 
countries adopting Westernised eating habits.281 However, the results from most 
studies investigating diet have been inconclusive and inconsistent.282-283  
This introductory chapter will review both the descriptive and aetiological 
epidemiology of pancreatic cancer. To identify the relevant literature, searches of 
Medline (OVID and PubMed) were performed identifying English language 
articles, between the years 1950 and March 2011, using terms related to each 
section in this thesis and the keywords “pancreatic cancer” and “pancreatic 
carcinoma”. The bibliographies of retrieved articles were reviewed to identify 
further relevant references. 
 
Definition of pancreatic cancer 
Tumours of the pancreas gland arise from either endocrine or exocrine 
cells, with exocrine tumours accounting for around 97% of all such cancers.284 This 
review concerns pancreatic exocrine cancer, commonly referred to in the literature 
as “pancreatic cancer”. Exocrine tumours are classically ductal adenocarcinomas 
(80%) which show ductal differentiation often with an intense desmoplastic 
reaction in the surrounding stroma. Histological variants of ductal adenocarcinoma 
contribute a further 10% of exocrine pancreatic tumours, namely serous or 
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mucinous cystadenocarcinoma (4%), intraductal papillary-mucinous neoplasms 
(3%) or acinar cell carcinoma (2%).285  
 
1. Descriptive Epidemiology 
 
Incidence 
In the year 2008, 7 781 deaths from pancreatic cancer were reported in the 
United Kingdom (UK).21, 273 The lifetime risk of developing pancreatic cancer in 
the UK is 1 in 86, with most patients dying of the illness, making it the 6th 
commonest cause of death from any cancer.21 The incidence increases rapidly with 
age in both genders, with less than 5% of cases occurring before the age of 50 
years. Between the ages of 50-54 years, the annual incidence of disease is 9.6 cases 
per 100 000 population per year, which rises to 70.0 cases per 100 000 per year in 
people aged 75-79 years (Table 15).21 The largest absolute number of cases occurs 
in those between the ages of 70-79 years, although the rate continues to rise in 
older people. 
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Figure 11. Number of new cases and age specific incidence rates of pancreatic 
cancer by sex, in the United Kingdom 2007 (Source; Cancer Research UK, 200921). 
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Sex 
Worldwide there are approximately 120 000 deaths each year in men and 
107 000 in women.281 In the UK, the age-standardised rates of pancreatic cancer 
are higher for males, although they have declined since the 1970s (12.3 cases per 
100 000 in 1975, 10.1 per 100 000 in 2007), whereas the rates in women have 
remained fairly constant (9.4 cases per 100 000 in 1975, 9.0 per 100 000 in 2007) 
(Figure 12).21 The decrease in men is likely be due to the decline of tobacco 
smoking in males, as this probably accounts for up to 20% of pancreatic cancer 
cases in the UK.277 Although men have a higher age-standardised incidence than 
women, in 2007, females accounted for more cases of disease due to their 
increased longevity (men 3 748 cases vs 3 936 in women).21 
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Figure 12. Age standardised incidence rates of pancreatic cancer for the UK, 1975-
2007 (Source; Cancer Research UK, 200921). 
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Geographic and socioeconomic variation 
Pancreatic cancer is commoner in developed countries where the rates are 
nearly three times greater than in low and middle income ones.283 The highest 
incidence of disease has been reported among Maoris in New Zealand281 and in 
South Koreans286 which may reflect their high rates of smoking. In Western Europe 
(UK, Germany, France, Belgium, Netherlands) the mortality due to pancreatic 
cancer fell towards the end of the last millennium, whilst there were increased rates 
in Southern Europe (Greece, Italy, Macedonia, Portugal).286 The rise in incidence 
in Southern Europe may have occurred due to changes in lifestyle and diet, or the 
increased use of cross sectional imaging, leading to increased diagnosis. This 
initially occurred in the 1980’s in Western Europe and in the 1990’s in Southern 
Europe. In the United States the incidence is stable, although it is noticeable that 
the US black population has a higher annual incidence than whites (10.2 vs 6.6 per 
100 000, 1996-2000).287 Japan experienced a significant increase in age-
standardized mortality rates between 1950 (1.4 per 100 000 population) and 1995 
(12.5 per 100 000 population) 288 which again could be partly due to improved 
diagnostic test or the adoption of a westernised lifestyle. 
Data on the impact of social class on pancreatic cancer risk is limited with 
only two cohort studies published.289-290 The prospective UK Whitehall Study of 19 
019 male government employees reported no effect of socioeconomic status 
(RR=0.95, 95% CI=0.59-1.51), although importantly the cohort did not include 
manual or industrial workers.289 A Norwegian cohort study of 63 374 men and 
women identified 166 incident cases of pancreatic cancer.290 They reported an 
increased risk in women of higher compared to lower socioeconomic status 
(RR=2.5; 95% CI=1.2-5.2), and among men employed in farming, agriculture or 
forestry compared to those with a lower socioeconomic status (RR=2.1; 95% 
CI=1.1-4.0). However, cohort studies have limitations for assessing the impact of 
socioeconomic status on the risk of developing disease, as the population studied 
will not reflect the spectrum of socioeconomic statuses in society. Therefore, 
currently there is insufficient evidence to suggest that socioeconomic status is a 
risk factor for pancreatic cancer. 
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2. Biology of pancreatic cancer 
 
Pancreatic precursor lesions 
 Pancreatic ductal adenocarcinoma is the commonest histological variant of 
this cancer and has precursor lesions, termed pancreatic intraepithelial neoplasia or 
PanIN. PanIN lesions are classified as PanIN-1a, PanIN-1b, PanIN-2 and PanIN-3 
(Figure 13) and are associated with progressive genetic alterations, with mutations 
of oncogenes and tumour suppressor genes such as Ki-RAS, p53 and BRCA2.291 
These genetic alterations cause cytological and architectural atypia, leading 
ultimately to carcinoma in situ as found in PanIN-3.292 PanIN lesions are often 
detected in patients undergoing pancreatectomy for chronic pancreatitis and also in 
post-mortem examinations of normal pancreas glands, although there are likely to 
be other precursor lesion yet to be described.293 
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Figure 13. Histology of normal pancreas and histopathology of pancreatic 
intraepithelial neoplasia (PanIN) lesions and adenocarcinoma from a mouse model 
of pancreatic cancer (source; Tinder et al. J Immunol 2008294). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Haematoxylin and eosin (H & E) staining of pancreatic tissue from a mouse model 
of preinvasive and invasive ductal pancreatic cancer. Representative images are 
shown of the various stages of PanIN lesions and adenocarcinoma. The arrows 
indicate the foci of the PanINs. D: duct, I: Islet and A: Acinar.  
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Molecular pathogenesis 
 Pancreatic cancer is fundamentally a genetic disease, due either to somatic 
(acquired) or inherited mutations of cancer-associated genes, with environmental 
factors (including dietary factors) promoting somatic mutations. A worldwide 
collaboration performed a comprehensive genomic analysis on 24 samples of 
pancreatic adenocarcinoma, sequencing 20 661 genes and identifying 63 genetic 
alterations.295 These genetic mutations are involved in a core set of 12 cellular 
signalling pathways that become dysregulated and are key processes in pancreatic 
carcinogenesis.295 These molecular pathways are now the target of research into 
potential future treatments, and have diverse roles in the promotion of tumour 
growth, resistance to apoptosis, invasion, metastasis and angiogenesis (Figure 14). 
One of the cellular signalling pathways identified is the Ras family of genes which 
can initiate carcinogenesis and are critical DNA targets for chemical carcinogens. 
KRAS is a member of the Ras family and encodes membrane bound GTP-binding 
proteins. Somatic mutations in the KRAS oncogene are an early and fundamental 
event in the pathogenesis of most exocrine pancreatic cancer.296 These somatic 
mutations are the most frequent oncogene alterations in human cancer, and a prime 
example of activation by point mutation. Mutations in KRAS are very frequent in 
pancreatic cancer (present in up to 95% of pancreatic cancer cases), resulting in 
impaired cell signalling and triggering a variety of cellular processes such as 
transcription, translation and enhanced cell survival that initiate the early phases of 
pancreatic carcinogenesis.296 
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Figure 14. The multiple molecular pathways and processes involved in pancreatic 
carcinogenesis (source; Wong et al. Nat Rev Gastroenterol Hepatol 2009296) 
 
The pathways and processes involved in pancreatic carcinogenesis. Entities 
involved in the “signal-transduction pathways” have diverse roles in the promotion 
of tumour growth, resistance to apoptosis, invasion, metastasis and angiogenesis. 
Reactivation of physiological “embryonic signalling pathways” are also important. 
“Other factors” involve MMP (matrix metalloproteinase) which are important for 
tumour invasion and neovascularisation. Telomerase is involved in the 
maintenance of telomeres and is activated in the majority of pancreatic cancers. 
The miRNAs (microRNAs) regulate gene expression post-transcriptionally. 
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3. The aetiology of pancreatic cancer 
 
In assessing the evidence for pancreatic cancer risk factors, the same 
process was followed as detailed in the previous chapter, “Selection of 
epidemiological study evidence”. 
 
Genetic syndromes predisposing to pancreatic cancer 
There are several genetic and family syndromes predisposing to pancreatic 
cancer that can be classified into three broad categories: i) patients diagnosed with 
a syndrome associated with pancreatic cancer, ii) those with a gene mutation 
susceptible for pancreatic cancer on genetic profiling and iii) those with a family 
history of pancreatic cancer. Inherited syndromes have been identified which 
significantly increase the risk of developing pancreatic cancer, although no 
common genetic abnormality has been identified in all these conditions. Hereditary 
pancreatitis is characterised by the familial occurrence of pancreatitis with an early 
age of onset due to mutations in the cationic trypsinogen gene (PRSS1) in 75% of 
cases with the remaining 25% unknown genetic aetiology.297 This results in a gain 
in function of the digestive enzyme trypsin which induces persistent inflammation 
and provides a mitogenic stimulus.298 Patients with hereditary pancreatitis have an 
estimated 53 times greater risk (95% CI=23-105) of developing pancreatic cancer 
with a lifetime risk of 1 in 2.5.299 In Peutz-Jeghers syndrome (also known as 
hereditary intestinal polyposis syndrome), a germ line mutation in the STK 11 gene 
prevents the action of this tumour suppressor gene in the earliest steps in the 
progression of hamartomas into adenocarcinomas.300. This leads to a marked 
increased risk of developing pancreatic cancer with an estimated relative risk of 
132 (95% CI= 44-261) and a cumulative lifetime risk of 36%.301 Patients with 
familial atypical multiple mole melanoma (FAMMM) syndrome have a 
significantly elevated risk of developing pancreatic cancer, with a cumulative 
lifetime risk of 17%.302 Further cancer syndromes which increase the risk of 
pancreatic cancer include hereditary non-polyposis colorectal cancer (HNPCC) 
with an 8.6 fold increased risk,303 and familial breast-ovarian cancer (BRCA1 
mutations with a 2-fold increased risk and BRCA2 mutations with 5% lifetime risk 
304-305). A German study investigating families with two or more members 
diagnosed with pancreatic cancer reported that 19% of the studied families had a 
BRCA2 gene mutation.306 
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Family history of pancreatic cancer 
A family history of pancreatic cancer is present in 10% of patients,307 with 
the presence of a first degree relative with disease associated with an increased 
relative risk of between 2.5 to 5.3.(20;22;84;91)308 Familial pancreatic cancer 
includes patients with a strong family history but without an identified genetic 
syndrome. Although the definition of familial pancreatic cancer is debated, it is 
generally defined as at least two first-degree relatives with pancreatic cancer, 
without meeting criteria for one of the above syndromes. The risk in familial 
pancreatic cancer increases with the more relatives affected, with a relative risk of 
6.4 (95% CI=1.8-16.4) in those with two affected relatives, rising to 32.0 (95% 
CI=10.2-74.7) in those with three affected relatives.309 The increased risk to family 
members could be due to genetic factors, lifestyle habits or an interaction of both, 
which are similar in different generations, and example being smoking habits. A 
case-control study, conducted in Michigan US, addressed this possibility in an 
investigation involving 247 incident patients and 420 population-based controls 
which assessed the family history of pancreatic cancer in both groups.308 Pancreatic 
cancer in a first degree relative (parent, sibling, offspring) was associated with a 
statistically significant increased risk of cancer in an individual, with a RR of 2.5 
(95% CI=1.3-4.7) after adjusting for smoking in the patient’s relative. An 
interaction was found between the two factors, with the risk 6.0 times greater (95% 
CI = 2.0 – 18.3) in those with an affected relative who also smoked. 
 
Screening high risk individuals 
Genetic conditions are rare, so the absolute contribution they make to all 
cases of pancreatic cancer are small. Potentially these groups of patients could be 
screened with the aim to identify an early stage of disease allowing more effective 
treatment and improved survival. Recent studies investigating the benefits of 
screening in high risk populations have shown mixed results.310-311 A German study 
screened 76 high-risk individuals over a 5 year period, performing a total of 182 
examinations of both MRI and EUS. They detected 3 PanIN lesions (one PanIn1 
and two PanIN2) and 4 low grade neoplasm (1 Intraductal papillary mucinous 
neoplasm and 3 serous oligocystic adenomas). However, the natural history for 
PanIN lesion is not yet established and most may not progress to cancer. The 
authors concluded that considering the cost and psychological stress incurred, 
screening had not produced a justifiable benefit.310 The most recent study screened 
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51 high-risk individuals in New York, US, (50% of Ashkenazi Jewish descent) 
with radiology and endoscopic ultrasonography, detecting six pancreatic cancers 
(11.8%), with one having metastatic disease and five others who underwent 
resection surgery (one total pancreatectomy for pancreatic cancer, three distal and 
one central pancreatectomy for pancreatic intraepithelial neoplasia 2 and IPMN). A 
further four cases of non-pancreatic tumours were identified through the screening 
programme (a retroperitoneal carcinoid, thyroid, uterine and ovarian cancer) with 
all patients surviving during the follow-up period of between 1 to 4 years.311 The 
findings in this New York population suggest that screening has benefits, although 
this cannot be extrapolated to different high-risk population groups. Currently, 
screening high-risk individuals should only take place within a research 
programme which hopefully will lead to the future development of evidenced 
based guidelines. Further work in high-risk individuals could also determine if any 
environmental risk factors interact to affect their risk of developing disease. 
 
Concomitant illness predisposing to pancreatic cancer 
Pancreatitis  
 Acute and chronic pancreatitis are both associated with an increased risk of 
pancreatic cancer. Chronic pancreatitis is rarely inherited in an autosomal-
dominant pattern (1% of all chronic pancreatitis patients) when it is described a 
hereditary pancreatitis (discussed previously on p145) although most commonly 
chronic pancreatitis is due to alcohol (75-80% of patients), sporadic (20%) or 
familial (3%) which may all be associated with mutations of the PRSS1 gene as 
well as SPINK1 (pancreatic secretory trypsin inhibitor) or CFTR (cytic fibrosis 
transmembrane conductance regulator). Those who are heterozygous for both 
SPINK1 and CFTR carry a 20-40 increased risk of developing chronic 
pancreatitis.297 
Investigations have clarified the risk chronic pancreatitis incurs on the 
development of pancreatic cancer. A large multi-national collaboration from four 
countries (Australia, Canada, the Netherlands, and Poland) of 823 cases of chronic 
pancreatitis and 1679 controls reported that acute or chronic pancreatitis was 
associated with an increased risk of cancer (OR=4.68, 95% CI=2.23-9.84) with a 
markedly increased risk observed within the first year of being diagnosed with 
pancreatitis (OR=13.8, 95% CI=2.52-75.5).312 If a patient had pancreatitis for more 
than 1 year the effect was attenuated (OR=3.93, 95% CI=1.64-9.46) with a similar 
risk if pancreatitis was diagnosed more than 10 years previously (OR=3.82, 95% 
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CI 1.26-11.6). These results suggest that pancreatitis can be induced by pancreatic 
cancer as well as being a risk factor for developing cancer. A previous large cohort 
study also found a history of chronic pancreatitis increased the risk of pancreatic 
cancer. After excluding patients that developed pancreatic cancer within the first 2 
years, pancreatitis was associated with an odds ratio of 14.4 (95% CI=8.5 to 
22.8).313 In a French prospective study of 373 consecutive patients (86% men) with 
proven chronic pancreatitis (85% alcohol related), followed-up for a median of 9.2 
years, four cases of pancreatic cancer were identified. The relative risk compared to 
the normal population was 19.0 (95% CI=7.3-68.3), although no adjustment was 
made for cigarette smoking or diabetes (which were present in 2 of the four cases). 
This result is therefore likely to be an overestimate of the effect of chronic 
pancreatitis.314 Pancreatitis and pancreatic cancer could share similar aetiological 
factors, which was investigated in the multi-national collaboration from Australia, 
Canada, the Netherlands and Poland of 823 cases of pancreatic cancer matched 
with 1679 controls. They reported that in those with a history of both pancreatitis 
and smoking there was a significantly increased risk of cancer (OR=15.4, 95% 
CI=3.2-74.9) implying an interaction between pancreatitis and smoking in the 
aetiology of pancreatic cancer.312  
 
Type 2 Diabetes mellitus 
 Type 2 diabetes mellitus is known to be associated with pancreatic cancer, 
although previously it was uncertain if diabetes increased the risk of pancreatic 
cancer or if was a manifestation of pancreatic cancer due to islet cell destruction. 
Diabetes could act via three different mechanisms in the carcinogenic process. 
Firstly, pancreatic cancer and diabetes could have a shared aetiology, secondly the 
metabolic effects of diabetes could promote pancreatic cancer and thirdly 
treatments of diabetes could hypothetically lead to pancreatic cancer. Type 2 
diabetes, like obesity, is characterised by insulin resistance and 
hyperinsulinaemia.315 Raised serum insulin levels could promote pancreatic cancer 
by stimulating the proliferation of pancreatic cancer cells.316-317 Insulin in animal 
models increases pancreatic cancer risk by activating the IGF receptor, although 
these effects occur at supraphysiologic levels of insulin.318 The hormone can also 
modify intermediate pathways, possibly by reducing levels of insulin-like growth 
factor binding protein-1 (IGFBP-1) which is associated with an increased risk of 
pancreatic cancer.319 
 Many epidemiological studies have investigated type 2 diabetes and 
pancreatic cancer with a meta-analysis published in 1995 of 20 case-control and 
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cohort studies reporting an overall estimated relative risk of diabetes of 2.1 (95% 
CI=1.6-2.8).320  This did not change significantly when the analyses were restricted 
to diabetes with a duration of at least 5 years (RR=2.0, 95% CI=1.2-3.2). A second 
meta-analysis in 2005 of type 2 diabetes, included 17 case-control and 19 cohort 
studies published between the years 1996 to 2005 and reported an similar odds 
ratio of 1.8 (95% CI=1.7-1.9).278 These two meta-analyses reporting consistent 
findings support a modest association between type 2 diabetes and pancreatic 
cancer. Recent onset diabetes, i.e. within one year of developing pancreatic cancer, 
is particularly associated with an increased risk and is probably secondary to 
pancreatic cancer destroying islet cells and decreasing insulin production (reverse 
causality). Recent onset diabetes is associated with a 4 to 7 fold increase in risk, 
such that 1% to 2% of patients with recent-onset diabetes will develop pancreatic 
cancer within 3 years.321 The epidemiological data is supported by biological 
marker studies which are positively associated with pancreatic cancer which 
include pre-diagnostic elevations in post-load plasma glucose,322-323 serum and 
plasma glucose, 324-325 insulin326 and plasma C-peptide.327 A Swedish cohort study 
of 33 293 women and 31 304 men identified 62 cases of incident pancreatic cancer 
and found that fasting glucose, but not post-load glucose, was associated with an 
increased risk of developing pancreatic cancer (top vs lowest quartile, RR=2.49, 
95% CI=1.23-5.45, p for trend=0.006).324 A US study combined data from four 
large prospective studies and assessed C-peptide levels and the risk of developing 
pancreatic cancer. C-peptide formed by the cleavage of pro-insulin to form insulin 
and C-peptide, is a more reliable marker of insulin secretion, than insulin itself, as 
it has a longer half life and a more predictable metabolic clearance. The North 
American study identified 179 cases of pancreatic cancer after a maximum of 20 
years follow-up. Pre-diagnostic plasma C-peptide was positively associated with 
pancreatic cancer risk (OR=1.52; 95% CI=0.87-2.64, highest compared with the 
lowest quartile, P for trend = 0.005), with the association not modified by body 
mass index or physical activity. The results from these biological markers of 
glucose and insulin homeostasis indicate that poor glycaemic control and raised 
insulin levels are associated with an increased risk of pancreatic cancer. The 
consistency of the evidence from both epidemiological and biomarker data 
suggests diabetes and hyperinsulinaemia are a causal agents in promoting 
pancreatic cancer. 
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Gallstones and cholecystectomy 
 Epidemiological studies have evaluated the relationship between gallstone 
disease, cholecystectomy and pancreatic cancer, and there are plausible biological 
mechanisms to account for a possible carcinogenic effect. Cholecystectomy 
elevates the levels of the gut hormone cholecystokinin-pancreozymin which can 
induce pancreatic hyperplasia and hypertrophy.328-329 In the only large cohort study 
(104 856 women from the US Nurses' Health Study and 48 928 men from the US 
Health Professionals Follow-up Study) to investigate this relationship, 349 cases of 
pancreatic cancer were identified after 16 years of follow-up. The adjusted 
(including smoking, BMI, physical activity and diabetes) relative risk of 
developing pancreatic cancer was RR=1.11 (95% CI=0.78-1.56) suggesting 
gallstones and cholecystectomy are not significant risk factors.330 In the largest 
case-control study to investigate the association, a modest increase was seen 
(OR=1.42 95% CI=1.09-1.84), although no adjustment was made for diabetes and 
obesity which are probably confounders for gallstone disease and pancreatic 
cancer. Gallstones and cholecystectomy have been reported as a risk factor in 
several previous case-control studies, with estimates in the range of 1.3 to 2.8,331-334 
although again, none of these studies adjusted for potential confounders. Therefore, 
due to the inconsistent findings and lack of adjustment for co-variates in some 
studies, gallstone disease is not established as a causal factor for pancreatic cancer 
and more work is required. 
 
Helicobacter Pylori infection 
Helicobacter pylori (H. Pylori) has been implicated in the pathogenesis of 
pancreatic cancer by inducing atrophic gastritis which promotes hypergastrinaemia 
and increased secretin levels, both of which can stimulate pancreatic cancer cell 
growth.335-336 The ideal epidemiological study to investigate this association would 
be a cohort study where H. Pylori status is measured before the development of 
cancer. In a case-control study it would be unclear whether H. Pylori infection 
preceded the development of pancreatic cancer or occurred as a consequence of it, 
although infection with H. Pylori usually occurs in childhood.337 In 2011, a meta-
analysis of all previous major epidemiological studies, included three case-control 
studies and three nested case-control studies, with a total of 2 335 pancreatic cancer 
patients and which reported a statistically significant adjusted odds ratio of 1.38 
(95% CI=1.08-1.75).338 However, the adjustment for potential confounders varied 
between studies, with one not adjusting for smoking, two studies failing to adjust 
for age and three not adjusting for sex. This is important as all these co-variates for 
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pancreatic cancer are associated with the risk of H. Pylori infection. Only one 
study corrected for the potential confounders of BMI and alcohol intake and its 
results were not significant (OR=1.25, 95% CI=0.75-2.09).339 Therefore, the 
current evidence cannot confirm an effect of H. Pylori and further studies 
measuring potential confounders are required. 
 
Pregnancy 
 There are biological hypotheses which could account for a protective effect 
of pregnancy and increased parity against the development of pancreatic cancer. 
Pregnancy reduces total body iron stores and induces changes in the IGF (insulin- 
like growth factor) axis, both of which may lower the risk of pancreatic cancer. 
Elevated IGF promotes cellular proliferation and inhibits apoptosis which could 
predispose the individual to pancreatic cancer,318, 340 and women with four or more 
births, compared to nulliparous women, have a lower concentration of IGF-1 
(180ng/ml vs 212ng/ml, p for trend= 0.003).341 Free iron induces DNA damage by 
causing oxidative stress 342 with case-control studies reporting raised serum iron 
concentration and increased iron consumption are positively associated with 
pancreatic cancer.343-344 Several epidemiological studies have investigated parity 
and pancreatic cancer and found increased parity reduces the risk of pancreatic 
cancer 345-348 which could explain why women have a lower incidence of the 
cancer. These studies recorded a reduction in risk of at least 20% in women who 
had 4 or more children. Two Scandinavian studies 349-350 and a Japanese study 351 
found no association, although the Scandinavian reports did not adjust for the 
possible confounding effect of smoking. Overall, despite plausible biological 
mechanisms, the epidemiological evidence is inconsistent and should be clarified 
by future work considering all potential confounders. 
  
Smoking 
Cigarette smoking is the most consistent risk factor for developing 
pancreatic cancer.283 Smoke contains N-nitrosamines which cause lung and 
pancreatic adenocarcinomas in animal models, and these are largely responsible for 
cancers in smokers.352 Both case-control and cohort studies can be used to assess 
smoking exposure since recall bias in the former should be low. Two recent meta-
analysis reported  that cigarette smoking is associated with a 75% increased risk of 
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pancreatic cancer, and that there is a dose-dependent effect, with the excess risk 
from smoking persisting for at least 10 years after cessation.353 354 The European 
Prospective Investigation into Cancer (EPIC) study used a large cohort of 465 910 
participants to assess the risk of smoking.355 A total of 524 incident cases of 
pancreatic cancer were identified with current smokers having a hazard ratio of 
1.71 (95% CI=1.36-2.15) compared to never smokers. Exposure to environmental 
tobacco smoke, or passive smoking, at work or at home also increased the risk 
(HR=1.54, 95% CI=1.00-2.39).355 Exposure to environmental tobacco smoke in 
childhood was also associated with an increased risk of disease in EPIC (HR=2.61, 
95% CI=0.96-7.10) with the positive association replicated in one other cohort 
study of US women,356 but not in another US study.357 The consistency of 
experimental and epidemiological evidence suggests both active and passive 
smoking are associated with an increased risk of pancreatic cancer. Hence, 
smoking should always be measured and adjusted for in aetiological 
epidemiological studies of pancreatic cancer and encouraging a population to never 
smoke or stop smoking should reduce the incidence. Currently it is estimated that 
the worldwide population attributable risk of smoking is 25% of all cases of 
pancreatic cancer.277, 358 
 
Alcohol 
Alcohol is a known risk factor for many cancers including breast, colon, 
oesophagus and liver.359-360 A high alcohol intake can cause pancreatitis, which pre-
disposes to pancreatic cancer, although alcohol could exert an effect independent of 
pancreatitis through several mechanisms. Firstly, acetaldehyde is the first 
metabolite of alcohol, and is a well established carcinogen.361 Secondly, the 
breakdown products of ethanol are fatty acid ethyl esters which accumulate in the 
pancreas and may induce cell injury. Alcohol also increases the production of 
reactive oxygen species, resulting in oxidative DNA damage and alters the effect of 
dietary antioxidants. Alcohol may also cause gene mutations in enzymes related to 
cytochrome P450, glutathione S-transferase, aldehyde dehydrogenase, cationic 
trypsinogen, and pancreatic secretory trypsin inhibitor. Gene mutations lead to a 
loss of function in these enzymes which regulate normal pancreatic homeostasis 
and in particular inhibit localised damage from pancreatic digestive enzymes.362 
Many epidemiological studies have investigated whether alcohol is 
positively associated with the development of pancreatic cancer. In the EPIC 
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(European Prospective Investigation into Cancer), 478 000 participants were 
followed-up for 9 years and 555 cases of exocrine pancreatic cancer identified. An 
alcohol intake of >30grams per day at recruitment compared to 0.1-4.9g/day, used 
as the reference value, did not affect the risk (RR=0.94, 95% CI=0.69-1.27) and no 
effect was found between abstainers and the reference category (RR=1.06, 
CI=0.79-1.41).363 The PanScan collaborative study of twelve cohort and one case-
control investigation, with 1 530 cases and 1 530 controls, did not report an 
association between total alcohol intake and pancreatic risk in multi-variate 
analysis (OR=1.38, 95% CI=0.86-2.23 comparing >60g alcohol/day vs >0-<5g 
alc/day).364 However, in men consuming > 45g/day (5.7 units) of alcohol from 
liquor/day there was a doubling in risk compared to abstainers (OR=2.23, 95% 
CI=1.02-4.87). Results from another large cohort study of 470 681 American men 
and women also reported that those consuming high amounts of alcohol from 
liquor (spirits) had a 62% increased risk (HR=1.62, 95% CI=1.24-2.10) of 
pancreatic cancer compared to abstainers.365 A high alcohol intake is associated 
with several lifestyle factors which could be linked to pancreatic cancer, such as 
increased exposure to environment tobacco smoke which was not adjusted for in 
any of the analyses. Furthermore, alcohol causes pancreatitis, a known risk factor 
for pancreatic cancer. Overall, the evidence indicates that moderate alcohol intake 
does not affect the risk of developing pancreatic cancer, although a high intake, 
particularly of liquor, could be positively associated but this may be mediated by 
inducing pancreatitis. Alcohol data from EPIC-Norfolk was already presented 
within the multicentre EPIC study discussed previously.363  
 
Obesity 
There are plausible biological mechanisms for how obesity may promote 
pancreatic cancer. Obesity increases insulin resistance, insulin levels and the risk of 
developing type 2 diabetes, all of which are associated with the development of 
pancreatic adenocarcinoma.278 Obesity may increase the risk via hyperinsulinaemia 
and activation of the insulin-like growth-factor (IGF) axis. Both excess insulin and 
IGF axis activity can stimulate carcinogenesis by altering cell division and 
preventing the programmed death of defective cells (apoptosis).366 Over the past 10 
years, many epidemiological studies have reported an elevated risk of pancreatic 
cancer with obesity.279, 367-373 Obesity may need to be present for many years to 
influence pancreatic carcinogenesis, and for this reason prospective studies, which 
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collect anthropometric data many years before the development of symptoms are 
required to investigate the relationship. Data collected from EPIC-Norfolk 
participants has already been evaluated within the main EPIC cohort, with a total of 
438 405 men and women followed-up for approximately 6 years with 324 incident 
cases identified.374 There was a non-significant increased risk of pancreatic cancer 
with increasing body mass index (RR=1.09, 95% CI=0.95-1.24 per 5 kg/m2) with 
an increased waist circumference significantly associated (RR per 10 cm 
increase=1.13; 95% CI=1.01-1.26; P for trend=0.03). The two largest studies have 
performed pooled analyses from multiple large cohort studies.280, 375 The largest 
pooled analysis of 12 cohort studies and 1 case-control study of 2 170 cases and 2 
209 controls reported a 33% increased risk of developing pancreatic cancer in those 
within the highest cohort specific quartile of BMI.280 However, although 
adjustments were made for age, smoking and diabetes none were made for physical 
activity and energy intake which could be confounders. Evidence from a large US 
case-control study of 841 cases and 754 controls showed that obesity not only 
increased the risk of developing pancreatic cancer, but that more young patients 
with pancreatic cancer were overweight and had shorter survival times.279 The 
authors noted that a raised body mass index aged 40 years was more important than 
that in later life in influencing the risk of pancreatic cancer. Current evidence 
suggests obesity is a risk factor for pancreatic cancer and hence it should be 
adjusted for as a co-variate when analysing other risk factors. The rising trend of 
obesity in most westernised nations may therefore lead to an increased incidence of 
pancreatic cancer and is a concern. 
 
Physical activity 
Physical activity may decrease the risk of developing pancreatic cancer by 
improving both glucose tolerance and insulin sensitivity, by increasing insulin-
stimulated glycogen synthesis and enhancing skeletal muscle glucose transport.376-
377
 Raised serum insulin levels have been implicated in the proliferation of 
pancreatic cancer cells,316-317 activation of the insulin-like growth factor (IGF) 
receptor,318 and modification of intermediate pathways of glucose metabolism, 
such as insulin-like growth factor binding protein-1 (IGFBP-1), which has been 
associated with an increased risk of pancreatic cancer.319 
 To investigate physical activity, cohort studies are a more robust 
methodology than case-control work as the former report current activity rather 
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than recalled activity levels. Two meta-analyses have been published which 
included similar studies. One in the year 2008 included 16 cohort studies, 1 nested 
case-control and 2 retrospective case-control studies378 and a second meta-analysis 
in 2010 assessed, 22 prospective studies and 6 retrospective case control studies.379 
Neither reported an effect from increased leisure activity with the second meta-
analysis reporting a RR=0.96, 95% CI=0.89-1.03, although occupational activity 
did have a protective effect. Both meta-analyses quoted a reduction in risk for the 
highest vs the lowest of four categories of physical activity at work of a quarter 
(2010 meta-analysis RR=0.75, 95% CI=0.59-0.96).379 A case-control study which 
evaluated physical activity during teenage years, early adult years and mid-life 
found no association with the risk of developing pancreatic cancer.380 These studies 
were limited by the method used to assess physical activity, with none using a 
questionnaire which had been accurately and comprehensively validated against 
physiological measures of energy expenditure. Before a final conclusion on 
physical activity and disease risk can be reached, further investigations are required 
using such validated questionnaires to accurately measure all forms of physical 
activity in representative populations. Physical activity is difficult to measure, and 
hence imprecisions in its assessment (measurement error) will lead to an 
underestimate of an effect if one truly exist. Furthermore, physical activity may be 
associated with many confounders for pancreatic cancer, such as obesity and diet, 
and this must be considered in the evaluation of physical activity. We aim to 
evaluate the physical activity in EPIC-Norfolk using a questionnaire which has 
been validated against physiological measures of cardiorespiratory function and 
energy expenditure. Since physical activity is mostly derived from the level of 
activity at work, we aim to investigate the effect of physical activity in the whole 
cohort, but also just in participants younger than 65 years of age, when they are 
more likely to be in employment. 
 
Drugs 
Aspirin 
 There is emerging evidence that aspirin, statins and metformin may reduce 
the risk of pancreatic cancer. Aspirin is a cyclo-oxygenase inhibitor that reduces 
the incidence or growth of several cancers in animal models.381 These biological 
effects are believed to be mediated by a reduced production of prostaglandins and 
other inflammatory mediators which have carcinogenic properties. Case-control 
studies have failed to show an association,382 which may be due to inaccuracies in 
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the measurement of aspirin use before symptoms. Randomised controlled trials 
(RCTs) of aspirin use, originally designed to investigate aspirin in preventing 
cardiovascular disease, are now available to provide data on its potential role in 
cancer. Since most RCTs are on populations too small to evaluate the risk of 
developing pancreatic cancer, a study has combined data from eight RCTs of daily 
aspirin use (75mg–1200mg) for at least 4 years, to a maximum of 9 years, 
including 25 570 patients taking either aspirin or placebo.383 During the period of 
intervention, 45 participants died from pancreatic cancer. No effect was found for 
aspirin taken for 0-5 years on the risk of pancreatic cancer death (HR=0.88 95% 
CI=0.44-1.77), but aspirin use for more than 5 years did reduce pancreatic cancer 
deaths by 75% (HR=0.25 95% CI=0.07-0.92, p=0.04). After aspirin was stopped 
there was no continued protective effect for up to 20 years’ follow-up (HR for 
pancreatic cancer death=0.81 95% CI=0.51-1.26). The results from both 
experimental studies and a single pooled RCT provide evidence that aspirin used 
for longer than 5 years prevents pancreatic cancer deaths, although further trial 
evidence is required before recommending the routine use of aspirin as prophylaxis 
against pancreatic cancer.  
 
Statins 
Statins (HMG-CoA reductase inhibitors) reduce serum cholesterol by 
inhibiting the rate limiting step in cholesterol synthesis and are used in the primary 
and secondary prevention of cardiovascular disease. In addition to cholesterol, 
there are several other products derived from HMG-CoA reductase, including 
farnesyl pyrophosphate and geranylgeranyl pyrophosphate and by reducing these 
metabolites statins may also have effects on the carcinogenic process. These 
metabolites affect GTPase signalling proteins whose functions can influence cell 
proliferation.384 Therefore it is plausible that patients prescribed statins may have a 
reduced risk of pancreatic cancer. The strongest methodology for demonstrating a 
protective effect of statins would be a RCT which removes the biases and 
confounding associated with observational epidemiological work. A recent meta-
analysis of 3 RCTs, 4 cohort studies, and 5 case-control studies found no evidence 
of an association between statin use and pancreatic cancer among either the RCTs 
(RR=0.99, 95% CI=0.44-2.21) or the observational work (RR=0.86, 95% CI=0.60-
1.24).385 However, the largest cohort study to be undertaken in this area of nearly 
half a million US Veterans, reported statin use of more than 6 months was 
associated with a reduction in pancreatic cancer risk, with an odds ratio of 0.33 
(95% CI=0.26-0.41, p<0.01).386 A nested case-control study using the world’s 
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largest prescribing database of around 5 million people, the UK General Practice 
Research Database (GPRD), identified 1 141 cases of pancreatic cancer. There 
were no associations with either any previous statin use (OR=0.93, 95% CI=0.76-
1.14) or long-term use (OR=0.71, 95% CI=0.42-1.20).387 The inconsistencies of 
these reported results may be due to the different populations studied, the types and 
doses of statins used and the differing study methodologies. Despite the 
chemopreventive potential of statins demonstrated in experimental studies, current 
evidence does not support the using these drugs to reduce the risk of pancreatic 
cancer although future work is required to clarify if they have an effect in 
preventing pancreatic cancer. 
 
Metformin 
There is emerging evidence that metformin may prevent pancreatic cancer. 
Metformin is a biguanide that interacts with the enzyme AMPK (AMP activated 
protein kinase) and induces muscles to take up glucose from the blood. The 
upstream regulator of AMPK is the protein kinase, LKB1, which has tumour 
suppressive activity.388 AMPK is activated via LKB1, achieved by both metformin 
and exercise, and could explain why exercise is beneficial in the primary and 
secondary prevention of certain cancers.389 In hamster models of pancreatic cancer, 
metformin had a significant protective effect against tumour development.390 
Epidemiological studies have reported that diabetic patients treated with metformin 
were less likely to develop cancers of any type,391-392 although only one 
investigation has assessed the association between metformin and pancreatic 
cancer. This was a case-control study which recruited 973 patients with pancreatic 
cancer (259 were diabetic) and 863 matched controls (109 diabetic). Diabetic 
patients prescribed metformin had a significantly lower risk than diabetics who 
were not prescribed metformin of pancreatic cancer (OR=0.38, 95% CI=0.22-
0.69).393 These findings require clarification in further investigations, particularly 
in large scale cohort studies. If metformin is confirmed to protect against 
pancreatic cancer, the drug may offer a method of reducing the incidence of disease 
in all patients with type 2 diabetes, a group at increased risk. 
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4. Diet as a risk factor for pancreatic cancer 
 
 
Diet is a plausible environmental factor to investigate in the aetiology of 
pancreatic cancer, although nutritional epidemiology has many methodological 
difficulties. These have already been discussed in chapter one, in the section 
“Measuring dietary intake”. The risk of developing pancreatic cancer may be 
modulated by diet, as different nutrients have potential causative and protective 
effects on the process of carcinogenesis. Dietary factors which may induce these 
effects include food groups, macronutrients, micro-nutrients, beverages and 
cooking methods. Many cohort studies have investigated dietary factors although 
several studies were not included in this review due either to not using a validated 
questionnaire 394 or the populations were not generalizable (e.g. a population of 
Californian Seventh-day Adventists395 and of Japanese atomic bomb survivors396). 
The prospective cohort studies reviewed (Table 24) all used food frequency 
questionnaires (FFQs) to measure dietary intake which had been validated against 
internal methods, namely 24-hour recall or diary histories.  
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Table 24. Cohort studies investigating the diet and pancreatic cancer. 
  
Study 
name  Country Number of Sex Age  Dietary Validation 
  
and 
acronym   participants   (years) assessment method 
1 Alpha-Tocopherol, Beta-Carotene Cancer prevention study 
ATBC Finland 27 111 Male 50-69 FFQ 2-DFD 
2 Swedish Cohort Study 
SCS Sweden 77 797 Both FFQ 7-DFD 
3 Multiethnic Cohort Study 
MEC US 215 000 Both 45-75 FFQ 24-hr recall + FFQ 
4 US Nurses' Health Study 
NHS US 88 794 Women 30-55 FFQ 24-hr recall 
5 US Health Professionals Follow-up Study 
HPFS US 49 364 Men 40-75 FFQ 24-hr recall 
6 Singapore Chinese Health Study 
SCHS Singapore 60 524 Both 45-74 FFQ 
24-hr recall + 
biomarkers 
7 National Institutes of Health (NIH)-American Association of Retired Persons(AARP) Diet & Health Study 
NIH-AARP >500 000 Both 50-71 FFQ 24hr recall 
8 Netherlands Cohort Study 
NLCS Holland 120 853 Both 55-69 FFQ 3-DFD 
9 European Prospective Investigation into Cancer 
EPIC Europe 521 000 Both 35-70 FFQ 24-hr recall 
10 The Iowa Women's Health Study 
IWHS US 41 837 Women 55-69 FFQ 24-hr recall 
11 Prospective study of pancreatic cancer in the elderly 
      US 13 979 Both 65-85 FFQ 24-hr recall 
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Total energy intake 
Total energy intake may contribute to the risk of pancreatic cancer via 
weight gain and obesity, although surprisingly previous prospective 
epidemiological studies have failed to demonstrate that total energy intake 
promotes weight gain155-156 157 There are no other plausible biological mechanisms 
for how increased energy intake per se may alter the risk of pancreatic cancer, 
although it may reflect the intake of other nutrients or could be due to increased 
energy expenditure and hence increased physical activity.397 Previous 
epidemiological studies in this area have reported mixed results between energy 
intake and the risk of pancreatic cancer. In the alpha-tocopherol beta-carotene 
(ATBC) cancer prevention study, total energy intake, adjusted for smoking and 
age, had a negative association with pancreatic cancer risk (highest vs lowest 
quintile HR=0.62, 95% CI=0.36-1.07, p for trend=0.05).398 These findings may 
represent a confounding effect, as those with a high energy intake are likely to be 
more physically active and have different lifestyle and dietary behaviours. A 
prospective study of 33 976 post-menopausal women from Iowa, United States, did 
not find an association (highest vs lowest tertile of calorie intake, RR=1.20 95% 
CI=0.67-2.15).399 Currently the lack of a confirmed biological mechanism and 
inconsistent epidemiological findings suggest that energy intake is unlikely to be 
involved in pancreatic cancer aetiology. However, in analyses of dietary factors, it 
is important to measure energy intake to include multi-variate analyses (see section 
on energy adjustment page 79), as a crude adjustment for body-size, physical 
activity and metabolic rate. Adjustment for energy intake therefore gives an 
assessment of the nutritional density effect of a food, rather than the actual amount. 
 
Dietary fat and fatty acid groups 
 Fat could act via several mechanisms to induce pancreatic neoplasia. 
Dietary fat stimulates the release of the hormone cholecystokinin which provokes 
pancreatic enzyme release and hypertrophy and hyperplasia of acinar cells, causing 
susceptibility to carcinogens.400 In rodents fed high-fat diets, compared to rats fed a 
low fat diet, there was a higher incidence of pancreatic cancer.401 Individual fatty 
acids can also exert specific effect that could also influence pancreatic 
carcinogenesis with evidence that saturated fatty acids induce insulin resistance,402 
through altered insulin secretion and decreased insulin sensitivity.173-176 Insulin 
resistance may be a precursor to pancreatic cancer,326 with insulin a possible 
carcinogen. 
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Several epidemiological studies have investigated the effect of dietary fats 
with a summary of results in Table 25. The US National Institute of Health - 
American Association of Retired Persons (NIH-AARP) is the largest cohort study 
undertaken, of 308 736 men and 216 737 women, which identified 865 cases of 
incident pancreatic cancer in men and 472 in women after 6.3 years follow-up.403 
An increased risk of disease was found in those with the highest intake of total fat 
(highest vs lowest quintile HR=1.23 95% CI=1.03-1.46), saturated fat (HR=1.36, 
CI=1.14-1.62) and monounsaturated fat (HR=1.22 CI=1.02-1.46). The strongest 
association was reported for saturated fat derived from animal sources (HR=1.43, 
95% CI=1.20-1.70) with no effects for mono or polyunsaturated fatty acids. 
Adjustment for occupational physical activity made little difference to the results. 
Saturated fat intake is correlated with meat intake which includes heterocyclic 
amines and polyaromatic hydrocarbons found in cooked meats that could have 
carcinogenic effects and act as confounders.398 The Multi-Ethnic Cohort (MEC) 
Study found no association with intakes of total fat and different types of fats 
derived from all food types.404 However, fat intake derived solely from meat was 
associated with an increase in pancreatic cancer (highest quintile vs lowest quintile 
of energy from fat derived from red meat and processed meat, HR 1.44, 95% 
CI=1.18 to 1.76). The Netherlands Cohort Study (NCS), with 350 cases diagnosed 
after 13.3 yrs of follow-up, did not find any association with total fat intake or fatty 
acid groups,405 and neither did the the US Nurses’ Health Study which identified 
178 cases of disease after 18 years of follow-up.406 All the above cohort studies 
used an FFQ to record dietary intake, which had been validated against an internal 
measure (such as 24-hour recall) rather than an external measure such as urinary 
biomarkers or weighed records. The results from the NIH-AARP, ATBC and MEC 
studies suggests that fat derived from meat or animal products is more likely to 
have a positive association with pancreatic cancer risk. Further studies are required 
using accurate dietary assessment measures such as food diaries which have been 
validated against external measures. 
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Table 25. Cohort studies investigating dietary fats and pancreatic cancer. 
    
             Study   Country Number of Sex Age Total fat Saturated Monounsat Polyunsat Trans n-6 n-3 
      participants     
(p for 
trend) (p for trend) (p for trend)       
(p for 
trend) 
             ATBC398 
 
Finland 27 111 Male 50-69 + (0.07) + (0.02) 0 0 ND 0 0 
             MEC404 
 
US 215 000 Both 45-75 0 0 ND ND ND ND ND 
             NHS406 
 
US 88 794 Women 30-55 0 0 0 0 0 0* ND 
             NIH-AARP403 US >500 000 Both 50-71 + (0.03) + (<0.001) + (0.05) 0 0 0 + (0.01) 
             NLCS405   Netherlands 120 853 Both 55-69 0 0 0 0 0 ND 0# 
             ATBC=Alpha-Tocopherol, Beta-Carotene Cancer prevention study; MEC=Multiethnic Cohort Study; 
    NHS=Nurses’ Health Study; NIH-AARP=National Institutes of Health (NIH)-American Association of Retired Persons (AARP) Diet and Health Study 
NLCS=Netherlands Cohort Study. 
         0 no association; + positive association; ND no data   
       
*data only from linoleic acid, #data from individual n-3 fatty acids 
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Trans fatty acids 
The trans fatty acid, elaidic acid, has been shown to increase insulin 
resistance407 and cholesteryl ester transfer protein (CETP) activity, which  causes 
dyslipidaemia by raising VLDL and lowering HDL cholesterol.408 Elevated levels 
of trans fatty acids have been associated with both breast and prostate cancer. The 
three cohort studies (NIH-AARP, NHS and NLCS) that investigated trans fats and 
pancreatic cancer have failed to find an association with pancreatic cancer,403, 406 
which was also the outcome in a Canadian case-control studies.409 Despite a 
plausible mechanism for trans fatty acids increasing the risk of pancreatic cancer, 
epidemiological results have not found any associations for trans fatty acids, 
although studies using more precise methods of measuring their intake could be 
required if they only exert a small effect size. 
 
N-6 polyunsaturated fatty acids 
 There is an established relationship between inflammation and the 
development of pancreatic cancer,410 highlighted by the 5-fold increased risk of 
cancer in patients with pancreatitis.312 N-6 fatty acids promote the production of 
inflammatory cytokines which, in turn, can stimulate oncogenic pathways such as 
cell proliferation, apoptosis, and angiogenesis which favour tumour growth.411 The 
n-6 polyunsaturated fatty acid (PUFA), arachidonic acid, is found in the diet or is 
formed from the conversion of the n-6 PUFA, linoleic acid. Arachidonic acid is 
incorporated into the phospholipid epithelial membrane and once metabolised 
produces the pro-inflammatory eicosanoids, including prostaglandin E2 (PGE2), 
leukotriene B4 and thromboxane A2. Experiments in mice injected with human 
pancreatic cancer cells have demonstrated a tumour stimulating effect of a diet rich 
in arachidonic acid, with these effects mediated by COX-2 generated prostaglandin 
E2 (PGE2).412 In mice fed the n-3 fatty acid, eicosapentaenoic acid, there was the 
opposite effect, with increased generation of prostaglandin E3, decreased 
production of PGE2 and reduced growth of pancreatic cancer. These findings 
suggest that the dietary intake of n-3 and n-6 fatty acids can alter the n3/n-6 ratio, 
and hence prostaglandin production, which can impact on pancreatic cancer 
growth. However, n-6 fatty acids can reduce insulin resistance 174 which could 
reduce the risk of developing pancreatic cancer and hence the role of dietary n-6 
fatty acids in this disease needs to be clarified in further work. 
166 
 
 Previous cohort studies have investigated the effects of dietary n-6 fatty 
acids. The Finnish ATBC cohort study and the US Nurses’ Health Study assessed 
dietary n-6 PUFA intake and found no associations after adjusting for co-
variates.398, 406 In the NIH-AARP study, no association was found for total n-6 
intake, or linoleic acid intake, although the intake of arachidonic acid was 
positively associated with pancreatic cancer, with the highest quintile of intake 
HR=1.33 (95% CI=1.12-1.58, p for trend=0.002).403 No effect was found for the n-
6 PUFAs, linoleic acid or arachidonic acid, in two large case-control studies, one 
from San-Francisco413 and one from Canada.409 More data from further 
epidemiological studies is required using detailed assessments of n-6 PUFAs to 
clarify if they have an effect on the risk of pancreatic cancer. 
N-3 polyunsaturated fatty acids 
N-3 fatty acids all have their first carbon-carbon double bond at the third 
carbon site from the terminal methyl end of the carbon chain. The three main n-3 
fatty acids in human nutrition are α–linolenic acid, eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA). Humans have very little ability to synthesise 
EPA and DHA so concentrations in the tissues are derived mostly from the 
diet,414 particularly fish oils. Marine phytoplankton and zoo plankton readily 
elongate and desaturate α–linolenic acid to produce abundant EPA and DHA 
which leads to the incorporation of n-3 fatty acids into the marine food chain. 
 Laboratory results have demonstrated n-3 fatty acids prevent the 
proliferation of mammary, prostate, colon, and pancreatic tumours.415-416 The n-3 
fatty acids EPA and DHA have inhibitory effects on the growth of human 
pancreatic cancer cell lines in vitro.412, 414, 417 In mice models of pancreatic cancer, 
a feed rich in n-3 PUFA’s lead to a reduced incidence, frequency, and 
proliferative index of pancreatic cancer cells.418 In vitro, the effect of the omega-3 
fatty acid, docosahexaenoic acid (DHA), on two pancreatic cancer cell lines was 
assessed, which was associated with a dose-dependent decrease in proliferation, 
through G1/G0 cell cycle arrest and induction of apoptosis.418 How n-3 fatty acids 
achieve these reductions of tumour incidence and proliferation in experimental 
models is not certain although several mechanism have been proposed including 
alteration of the eicosanoid profile (consisting of prostaglandins, thromboxanes and 
leukotrienes), reduction of oncogenic mutations and induction of apoptosis.419  
The fatty acid profile of the phospholipid epithelial membrane determines 
the fatty acid used as a substrate in the production of eicosanoids. Arachidonic is 
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the substrate predominantly although if EPA and DHA are present they will be 
incorporated into the phospholipid membrane at the expense of arachidonic acid.420 
An example of the alteration in the eicosanoid profile due to the available substrate 
is demonstrated in the the leukotriene family. If 5-lipoxygenase metabolises 
arachidonic acid the leukotrienes are derived (4-series leukotrienes) have stronger 
inflammatory effects compared to those derived from EPA and DHA (5-series 
leukotrienes).  
Many of these results have often been achieved at supra-physiological 
doses of n-3 PUFAs, with accompanying alterations in the general composition 
of the diet, particularly by lowering the n6/n3 fatty acid ratio, so benefits could 
be due to a reduced n-6 contribution to the diet rather than an the effects of n-3s 
per se.421 N-3 fatty acids may prevent the acquisition of genetic mutations. One 
example of the protective effect of n-3 fatty acids has been described in K-ras 
genes, which are involved in the initiation of carcinogenesis and are DNA targets 
for chemical carcinogens.  K-ras mutations are an early and fundamental event in 
the pathogenesis of most exocrine PC422 and are the most frequent oncogenic 
alterations in human cancer, and a prime example of activation by point mutation. 
Ras proteins are vital for cell functions including the regulation of growth, 
differentiation and apoptosis with K-ras point mutations found in 75-90% of 
pancreatic cancers.296, 422 In a study of pancreatic cancer cases, those with K-ras 
mutations (78%) were compared to those without K-ras mutations (22%) and a 
food frequency questionnaire used to assess differences in n-3 intake over the 
preceding year. The highest tertile of dietary n-3 PUFA intake was associated with 
a reduced rate of K-ras mutation (OR=0.19, 95% CI=0.05-0.81) with a significant 
trend across tertiles (p=0.024).422 Thus the prevention this and potentially other 
oncogenic mutations in the pathway to pancreatic carcinogenesis could account for 
a protective effect of n-3 PUFAs against the development of cancers. 
The Finnish ATBC, US NHS and Netherlands Cohort Study investigated 
the effects of n-3 fatty acids and fish intake on pancreatic cancer but none found 
any associations.398, 405-406 The NIH-AARP study reported an increased risk of 
pancreatic cancer for total n-3 intake (highest quintile vs lowest HR=1.21 95% 
CI=1.02-1.44).403 Hence the experimental data, suggesting that n-3 fatty acids 
may prevent pancreatic cancer development, is not currently supported by the 
epidemiological evidence, although further studies are required since the 
experimental work provides substantial plausible protective biological 
mechanisms. 
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Oleic Acid 
Oleic acid is an n-9 monounsaturated fatty acid found in animal and 
vegetable oils, especially olive oil, as well as in rapeseed oil, avocado and nuts. 
This nutrient occurs naturally in greater quantities than any other fatty acid. Oleic 
acid is a major component of the Mediterranean diet, which in a meta-analysis was 
associated with both a reduced all cause mortality as well as mortality from cancer 
(RR=0.94, 95% CI=0.92-0.96).423 The mechanisms for its protective effect are yet 
to be clearly defined, although oleic acid down regulates the oncogenic promoter 
region of “Her-2/neu” which leads to breast, ovarian and gastric tumours.424 
Two cohort studies have evaluated oleic acid and the risk of pancreatic 
cancer, with both the Nurses’ Health Study and the NIH-AARP study reporting no 
differences between the highest and lowest quintile of intake.403, 406 In a Canadian 
case-control study of 462 cases of pancreatic cancer and 4721 controls, oleic acid 
was associated with a reduced risk of pancreatic cancer (highest vs lowest intake 
OR=0.75, 95% CI=0.55-1.02).409 However, the same study found several fatty acid 
groups were associated with a decreased risk, including saturated and MUFAs, 
which could represent a correlated effect of nutrients in this study. A case-control 
study from San Francisco reported oleic acid was associated with an increased risk 
of pancreatic cancer (highest vs. lowest quartile OR=1.4, 95% CI=1.1-1.9, p-
trend=0.008). The inconsistencies of these findings suggest that oleic acid may not 
be involved in the aetiology of pancreatic cancer although further work to clarify 
the association is required. 
 
Meat and heterocyclic amines 
Meat may increase the risk of pancreatic cancer, especially red meat, after 
it has been cooked as this produces heterocyclic amines (HCAs) and N-nitroso 
compounds, both of which promote carcinogenesis. HCAs are formed during the 
high-temperature cooking of meat from reactions involving creatine or creatinine, 
amino acids, and sugar,425 with the amount of HCAs produced dependent on both 
cooking times and the temperature. Evidence from both animal and human studies 
suggest that HCAs play a role in the pathogenesis of some cancers including 
pancreatic cancer.426 HCAs are highly mutagenic toward mammalian cells, and in 
dietary animal studies, they cause cancers in many organs. When these tumours 
have been examined, gene alterations have been found in several signalling 
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systems (Apc, beta-catenin, Ras) by the bonding of HCA adducts to DNA.427 
Proportionally more HCAs are produced from red than white meat. 
Epidemiological studies have investigated meat and cooking methods in 
relation to the risk of developing pancreatic cancer. In the Swedish cohort studies, 
an increased risk was reported in those with the highest consumption of red meat 
(HR=1.73, 95% CI=0.99-2.98) with the greatest intake of poultry associated with a 
reduced risk (HR=0.44, 95% CI=0.20-0.97).428 The NIH-AARP, a cohort study 
study of over half-a-million people, evaluated the risk of HCA exposure using a 
meat-specific questionnaire.429 A meat mutagen and mutagenic activity index was 
derived which found that men in the highest vs lowest quintile had more than a 2-
fold increased risk of developing pancreatic cancer (HR=2.32 95% CI=1.52-3.52, 
trend across quintiles p=0.001), but no association was found in women. The intake 
of total red meat and meat cooked at high temperatures were all positively 
associated with pancreatic cancer among men (fifth versus first quintile: HR=1.41, 
95% CI=1.08-1.83, p-trend=0.001; HR=1.42, 95% CI=1.05-1.91, p-trend=0.01; 
and HR, 1.52, 95% CI, 1.12-2.06, p-trend=0.005, respectively) but again, no 
associations were found in women. Meat and heterocyclic amines need to be 
investigated in greater detail to clarify their precise effect using information 
derived from food diaries. 
 
Antioxidants 
There are plausible biological mechanisms for how dietary antioxidants 
may inhibit carcinogenesis including that in the pancreas. Antioxidants including 
vitamin C and E, selenium and zinc, stimulate immune function 430-431 and prevent 
oxidative DNA damage which precedes carcinogenesis 432.  Free radicals can be 
produced from oxidative damage to cell membranes which has a carcinogenic 
effect. Ras genes are involved in the initiation of carcinogenesis and are DNA 
targets for chemical carcinogens. Somatic (acquired) mutations in the K-ras 
oncogene are an early and fundamental event in the pathogenesis of most exocrine 
PC.422 They are the most frequent oncogene alterations in human cancer, and a 
prime example of activation by point mutation. Ras proteins are vital for cell 
functions including the regulation of growth, differentiation and apoptosis. K-ras 
point mutations are found in 75-90% of pancreatic cancers.296, 422 In a study of 
pancreatic cancer cases with K-ras mutations (78%) and without K-ras mutations 
(22%), those with the highest tertile of dietary vitamin E intake had a reduced rate 
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of K-ras mutation (OR=0.24 95% CI=0.06-0.98, p for trend=0.036) and for vitamin 
C OR=0.57 (95% CI=0.14-2.38, p for trend=0.28), although other antioxidants 
were not assessed.422  
 Antioxidants may exert their biological effect through inhibiting 
inflammation which is a recognised risk factor for the development of several 
cancers. Chronic inflammation may play a role in pancreatic carcinogenesis,433 
with both hereditary and non-genetic pancreatitis significant risk factors for 
developing cancer by factors of 53 and 17 respectively.313, 434 Chronic pancreatitis 
is associated with the generation of reactive oxygen species. When antioxidant 
enzyme levels are assessed in pancreatic tissue, there is a gradual decrease in 
antioxidant enzyme expression in pancreatic cells from normal to chronic 
pancreatitic to pancreatic cancer cells.435 In placebo controlled trials in patients 
with chronic pancreatitis, antioxidants reduced levels of pain and markers of 
oxidative stress.436-438 
The experimental data on the effects of antioxidants is supported by 
limited epidemiological work in pancreatic cancer, with only two prospective 
cohort studies investigating these micronutrients. The Finnish ATBC study of 27 
111 male smokers, reported no associations for the dietary intakes of vitamins C 
and E and selenium,398 but that higher serum levels of vitamin E were associated 
with nearly a halving of risk (highest compared with lowest quintile HR=0.52 95% 
CI=0.34-0.80, p for trend 0.03). The only other prospective study, which assessed 
antioxidants, was of 13 979 residents in a retirement community that identified 65 
incident cases of pancreatic cancer after 9 years of follow-up.439 Higher intakes of 
vegetables, fruits, dietary beta-carotene, and vitamin C were each associated with a 
reduced risk, although none of these associations were statistically significant. 
Intakes of vitamin E, selenium and zinc were not assessed. Cohort studies assessing 
the intake of fruit and vegetables, which are rich in antioxidants, have largely failed 
to find an association with pancreatic cancer.398, 440 However, associations of 
smaller magnitude could be undetected because of measurement error in the dietary 
assessment methods. The latter is particularly applicable to data collected using 
FFQs and 24-hour recall. A Swedish cohort study, reported a statistically 
significant inverse association with the intake of cruciferous vegetables (>=1 
serving/week vs never consumption: HR=0.62, 95% CI=0.39-0.99).441 This 
protective effect may be due to the high content of glucosinolates, which following 
degradation into isothiocyanates,442 inhibit both pancreatic carcinogenesis in 
animal models and the growth of human pancreatic cancer cell lines.443-444 A meta-
analysis of citrus fruit consumption reported a high intake was associated with a 
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modest reduction in risk of pancreatic cancer (OR=0.83; 95% CI, 0.70-0.98),445 and 
this effect could in part be due to the high vitamin C content found in citrus fruit or 
other residual confounders. 
Randomised controlled trials (RCTs) provide the strongest evidence, and 
these have been conducted to assess potential health benefits of antioxidants in the 
prevention of other chronic conditions, particularly cancers and cardiovascular 
disease. One RCT has specifically assessed antioxidant supplementation and 
pancreatic cancer, the Finnish ATBC study, which randomised 29 133 male 
smokers to either alpha-tocopherol (AT; 50 mg/day), beta-carotene (BC; 20 
mg/day), both AT and BC, and placebo daily for 5-8 years. No statistically 
significant differences were found between the treatment groups for pancreatic 
cancer incidence (AT vs placebo, RR1.34 95% CI=0.88-2.05) or mortality 
(RR=1.11 95% CI=0.72-1,72).446 The study population of just male smokers was 
an appropriate cohort to assess the potential benefits of vitamin E supplementation, 
as this group has a higher incidence of disease than non-smokers and females. 
However, the results do not establish whether vitamin E may be of benefit in the 
latter groups. A Cochrane review which combined 6 RCTs which used other health 
end-points as the primary outcome, did not find any effect from antioxidant 
supplementation against pancreatic cancer (RR 1.16, 95% CI 0.90-1.50).447 To 
clarify the inconsistencies in the literature of the effects of antioxidants, more 
cohort studies are required using data derived for the first time from food diaries. 
 
Sugar 
The increased risk of pancreatic cancer associated with obesity and type 2 
diabetes is probably partly due to raised insulin levels. Cohort studies have 
reported elevated baseline levels of fasting serum glucose and fasting insulin 
concentrations associated with a doubling  the risk of pancreatic cancer.325-326 
Excess dietary sugar which stimulates insulin release may therefore increase the 
risk. There is supportive evidence for a role of sugar from both experimental and 
biomarker data, although results from epidemiological studies on total sugar intake 
are inconsistent. An investigation of 77 797 Swedish men and women reported that 
those with the highest quarter dietary of sugar intake had nearly a doubling of risk 
pancreatic cancer (RR=1.95 95% CI=1.10-3.46).448 Soft drinks consumption has 
been studied, as they are a major source of added sugar intake in the Western diet, 
with around 10 grams of added sugar per 100mls. In the US, the consumption of  
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≥3 sugar-sweetened soft drinks a week was associated with a 57% (RR=1.57, 95% 
CI=1.02-2.41) increased risk of developing pancreatic cancer in a cohort of 88 794 
women, although no association was found in 49 364 American men.449  A similar 
investigation of 60 524 men and women in Singapore reported those consuming ≥2 
soft drinks a week had an 87% (HR=1.87, 95% CI=1.10-3.15) increased risk of 
developing pancreatic cancer compared to those who drank <1 soft drink a 
month.450 However, not all investigations have linked sugar consumption to an 
increased risk of pancreatic cancer. A cohort investigation of 487 922 American 
men and women, with 1 258 incident cases, found no effect of total added sugar or 
sugar-sweetened foods and beverages.451 The data was derived from food 
frequency questionnaires which have inaccuracies for measuring diet. Several other 
cohort studies using similar methods also found no effect of sugar or sucrose 
intake.452-455 The discrepancies in the sugar data may be due to error in the methods 
used for recording diet and in the definitions used for sugar. The term “sugar” is 
most commonly used when referring to “sucrose”. However, sugars can be either 
single sugar molecules (monosaccharides) of glucose, galactose or fructose, or two 
sugar molecules (disaccharides) of sucrose (glucose + fructose), lactose (glucose + 
galactose) and maltose (glucose + glucose). Added sugar in the diet is usually in 
the form of sucrose although particularly in North America, it may be high-fructose 
corn syrup (a glucose-fructose syrup). Clarification on the role of sugar is required 
from further cohort studies using accurate measures of dietary assessment, 
although most current evidence suggests that sugar and sucrose in particular may 
increase the risk of developing disease, but that the source of sugar is important. 
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5. Summary of introduction 
 
To date, the recognised risk factors identified for pancreatic cancer are 
genetic syndromes (i.e. hereditary pancreatitis, Peutz-Jeghers), a family history of 
pancreatic cancer, previous pancreatitis, type 2 diabetes, tobacco smoking and 
obesity. Factors with substantial, but not clear evidence of an effect include 
physical activity, Helicobacter Pylori infection, and the use of aspirin and 
metformin. Dietary nutrients which may be involved in the aetiology of disease are 
fatty acids, antioxidants and sugar. The lack of defined risk factors for pancreatic 
cancer could be due to previous work having methodological weaknesses in the 
study design and imprecise methods to measure exposure risk. This prospective 
cohort study, of over 25 000 participants, aims to address these limitations, by 
comparing baseline characteristics and dietary intake in those who develop disease, 
to those who do not. The investigation minimises measurement error by using a 
physical activity validated against physiological measures of cardio-respiratory 
fitness, and also a unique method of recording dietary intake, namely 7-day food 
diaries, which produces a more accurate measure of nutrient intake compared to 
other methods.47 Hence the study design may allow the identification of new risk 
factors, in particular those with small effect sizes. 
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Methods 
 
Preface to methods 
 
EPIC-Norfolk was used as the study population which is previously described 
in chapter 1 (p22-26) as well as the methods used to measure demography (p27), 
anthropometry (p27), physical activity (p27-28), dietary assessments (p30-33), 
supplement use (p34), alcohol use (p34) and blood samples (p34).Methods 
specifically pertaining to the investigation of pancreatic cancer are discussed here. 
 
1. Case ascertainment 
 
The cohort was monitored after recruitment to identify those participants 
who developed incident pancreatic cancer up to June 2010, i.e. a maximum follow-
up time of 17 years after recruitment. Participants with pancreatic cancer were 
identified by matching the EPIC-Norfolk database with the Norfolk Health 
Authority records of hospital admissions, the Eastern Cancer Registry and 
Information Centre (ECRIC) and death certificate records. The International 
Classification of Diseases-10 (ICD-10) code used was C-25 (malignant neoplasm 
of the pancreas) and its subdivisions (Table 26).252 The notes of all potential cases 
were reviewed by a single medical gastroenterologist (Paul Banim) to verify the 
diagnoses and obtain clinical diagnostic and staging information. Cases were only 
included if the diagnosis was compatible with the clinical features of pancreatic 
exocrine cancer and confirmed either by radiological, endoscopic, surgical or 
histological investigation. The Eastern Cancer Registry accessed microfilmed data 
and records on patients diagnosed outside the geographic area to aid case-
ascertainment. Cases were excluded if there was diagnostic uncertainty, the 
diagnosis was endocrine pancreatic cancer, participants had pancreatic cancer prior 
to enrolment, and if the diagnosis was made within 6 months of entering the study. 
The later ensured that the dietary data was truly prospective before the 
development of symptoms. 
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Table 26. The ICD-10 codes of pancreatic cancer used to identify potential cases of 
pancreatic cancer in EPIC-Norfolk participants. 
C25 
C25.0 
C25.1 
C25.2 
C25.3 
C25.4 
C25.7 
C25.8 
C25.9 
Malignant neoplasm of pancreas 
Malignant neoplasm of head of pancreas 
Malignant neoplasm of body of pancreas 
Malignant neoplasm of tail of pancreas 
Malignant neoplasm of pancreatic duct 
Malignant neoplasm of endocrine pancreas 
Malignant neoplasm of other parts of pancreas 
Malignant neoplasm of overlapping sites of pancreas 
Malignant neoplasm of pancreas 
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Statistical analyses 
The statistical analysis was performed using the computer program 
STATA Version 10 (Stata, College Station, Texas, USA). In the analysis, baseline 
characteristics were compared between participants with and without incident 
pancreatic cancer using a t-test for normally distributed continuous variables, a 
Mann-Whitney U test for non-parametric continuous variables and a chi-squared 
test for categorical ones. Known risk factors for pancreatic cancer and nutritional 
study exposures studied were defined and classified into categories as shown in 
Table 27. Cox proportional regression models estimated the hazard ratios (with 
95% confidence intervals) of developing incident pancreatic exocrine cancer 
according to each category of exposure, using the lowest level of exposure as the 
baseline value, with further analyses made of the trends across categories. All 
analyses were adjusted for the potential covariates of age at recruitment, gender, 
cigarette smoking, type 2 diabetes and body mass index (BMI). In the dietary 
analysis further adjustment was made for the average daily total energy intake 
(kcal) derived from the 7-DFD and in the antioxidants further adjustment was made 
for supplements containing the respective antioxidant. 
The primary analysis, for each variable, was performed after 10 years of 
follow-up and the secondary analysis after 17 years, which was the maximum 
length of follow-up. Ten years was considered the time during which a single 
measure of dietary intake from the physical activity questionnaire or 7-DFD may 
be representative of that measured at recruitment. This technique would reduce 
regression dilution bias caused by a proportion of the cohort altering their 
behaviour during follow-up which introduces measurement error. The secondary 
outcome was the risk of pancreatic cancer after the full follow up period of 17 
years after recruitment. 
 
Physical activity analysis 
A cohort analysis using Cox regression was made of physical activity 
which was categorised using the four level physical activity index (Table 1). Since 
the physical activity index score was predominantly derived from the level of 
occupational physical activity, a separate analysis was made excluding all 
participants aged 65 years (the state retirement age) and over at enrolment, as those 
not working were less likely to have their level of physical activity correctly 
classified which would have introduced measurement error. 
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Alcohol analysis 
 Alcohol intake was estimated from the food frequency questionnaire with 
data available on the whole cohort of 25 639 participants. Alcohol was analysed as 
a categorical variable as defined in Table 27.  
 
 
Dietary analysis 
For the dietary variables a case-cohort analysis was performed using a 
representative subset of 3 970 randomly selected participants who did not develop 
pancreatic cancer. This analysis was required as most but not all of the completed 
diaries had been coded. Each nutrient was divided into fifths of intake across the 
distribution of the whole cohort. To evaluate for possible nutrient threshold effects, 
the lowest fifth of intake was compared to a summation of the four higher fifths.  
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Table 27. Characteristics and exposures with units and cut-points used in analysis 
Characteristic Units 
 
Cut-points 
    
   Age at 
recruitment Years Continuous variable 
Smoking status -- Never smoked 
Previous smoker 
Current smoker 
Diabetes -- Reported at baseline 
Not reported at baseline 
Body mass index kilograms/metre
2
 <25  (normal) 
25-<30 (overweight) 
30-<35 (obese class I) 
>35 (obese class II & III) 
 
Alcohol intake units per week   Zero 
  (1 UK unit = >0-<7 
  7.9 grams or 7-<14 
  10 mls) 14-<21 
  
  
≥21   
      Physical activity Derived from physical  
 
Inactive 
 
activity index  
 
Moderately inactive 
 
(table 2) 
 
Moderately active 
   
Active 
     Dietary nutrients Average daily intake 
 
Fifths 
     
 
  
 
  
179 
 
Results 
 
1. Case ascertainment  
 
From the cohort of 25 639 participants (54.7% women) who attended the 
baseline health check, 111 cases of potential incident pancreatic cancer were 
identified who had their notes reviewed by a gastroenterologist specialist. Of these, 
53 participants (41.5% women) had confirmed incident exocrine pancreatic cancer 
after 10 years follow-up, with 93 cases (52.7% women) 17 years follow-up. The 
remaining 18 cases were excluded from analysis with the reasons for exclusion 
listed in Table 28. Comparing the clinical diagnoses of pancreatic cancer from 
review of the notes and those at Eastern Cancer Registry and Information Centre 
(ECRIC) it was possible to calculate the specificity of the cancer registry process if 
review of the clinical notes was deemed to be the gold standard. A maximum of 9 
out of the total 93 cases had not had time to be registered at ECRIC and they were 
excluded from the analysis. Three patients had not been registered at ECRIC 
despite reasonable clinical evidence on note review of pancreatic cancer, giving a 
sensitivity of 96.4% (81/84 x 100). 
 
Clinical features of participants developing pancreatic cancer 
The 53 cases diagnosed after 10 years follow-up had a mean age at 
diagnosis of 69.7 years (SD=8.6 years) (Table 29). The stage of disease at 
diagnosis was mostly either distant metastatic disease (43.4%, American Joint 
Committee on Cancer, AJCC stage 4 disease) or locally advanced disease (18.9%, 
AJCC stage 3)(Table 29). Only 15.1% had cancer localised to the pancreas (stage 
0, 1A or 1B) with 9.4% classified as having locally invasive disease (stage 2A or 
2B)(Table 29). Histological confirmation of adenocarcinoma was made in 37.8% 
patients. In those without histology the diagnosis was made using at least two 
imaging modalities from either: USS, CT, ERCP, MRI. Patients were treated with 
either: surgery (13.5%), chemotherapy (38.5%) or with palliative measures 
(48.1%). The median survival of all patients was 4 months (range 0.25 to 25 
months) with a mean survival of 6.8 months (SD=6.4 months). In the 93 cases 
diagnosed after 17 years follow-up, the mean age at diagnosis was 72.3 years 
(SD=8.9 years) with similar clinical features to those diagnosed after 10 years 
(Table 29).  
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Table 28. The reasons for exclusion following review of cases notes. 
 
  
Reason for exclusion Number 
of cases 
  
No record of pancreatic cancer in hospital records or at ECRIC* 3 
Prevalent case of pancreatic cancer 4 
Neuroendocrine pancreatic cancer 3 
Cholangiocarcinoma 2 
Ampullary carcinoma 2 
Pancreatitis 1 
Mesothelioma  1 
Carcinomatosis of uncertain origin 1 
Diagnosis uncertain 1 
Total 18 
*ECRIC=Eastern Cancer Registry and Information Centre 
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Table 29. Clinical features of all cases of pancreatic cancer identified. 
Cases Cases 
Variable 10 yrs follow-up 17 yrs follow-up 
Total number of cases 53 93 
Age at diagnosis (years, mean (SD)) 69.7 (8.6) 72.3 (8.9) 
AJCC stage of disease, n (%) 
Localised within pancreas (stages 0, 1A & 1B) 8 (15.1) 14 (15.1) 
Locally invasive (stages 2A & 2B) 5  (9.4) 9  (9.7) 
Locally advanced (stage 3) 10 (18.9) 20 (21.5) 
Distant metastases (stage 4) 23 (43.4) 42 (45.2) 
No staging data available 7  (13.2) 8  (8.6) 
Investigations, n (%) 
One modality 1 (1.1) 1 (1.1) 
Two modalities 19 (35.9) 38 (40.8) 
Three modalities 13 (24.5) 22 (23.7) 
Histology available 20 (37.8) 32 (34.3) 
Treatment, n (%) 
Surgical 7 (13.5) 8 (8.6) 
Oncological 20 (38.5) 32 (34.4) 
Palliative 25 (48.1) 51 (54.8) 
Missing data 1 (1.9) 2 (2.2) 
Survival following diagnosis 
Available data, n (%) 53 (100) 83 (89.2) 
Mean, months (SD) 6.8 (6.4) 5.9 (6.1) 
Median, months (range) 4.0 (0.25-25) 4.0 (0.25-25) 
        
AJCC=American Joint Committee on Cancer 
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2. Physical activity and alcohol intake 
 
 
Comparison of baseline characteristics used in the physical activity and 
alcohol analysis 
From the cohort of 25 639 participants who attended the baseline health 
check and completed the physical activity questionnaire, 53 people (41.5% women) 
developed incident exocrine pancreatic cancer after 10 years follow-up, with 93 
cases identified after 17 years (Table 30). Comparison of those with, and without 
incident disease showed that after both 10 years, and 17 years of follow-up, cases 
were older at recruitment than those without disease (p<0.001). After 10 years of 
follow-up, cases were more likely to be male, although there were no gender 
differences after 17 years. There were no statistical differences between cases and 
non-cases in the average or categories of body mass index (BMI), cigarette 
smoking or diabetes at baseline (Table 30). After 10 years the age and sex adjusted 
hazard ratio, compared to BMI <25, for a BMI 25-<30 HR=0.95 (95% CI=0.53-
1.69), BMI 30-<35 HR=0.40 (95% CI=0.12-1.35) and BMI >35 HR=1.31 (95% 
CI=0.31-5.61). The age and sex adjusted hazard ratio, compared to never smoker, 
for a previous smoker HR=0.61 (95% CI=0.21-1.75) and for a current smoker 
HR=0.83 (95% CI=0.28-2.44). The age and sex adjusted hazard ratio for the 
presence of diabetes compared to no diabetes, HR=0.86 (0.21-3.54).  
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Table 30. Baseline characteristics of the whole cohort (used in the physical activity 
and alcohol analysis). 
Non-incident Cases Cases 
    disease 10 yrs follow-up 17 yrs follow-up 
Number of participants 25 546 53 93 
Age at recruitment (years, mean (SD)) 59.2 (9.3) 63.7 (8.6)† 63.7 (8.1)† 
Age at diagnosis (years, mean (SD)) - 69.4 (8.7) 72.3 (8.9) 
Interval to diagnosis (years,mean (SD)) - 5.6 (2.6) 8.6 (4.0) 
Gender 
Male, n (%) 11 563  (45.3) 31 (58.5)# 44 (47.3) 
Female, n (%) 13 983 (54.7) 22 (41.5) 49 (52.7) 
Body mass index (mean (SD)kg/m2) 26.3 (3.9) 26.3 (3.6) 25.8 (3.5) 
Cigarette smoking status 
Current smoker, n (%) 2 975 (11.8) 4 (7.6) 9 (9.7) 
Former smoker, n (%) 10 721 (42.3) 30 (56.6) 41 (44.1) 
Never smoked, n (%) 11 631 (45.9) 19 (35.9) 43 (46.2) 
Presence of diabetes 
Present 85 (3.3) 2 (3.8) 4 (4.3) 
not present 24 695 (96.7) 51 (96.2) 89 (95.7) 
          
SD=Standard deviation, kg=Kilograms, m2=metres squared, 
n=number 
†p<0.001 using unpaired t-test 
#p=0.053 using Pearson's chi-square test 
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Physical activity results 
In the whole cohort after 10 years follow-up, the incidence of disease in the 
most active category compared to the least active was lower (0.13 cases per 1 000 
person-years vs 0.24 cases per 1 000 person-years), although after adjustment for 
co-variates the hazard ratio was non-significant (HR=0.69, 95% CI=0.28-1.79, 
p=0.45), with no trend across categories (HR=0.98, 95% CI=0.75-1.27, p=0.88) 
(Table 31). After 17 years follow-up, the multivariate hazard ratio for the most 
active vs inactive category was 1.05 (95% CI=0.55-1.99, p=0.88), with the trend 
across categories HR=1.04 (95% CI=0.85-1.27, p=0.68)(Table 31).  
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Table 31. Physical activity and the risk of developing pancreatic cancer. 
Categories of physical activity 
    Inactive Moderately inactive Moderately active Active 
Number of participants 7 863 7 351 5 776 4 648 
% of whole cohort 30.7 28.7 22.5 18.1 
10 years follow-up 
Number of P-Y 78 581 73 458 57 688 46 458 
Number of cases 19 13 15 6 
Cases per 1000 P-Y 0.24 0.18 0.26 0.13 
HR (95% CI)1 1.00 0.91 (0.45-1.85) 1.41 (0.71-2.84) 0.72 (0.28-1.84) 
HR (95% CI)2 1.00 0.88 (0.44-1.85) 1.37 (0.70-2.81) 0.69 (0.28-1.79) 
17 years follow-up 
Number of P-Y 99 240 93 149 73 246 59 016 
Number of cases 32 23 23 15 
Cases per 1000 P-Y 0.32 0.25 0.31 0.25 
HR (95% CI)1 1.00 0.91 (0.53-1.56) 1.22 (0.70-2.14) 1.10 (0.58-2.07) 
HR (95% CI)2 1.00 0.88 (0.53-1.56) 1.17 (0.67-2.05) 1.05 (0.55-1.99) 
            
HR=hazard ratio, CI=confidence interval, P-Y=person-years. 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking, diabetes and BMI categories. 
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When the cohort was restricted to those aged less than 65 years at 
recruitment, physical activity was associated with a reduced risk of pancreatic 
cancer. Participants <65years are more likely to be employed, with occupational 
physical activity in the physical activity questionnaire the main determinant of the 
physical activity index. After 10 years of follow-up, the most active category 
compared to the least active, had a multi-variate hazard ratio=0.11 (95% CI=0.01-
0.88), with a borderline statistically significant trend across categories (HR=0.72, 
95% CI=0.49-1.05, p=0.092) (Table 32). After 17 years of follow-up the results 
were attenuated (most vs least active HR=0.47, 95% CI=0.19-1.14). In summary, 
increased physical activity was associated with a reduced risk of pancreatic cancer 
in those aged less than 65 years at recruitment, although no effect was found in the 
analysis of participants of all ages. 
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Table 32. Physical activity and the risk of developing pancreatic cancer if aged <65 
years at recruitment. 
Categories of physical activity 
    Inactive Moderately inactive Moderately active Active 
Number of participants 4 098 5 098 4 514 3 826 
% of whole cohort 23.4 29.1 25.7 21.8 
10 years follow-up 
Number of P-Y 40 953 50 965 45 098 38 363 
Number of cases 10 5 10 1 
Cases per 1000 P-Y 0.24 0.10 0.22 0.03 
HR (95% CI)1 1.00 0.44 (0.15-1.34) 0.99 (0.41-2.38) 0.11 (0.01-0.90) * 
HR (95% CI)2 1.00 0.43 (0.15-1.27) 0.96 (0.39-2.33) 0.11 (0.01-0.88) * 
17 years follow-up 
Number of P-Y 51 356 64 211 57 069 48 431 
Number of cases 17 10 14 7 
Cases per 1000 P-Y 0.32 0.16 0.25 0.14 
HR (95% CI)1 1.00 0.50 (0.23-1.10) 0.75 (0.36-1.54) 0.50 (0.20-1.20) 
HR (95% CI)2 1.00 0.48 (0.22-1.06) 0.71 (0.34-1.48) 0.47 (0.19-1.14) 
            
HR=hazard ratio, CI=confidence interval, P-Y=person-years. 
*
 p for trend<0.10 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes and BMI category. 
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Alcohol results 
In the whole cohort after 10 years follow-up, the incidence of pancreatic 
cancer did not significantly change with increased alcohol intake. The highest 
category of alcohol intake (>21 units per week) compared to those with zero intake 
had a hazard ratio=0.43 (95% CI=0.12-1.59)(Table 33). After 17 years follow-up, 
the multivariate hazard ratio for the highest alcohol intake vs zero intake was 0.71 
(95% CI=0.27-1.82). However, those with an intake of >0 to <7 units per week had 
a significantly reduced risk of developing disease compared to those with zero 
intake of alcohol (HR=0.51, 95% CI=0.30-0.86)(Table 33). 
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Table 33. Alcohol intake and the risk of developing pancreatic cancer.  
 
Categories of alcohol intake  
    0 > 0 to < 7 7 to <14 14 to <21 ≥ 21 
 
Number of participants 3 638 13 675 4 525 1 927 1 874 
% of whole cohort 14.2 53.3 17.7 7.5 7.3 
 
10 years follow-up  
Number of P-Y 36 351 136 668 45 216 19 232 18 729 
Number of cases 12 21 9 8 3 
Cases per 1000 P-Y 0.33 0.15 0.20 0.42 0.16 
 
HR (95% CI)1 1.00 0.52 (0.25-1.06) 0.64 (0.26-1.54) 1.30 (0.52-3.28) 0.47 (0.13-1.74) 
HR (95% CI)2 1.00 0.49 (0.24-1.00) 0.57 (0.24-1.39) 1.17 (0.46-2.97) 0.43 (0.12-1.59) 
 
17 years follow-up  
Number of P-Y 46 459 173 747 56 894 24 119 23 443 
Number of cases 22 35 15 10 6 
Cases per 1000 P-Y 0.47 0.22 0.26 0.50 0.26 
 
HR (95% CI)1 1.00 0.51 (0.30-0.88) 0.68 (0.35-1.33) 1.32 (0.64-2.72) 0.69 (0.27-1.78) 
HR (95% CI)2 1.00 0.51 (0.30-0.86) 0.66 (0.33-1.30) 1.29 (0.62-2.86) 0.71 (0.27-1.82) 
             
HR=hazard ratio, CI=confidence interval, P-Y=person-years.  
1 Adjusted for age and sex.  
2 Adjusted for age, sex, smoking, diabetes and BMI categories.  
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3. Dietary outcomes using 7-day food diaries 
 
Comparison of baseline characteristics used in the dietary analysis 
In the 23 658 participants (92.3% of those attending the health check) who 
completed the 7-day food diary (7DFD) 51 participants were diagnosed with 
pancreatic cancer (43% women) after 10 years of follow-up, which increased to 88 
cases (54% women) after 17 years. Not all food diaries from the whole cohort are 
currently coded, so a random sample of 3 970 participants had their diaries coded 
and were used as the comparison population. The baseline characteristics were 
compared between participants with and without incident disease and are listed in 
Table 34. Cases were older at recruitment and after 10 years follow-up were more 
likely to be male. There were no statistical differences in the averages or 
proportions of body mass index, cigarette smoking and diabetes. 
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Table 34. Baseline characteristics of the cohort (used in dietary analysis). 
Non-incident Cases Cases 
    disease 10 yrs follow-up 17 yrs follow-up 
Number of participants 3 970 51 88 
Age at recruitment (years, mean (SD)) 59.3 (9.4) 64.1 (8.3)† 64.2 (7.8)† 
Age at diagnosis (years, mean (SD)) 69.7 (8.6) 72.6 (8.8) 
Interval to diagnosis (years,mean (SD)) 5.6 (2.6) 8.4 (3.9) 
Gender 
Male (%) 1 740  (43.8) 29 (56.9) 40 (45.5) 
Female (%) 2 230 (56.2) 22 (43.1) 48 (54.5) 
Body mass index (mean (SD) kg/m2) 26.3 (3.9) 26.3 (3.7) 25.7 (3.5) 
Cigarette smoking status 
Current smoker (%) 451 (11.5) 4 (8.0) 8 (9.1) 
Former smoker (%) 1 670 (42.4) 28 (56.0) 40 (45.5) 
Never smoked (%) 1 818 (46.1) 18 (36.0) 40 (45.5) 
Presence of diabetes 
present n (%) 121 (3.0) 2 (3.9) 4 (4.5) 
not present 3 849 (97.0) 49 (96.1) 84 (95.5) 
          
†p<0.001 using unpaired t-test 
#p=0.062 using Pearson's chi-square test 
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Energy and macronutrients 
 In the primary outcome after 10 years of follow-up, each higher quintile of 
total energy intake was associated with reduced hazard ratios of developing 
pancreatic cancer, although none reached statistical significance (highest vs lowest 
quintile, HR=0.46 95% CI=0.17-1.23, p=0.12) with a HR for the trend across 
categories of 0.87 (95% CI=0.69-1.10, p=0.24) (Table 35). To assess whether 
participants may have pre-clinical symptoms causing a reduced energy intake a 
sensitivity analysis was performed, excluding those diagnosed with pancreatic 
cancer <2 years after enrolment, with similar results (highest vs the lowest quintile 
HR=0.41, 95% CI=0.14-1.18, p=0.099) and the trend across quintiles HR=0.84 
(95% CI=0.66-1.07, p=0.16). After 17 years of follow-up, energy intake was not 
associated with pancreatic cancer risk, with the trend across categories HR=0.93 
(95% CI=0.78-1.12, p=0.45).  
After 10 years of follow-up, all quintiles of increased total fat and protein 
intake had negative associations compared to the lowest, although again, none were 
statistically significant (Table 35), with the trends across categories showing no 
associations (total fat, trend HR=1.00, 95% CI=0.69-1.44, total protein trend 
HR=0.94, 95% CI=0.70-1.25). Total carbohydrate intake had no relationship with 
the risk of developing pancreatic cancer (trend across quintiles, HR=1.03, 95% 
CI=0.72-1.46). After 17 years follow-up, no associations were found between 
macronutrients and pancreatic cancer (Table 35). 
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Table 35. Total energy and macronutrient intake and the risk of developing 
pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of participants 812 812 811 812 811 
Total energy intake 
Cut points (kcal/day) 322 to <1496 1496 to <1765 1765 to <2027 2027 to <2341 2341 to <6050 
10 years of follow-up 
Cases 14 8 7 13 9 
HR (95% CI)1 1.00 0.52 (0.22-1.27) 0.42 (0.17-1.07) 0.72 (0.31-1.67) 0.49 (0.18-1.28) 
HR (95% CI)2 1.00 0.52 (0.22-1.28) 0.40 (0.15-1.01) 0.67 (0.29-1.57) 0.46 (0.17-1.23) 
17 years of follow-up 
Cases 22 17 15 22 12 
HR (95% CI)1 1.00 0.78 (0.41-1.48) 0.70 (0.36-1.37) 1.09 (0.57-2.10) 0.64 (0.28-1.42) 
HR (95% CI)2 1.00 0.76 (0.41-1.48) 0.66 (0.35-1.36) 1.00 (0.52-1.94) 0.59 (0.26-1.33) 
Total fat 
Cut points (grams/day) 10.7 to <53.5 53.5 to <65.8 65.8 to <77.7 77.7 to <93.5 93.5 to <339.9 
10 years of follow-up 
Cases 16 6 8 9 12 
HR (95% CI)1 1.00 0.35 (0.14-0.89) 0.43 (0.18-1.02) 0.48 (0.20-1.12) 0.63 (0.27-1.45) 
HR (95% CI)2 1.00 0.39 (0.13-1.13) 0.48 (0.15-1.57) 0.55 (0.14-2.13) 0.91 (0.21-3.96) 
17 years of follow-up 
Cases 27 12 19 15 15 
HR (95% CI)1 1.00 0.44 (0.22-0.87) 0.71 (0.39-1.29) 0.58 (0.30-1.12) 0.63 (0.31-1.26) 
HR (95% CI)2 1.00 0.39 (0.18-0.86) 0.53 (0.24-1.27) 0.39 (0.15-1.05) 0.49 (0.16-1.48) 
Total carbohydrate 
Cut points (grams/day) 10.7 to <53.5 53.5 to <65.8 65.8 to <77.7 77.7 to <93.5 93.5 to <339.9 
10 years of follow-up 
Cases 13 7 10 13 8 
HR (95% CI)1 1.00 0.53 (0.21-1.34) 0.68 (0.29-1.57) 0.85 (0.38-1.89) 0.51 (0.19-1.32) 
HR (95% CI)2 1.00 0.77 (0.28-2.20) 1.20 (0.38-4.10) 1.44 (0.41-5.54) 0.85 (0.20-4.06) 
17 years of follow-up 
Cases 20 17 14 23 14 
HR (95% CI)1 1.00 0.88 (0.46-1.69) 0.71 (0.35-1.41) 1.25 (0.67-2.36) 0.85 (0.40-1.81) 
HR (95% CI)2 1.00 1.02 (0.50-2.21) 0.92 (0.38-2.39) 1.64 (0.67-4.65) 1.33 (0.46-4.58) 
Total protein 
Cut points (grams/day) 23.5 to <57.9 57.9 to <67.2 67.2 to <75.6 75.6 to <86.4 86.4  to <175.3 
10 years of follow-up 
Cases 13 9 8 12 9 
HR (95% CI)1 1.00 0.65 (0.28-1.52) 0.52 (0.21-1.28) 0.72 (0.31-1.67) 0.55 (0.21-1.40) 
HR (95% CI)2 1.00 0.78 (0.32-1.93) 0.67 (0.23-1.83) 0.91 (0.31-2.52) 0.71 (0.20-2.30) 
17 years of follow-up 
Cases 18 18 17 21 14 
HR (95% CI)1 1.00 1.01 (0.52-1.94) 0.93 (0.47-1.83) 1.23 (0.63-2.39) 0.91 (0.42-1.97) 
  HR (95% CI)2 1.00 1.15 (0.58-2.28) 1.11 (0.49-2.27) 1.50 (0.64-3.15) 1.25 (0.44-2.94) 
HR=hazard ratio, CI=confidence interval. 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Polyunsaturated fatty acids 
 Total PUFAs had negative associations with pancreatic cancer for all 
higher quintiles of intake compared to the lowest, after both 10 and 17 years 
follow-up, although none were statistically significant with no effect for the trend 
across quintiles (at 10 years, trend for total PUFA, HR=0.98 95 % CI=0.92-1.05, 
p=0.35). N-6 PUFAs had no patterns of association with the risk of pancreatic 
cancer (trend HR=1.03, 95% CI=0.80-1.33, p=0.81)(Table 36). However, total n-3 
intake had statistically significant negative associations with pancreatic cancer after 
10 years of follow-up in the age and sex adjusted analysis (highest vs lowest 
quintile HR=0.25 95% 0.09-0.94, p=0.041) with the multivariate analysis of 
borderline statistical significance (HR=0.30 95% CI=0.07-1.21, p=0.092) There 
was no trend across quintiles (HR=0.84 95% CI=0.67-1.07, p=0.16) (Table 36). 
Total n-3 fatty acid intake analysed as a continuous variable per gram/day had a 
multivariate HR=0.42 (95% CI=0.22-0.82, p=0.011). After 17 years of follow-up, 
the results for total n-3 intake were attenuated, with inverse non-significant 
associations for individual quintiles and trend across categories. Total n-3 intake as 
a continuous variable was of borderline statistical significance (HR=0.67, 95% 
CI=0.43-1.05, p=0.078). 
Individual n-3 polyunsaturated fatty acids 
An analysis was performed to verify which individual n-3 fatty acids may 
account for the inverse associations reported for total n-3 intake. After 10 years of 
follow-up, docosahexaenoic acid (DHA) intake was negatively associated with 
pancreatic cancer for each higher quintile of intake, with the highest vs lowest 
quintile associated with a 60% protective effect (HR=0.40 95% CI=0.15-1.08, 
p=0.070) and a statistically significant multivariate trend across quintiles 
(HR=0.80, 95% CI=0.65-0.98, p=0.031). After 17 years of follow-up, DHA had 
negative associations for the highest two quintiles of intake but these were not 
statistically significant (trend across quintiles HR=0.92, 95% CI=0.79-1.07, 
p=0.28) (Table 37). For eicosapentaenoic acid (EPA) the three higher quintiles of 
intake were associated with a non-significant decreased risk after 10 years of 
follow-up, with the age and sex adjusted trend across categories of borderline 
statistical significance (HR=0.84, 95% CI=0.69-1.02, p=0.084). After 17 years, 
individual categories and trends of EPA had no relationship with disease (Table 
37). The essential n-3 fatty acid, alpha-linolenic acid, had no relationship with the 
risk of developing pancreatic cancer (table 7), after either follow-up period. 
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Table 36. Total polyunsaturated fatty acid (PUFA), n-3 & n-6 PUFA intake and the 
risk of developing pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of 
participants 812 812 811 812 811 
Total polyunsaturated fat 
Cut points (grams/day) 1.89 to <9.5 9.5  to <12.0 12.0  to <14.5 14.5  to <18.0 18.0 to <84.6 
10 years of follow-up 
Cases 15 8 8 9 11 
HR (95% CI)1 1.00 0.49 (0.21-1.16) 0.50 (0.21-1.19) 0.54 (0.23-1.27) 0.69 (0.30-1.61) 
HR (95% CI)2 1.00 0.58 (0.23-1.42) 0.62 (0.23-1.67) 0.69 (0.25-1.94) 0.91 (0.31-2.67) 
17 years of follow-up 
Cases 27 15 13 17 16 
HR (95% CI)1 1.00 0.57 (0.30-1.07) 0.52 (0.26-1.02) 0.70 (0.37-1.33) 0.76 (0.39-1.48) 
HR (95% CI)2 1.00 0.55 (0.28-1.07) 0. 50 (0.24-1.07) 0.68 (0.32-1.46) 0.77 (0.34-1.79) 
n-3 PUFA 
Cut points (grams/day) 0.25 to <1.04 1.04 to <1.31 1.31 to <1.58 1.58 to <1.97 1.97 to <6.58 
10 years of follow-up 
Cases 10 12 15 11 3 
HR (95% CI)1 1.00 1.10 (0.47-2.56) 1.38 (0.61-3.10) 0.97 (0.40-2.34) 0.25 (0.09-0.94) * 
HR (95% CI)2 1.00 1.29 (0.54-3.12) 1.71 (0.70-4.11) 1.16 (0.44-3.04) 0.30 (0.07-1.21) 
17 years of follow-up 
Cases 21 20 19 17 11 
HR (95% CI)1 1.00 0.95 (0.51-1.75) 0.94 (0.50-1.77) 0.87 (0.45-1.68) 0.56 (0.26-1.19) 
HR (95% CI)2 1.00 0.94 (0.50-1.82) 0.96 (0.49-1.91) 0.87 (0.42-1.78) 0.57 (0.25-1.30) 
n-6 PUFA  
Cut points (grams/day) 1.3 to <7.8 7.8 to <9.9 9.9 to <12.3 12.3 to <15.6 15.6 to <79.8 
10 years of follow-up 
Cases 15 8 7 9 12 
HR (95% CI)1 1.00 0.52 (0.22-1.22) 0.44 (0.18-1.08) 0.58 (0.25-1.36) 0.79 (0.35-1.79) 
HR (95% CI)2 1.00 0.58 (0.24-1.44) 0.54 (0.20-1.46) 0.75 (0.28-2.04) 1.04 (0.38-2.87) 
17 years of follow-up 
Cases 28 14 12 17 17 
HR (95% CI)1 1.00 0.52 (0.27-0.99) 0.46 (0.23-0.91) 0.71 (0.38-1.33) 0.78 (0.41-1.50) 
  HR (95% CI)2 1.00 0.51 (0.26-1.00) 0.45 (0.21-0.95) 0.70 (0.34-1.44) 0.81 (0.37-1.77) 
HR=hazard ratio, CI=confidence interval, * borderline statistical significant trend across quintiles (p=0.072) 
*denotes p for trend<0.05 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Table 37. Individual n-3 fatty acids and the risk of developing pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of participants 812 812 811 812 811 
Alpha Linolenic acid (C18:3n3c) 
Cut points (grams/day) 0.25 to <1.04 1.04 to <1.31 1.31 to <1.58 1.58 to <1.97 1.97 to <6.58 
10 years of follow-up 
Cases 9 13 13 12 4 
HR (95% CI)1 1.00 1.39 (0.59-3.26) 1.30 (0.55-3.10) 1.25 (0.52-3.06) 0.40 (0.12-1.36) 
HR (95% CI)2 1.00 1.81 (0.74-4.43) 1.76 (0.67-4.61) 1.66 (0.60-4.60) 0.51 (0.13-1.98) 
17 years of follow-up 
Cases 24 18 16 20 10 
HR (95% CI)1 1.00 0.78 (0.42-1.43) 0.71 (0.37-1.35) 0.95 (0.51-1.74) 0.49 (0.23-1.07) 
HR (95% CI)2 1.00 0.78 (0.42-1.52) 0.69 (0.34-1.43) 0.91 (0.45-1.88) 0.49 (0.20-1.19) 
Eicosapentaenoic acid (C20:5n3c) 
Cut points (grams/day) 0 to <0.02 0.02 to <0.04 0.04 to <0.07 0.07 to <0.16 0.16 to <1.72 
10 years of follow-up 
Cases 10 14 10 11 6 
HR (95% CI)1 1.00 1.24 (0.55-2.79) 0.84 (0.35-2.02) 0.88 (0.37-2.08) 0.45 (0.16-1.26) * 
HR (95% CI)2 1.00 1.31 (0.57-2.97) 0.90 (0.37-2.19) 0.95 (0.40-2.28) 0.50 (0.17-1.39) 
17 years of follow-up 
Cases 15 22 17 20 14 
HR (95% CI)1 1.00 1.31 (0.68-2.52) 1.00 (0.50-2.00) 1.10 (0.56-2.15) 0.75 (0.36-1.56) 
HR (95% CI)2 1.00 1.34 (0.68-2.55) 1.00 (0.50-2.05) 1.12 (0.57-2.21) 0.78 (0.36-1.60) 
Docosahexaenoic acid (C22:6n3c) 
Cut points (grams/day) 0 to <0.02 0.02 to <0.05 0.04 to <0.10 0.10 to <0.25 0.25 to <1.98 
10 years of follow-up 
Cases 12 14 10 9 6 
HR (95% CI)1 1.00 0.99 (0.45-2.13) 0.69 (0.30-1.60) 0.59 (0.25-1.40) 0.39 (0.15-1.04) ** 
HR (95% CI)2 1.00 0.98 (0.46-2.16) 0.70 (0.30-1.66) 0.60 (0.25-1.43) 0.40 (0.15-1.08) ** 
17 years of follow-up 
Cases 16 20 22 14 16 
HR (95% CI)1 1.00 1.08 (0.56-2.09) 1.14 (0.60-2.18) 0.70 (0.34-1.43) 0.82 (0.41-1.64) 
  HR (95% CI)2 1.00 1.06 (0.55-2.06) 1.12 (0.59-2.15) 0.69 (0.33-1.42) 0.81 (0.40-1.63) 
HR=hazard ratio, CI=confidence interval, *borderline significant trend across quintile (p=0.084), **significant trend where p<0.05 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Monounsaturated fatty acids 
 Total monounsaturated fatty acid (MUFA) intake was negatively 
associated with pancreatic cancer for all higher quintiles, compared to the lowest, 
after both 10 and 17 years follow-up, although none were statistically significant 
(Table 38). There was no effect for the trend across quintiles (after 10 years follow-
up, trend for total MUFA intake, HR=0.97, 95% CI=0.92-1.03). After 17 years, 
total MUFA intake had a borderline protective effect when the highest quintile was 
compared to the lowest (HR=0.38 95% CI=0.13-1.14, p=0.085). As well as the 
effect of total MUFA intake, individual MUFAs were assessed, namely oleic acid, 
palmitoleic acid and vaccenic acid. After 10 years of follow-up, oleic acid had 
negative associations for all higher quintiles of intake although these were not 
statistically significant (Table 38), and no effect for the trend across quintiles 
(HR=0.83, 95% CI=0.60-1.15, p=0.26). However after 17 years of follow-up, there 
was a significant reduced risk of pancreatic cancer for the highest quintile of intake 
(highest vs lowest HR=0.29, 95% CI=0.11-0.84, p=0.022), with a significant trend 
across quintiles (HR=0.73 95% CI=0.57-0.93, p=0.013)(Table 38). The 
monounsaturated fatty acid, palmitoleic acid, had positive associations with 
pancreatic cancer after 10 years (highest vs lowest HR=2.64, 95% CI=0.84-8.30, 
p=0.097), although none after 17 years follow-up. Vaccenic acid was not 
associated with pancreatic cancer in any of the analyses. 
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Table 38. Total and individual monounsaturated fatty acid (MUFA) intake and the 
risk of developing pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of participants 812 812 811 812 811 
Total monunsaturated fat 
Cut points (grams/day) 3.2 to <18.3 18.3 to <22.7 22.7 to <26.8 26.8 to <32.8 32.8 to <103.8 
10 years of follow-up 
Cases 15 9 6 13 8 
HR (95% CI)1 1.00 0.54 (0.23-1.24) 0.35 (0.14-0.92) 0.70 (0.32-1.55) 0.44 (0.17-1.11) 
HR (95% CI)2 1.00 0.61 (0.23-1.57) 0.38 (0.11-1.32) 0.67 (0.21-2.32) 0.45 (0.10-1.80) 
17 years of follow-up 
Cases 26 16 15 19 12 
HR (95% CI)1 1.00 0.60 (0.32-1.11) 0.60 (0.31-1.14) 0.74 (0.39-1.37) 0.52 (0.24-1.08) 
HR (95% CI)2 1.00 0.53 (0.29-1.09) 0.46 (0.19-1.07) 0.51 (0.20-1.27)  0.38 (0.12-1.08) 
Palmitoliec Acid (C16:1n7c) 
Cut points (grams/day) 0.11 to 0.64 0.64 to <0.81 0.81 to <0.98 0.98 to <1.23 1.23 to <3.39 
10 years of follow-up 
Cases 8 12 9 8 14 
HR (95% CI)1 1.00 1.32 (0.53-0.25) 0.98 (0.37-2.59) 0.84 (0.31-2.29) 1.40 (0.55-3.55) 
HR (95% CI)2 1.00 1.73 (0.67-4.40) 1.46 (0.2-4.16) 1.41 (0.45-4.38) 2.64 (0.83-8.31) 
17 years of follow-up 
Cases 15 21 16 18 18 
HR (95% CI)1 1.00 1.03 (0.67-2.53) 1.03 (0.51-2.11) 1.17 (0.58-2.36) 1.17 (0.57-2.44) 
HR (95% CI)2 1.00 1.41 (0.71-2.82) 1.20 (0.55-2.59) 1.42 (0.64-3.15) 1.55 (0.65-3.73) 
Vaccenic Acid (C18:1n7c) 
Cut points (grams/day) 0 .03 to <1.20 1.20 to <1.57 1.56 to <1.97 1.97 to <2.51 2.51 to <10.68 
10 years of follow-up 
Cases 11 11 6 10 13 
HR (95% CI)1 1.00 0.88 (0.38-2.04) 0.46 (0.17-1.28) 0.75 (0.31-1.83) 0.99 (0.41-2.37) 
HR (95% CI)2 1.00 1.10 (0.46-2.65) 0.65 (0.21-1.96) 1.08 (0.37-3.13) 1.62 (0.53-4.93) 
17 years of follow-up 
Cases 20 20 10 19 19 
HR (95% CI)1 1.00 0.95 (0.51-1.76) 0.49 (0.22-1.04) 0.96 (0.50-1.83) 1.03 (0.52-2.03) 
HR (95% CI)2 1.00 0.64 (0.31-1.35) 1.11 (0.55-2.22) 1.04 (0.48-2.28) 1.29 (0.55-3.00) 
Oleic acid (C18:1n9c) 
Cut points (grams/day) 2.5 to <13.2 13.2 to <16.4 16.4 to <19.4 19.4 to <23.7 23.7 to <78.4 
10 years of follow-up 
Cases 14 13 4 12 8 
HR (95% CI)1 1.00 0.83 (0.39-1.78) 0.24 (0.08-1.24) 0.72 (0.32-1.63) 0.48 (0.17-1.24) 
HR (95% CI)2 1.00 0.92 (0.38-2.21) 0.25 (0.06-0.95) 0.66 (0.20-2.12) 0.46 (0.11-1.80) 
17 years of follow-up 
Cases 27 22 11 16 12 
HR (95% CI)1 1.00 0.81 (0.45-1.43) 0.41 (0.20-0.83) 0.63 (0.33 (1.21) 0.51 (0.24-1.06) ** 
  HR (95% CI)2 1.00 0.64 (0.33-1.25) 0.27 (0.11-0.65) 0.35 (0.14-0.85) 0.29 (0.11-0.83) ** 
HR=hazard ratio, CI=confidence interval, ** significant trend across quintiles where p<0.05 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Saturated fatty acids and trans-fatty acids 
 There were no associations with the dietary intake of total saturated fats, 
total trans fatty acids, as well as the individual saturated fatty acids of myristic 
acid, palmitic acid and stearic acid and the risk of developing pancreatic cancer 
after both periods of follow-up (Table 39 and Table 40). 
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Table 39. Total and individual saturated fatty acid intake and the risk of developing 
pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of participants 812 812 812 812 812 
Total saturated fat intake 
Cut points (grams/day) 3.9 to <19.2 19.2 to <24.1 24.1 to <29.4 29.4 to <36.2 36.2 to <125.6 
10 years of follow-up 
Cases 12 8 8 12 11 
HR (95% CI)1 1.00 0.61 (0.24-1.50) 0.61 (0.24-1.50) 0.89 (0.38-2.04) 0.79 (0.33-1.90) 
HR (95% CI)2 1.00 0.83 (0.33-2.25) 0.98 (0.34-2.99) 1.51 (0.50-4.82) 1.58 (0.44-5.66) 
17 years of follow-up 
Cases 22 16 17 17 16 
HR (95% CI)1 1.00 0.70 (0.37-1.34) 0.78 (0.41-1.48) 0.82 (0.43-1.58) 0.79 (0.40-1.58) 
HR (95% CI)2 1.00 0.53 (0.29-1.09) 0.46 (0.19-1.07) 0.51 (0.20-1.27)  0.38 (0.12-1.08) 
Myristic acid (C14:0) 
Cut points (grams/day) 0.16 to <1.69 1.69 to <2.27 2.27 to <2.89 2.89 to <3.81 3.81 to <13.05 
10 years of follow-up 
Cases 9 11 9 9 13 
HR (95% CI)1 1.00 1.15 (0.48-2.78) 0.95 (0.37-2.39) 0.93 (0.36-2.36) 1.25 (0.52-3.00) 
HR (95% CI)2 1.00 1.47 (0.59-3.65) 1.31 (0.49-3.55) 1.41 (0.50-4.04) 2.00 (0.69-5.74) 
17 years of follow-up 
Cases 17 18 17 20 16 
HR (95% CI)1 1.00 1.00 (0.51-1.94) 0.99 (0.50-1.94) 1.22 (0.63-2.36) 0.94 (0.47-1.89) 
HR (95% CI)2 1.00 1.08 (0.55-2.17) 1.07 (0.53-2.25) 1.34 (0.67-2.93) 1.07 (0.49-2.52) 
Palmitic acid (C16:0) 
Cut points (grams/day) 2.16 to <9.89 9.89 to <12.46 12.46 to <14.96 14.96 to <18.43 18.43 to <64.24 
10 years of follow-up 
Cases 14 6 9 10 12 
HR (95% CI)1 1.00 0.38 (0.14-0.99) 0.56 (0,23-1.31) 0.61 (0.25-1.42) 0.73 (0.31-1.69) 
HR (95% CI)2 1.00 0.48 (0.18-1.40) 0.85 (0.29-2.51) 0.98 (0.29-3.30) 1.42 (0.37-5.25) 
17 years of follow-up 
Cases 25 13 17 16 17 
HR (95% CI)1 1.00 0.48 (0.24-0.94) 0.67 (0.36-1.24) 0.67 (0.35-1.29) 0.75 (0.38-1.47) 
HR (95% CI)2 1.00 0.48 (0.23-1.01) 0.64 (0.29-1.41) 0.62 (0.25-1.52) 0.81 (0.29-2.12) 
Stearic acid (C18:0) 
Cut points (grams/day) 0.71 to <4.29 4.29 to <5.46 5.46 to <6.63 6.63 to <8.21 8.21 to <29.52 
10 years of follow-up 
Cases 9 14 5 13 10 
HR (95% CI)1 1.00 1.49 (0.64-3.46) 0.49 (0.16-1.48) 1.29 (0.53-3.11) 1.01 (0.39-2.65) 
HR (95% CI)2 1.00 2.02 (0.85-5.14) 0.79 (0.23-2.77) 2.23 (0.72-7.23) 2.01 (0.54-7.45) 
17 years of follow-up 
Cases 21 20 15 17 15 
HR (95% CI)1 1.00 0.97 (0.52-1.80) 0.70 (0.36-1.38) 0.87 (0.45-1.67) 0.82 (0.40-1.68) 
HR (95% CI)2 1.00 1.00 (0.52-1.99) 0.71 (0.33-1.59) 0.85 (0.36-2.00) 0.91 (0.33-2.26) 
HR=hazard ratio, CI=confidence interval  1Adjusted for sex  and age      
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Table 40. Total trans fatty acid intake and the risk of developing pancreatic cancer. 
 
    Quintile     
    1 2 3 4 5 
Number of 
participants 812 812 811 812 811 
Cut points (grams/day) 0.1 to <1.7 1.7 to <2.4 2.4 to <3.0 3.0 to <3.8 3.8 to <16.0 
10 years of follow-up 
Cases 12 6 10 12 11 
HR (95% CI)1 1.00 0.47 (0.18-1.25) 0.75 (0.32-1.77) 0.89 (0.39-2.03) 0.79 (0.33-1.98) 
HR (95% CI)2 1.00 0.59 (0.22-1.64) 1.11 (0.44-2.97) 1.40 (0.52-3.84) 1.43 (0.46-4.42) 
17 years of follow-up 
Cases 22 15 15 21 15 
HR (95% CI)1 1.00 0.68 (0.35-1.32) 0.67 (0.35-1.30) 0.99 (0.54-1.82) 0.71 (0.35-1.41) 
HR (95% CI)2 1.00 0.71 (0.35-1.40) 0.70 (0.33-1.45) 1.04 (0.50-2.17) 0.79 (0.34-1.87) 
              
HR=hazard ratio, CI=confidence interval 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
  
202 
 
Meat and fish food groups 
Red meat is a rich source of n-6 PUFAs, while fish, in particular fatty fish, 
has a high content of n-3 PUFAs. White, red and processed meats had no 
associations with the development of pancreatic cancer for individual categories or 
trends (Table 41). Fatty fish was not divided into fifths, due to the large number 
who ate none, and instead was divided into four categories of intake. After 10 years 
follow-up, but not 17 years, fatty fish intake was inversely associated with the risk 
of pancreatic cancer in the three higher quartiles of intake, although none reached 
statistical significance (trend HR=0.89, 95% CI=0.75-1.05, p=0.17) (Table 42). 
White fish intake had no association with the development of pancreatic cancer 
(trend across categories HR=0.94 95% CI=0.79-1.13, p=0.53) (Table 42).  
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Table 41. Meat groups and the risk of developing pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
White meat intake 
Number of participants 905 684 802 789 790 
Cut points (grams/day) 0 to <0.1 0.15 to <14.4 14.5 to <25.3 25.4 to <41.4 41.5 to <347.8 
10 years of follow-up 
Cases 10 12 5 17 7 
HR (95% CI)1 1.00 1.59 (0.69-3.68) 0.57 (0.19-1.66) 1.87 (0.85-4.08) 0.83 (0.32-2.20) 
HR (95% CI)2 1.00 1.60 (0.69-3.72) 0.59 (0.20-1.74) 1.92 (0.88-4.20) 0.86 (0.33-2.27) 
17 years of follow-up 
Cases 12 23 11 27 15 
HR (95% CI)1 1.00 2.45 (1.22-4.93) 1.03 (0.45-2.34) 2.54 (1.28-5.03) 1.56 (0.73-3.34) 
HR (95% CI)2 1.00 2.43 (1.20-4.89) 1.04 (0.46-2.37) 2.54 (1.29-5.03) 1.59 (0.74-3.40) 
Red meat intake 
Number of participants 812 812 811 812 811 
Cut points (grams/day) 0 to <8.6 8.7 to <23.0 23.1 to <36.9 37.0 to <55.7 55.7 to 349.3 
10 years of follow-up 
Cases 12 8 6 15 10 
HR (95% CI)1 1.00 0.61 (0.25-1.50) 0.46 (0.17-1.23) 1.10 (0.51-2.36) 0.71 (0.30-1.66) 
HR (95% CI)2 1.00 0.63 (0.26-1.55) 0.48 (0.18-1.29) 1.14 (0.53-2.46) 0.76 (0.32-1.80) 
17 years of follow-up 
Cases 20 17 12 26 13 
HR (95% CI)1 1.00 0.79 (0.41-1.51) 0.54 (0.26-1.10) 1.14 (0.63-2.04) 0.59 (0.29-1.19) 
HR (95% CI)2 1.00 0.79 (0.41-1.52) 0.54 (0.26-1.11) 1.13 (0.62-2.03) 0.59 (0.29-1.21) 
Processed meat intake 
Number of participants 800 790 793 796 791 
Cut points (grams/day) 0 to <5.43 5.46 to <14.2 14.3 to <23.1 23.2 to <36.1 36.2 to <192.0 
10 years of follow-up 
Cases 8 13 10 8 12 
HR (95% CI)1 1.00 1.46 (0.61-3.53) 1.07 (0.42-2.73) 0.84 (0.31-2.23) 1.22 (0.49-3.03) 
HR (95% CI)2 1.00 1.51 (0.62-3.67) 1.12 (0.44-2.88) 0.89 (0.33-2.39) 1.30 (0.52-3.26) 
17 years of follow-up 
Cases 13 21 18 17 19 
HR (95% CI)1 1.00 1.43 (0.71-2.86) 1.22 (0.60-2.50) 1.18 (0.57-2.44) 1.39 (0.67-2.85) 
  HR (95% CI)2 1.00 1.44 (0.72-2.90) 1.24 (0.60-2.54) 1.21 (0.58-2.50) 1.41 (0.69-2.92) 
HR=hazard ratio, CI=confidence interval 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Table 42. Fish intake and the risk of developing pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
White fish intake 
Number of participants 1 504 101 871 730 801 
Cut points (grams/day) 0 0.2-<6.4 6.5-<16.3 16.4-<26.5 26.5-250.0 
10 years of follow-up 
Cases 19 0 14 8 10 
HR (95% CI)1 1.00 Not available 1.10 (0.55-2.20) 0.73 (0.32-1.67) 0.79 (0.37-1.71) 
HR (95% CI)2 1.00 Not available 1.12 (0.56-2.26) 0.76 (0.33-1.74) 0.80 (0.37-1.72) 
17 years of follow-up 
Cases 30 2 22 18 16 
HR (95% CI)1 1.00 0.96 (0.23-4.02) 1.06 (0.61-1.84) 1.05 (0.58-1.89) 0.79 (0.43-1.45) 
HR (95% CI)2 1.00 0.95 (0.23-4.00) 1.07 (0.61-1.86) 1.08 (0.60-1.95) 0.79 (0.43-1.45) 
Fatty fish intake 
Number of participants 1 988 Not available 448 811 811 
Cut points (grams/day) 0 Not available 0.01-8.57 8.6-22.6 22.7-259.2 
10 years of follow-up 
Cases 30 Not available 6 6 9 
HR (95% CI)1 1.00 Not available 0.89 (0.37-2.14) 0.48 (0.20-1.16) 0.70 (0.33-1.48) 
HR (95% CI)2 1.00 Not available 0.90 (0.38-2.22) 0.50 (0.21-1.20) 0.73 (0.34-1.54) 
17 years of follow-up 
Cases 44 Not available 13 14 17 
HR (95% CI)1 1.00 Not available 1.29 (0.70-2.40) 0.76 (0.42-1.39) 0.93 (0.53-1.62) 
HR (95% CI)2 1.00 Not available 1.30 (0.70-2.41) 0.75 (0.41-1.37) 0.94 (0.54-1.65) 
              
HR=hazard ratio, CI=confidence interval 
1 Adjusted for age and sex. 
2 Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
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Dietary antioxidants 
There were inverse associations for the dietary intakes of vitamin C, 
vitamin E and selenium for all the higher quintiles of intake (HRs ranging from 
0.47 to 0.84) at 10 and 17 years of follow-up, although no individual one reached 
statistical significance. Dietary zinc had no association with the risk of developing 
pancreatic cancer in any analysis (Table 43). Adjusting for the use of supplements, 
containing the same antioxidant, produced similar results. The inverse association 
with disease was of greatest magnitude for vitamin E, and in the primary analysis 
after 10 years of follow-up, the age and sex adjusted trend across quintiles was of 
borderline statistical significance (HR=0.84, 95% CI=0.68-1.03, p=0.086), with the 
multivariate result of the same effect size (HR=0.84 95% CI=0.67-1.07, p=0.16) 
(Table 43). As the risk reduction across each quintile was similar for vitamin C, 
vitamin E and selenium, the threshold effect for each antioxidant was calculated. 
The lowest quintile of intake was compared against a summation of the four higher 
ones.  After 10 years of follow-up, the threshold effect for vitamin E in multivariate 
analysis was 0.53 (95% CI=0.27-1.04, p=0.065) (Table 44). If adjustment was 
made for the use of supplements containing vitamin E, the HR=0.48 (95%=0.26-
0.88, p=0.018), with a similar result after 17 years (Table 44). Dietary vitamin C, 
adjusted for vitamin C supplement use had a threshold effect after 10 years of 
follow-up (HR=0.58, 95% CI=0.32-1.08, p=0.087) and after 17 years (HR=0.61, 
95% CI=0.38-0.99, p=0.045) (Table 44). The threshold effect for selenium after 10 
years was statistically significant after adjusted for selenium supplement use 
(HR=0.53, 95% CI=0.29-0.99, p=0.048), although not after 17 years (HR=0.69, 
95% CI=0.42-1.13, p=0.14). In a post hoc analysis, those in the lowest quintiles for 
all intakes of vitamin C, vitamin E and selenium intakes were compared to those 
with higher one. The multivariate HR for developing pancreatic cancer in those 
with the lowest intakes of all three antioxidants was 5.26 (95%=2.04-14.3, 
p=0.001), with adjustment for antioxidant supplementation not altering the effect 
size (Table 45). After 17 years, those with the lowest intake of all three 
antioxidants the HR=3.70 (95% CI=1.59-8.33, p=0.002). 
Serum vitamin C levels were measured at baseline in 22 474 (87.7%) of 
the initial 25 639 participants who attended the initial health check in EPIC-
Norfolk. After 10 and 17 years follow-up, all increasing quintiles of serum vitamin 
C were inversely associated with the risk of pancreatic cancer (Table 46). After 10 
years, 44 incident cases of pancreatic cancer were diagnosed in those with baseline 
serum vitamin C levels, with a statistically significant reduced risk of developing 
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pancreatic cancer in the highest vs the lowest quintile (multivariate HR=0.16 (95% 
CI=0.04-0.73, p=0.018) with a trend across quintiles HR=0.73 (95% CI=0.57-0.92, 
p=0.008) (Table 46). After 10 years, serum vitamin C as a continuous variable (per 
micro mol/litre) had a multi-variate inverse association (HR=0.98, 95% CI=0.97-
1.00, p=0.026). After 17 years of follow-up, 78 participants who had undergone 
baseline measurement of serum vitamin C were diagnosed with pancreatic cancer. 
In this group all higher quintiles were negatively associated, with the highest vs the 
lowest quintile of serum vitamin C multivariate HR=0.48 (95% CI=0.21-1.11, 
p=0.085), with a non-significant negative trend across quintiles (HR=0.88 95% 
CI=0.74-1.04, p=0.12). 
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Table 43. Quintiles of dietary antioxidant intake and the risk of pancreatic cancer. 
    Quintile     
    1 2 3 4 5 
Number of participants 812 812 811 812 811 
Vitamin C 
Cut points (mg/day) 0 to <46.9 47.0 to <65.3 65.4 to <89.1 89.2 to <123.1 123.2 to <654.8 
10 years of follow-up 
Cases 16 8 9 7 11 
HR (95% CI)1 1.00 0.50 (0.21-1.18) 0.57 (0.25-1.29) 0.44 (0.18-1.08) 0.71 (0.33-1.52) 
HR (95% CI)2 1.00 0.51 (0.21-1.21) 0.61 (0.26-1.39) 0.47 (0.19-1.17) 0.76 (0.34-1.70) 
HR (95% CI)3 1.00 0.51 (0.22-1.21) 0.61 (0.27-1.40) 0.48 (0.19-1.18) 0.77 (0.34-1.72) 
17 years of follow-up 
Cases 24 15 16 13 20 
HR (95% CI)1 1.00 0.62 (0.32-1.17) 0.66 (0.35-1.25) 0.53 (0.27-1.04) 0.85 (0.47-1.54) 
HR (95% CI)2 1.00 0.61 (0.32-1.17) 0.65 (0.34-1.24) 0.53 (0.26-1.05) 0.85 (0.45-1.57) 
HR (95% CI)3 1.00 0.61 (0.32-1.17) 0.64 (0.34-1.22) 0.51 (0.25-1.02) 0.81 (0.44-.152) 
Vitamin E 
Cut points (mg/day) 0.9 to <6.8 6.8 to <8.5 8.5 to <10.4 10.4 to <13.1 13.1 to <75.0 
10 years of follow-up 
Cases 17 9 8 9 8 
HR (95% CI)1 1.00 0.53 (0.24-1.19) 0.46 (0.20-1.08) 0.53 (0.23-1.21)  0.47 (0.20-1.11)*  
HR (95% CI)2 1.00 0.56 (0.24-1.30) 0.48 (0.19-1.17) 0.58 (0.23-1.44) 0.47 (0.17-1.27) 
HR (95% CI)3 1.00 0.56 (0.24-1.31) 0.48 (0.19-1.18) 0.58 (0.23-1.45) 0.47 (0.17-1.28) 
17 years of follow-up 
Cases 27 15 18 12 16 
HR (95% CI)1 1.00 0.59 (0.31-1.11) 0.72 (0.39-1.31) 0.52 (0.26-1.04) 0.73 (0.39-1.39) 
HR (95% CI)2 1.00 0.58 (0.30-1.10) 0.68 (0.36-1.29) 0.50 (0.23-1.06) 0.70 (0.33-1.46) 
HR (95% CI)3 1.00 0.58 (0.32-1.11) 0.68 (0.36-1.30) 0.51 (0.24-1.07) 0.70 (0.34-1.48) 
Selenium 
Cut points (µg/day) 7.9 to <40.8 40.8 to <51.4 51.4 to <62.1 62.1 to <76.7 76.7 to <275.5 
10 years of follow-up 
Cases 15 8 9 9 10 
HR (95% CI)1 1.00 0.51 (0.22-1.21) 0.53 (0.23-1.21) 0.51 (0.22-1.20) 0.53 (0.23-1.24) 
HR (95% CI)2 1.00 0.55 (0.23-1.32) 0.59 (0.25-1.39) 0.59 (0.24-1.43) 0.62 (0.25-1.56) 
HR (95% CI)3 1.00 0.55 (0.23-1.32) 0.58 (0.24-1.39) 0.59 (0.24-1.43) 0.63 (0.25-1.57) 
17 years of follow-up 
Cases 23 15 15 19 16 
HR (95% CI)1 1.00 0.63 (0.33-1.22) 0.62 (0.32-1.20) 0.79 (0.42-1.47) 0.69 (0.35-1.35) 
HR (95% CI)2 1.00 0.64 (0.33-1.24) 0.65 (0.33-1.27) 0.84 (0.43-1.61) 0.75 (0.36-1.54) 
HR (95% CI)3 1.00 0.64 (0.33-1.25) 0.64 (0.33-1.27) 0.84 (0.43-1.61) 0.75 (0.36-1.55) 
Zinc 
Cut points (mg/day) 0.8 to <6.3 6.3 to <7.5 7.5 to <8.7 8.7 to <10.3 10.3 to <24.5 
10 years of follow-up 
Cases 12 7 12 10 10 
HR (95% CI)1 1.00 0.59 (0.23-1.51) 0.90 (0.40-2.02) 0.70 (0.29-1.68) 0.69 (0.28-1.68) 
HR (95% CI)2 1.00 0.72 (0.27-1.90) 1.17 (0.47-2.92) 0.92 (0.33-2.56) 0.90 (0.31-2.67) 
HR (95% CI)3 1.00 0.71 (0.27-1.88) 1.17 (0.47-2.91) 0.92 (0.33-2.57) 0.88 (0.30-2.61) 
17 years of follow-up 
Cases 20 15 22 16 15 
HR (95% CI)1 1.00 0.79 (0.40-1.54) 1.11 (0.60-2.05) 0.79 (0.40-1.56) 0.78 (0.39-1.60) 
HR (95% CI)2 1.00 0.84 (0.42-1.69) 1.18 (0.59-2.34) 0.82 (0.38-1.77) 0.85 (0.37-1.97) 
  HR (95% CI)3 1.00 0.83 (0.41-1.68) 1.17 (0.59-2.32) 0.81 (0.37-1.76) 0.84 (0.36-1.95) 
HR=hazard ratio, CI=confidence interval, * borderline significant trend across quintiles (p=0.086). 
1 Adjusted for age and sex.           2Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake 
3Same as model 2 with the addition of the respective antioxidant supplement e.g, vit C adjusted for vitamin C supplementation. 
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Table 44. The threshold effect of dietary antioxidants and the risk of pancreatic 
cancer. 
Threshold effect of Q1 vs Q2-5   
    Q1 Q 2-5 p value 
Number of participants 812 3 246 
Vitamin C 
Cut points (mg/day) 0 to 46.95 46.95 to 654.8 
10 years of follow-up 
Cases 16 35 
HR (95% CI)1 1.00 0.55 (0.31-1.00) 0.051 
HR (95% CI)2 1.00 0.58 (0.31-1.07) 0.084 
HR (95% CI)3 1.00 0.58 (0.32-1.08) 0.087 
17 years of follow-up 
Cases 24 64 
HR (95% CI)1 1.00 0.66 (0.42-1.06) 0.088 
HR (95% CI)2 1.00 0.65 (0.40-1.06) 0.085 
HR (95% CI)3 1.00 0.61 (0.38-0.99) 0.045 
Vitamin E 
Cut points (mg/day) 0.87 to 6.76 6.77 to 74.9 
10 years of follow-up 
Cases 17 34 
HR (95% CI)1 1.00 0.50 (0.28-0.91) 0.023 
HR (95% CI)2 1.00 0.53 (0.27-1.04) 0.065 
HR (95% CI)3 1.00 0.48 (0.26-0.88) 0.018 
17 years of follow-up 
Cases 27 61 
HR (95% CI)1 1.00 0.64 (0.40-1.01) 0.058 
HR (95% CI)2 1.00 0.61 (0.36-1.02) 0.062 
HR (95% CI)3 1.00 0.61 (0.38-0.98) 0.040 
Selenium 
Cut points (µg/day) 7.90 to 40.82 40.83 to 275.5 
10 years of follow-up 
Cases 15 36 
HR (95% CI)1 1.00 0.52 (0.28-0.97) 0.040 
HR (95% CI)2 1.00 0.58 (0.30-1.13) 0.11 
HR (95% CI)3 1.00 0.53 (0.29-0.99) 0.048 
17 years of follow-up 
Cases 23 65 
HR (95% CI)1 1.00 0.68 (0.42-1.11) 0.12 
HR (95% CI)2 1.00 0.70 (0.42-1.18) 0.18 
HR (95% CI)3 1.00 0.69 (0.42-1.13) 0.14 
Zinc 
Cut points (mg/day) 0.75 to 6.33 6.34 to 24.51 
10 years of follow-up 
Cases 12 39 
HR (95% CI)1 1.00 0.72 (0.37-1.41) 0.34 
HR (95% CI)2 1.00 0.90 (0.41-1.97) 0.79 
HR (95% CI)3 1.00 0.90 (0.41-1.97) 0.79 
17 years of follow-up 
Cases 20 68 
HR (95% CI)1 1.00 0.88 (0.52-1.47) 0.62 
HR (95% CI)2 1.00 0.93 (0.51-1.68) 0.81 
  HR (95% CI)3 1.00 0.97 (0.31-3.09) 0.96 
HR=hazard ratio, CI=confidence interval, µg=microgram, mg=milligram 
1The model adjusted for age and sex. 
2The mulitvariate model adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy. 
3
 Same as model 2 with the addition of the respective antioxidant supplement e.g. vit C adjusted for vitamin C 
supplementation. 
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Table 45. The lowest quintile of intake for all of vitamin C, vitamin E and selenium 
and the risk of pancreatic cancer. 
 
Q1 for all of Q2-5 for any of  
    vit C, E & selenium vit C, E or selenium p value 
Number of participants 98 3 960 
10 years of follow-up 
Cases 6 45 
HR (95% CI)1 1.00 0.17 (0.07-0.41) <0.001 
HR (95% CI)2 1.00 0.19 (0.07-0.48) 0.001 
HR (95% CI)3 1.00 0.19 (0.07-0.49) 0.001 
17 years of follow-up 
Cases 7 81 
HR (95% CI)1 1.00 0.29 (0.13-0.63) 0.002 
HR (95% CI)2 1.00 0.27 (0.12-0.63) 0.002 
HR (95% CI)3 1.00 0.28 (0.12-0.64) 0.003 
          
HR=hazard ratio, CI=confidence interval, Q1=lowest quintile of intake. 
1Adjusted for age and sex. 
2Adjusted for age, sex, smoking status, diabetes, BMI category and quintile of energy intake. 
3
 Same as model 2 with the addition of vit C, vit E & selenium antioxidant supplementation. 
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Table 46. Serum vitamin C and the risk of developing pancreatic cancer. 
 
    Quintile     
    1 2 3 4 5 
Number of participants 4691 4362 4459 4689 4273 
% of original cohort 18.3 17.0 17.4 18.3 16.7 
Cut points (µmol/litre) 3.0 to 37.0 37.4 to 49.0 49.5 to 58.0 58.7 to 69.0 69.1 to 242.0 
10 years follow-up 
Number of P-Y 46 854 43 566 44 573 46 861 42 723 
Number of cases 
(n=44) 15 12 7 8 2 
Cases per 1000 P-Y 0.32 0.28 0.16 0.17 0.05 
HR (95% CI)1 1.00 0.93 (0.43-1.99) 0.55 (0.22-1.37) 0.62 (0.26-1.49) 0.17 (0.04-0.77)** 
HR (95% CI)2 1.00 0.91 (0.42-1.96) 0.52 (0.21-1.31) 0.59 (0.24-1.44) 0.16 (0.04-0.73)** 
17 years follow-up 
Number of P-Y 59 693 55 234 56 417 59 194 53 717 
Number of cases 
(n=78) 20 17 15 17 9 
Cases per 1000 P-Y 0.34 0.31 0.27 0.29 0.17 
HR (95% CI)1 1.00 0.97 (0.51-1.86) 0.85 (0.43-1.67) 0.91 (0.47 1.77) 0.51 (0.23-1.15) 
HR (95% CI)2 1.00 0.96 (0.50-1.84) 0.83 (0.42-1.65) 0.88 (0.45-1.72) 0.49 (0.21-1.10) 
              
HR=hazard ratio, CI=confidence ratio, P-Y=person-years, **p for trend <0.05 
1 Adjusted for age & sex. 
2 Adjusted for age, sex, smoking status, diabetes and BMI category. 
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4. Summary of results 
The primary analysis was the risk of developing pancreatic cancer after 10 
years follow-up, adjusted for the co-variates of age, sex, cigarette smoking, 
diabetes and body mass index category, plus total energy intake for dietary 
nutrients. The main findings were statistically significant inverse associations for 
following; first, increased physical activity in participants younger than 65 years; 
second, increased dietary DHA intake; third, a threshold effect for dietary vitamin 
E and selenium; fourth, increased serum vitamin C levels. Borderline statistically 
significant negative associations were found for both total n-3 fatty acid intake and 
the threshold effect of vitamin C. No other associations were reported with either 
macro-nutrient or food groups during the 10 year follow-up period. The secondary 
outcomes, analysed after 17 years of follow-up, reported a statistically significant 
negative association with oleic acid intake and a threshold effect for vitamin C and 
vitamin E. 
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Discussion 
 
The main findings in this study of pancreatic cancer aetiology were for the 
primary outcomes, after 10 years of follow-up, statistically significant inverse 
associations for increased dietary DHA intake and a threshold protective effect for 
vitamin E and selenium with increased physical activity protective in participants 
aged less than 65 years. Borderline statistically significant negative associations 
were found for total n-3 fatty acid intake and a threshold effect of vitamin C which 
was supported by the serum vitamin C data that had a statistically significant 
negative association with the risk of developing disease. No other statistically 
significant associations were reported during the 10 year follow-up period. The 
secondary outcomes, analysed after 17 years of follow-up, found a statistically 
significant negative association with oleic acid intake and a threshold effect for 
vitamin C and vitamin E. A borderline result was found for physical activity in 
those aged less than 65 years with the remaining results non-significant. The effect 
sizes were large with at least a 50% reduction is risk for the highest category of 
most risk factors. This work is the first to investigate the aetiology of pancreatic 
cancer using physical activity questionnaires that have been validated against 
physiological measures and food diaries in a prospective cohort study. The findings 
support measuring these variables in future aetiological studies of pancreatic 
cancer. Factors affecting the interpretation of results will now be discussed. 
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1. Lifestyle risk factors; physical activity and alcohol use 
Physical activity 
After 10 years of follow-up, physical activity was associated with a 
reduced risk of pancreatic cancer in those aged less the 65 years at enrolment, 
although no effects were found in the whole cohort. The study benefitted from the 
use of a physical activity questionnaire that had been previously validated against 
physiological measures of cardio-respiratory fitness, giving a novel attribute to the 
study design. Measurement tools with a higher degree of accuracy allow the 
detection of smaller magnitudes of effect. The a priori hypothesis was that physical 
activity could reduce the risk of pancreatic cancer by firstly, improving glucose 
tolerance and insulin sensitivity, and secondly, reducing serum insulin levels.376-377 
Raised insulin levels are associated with an increased risk of pancreatic cancer 278 
by stimulating the proliferation of pancreatic cancer cells.316-317 Exercise also 
increases the rate of fat oxidation which enables metabolism of a high fat diet,408 
contrasting with diabetes and obesity which are both risk factors for pancreatic 
cancer, that decrease the capacity to oxidise fatty acids, allowing some fatty acids 
to induce insulin resistance.456 
The findings in this study reflect some, but not all previous 
epidemiological work. Several investigations did not report an effect of physical 
activity,289 380 including the largest prospective cohort study in 1.3 million UK 
women undergoing breast cancer screening between the years 1996-2001.457 After 
a maximum of 11 years follow-up, 1 710 women died from pancreatic cancer. 
Physical activity was assessed in a questionnaire that categorised participants by 
the number of occasions they exercised each week. The findings were adjusted for 
smoking, BMI and height, with no effect reported for frequency of  physical 
activity (p for trend=0.6).457 However, the physical activity questionnaire had not 
been previously validated and mostly assessed leisure time physical activities, 
which have been shown to be a poor indicator of physiological activity when 
compared to physiological measures of cardio-respiratory fitness.458 Physical 
activity has been investigated in a large number of other epidemiological 
investigations, leading to two recent meta-analyses, the first from 2008. This meta-
analysis concluded there was no evidence of an effect of physical activity derived 
from leisure activity, although data taken from three cohort studies showed 
occupational activity was associated with a 25% decreased risk of pancreatic 
cancer (highest quartile vs lowest RR=0.75; 95% CI=0.58-0.96),378 consistent with 
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data from another meta-analysis in 2011.379 The finding that occupational physical 
activity exerts a protective effect against the development of pancreatic cancer is 
consistent with this study’s results in those aged below 65 years. The lack of an 
association of physical activity in the whole cohort, and hence including those over 
the age of 65 years, is likely to be due to several reasons. Firstly, the physical 
activity index was derived mostly from occupational physical activity, and those 
aged 65 years and over will probably have retired, so exercise is likely to be less 
and potentially have a reduced impact on disease. Furthermore, as participants 
stopped working and entered retirement, physical activity levels would be expected 
to change, leading to a regression dilution effect as their activity would be 
misclassified. Finally, physical activity at work is the most discriminating question 
to determine the level of total physical activity. If it is no longer applicable to an 
individual, it becomes very difficult to reliably classify someone’s level of physical 
activity.458 In those aged over 65 years or not working, there are currently no 
validated physical activity questionnaires which reliably categorise such people, 
and hence no effects of physical activity have been demonstrated in this group, in 
either this study, or previous work. To address the limitations of current work, 
future studies could include repeated assessments of physical activity. These were 
obtained in the EPIC-Norfolk participants who completed the physical activity 
questionnaire after 18 months and 3 years of follow-up. More accurate methods of 
recording physical activity could also be used, with previous work suggesting a 
role for heart rate monitoring over several days which improves estimates of 
physical activity energy expenditure.459 
The weaknesses of the study were the relatively small number of cases 
identified, with only 53 cases diagnosed after 10 years of follow-up, which 
increases the risk of chance findings. However, it was decided to perform the 
primary analysis after 10 years, rather than 17 years, to reduce the effects of 
regression dilution bias which could have been considerable. Physical activity 
remains a difficult exposure to assess reliably and hence reducing the time to 
analysis improves the accuracy of a single baseline measure. Evidence from this 
and previous studies suggests occupational physical activity does reduce the risk of 
pancreatic cancer, but until more reliable methods are found to assess leisure time 
activity, particularly in those aged over 65 years, it will remain unclear whether 
this also has an effect on disease risk. 
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Alcohol intake 
 Increasing alcohol intake did not significantly alter the risk of pancreatic 
cancer, although those with a moderate intake (>0 to <7 units per week) did have a 
reduced risk of disease compared to abstainers of alcohol after 17 years of follow-
up. There was no effect of having a high intake of alcohol (>21 units per week). 
The lack of effect of an increased intake of alcohol is in agreement with previous 
large cohort studies which have reported similar results.363-364 This study did not 
have sufficient numbers to evaluate those with a very high alcohol intake (>35 
units/week) which has previously been associated with an increased of disease.364-
365
 Hence, the results from this study add to the growing evidence that moderate 
and high intakes of alcohol do not increase the risk of pancreatic cancer. The 
finding that moderate intake may be associated with a decreased risk compared to 
abstainers was replicated by the largest study of moderate alcohol intake 
undertaken in the Million Women Study. This study, of 1 280 296 middle-aged 
women in the UK, separated alcohol categories into; non-drinkers, those 
consuming ≤2 drinks/week, 3-6 drinks/week, 7-14 drinks/week and ≥15 
drinks/week. Using those drinking ≤2 drinks/week as the comparison group it 
reported that those consuming 3-6 drinks per week had a reduced risk of 
developing disease (RR=0.88 95% CI=0.78-1.00) with a non-statistical increased 
risk in non-drinkers (RR=1.07 95% CI=0.97-1.20) and those with the highest 
intake (RR=1.07, 95% CI=0.85-1.35).460 Hence, the results from this study and 
previous large cohort studies suggest a possible J-shaped relationship between 
alcohol intake and pancreatic cancer risk with a moderate intake (>0 to <7 units per 
week) associated with a decreased risk of disease, although there could be a 
residual confounder effect of either the lifestyle or dietary patterns. 
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2. Dietary analysis 
 
Diet is a plausible environmental factor to investigate in the aetiology of 
pancreatic cancer, with different nutrients having potential causative and protective 
effects. When assessing the role of diet in disease there are four main limitations to 
epidemiological studies. First, measurement of diet lacks precision and specificity. 
Second, nutrient intakes are highly correlated and therefore attribution of causation 
to one nutrient considered to be acting on its own may be misleading. Thirdly, 
biological measures of nutrients in tissues may not accurately and reliably reflect 
dietary intake. Fourth, the physical attributes of a food are not taken into 
consideration i.e. cooking style and preparation, freshness etc.260 Each of these 
limitations should be considered when drawing conclusions from results obtained. 
 
Total energy intake 
The results from this study showed negative associations for each higher 
quintile of total energy intake after 10 and 17 years follow-up, although none 
reached statistical significance (10 yr F/U, highest vs lowest quintile, HR=0.46 
95% CI=0.17-1.23, p=0.12). The study benefitted from the use of a 7-DFD which 
had been validated in previous studies against 16-day weighed records. Better 
correlation coefficients for total energy intake were achieved using 7-DFDs when 
compared to FFQs and 24-hour recalls which were the dietary assessment methods 
used in previous cohort studies (r=0.59 for 7-DFD vs r=0.52 for FFQ vs r=0.42 for 
24-hour recall).51 To exclude possibility of pre-clinical disease leading to a reduced 
energy intake, cases diagnosed within 2 years were removed from the analysis, 
which lead to an accentuation of the effect (10 year F/U, highest vs the lowest 
quintile HR= 0.41 95% CI=0.14-1.18, p=0.099). There are few biological 
mechanisms to explain a protective effect of total energy intake, although, 
increased energy intake may be due to increased physical activity levels.397 
Only two previous cohort studies have investigated total energy intake and 
pancreatic cancer. This study’s finding of a negative association of energy intake 
with pancreatic cancer has been replicated in the Finnish ATBC cohort study of 27 
111 male smokers with 163 incident cases of pancreatic cancer, which reported the 
highest vs lowest quintile HR=0.62 (95% CI=0.36-1.07, p for trend=0.05).398 The 
other cohort study was the Iowa Women’s Health Study, which reported no 
association (highest vs lowest tertile RR=1.20, 95% CI=0.67-2.15, p for 
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trend=0.54).399 Previous cohort studies and results from EPIC-Norfolk, listed in 
table 5, are not adjusted for physical activity, which is likely to be a confounder for 
energy intake. However, an analysis was made including physical activity but the 
results were not significantly altered (adjusting for physical activity, highest vs 
lowest quintile HR=0.47 95% CI=0.17-1.23; without physical activity HR=0.46 
95% CI=0.18-1.25). In future work, energy intake should be adjusted for physical 
activity to exclude the possibility of total energy intake being a surrogate marker of 
physical activity and to clarify if total energy intake does have an effect on 
pancreatic cancer risk. 
Dietary fats 
This study assessed the effects of total fats, fatty acid classes, fatty acid 
sub-classes and individual fatty acids. In the primary analysis, after 10 years of 
follow-up, total fat had negative associations for higher quintiles of intake 
compared to the lowest, although none were statistically significant. The study 
benefitted from the use of 7-DFDs which had improved correlation coefficients for 
fat intake compared to other dietary assessment methods (r=0.63 for 7-DFD vs 
r=0.55 for FFQ vs r=0.40 for 24-hour recall).51 Total fat intake has limited 
plausible biological mechanisms which could alter pancreatic risk. Fat could 
increase the risk of disease via stimulation of cholecystokinin release which 
induces hypertrophy of acinar cells,400 but there are no plausible biological 
mechanism to account for a protective effect of total fat intake. Previous cohort 
studies have either found no effect 399, 404-406 or an increased risk of disease with 
increased total fat intake (Table 25).398, 403 Therefore, the non-significant negative 
association found in EPIC-Norfolk, combined with inconsistencies of previous 
work, suggests that total fat intake is not a risk factor for pancreatic cancer. 
 
Saturated fats 
 In the primary analysis, no statistically significant associations with 
pancreatic cancer were found for total saturated fat intake or any of the individual 
saturated fatty acids. However, all of the highest quintiles had a positive 
association with disease, with the greatest magnitude found with stearic acid 
(HR=2.01, 95% CI=0.54-7.45, p for trend=0.36). Saturated fatty acids have 
biological actions which could account for an increased risk of pancreatic cancer. 
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Saturated fatty acids induce insulin resistance,402 by increasing insulin secretion 
and decreasing insulin sensitivity,173-176 with insulin resistance and raised insulin 
levels a possible precursor to pancreatic cancer.326 
Previous large cohort studies have investigated the association of saturated 
fatty acids and pancreatic cancer. The US National Institute of Health - American 
Association of Retired Persons (NIH-AARP) is the largest cohort study undertaken 
in this area, of 308 736 men and 216 737 women, which identified 865 cases of 
incident pancreatic cancer in men and 472 in women after 6.3 years follow-up.403 
An increased risk of disease was found in those with the highest intake of saturated 
fat (HR=1.36, CI=1.14-1.62). The Finish ATBC study found a borderline increased 
risk with saturated fat intake (HR=1.60, 95% CI=0.96-2.64, p for trend=0.02)398 
The three remaining cohort studies that have published saturated fatty acid data 
reported no association with pancreatic cancer.404-406 
The lack of a statistically significant association in EPIC-Norfolk, for 
saturated fatty acid intake, could be due to a low sample size, with only 51 incident 
cases for analysis after 10 years. By extending the follow-up period to 17 years, 
and increasing the number of incident cases to 88, regression dilution bias has a 
greater effect and no pattern of association was apparent. The NIH-AARP study 
benefitted from a larger cohort size, with 1 337 cases after only 6.3 years follow-
up, and hence their statistically significant findings could be of greater relevance. 
When interpreting saturated fat results, there is the risk of a residual confounding, 
as saturated fat intake is correlated with meat intake. Meat has a high concentration 
of many compounds which could have carcinogenic effects including iron, 
heterocyclic amines and polyaromatic hydrocarbons which are found in cooked 
meats.398 The results from this study did not show a clear association of saturated 
fatty acid intake and pancreatic cancer, although previous studies have reported an 
increased risk, indicating that future work is required to clarify the association, 
using detailed methods of assessing dietary intake of saturated fats, in a cohort 
large enough to detect potential small effect sizes.   
 
Monounsaturated fatty acids 
After 10 years of follow-up, no statistically significant associations were 
found for total monounsaturated fatty acid (MUFA) intake or any of the individual 
219 
 
MUFAs. After 17 years follow-up, oleic acid had a statistically significant negative 
association with pancreatic cancer and palmitoleic acid had a positive association, 
though not statistically significant. Experimental work has been undertaken to 
clarify if oleic acid has anti-carcinogenic effects. It is predominantly found in 
vegetable oils, particularly olive oil, which is an integral component of the 
“Mediterranean diet”. Olive oil may have a role in lowering the risk of cancers, 
with previous epidemiological work suggesting that it is associated with a reduced 
risk of prevent breast cancer,461-464 colorectal cancer,465-466 and gynaecological 
cancer.467-468 The benefits of olive oil could either be attributable to the high 
content of oleic acid, or the antioxidant components of the unsaponifiable fraction. 
Oleic acid can modify key cancer oncogenes, with experiments showing oleic acid 
is able to down-regulate the transcription of the key oncogene, Her-2/neu, in breast, 
ovarian and gastric cancer.424 The presence of Her-2/neu in pancreatic 
adenocarcinoma has been assessed in 154 patients, with 32 (21%) showing 
positivity. Hence, oleic acids ability to down-regulating Her-2/neu, could account 
for the prevention of some pancreatic cancer cases.469 Not all experimental work 
supports a protective effect of oleic acid in cancers. A prospective study from Italy 
analysed the relationship between erythrocyte membrane fatty acids and 
postmenopausal breast cancer risk. They found that a higher concentration of oleic 
acid in the erythrocyte membrane was associated with an increased risk of cancer 
(highest versus lowest tertile of percentage of total fatty acids, OR=2.79; 95% 
CI=1.24-6.28).470  
Previous epidemiological investigations of the effects of total MUFA 
intake reported a decreased risk of pancreatic cancer in early case-control studies 
although these findings were not repeated in large cohort control studies. The 
Finnish ATBC study found no effect398 and the NIH-AARP study reported an 
increased risk of pancreatic cancer for the highest quintile of total MUFA intake 
(HR=1.22, 95% CI=1.02-1.46).403 Only one previous cohort study and three case-
control studies have specifically assessed oleic acid intake and the risk of 
pancreatic cancer. The NIH-AARP Diet and Health Study reported no effect for 
oleic acid (highest vs lowest quintile HR=1.16 95% CI=0.97-1.39, p for 
trend=0.12). An Italian case-control study of 326 pancreatic cancer cases and 652 
controls used FFQ data collected by an interviewer during a hospital episode and 
found no effect of dietary oleic acid.471 A case-control study from San Francisco of 
532 cases and 1701 controls used a FFQ validated against a 7-day food diary, 
asking participants to report their average intake of foods one year previously.413 
They reported that oleic acid was associated with an increased risk of pancreatic 
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cancer (highest vs lowest quartile OR=1.4 95% CI=1.1-1.9). A Canadian case-
control study of 462 cases and 4721 matched controls used a self-administered 
FFQ to assess dietary intake 2 years prior to completion and reported that those in 
the highest vs lowest quartile had a reduced risk of pancreatic cancer, with a 
multivariate OR=0.75 (95% CI=0.55-1.02, p for trend=0.04).409 As previously 
discussed, case-control studies and the use of FFQ data, particularly when 
validated against 7-DFDs, is an inferior study design to that used in EPIC-Norfolk, 
and hence the results should be interpreted with caution. 
In EPIC-Norfolk, palmitoleic acid had non-statistically significant positive 
associations with pancreatic cancer for each higher quintile of intake (highest vs 
lowest, HR=2.64, 95% CI=0.84-8.30). Palmitoleic acid has actions which could 
modulate the risk of pancreatic cancer. It has been shown to negatively affect 
cholesterol metabolism and contribute to the metabolic syndrome, which leads to 
insulin resistance.472-473 Palmitoleic acid can also alter cell functions, although 
experimental work is unclear whether this could contribute to carcinogenesis.474 
The only other cohort study to publish data on this fatty acid was the NIH-AARP 
study, which also found a positive association (highest vs lowest quintile HR=1.34, 
95% CI=1.12-1.59, p for trend<0.001). A case-control study from San Francisco 
reported a positive association (highest vs lowest quartile OR=1.6, 95% CI=1.2-
2.1). Although there is limited epidemiological work on palmitoleic acid, the 
findings are consistent that it may increase the risk of pancreatic cancer. 
In summary, total MUFA intake did not alter the risk of pancreatic cancer 
in EPIC-Norfolk, although oleic acid and palmitoleic acid had possible opposing 
effects, indicating individual monounsaturated fatty acids may exert biological 
effects to modify the risk of developing pancreatic cancer. These need to be 
investigated in future experimental and epidemiological work, with the latter using 
sufficiently detailed methods of determining the dietary intake of these nutrients. 
 
Polyunsaturated fatty acids 
 Total PUFA had inverse, but statistically non-significant associations with 
pancreatic cancer risk. Four cohort studies have published in this area, none of 
which found effects (Table 25). Individual PUFAs exert a wide range of biological 
actions, which could hypothetically increase or decrease the risk of pancreatic 
cancer. N-6 PUFAs are a group of fatty acids with actions which may increase the 
risk of disease by promoting the production of inflammatory cytokines that 
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stimulate oncogenic pathways such as cell proliferation and angiogenesis which 
favour tumour growth.411 However, n-6 fatty acids can reduce insulin resistance 174 
which may reduce the risk of developing pancreatic cancer. In this study, total n-6 
fatty acid intake was not associated with pancreatic cancer. This null finding was 
also replicated in the three cohort studies to publish in this area (table 22), which 
suggests that n-6 PUFAs are not involved in the aetiology of pancreatic cancer. 
The highest quintile of total n-3 PUFA intake had a borderline statistically 
significant negative association with pancreatic cancer after 10 years of follow-up 
(HR=0.30, 95% CI=0.07-1.21, p=0.092), with the individual n-3 PUFAs, DHA and 
EPA, also demonstrating statistically significant or borderline significant negative 
associations.  The tumour suppressive effects of n-3 fatty acids have been 
demonstrated in laboratory work415-416 with EPA and DHA exerting inhibitory 
effects on the growth of human pancreatic cancer cell lines in vitro.412, 414, 417 N-3 
fatty acids may prevent somatic mutations in the K-ras genes, which are involved 
in the initiation of pancreatic carcinogenesis and are targets for chemical 
carcinogens. This mechanism of preventing one of the most common oncogenic 
mutations in the pathway to pancreatic carcinogenesis could account for a 
beneficial effect of n-3 fatty acids.422 There is also experimental evidence that n-3 
fatty acids may slow the improve outcomes in patients with pancreatic cancer 
although work has yet to be conducted demonstrating a survival benefit.414 
The inverse association of n-3 PUFA intake with pancreatic cancer in 
EPIC-Norfolk are not supported by the results of previous cohort studies, with no 
effect reported in the Finnish ATBC, US Nurses’ Health Study and Netherlands 
Cohort Study.398, 405-406 The NIH-AARP study reported an increased risk of 
pancreatic cancer with higher total n-3 intake (highest quintile vs lowest 
HR=1.21 95% CI=1.02-1.44).403 In total, the NIH-AARP study investigated three 
fatty acids classes (saturated, MUFA & PUFA), three fatty acid sub-classes (n-6, 
n-3 & trans) and 12 individual fatty acids (including DHA and EPA), all of 
which had positive associations with pancreatic cancer. All these groups may 
increase the risk, although there may have been either a biasing of results or a 
correlated effect as the dietary assessment method was unable to discriminate the 
source of dietary fat intake. No previous study has used 7-DFDs that provide the 
most accurate measure of dietary intake, and allow greater discrimination 
between nutrients and the assessment of smaller effect sizes.51  
The benefits seen in this study may not be solely from increased n-3 intake, 
but also from accompanying alterations in the general composition of the diet, 
particularly by lowering the n6/n3 fatty acid ratio. The benefits could be due to a 
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reduced n-6 contribution to the diet, rather than an the effects of n-3s per se,421 
although as previously discussed, n-6 PUFA do not appear to have a direct effect 
on pancreatic cancer risk. The results could also be accounted for by a residual 
confounding effect, given that EPA and DHA are strongly correlated with fish 
intake. Furthermore, the substitution of fish in the diet with meat may further 
confound this effect, as there will be reduced intake of the potential risk factors 
found in meat such as of iron, heterocyclic amines and polyaromatic hydrocarbons. 
A limitation of the analysis is that no adjustment has been made for supplementary 
intake of fish oils, with 24% of participants to known to use cod liver oil 
supplements in EPIC-Norfolk.49 
The findings from EPIC-Norfolk supports experimental data that 
suggests n-3 fatty acids may prevent pancreatic cancer development. There are 
inconsistencies in epidemiological work, though previous work may have been 
limited in the methods of determining dietary intake. N-3 PUFAs deserve further 
investigation as there appears to be emerging biological, epidemiological and 
intervention work that this group of fatty acids has protective effects against the 
development and progression of pancreatic cancer. 
 
Dietary antioxidants 
This is the first epidemiological study to report the effects of dietary 
antioxidants and pancreatic cancer using data collected from food diaries. The 
dietary antioxidants, vitamin C, vitamin E and selenium (but not zinc) had large 
inverse associations for the development of pancreatic cancer. The lowest quintile 
of antioxidant intake had at least a 40% greater risk of developing disease. The 
inverse associations existed in a threshold, rather than a dose-dependent manner. 
For vitamin C, the diary data was supported by the biomarker results, as increased 
serum vitamin C levels had a strong dose-dependent inverse association, with those 
in the highest vs lowest quintile having a 84% reduced risk of pancreatic cancer. 
For participants consuming the lowest quintiles of dietary intake for all of vitamins 
C and E and selenium, they had a 5 times greater risk of developing pancreatic 
cancer.  
This epidemiological data supports experimental work for how dietary 
antioxidants may prevent carcinogenesis by scavenging for free radicals, the latter 
of which can induce genetic mutations.475 Antioxidants also have effects 
stimulating the immune system which can be protect against carcinogenesis.431 
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Established risk factors for pancreatic cancer, such as diabetes and smoking, induce 
oxidative stress and free radical production which could be prevented by dietary 
antioxidants.476 Vitamin E had the largest inverse association with pancreatic 
cancer. Vitamin E, which is present in vegetable oils, nuts and egg yolk, inactivates 
free radicals formed from the polyunsaturated fatty acids present in lipid cell 
membrane.477 This fat soluble vitamin also prevents the formation of N-nitroso 
compounds, which are suspected carcinogens for pancreatic cancer.478-479 Vitamin 
C is present in fruit, vegetables and milk, and is a water soluble reducing agent that 
can detoxify hydroxyl and superoxide free radicals. Selenium is found in many 
different food types, including cereals and meat, with the mineral concentration in 
foods dependent upon the selenium content of the soil used in production. 
Selenium is incorporated into selenoproteins, including the enzyme glutathioione 
peroxidase, which catalyses the removal of hydroperoxides. The antioxidant effects 
of vitamin C, vitamin E and selenium all prevent oxidative stress480 which leads to 
genetic damage and carcinogenesis.475-476 A second anti-carcinogenic mechanism 
for antioxidants is their effects on the inflammatory process and suppression of 
chronic inflammation that may otherwise be involved in cancer development.433 
Both hereditary and non-familial pancreatitis are significant risk factors for 
pancreatic cancer,312, 434 with chronic pancreatitis associated with the generation of 
reactive oxygen species that requires antioxidant enzyme activity to inactivate. 
Biopsies taken from normal, inflamed and neoplastic pancreatic tissue showed a 
gradual decrease in antioxidant enzyme expression suggesting a lack of 
antioxidants may enable the progression to cancer.435 Antioxidants supplementation 
in patients with chronic pancreatitis reduces levels of pain and markers of oxidative 
stress.436-438 Finally, antioxidants have an effect on genetic mechanisms relevant to 
pancreatic cancer. Somatic mutations in the K-ras oncogene are an early and 
fundamental event in the pathogenesis of most exocrine pancreatic cancers. Ras 
proteins are vital for cell function and regulation of growth, differentiation and 
apoptosis and K-ras point mutations are found in 75-90% of pancreatic cancers.296 
In a study of 121 pancreatic cancer cases with (78%) and without (22%) K-ras 
mutations, those in the highest tertile of dietary vitamin E intake had a reduced rate 
of mutation (OR=0.24 95% CI=0.06-0.98).422 Although statistically non-
significant, an increased intake of vitamin C was also associated with reduced K-
ras mutations.422 These findings suggest that increased dietary antioxidant intake 
may prevent a key genetic mutation found in most cases of pancreatic cancer. 
To confirm the experimental data that dietary antioxidants do have a causal 
role in preventing pancreatic cancer supportive data epidemiological studies is 
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required, ideally from prospective cohort investigations. To the best of our 
knowledge, there are just two cohort investigations which have investigated dietary 
antioxidants. The first, a prospective study of diet in the elderly reported higher 
intakes of vegetables, fruits, dietary beta-carotene, and vitamin C were each 
associated with a reduced risk of pancreatic cancer, although none of these 
associations were statistically significant.439 The second cohort investigation was 
the Finnish ATBC study of 27 111 male smokers. It used FFQs to measure the 
dietary intake of vitamins C, E and selenium and reported no associations with 
pancreatic cancer.481 (5)There are studies that investigated food groups which 
contain antioxidants, such as citrus fruits which are rich in vitamin C. A meta-
analysis of four case-control studies of citrus fruit, reported an increased intake had 
an inverse association with pancreatic cancer (highest vs lowest quintile of intake 
OR=0.83; 95% CI=0.70-0.98), although such retrospective studies have 
methodological biases which limit their validity.445 A Cochrane review of 
randomised controlled trials of antioxidant supplements, including vitamins E, C 
and selenium, either solely or in combinations, did not find any effect of 
supplementation on the incidence of pancreatic cancer.447 The current uncertainty 
in the role of antioxidants is due to the relatively few studies, small numbers in 
some work, using less accurate measures of diet and unrepresentative populations. 
However, the data from EPIC-Norfolk, showing inverse associations of several 
dietary antioxidants in a threshold manner, supports the continued investigation of 
these micronutrients in the aetiology of pancreatic cancer. 
 
Serum antioxidants and serum vitamin C 
Biomarkers can be a more accurate measurement of diet than questionnaire 
based methods. In this study, serum vitamin C had a strong inverse association 
with pancreatic cancer. After 10 years of follow-up the highest vs the lowest 
quintile level had a multivariate HR=0.16 (95% CI=0.04-0.73, p=0.018) with a 
hazard ratio trend across quintiles of 0.73 (95% CI=0.57-0.92, p=0.008). After 17 
years of follow-up the results were attenuated with the highest v lowest quintile 
HR=0.48 (95% CI=0.21-1.11, p=0.085) and a trend across quintile HR=0.88 (95% 
CI=0.74-1.04, p=0.12). Serum vitamin C levels are mostly determined by dietary 
intake but are also influenced by demographic and lifestyle factors. This was 
demonstrated in a French study of 1 821 women and 1 307 men, that reported 
serum vitamin C concentrations were higher in women, non-smokers and the non-
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obese.482 Smoking reduces serum vitamin C levels due smoke-related oxidant 
production,483 resulting in an increased turnover of this antioxidant. However, in 
the French study, dietary intake of vitamin C was the strongest determinant of 
serum levels (Pearson correlation coefficient=0.28, p<0.0001). Hence serum 
vitamin C is likely to be a true reflection of intake, be it from the diet or 
supplements and in the EPIC-Norfolk analysis, adjustment was made for sex, BMI 
and smoking which are also known to affect serum vitamin C levels. 
Serum vitamin C levels and pancreatic cancer have not been previously 
investigated, although low baseline serum vitamin C was associated with an 
increased risk of all cancers in men in the French SU.VI.MAX (SUpplementation 
en VItamines et Mineraux AntioXydants) study.484 This was a randomised double-
blind, primary prevention trial of low-dose antioxidant supplementation (120mg of 
vitamin C, 30mg of vitamin E, 6mg of beta-carotene, 100µgrams of selenium & 
20mg of zinc) which reported antioxidant supplementation lowered total cancer 
incidence in men, but not in women.484 Furthermore, in the same study cohort men 
had lower baseline serum antioxidants levels than women, and men with low 
baseline serum antioxidant levels gained the greatest reduction in cancer risk with 
antioxidant supplementation.485 These findings support a threshold effect for 
antioxidants, with low levels of antioxidants positively associated with pancreatic 
cancer, but increased intakes not leading to a further reduction of risk. 
Serum levels of the antioxidants, vitamin E and selenium and the risk of 
pancreatic cancer have been previously investigated. The Finnish ATBC study, 
reported raised serum vitamin E levels at baseline were associated with a halving 
of risk of developing pancreatic cancer for those in the highest compared with the 
lowest quintile (HR=0.52; 95% CI-0.34-0.80; p for trend=0.03).481 These results 
contrast with a nested case-control study from a population of 25 620 men and 
women from Maryland, USA. They identified 22 cases of pancreatic cancer that 
were matched with 44 controls and reported the lowest tertile of vitamin E was 
associated with a lower risk of pancreatic cancer (OR=0.2, 95% CI=0.04-1.17).486 
However, the lowest tertile of serum selenium was associated with a 4 times 
greater risk (OR=3.9, 95% CI=1.13-13.2). Another study which evaluated baseline 
serum vitamin E levels was the Finnish Mobile Clinic Health Survey, undertaken 
in 36 365 men and women which identified 766 cancers after a mean follow-up of 
8 years. They reported individuals with a low level of vitamin E had a 1.5-fold (no 
confidence interval cited) increased risk of cancer compared with those with higher 
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concentrations. The association was strongest among non-smoking men and 
women with low levels of serum selenium.487 Seventeen cases of pancreatic cancer 
were identified in men, and in those with lower levels (lowest three quintile vs two 
highest quintiles) of serum vitamin E the relative risk of disease was 4.8 (no 
confidence interval cited) although no effects were found in women.486 In 
summary, there is emerging, but as yet incomplete evidence that dietary 
antioxidants prevent pancreatic cancer. This includes plausible biological 
mechanisms, some epidemiological data and a randomised controlled trial data. 
The findings in EPIC-Norfolk of inverse associations for increased dietary intake 
of antioxidants and serum levels of vitamin C supports this hypothesis. To confirm 
causality further large cohort investigations need to report their findings on 
antioxidants. Randomised controlled trials could also be undertaken which focus 
on those with a low intake or serum levels of antioxidants, as they are at particular 
risk of developing pancreatic cancer and evidence suggest they gain most benefit 
from antioxidant supplementation. 
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3. Strengths and limitations of the study 
 
Internal validity 
Chance 
The internal validity of a study is dependent on chance, bias, confounding 
and measurement error. There are several advantages and limitations to this study 
which need to be considered when interpreting the findings. A relatively large 
population cohort was used in EPIC-Norfolk, of over 25 000, but the number of 
incident cases of pancreatic cancer after 10 years was relatively small, at 53 cases, 
allowing chance findings to become more likely, although for all the associations 
found in this study there are plausible biological mechanisms to explain their 
action, with either supporting animal or human intervention studies. Studies such 
as the NIH-AARP and EPIC 363, 403 had more than 400 000 participants with over 
1300 incident cases of incident pancreatic cancer which reduces the likelihood of 
chance findings. However, these large cohort studies did not benefit from utilising 
the more accurate methods of measuring risk exposures used in EPIC-Norfolk, 
such as the 7-day food diaries, and hence due to measurement error, may be unable 
to detect small effects derived from exposures. 
 
Selection bias 
The prospective design of this study minimises several potential sources of 
bias. Since dietary data was collected and recorded in real time over a one week 
period, recall bias due to errors of estimation of food intake are reduced. The 
prospective study design also reduced selection bias as cases and non-cases are 
drawn from the same population. If cases and non-cases are compared at the time 
disease is identified, there is the potential for differential reporting of dietary 
intakes, which is a limitation of the case-control design. Also, symptoms may alter 
behaviour in those with pancreatic cancer, in particular they may alter their diet by 
decreasing foods which precipitate symptoms causing a “protopathic” bias123 and 
leading to  type 1 error. To minimise bias introduced by a disease altering 
behaviour prior to its diagnosis, no cases were included if they were diagnosed 
within 6 months of enrolment into EPIC-Norfolk. Furthermore, a sensitivity 
analysis was performed for total energy intake, whereby all those diagnosed within 
2 years were excluded, which made little difference to results, suggesting that 
energy intake was not altered in those later diagnosed with pancreatic cancer within 
two years of enrolment. 
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Regression dilution bias 
All the analyses relied on a single baseline measurement, which after 
prolonged follow-up, can lead to regression dilution bias due to participants 
altering their diet. Prospective studies which analyse disease risk from just one 
initial baseline survey of an exposure, may underestimate the magnitude of risk of 
disease after longer periods of follow-up. This effect is amplified if the analysis 
includes many co-variates, all of which become less accurate over time.257 This 
random measurement error occurs as some of the population will change their 
magnitude of exposure to the risk over time. In EPIC-Norfolk, we considered that 
physical activity and dietary intake were particularly vulnerable to variation over 
time. Ideally, the analysis should be made after the shortest period possible prior to 
the development of symptoms to minimise the effects of regression dilution bias. 
Since pancreatic cancer is relatively uncommon, the primary analysis was 
performed after ten years to allow the accumulation of a significant number of 
incident cases, and the secondary analysis after seventeen years of follow-up. In 
future work in the dietary analysis, we intend include data from diaries completed 
by participants after 18 months and 5 years of follow-up which will help to 
minimise regression dilution bias.   
 
Follow-up bias 
Follow-up bias could occur if those with a specific characteristic were 
more likely to move away from the catchment area of the local hospital where 
incident cases of pancreatic cancer were identified. For example; if more 
participants with a “high level” of physical activity moved outside the catchment 
area of the local hospital compared to “inactive” participants, then our study would 
conclude a higher level of physical is associated with a lower risk of disease. 
However, this is unlikely to occur on a large scale as the study population had little 
outward migration.41 Follow-up bias could also occur due to a limitation in the 
method of identifying cases of potential pancreatic cancer. However, the methods 
used were robust using three separate data records, namely the Norfolk Health 
Authority records of hospital admissions, the Eastern Cancer Registry and 
Information Centre (ECRIC) and death certificate records. It is unlikely that any 
significant number of pancreatic cancer cases were not identified, particularly since 
ECRIC was able to source cancer registry data throughout the UK. 
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Confounders 
In EPIC-Norfolk, multivariate analysis adjustment was made for the 
known risk factors of age, sex, smoking, diabetes and obesity (measured by body 
mass index). Pancreatitis is also a known risk factor for disease, but none of the 
incident cases of pancreatic cancer reported a history of pancreatitis at baseline. No 
assessment or adjustment was made for presence of the genetic disorders 
associated with pancreatic cancer (i.e. Peutz-Jeghers, HNPCC) or a family history 
of pancreatic cancer although these conditions are rare and only make a minimal 
contribution to the population’s risk of developing disease. 
 
External validity  
Generalisable and Valid 
 The results found in EPIC-Norfolk are generalisable to a white UK 
population of both genders.  The age group studied are the most susceptible to 
pancreatic cancer and the type of disease was representative of that seen clinically, 
with the staging at diagnosis and survival times equivalent to those reported in 
previous studies. The findings are valid as they have been demonstrated in a large, 
normal, diverse UK population rather than in animal models or in vitro models of 
disease. The level of physical activity or doses of nutrients that were associated 
with an effect were achieved in a population with a normal lifestyle or diet, rather 
than at exposures levels that are difficult to attain in normal living behaviour. 
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4. Summary of discussion findings 
 
The lifestyle risk factors for pancreatic cancer are not well established, due 
to several methodological issues. First, the disease has a relatively low incidence 
rate, so fewer cases are available for study in cohort studies. Second, the poor 
survival times of patients with pancreatic cancer causes difficulties in recruiting for 
case–control studies. Also there is an increased susceptibility of retrospective 
studies to recall bias, selection bias, and exposure misclassification. Thirdly, 
although studies of families with high rates of pancreatic cancer have identified 
several predisposing genetic variants, these variants are rare and contribute little to 
the overall population burden of pancreatic cancer. Fourth, with no screening tests 
able to detect pancreatic cancer at an early more treatable stage, risk factor 
identification may not impact on patient outcomes, in the absence of a clear 
commitment to risk factor modification or the development of novel screening 
modalities.488 This prospective cohort study of pancreatic cancer is the first to use 
7-day food diaries to evaluate dietary exposures, which are the most accurate 
pragmatic dietary assessment method in large scale epidemiological work. Dose-
dependent inverse associations were found for total n-3 fatty acids, 
docosahexaenoic acid and oleic acid with a threshold inverse association found for 
vitamin C, vitamin E and selenium. The findings for vitamin C were supported by 
the serum analysis, which also showed an inverse effect. Increased occupational 
physical activity also lowered the risk of pancreatic cancer in those aged less than 
65 years at enrolment. There is experimental data that provides plausible biological 
mechanisms to explain why these dietary nutrients and physical activity may 
protect against pancreatic cancer, but currently the evidence from aetiological 
epidemiological work is both minimal and inconsistent. However, our work on 
these fatty acids and antioxidants supports measuring these factors in future 
aetiological work. If causal associations are confirmed in such epidemiological 
studies, then population-based dietary recommendations may help prevent 
pancreatic cancer.  
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CHAPTER THREE 
 
THE ASSESSMENT OF NUTRITION AND 
DEPRESSION IN PATIENTS RECEIVING 
CHEMOTHERAPY FOR PANCREATIC 
CANCER 
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Abstract 
 
Background 
Nutritional depletion and depression are common in patients with 
pancreatic cancer. There is minimal work evaluating the most appropriate clinical 
service for identifying these problems to enable appropriate clinical treatment to be 
instituted. The aim of this clinical survey was to assess the value of a dedicated 
clinician screening for malnutrition and depression, document their prevalence and 
initiate relevant treatments through a “pancreatic support service (PASS)”. The 
efficacy of PASS was assessed by measuring survival and clinical outcomes of 
patients in a retrospective group (RG), before the implementation of PASS, and 
after, in a prospective group (PG) of patients with pancreatic cancer. 
 
Methods 
 The RG received one or more doses of palliative chemotherapy for 
exocrine pancreatic cancer during the year 2009 at the Norfolk and Norwich 
Hospital. The outcomes were compared with the PG, treated during 2010, who in 
addition to their standard care were also seen by PASS. The primary outcomes 
were survival rates and the number of chemotherapy doses received. The secondary 
outcomes were hospital admissions (number and length) in patients who died 
within 12 months of diagnosis, weight change, use of oral supplements and 
pancreatic enzyme replacement therapy (PERT), and whether depression had been 
screened for and assessed. Furthermore, the PG was screened for psychological 
symptoms using the hospital anxiety and depression (HAD) scale. 
 
Results 
Comparison of the RG (16 patients, 56% female) to the PG (19 patients, 
47% female) found no differences in survival rates at 12 months (RG 31% vs 42% 
PG, p=0.51) or the number of chemotherapy doses administered (RG=9 vs 6 PG, 
p=0.19). For secondary outcomes, the median number of hospital admissions was 
higher in the RG vs PG (2 vs 1, p=0.034), with a longer duration of admission in 
the former (11 days vs 4 days, p=0.017). PERT was prescribed less frequently in 
the RG (50% vs 79%, p=0.072). The RG had fewer patients with documented 
evidence of a psychological assessment (44% vs 74%, p=0.072), but a higher 
proportion were treated for psychological symptoms (5 patients vs 1 patients, 
p=0.042). The HAD scale identified 43% of patients met the criteria for further 
evaluation of depression or anxiety. There were no statistically significant 
differences in the use of oral nutritional supplements, dosing of PERT or weight 
change. Although the differences were not statistically significant, PG patients lost 
less weight (RG= -7.2% vs -2.9% in PG, p=0.38). 
 
Conclusion 
The introduction of PASS did not increase survival times or the number of 
doses of chemotherapy received, although was associated with a reduced number 
and duration of hospital admissions. The reasons for this should be explored in 
future work as this is a group of patients with an extremely poor prognosis. This 
preliminary data suggests a significant weight improvement might be achieved 
which should be assessed in more patients and also if such a service influences 
quality of life.  Screening for anxiety and depression identified over one third of 
patients had symptoms and emphasises this should be part of routine practice. 
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Introduction 
 
Pancreatic cancer may present with abdominal pain, jaundice, steatorrhoea, 
weight loss and depression. The latter two are common and lead to a deterioration 
in patients’ quality of life if not detected early and managed appropriately. Weight 
loss occurs in up to 90% of patients at diagnosis and involves three mechanisms; 
namely reduced calorie intake, malabsorption and altered metabolism. In patients 
undergoing chemotherapy for unresectable pancreatic cancer, weight loss is 
associated with poor clinical outcomes including a reduced quality of life, 
increased clinical complications and the early cessation of chemotherapy. The triad 
of weight loss, reduced oral intake and systemic inflammation characterise the 
cancer cachexia syndrome with associated poor outcomes. No randomised 
controlled trials have been conducted assessing nutritional therapies to arrest 
weight loss, and hence current recommendations by national societies are based on 
uncontrolled data. Weight may be stabilised with increased calorie and oral 
supplement drinks, which are associated with improved survival times. 
Malabsorption due to pancreatic exocrine deficiency can be corrected with 
pancreatic enzyme replacement therapy (PERT). Reduced endogenous pancreatic 
enzyme secretion occurs in 80% of patients with pancreatic cancer. Patients who 
undergo biliary stenting lose less weight if prescribed PERT. Depression is 
commoner in patients with pancreatic cancer than in other malignancies and is 
often the first symptom, characterised by a sense of impending doom. The 
depression is related to both specific biological processes induced by the tumour 
and the psychological consequences of the diagnosis. Depression has a significant 
impact upon morbidity by worsening patients’ pain, anorexia, anxiety and weight 
loss. This can be avoided if depression is identified and treated stage at an early 
stage. In patients receiving chemotherapy for pancreatic cancer, there is minimal 
data on the frequency of nutritional therapy use or frequency of depressive 
symptoms. A clinical service to screen for nutritional and depressive symptoms, 
plus providing appropriate therapy may improve clinical outcomes. This study 
evaluated such an approach. 
 Pancreatic cancer is relatively common and one of the most difficult 
cancers to treat as it usually presents at an advanced stage with few therapies to 
significantly improve survival. In this context, it is important to assess patients for 
treatable symptoms that may otherwise impair their quality of life, including 
weight loss and depression. This review describes pancreatic physiology, the 
clinical presentation and treatment of pancreatic cancer, specifically weight loss 
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and depression, assessing their prevalence, aetiological mechanisms and treatment 
in such patients. The PubMed database was used to search for relevant papers up to 
July 2011. The papers identified were also used to source references and citations 
that were not found on the electronic database. 
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1. Pancreatic physiology 
 
The pancreas is a gland with both endocrine and exocrine functions. The 
exocrine pancreas secretes pancreatic juice which consists of two components: 
firstly pancreatic enzymes released from the acinar cells and secondly an aqueous 
alkaline solution rich in sodium bicarbonate secreted by the ductal cells lining the 
pancreatic ducts (Figure 1). The acinar cells secrete three different types of 
pancreatic enzymes to facilitate digestion i) proteolytic enzymes for protein 
breakdown, such as trypsinogen, ii) pancreatic amylase to digest carbohydrate, and 
iii) pancreatic lipase to hydrolyse triglycerides. The three major pancreatic 
proteolytic enzymes are trypsinogen, chymotrypsinogen, and procarboxypetidase. 
Each is secreted in an inactivated form to prevent damage to the surrounding 
pancreatic parenchyma and ducts, though upon reaching the duodenum, an enzyme 
in the duodenal lumen called enterokinase initiate their activation. Pancreatic 
amylase hydrolyses the alpha-bonds of polysaccharides such as starch and 
glycogen to produce disaccharides including maltose. Pancreatic lipase hydrolyses 
dietary triglycerides to monoglycerides and free fatty acids. As the pancreas is the 
only significant source of lipase production, a deficiency results in fat 
malabsorption which manifests as steatorrhoea, defined as greater than 7g of fat in 
a 24 hour stool collection.489  
The endocrine function of the pancreas is provided by the Islet of 
Langerhan’s which consist of four cell types. These include alpha cells which 
secrete glucagon in response to low blood glucose and stimulate the conversion of 
hepatic glycogen to glucose. Beta cells release insulin that allows glucose to taken 
up by insulin-dependent tissues. Delta cells are located in the pancreas islet cells as 
well as the stomach and intestine and produce somatostatin, an inhibitory hormone 
that suppresses the release of many gastric (e.g. gastrin, cholecystokinin and 
secretin) and pancreatic (e.g. glucagon, insulin) hormones as well as pancreatic 
exocrine functions. Finally, F cells or PP cells are few in number and release 
pancreatic polypeptide which aids regulation of the endocrine and exocrine 
secretary function of the pancreas (Figure 15). 
 
Incidence, epidemiology and histology of pancreatic cancer 
 These have been previously described on pages 135-138. 
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Figure 15. The anatomy and histology of the pancreas.  
 
a) The gross anatomy of the pancreas. b) The exocrine pancreas. c) Histology of a 
single acinus. d) A pancreatic islet surrounded by acini. The acinar cells secrete 
digestive enzymes into the ducts, supplemented by an alkaline solution from the 
ductal cells. There are four types of islet cells which form the Islet of Langerhans 
and secrete hormones into the blood; Alpha cells (secrete glucagon), Beta cells 
(insulin), Delta cells (somatostatin) and PP cells (pancreatic polypeptide).490 
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Clinical symptoms and signs 
Patients with pancreatic cancer can present with upper abdominal and/or 
back pain and jaundice, although weight loss is the commonest symptom found in 
approximately 90%.491-492 Weight loss is often profound around the time of 
diagnosis, with an average loss of 3 kg per month.491 Psychological symptoms, and 
in particular depression, are common. Both weight loss and depression, though 
frequent, may not initially be recognised as a manifestation of pancreatic cancer as 
they can be attributed to other illnesses. Since the symptoms of pancreatic cancer 
are often non-specific, this can delay diagnosis. Other less common presentations 
include late onset diabetes mellitus in the absence of obesity, deep vein thrombosis 
and thombophlebitis migrans (Trousseau's syndrome) (Figure 16). The latter is 
characterised by the development of recurrent (i.e. migratory) superficial 
thrombophlebitis due to an acquired coagulopathy that is strongly associated with 
malignancy. The clinical signs of pancreatic cancer are jaundice, hepatomegaly, a 
palpable gallbladder (Courvoisier’s sign), Troisier’s sign (Virchow’s node), an 
abdominal mass and ascites.493 
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Figure 16. Thrombophlebitis migrans (Trousseau's syndrome) in a 62 year old 
patient. 
 
 
 
Thrombophlebitis migrans seen in the leg (top picture) and forearm (bottom) in a 
62 year old man with metastatic pancreatic cancer, characterised by pain, erythema 
and swelling of the extremities. 
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Diagnosis and staging of disease 
In patients presenting with jaundice, trans-abdominal ultrasound may 
identify the presence of an obstructed biliary tree, a pancreatic mass and liver 
metastases with a diagnostic accuracy of 75%.494 In anicteric patients or when 
common bile duct dilatation is confirmed on USS, a contrast-enhanced 
computerised tomography scan (CT scan) is the most useful diagnostic tool to 
identify a pancreatic mass lesion with a diagnostic sensitivity of 97% and 
specificity of 80%.495 In patients with unexplained weight loss, a CT scan is 
important to prevent delaying the diagnosis of a pancreatic lesion. Furthermore, a 
CT scan can stage and predict  unresectable lesions in 90% of cases, although it is 
less accurate in determining a resectable lesion.495 Positron emission tomography 
(PET) and PET-CT do not add any extra diagnostic accuracy for determining 
operability.285 Small hepatic metastases and peritoneal deposits are likely to remain 
undetected prior to laparotomy. Endoscopic ultrasonography (EUS) is used to 
characterise suspected pancreatic tumours and can detect smaller pancreatic mass 
lesions of only 2-3mm diameter.496 Magnetic resonance imaging (MRI) gives 
similar results to a non-enhanced CT scan though can be useful for characterising 
cystic lesions and for patients allergic to intravenous contrast. Prior to surgical 
resection, laparoscopy and laparoscopic ultrasound may be offered to aid the 
accuracy of disease staging, particularly in patients who present a major operative 
risk. 
Tumour markers can aid the diagnosis and management of patients with 
pancreatic cancer.  Serum carbohydrate antigen (CA) 19-9 is clinically most useful 
for monitoring a patient’s response to treatment although it is also the most widely 
used and validated tumour marker for pancreatic cancer, although it has its 
limitations in early tumours. The chosen cut-points for serum levels of CA 19-9 
determine the accuracy of the test which was demonstrated when comparing levels 
in patients with and without pancreatic cancer. Using a threshold of 37kU/l, CA 
19-9 has a sensitivity of 81% and a specificity of 90% for pancreatic cancer but by 
increasing the cut off to 100kU/l the specificity improves to 98%, but sensitivity 
drops to 68%.497 Several benign diseases elevate CA 19-9 including acute and 
chronic pancreatitis, liver cirrhosis, cholangitis and obstructive jaundice. Serum 
CA 19-9 is also elevated in 67% of patients with cholangiocarcinoma, 41% of 
patients with gastric cancer, 34% with colon cancer and 49% of those with 
hepatocellular cancer.498 Serum CA 19-9 should be used with caution in the initial 
investigation of patients with pancreatic cancer, when a significantly elevated level 
may increase the suspicion for disease, though a normal value should not prevent 
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further investigations.497 Serum CA 19-9 has a role in estimating prognosis 
following surgical resection and in monitoring patients receiving chemotherapy. 
Future work aims to establish more accurate markers of pancreatic cancer, which is 
currently being investigated using genomic analysis to identify proteins that are 
over-expressed in disease.295 If autoimmune pancreatitis is in the potential 
differential diagnosis, immunoglobulin G class subtypes should be measured to 
assess for elevated IgG4 levels. 
Patients with characteristic features of pancreatic cancer do not require a 
histological specimen prior to operation,499 although a diagnostic biopsy should be 
sought in patients with uncharacteristic lesions prior to surgery and in those 
referred for chemotherapy. Obtaining a histological sample can be difficult due to 
the anatomical location of the pancreas. If an endoscopic retrograde 
cholangiopancreatography (ERCP) is performed to gain biliary drainage, then 
biliary brushings can be taken for cytology. EUS and fine needle aspiration (FNA) 
can be used to acquire tissue with a diagnostic accuracy of >90% sensitivity and 
~100% specificity.285 FNA is the procedure of choice to gain histology in advanced 
pancreatic cancer or to diagnose small uncharacterised lesions. If liver metastases 
are present, percutaneous biopsy is used to obtain a tissue sample under USS or CT 
guidance. Confirmatory histology is required in planning chemotherapy and 
characterising prognosis and occasionally alternative diagnoses are made including 
lymphoma or autoimmune pancreatitis which have different treatments and clinical 
outcomes. 
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2. Treatments 
 
Resectable disease 
Prior to deciding treatment, accurate staging of the cancer is essential and 
the management requires a multidisciplinary approach. A tumour is unlikely to be 
resectable if it is >5cm diameter or if there is involvement of the superior 
mesenteric artery or celiac axis.500 Post-operative short and long-term survival 
results are improved in high-volume surgical centres.285 For tumours of the 
pancreatic head, a pylorus preserving pancreaticoduodenectomy is appropriate 
where a resection is made of the first and second part of the duodenum; the head of 
the pancreas; the common bile duct; and the gallbladder (Figure 17). The main 
advantage of this operation is that the pylorus, and thus normal gastric emptying, is 
preserved. If there is duodenal or gastric involvement then a proximal 
pancreaticoduodenectomy with antrectomy is required (classical Whipple) 
Figure 18). For tumours of the pancreatic body and tail tumours a distal 
(left) pancreatectomy is performed. In patients found to have unresectable disease 
at surgery, a surgical bypass (hepaticojejunostomy and/or gastroenterostomy) can 
be fashioned to prevent future biliary tract or duodenal obstruction. 
The survival following surgery can be improved with the use of adjuvant 
chemotherapy. The results from two large randomised controlled trials reported 
that adjuvant systemic chemotherapy with either 5-fluorouracil (5-FU) and folic 
acid (ESPAC-1 trial)501 or Gemcitabine (CONKO-001 trial)502 improved median 
disease-free survival from 6.9 months in the control group to 13.4 months in the 
gemcitabine arm (p<0.001).502 The ESPAC-3 trial was the largest adjuvant trial 
ever conducted for pancreatic ductal adenocarcinoma and reported no significant 
difference in survival between adjuvant 5-FU+folic acid vs Gemcitabine.503 The 
ESPAC-4 trial is currently recruiting, and randomizing patients to either adjuvant 
Gemcitabine or combination Gemcitabine and Capecitabine (GemCap). 
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Figure 17. Pylorus preserving pancreaticoduodenectomy. (Source Cancer 
Help UK http://cancerhelp.cancerresearchuk.org/type/pancreatic-
cancer/treatment/surgery/surgery-to-try-to-cure-pancreatic-
cancer#whipple) 
 
 
 
 
 
Figure 18. A proximal pancreaticoduodenectomy with antrectomy 
(classical Whipple). (Source Cancer Help UK) 
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Management of Inoperable disease 
Chemotherapy and radiotherapy only make a minor impact on survival and 
the quality of life in patients with inoperable pancreatic cancer. Gemcitabine is 
given to those with locally advanced or metastatic pancreatic cancer as randomised 
controlled clinical trials demonstrated superiority over 5-fluorouracil (5FU), with a 
small benefit in median survival (5.7 vs 4.4 months, p=0.0025) and an improved 1 
year survival (18% vs 2%, p=0.019) with improvement in disease-related 
symptoms.504 Despite several trials of gemcitabine combination regimens, only a 
small survival benefit has been reported by the addition of capecitabine.505 
Similarly, the incorporation of biological agents, such as Erlotinib, has also been 
disappointing. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal 
growth factor receptor, showing a survival improvement from 5.9 to 6.4 months 
(p=0.025).506 The recently published FOLFIRINOX study from France, 
randomised 342 patients with metastatic pancreatic cancer to either gemcitabine or 
a combination of oxaliplatin, irintecan, leucovorin and fluorouracil 
(FOLFININOX) and reported the new regime improved median survival from 6.8 
months to 11.1 months (p<0.001).507 FOLFIRINOX was associated with more 
adverse events although quality of life scores at 6 months were improved. The 
TeloVac trial is currently recruiting patients with locally advanced and metastatic 
disease to compare standard chemotherapy with a chemo-immunological agent 
(GV1001 telomerase vaccine). Telomeres are found at the end of a chromosome 
and are regions of repetitive DNA which protect the chromosome from 
deterioration. Cancer cells undergo frequent division leading to shortened 
telomeres, but if they become too short, the cell may die. Some cancer, including 
pancreatic, escape this fatal process by up-regulating an enzyme called telomerase, 
which adds telomeric DNA to critically shortened chromosomes and ensuring 
continued cell survival. Experimentally, the GV1001 vaccine targets the over-
expressed telomerase, enabling the immune response to recognise the enzyme and 
illicit an immune response against telomerase which prevents enzyme function and 
facilitates cancer cell death.508 
For non-metastatic inoperable pancreatic cancer, chemoradiation is the 
standard treatment in the USA, a policy based upon the results of the Gastro-
Intestinal Study Group trial. This reported an improved median survival for the 
combined-modality therapy group (radiation combined with 5-fluorouracil 
followed by streptozocin, mitomycin, and 5-fluorouraci) compared with 
chemotherapy (streptozocin, mitomycin, and 5-fluorouracil alone) of 42 weeks vs 
32 weeks survival (p<0.005).509 However, initial trials of gemcitabine and radiation 
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were terminated due to excess toxicity, but studies using lower radiotherapy doses 
demonstrated were better tolerated. Chemoradiation is of particular benefit in 
patients who after 3 months of induction chemotherapy are without disease 
progression and have a good performance status. Here the subsequent introduction 
of chemoradiotherapy improved median overall survival from 11.7 months to 15.0 
months (p=0.0009).510 The use of radiation with either concurrent gemcitabine or 
capecitabine following ‘induction’ GemCap chemotherapy is currently being 
investigated in the SCALOP trial, for inoperable tumours ≤6cm diameter. The 
rationale is to select patients with chemo-responsive disease from those with a 
more rapidly progressive clinical course. Significant clinical improvements in long-
term survival will probably only be achieved through continuing investigation of 
the pathophysiological processes of this cancer. 
 
Palliative treatments 
In many patients, palliative treatments are the principle focus, with pain the 
most important symptom to manage. The severity of pain in pancreatic cancer is 
related to the tumour size, the presence of lymph node metastases and tumour 
invasion of either the anterior pancreatic capsule, intrapancreatic, or coeliac plexus 
nerves. Increased pain correlates with a reduced median survival (9 months with 
severe pain vs 29 months if without pain).511 Treatment requires the early 
introduction of high-dose opioid analgesia with both long acting preparations and 
short acting ones for breakthrough symptoms. Postprandial epigastric pain can be 
due to pancreatic enzyme insufficiency which may respond to pancreatic enzyme 
replacement therapy (PERT). Pain control with neurolytic coeliac plexus block 
should be reserved for patients failing to benefit from opioid analgesia. Previous 
trial data established that coeliac plexus block improved pain control, though not 
the patients’ quality of life.512 Patients and their relatives should be reassured that 
increasing pain will be managed promptly to reduce the associated fear and stress 
that might otherwise occur. 
Obstructive jaundice is a common presenting symptom of pancreatic 
cancer and usually represents a tumour in the head of the pancreas. A survey of 381 
patients with pancreatic cancer reported that 48% of cases presented with jaundice, 
with most associated with pain (34%) rather than painless jaundice (13%).513 
Pruritis often complicates obstructive jaundice and is due to excess bile acids in the 
blood and skin 514 or elevated endogenous opioids.515 Achieving biliary drainage 
and consequent resolution of the jaundice should improve patients’ symptoms. If 
this cannot be achieved quickly topical treatment with aqueous cream or 
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emulsifying ointment should be administered. Medical therapies to be considered 
are anti-histamines and ondansetron (a 5-HT3 antagonist). If ondansetron is 
effective, it can be switched to a selective serotonin  reuptake inhibitor (such as 
paroxetine), a cheaper long-term alternative, which also has antagonist effects on 
the 5-HT3 receptor.516  
Biliary drainage is usually achieved using endoscopic retrograde 
cholangiopancreatography (ERCP) with stenting. Plastic stents usually obstruct 
after 3 months and hence should only be used in patients with a poor prognosis or 
undergoing surgery. Metal and covered stents, which are considerably more 
expensive than plastic stents, are used in patients where survival is expected to 
exceed 3 months.285 Duodenal obstruction occurs in around 15% of patients and 
can be treated with an expandable duodenal stent, placed either endoscopically or 
under radiological guidance. The complications of stents are perforation, bleeding 
and recurrent obstruction.517 In patients medically fit for surgery, biliary 
obstruction can be treated by performing a Roux-en-Y loop hepatojejunostomy, 
and duodenal obstruction can be managed with a gastrojejunostomy. 
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Prognosis 
Pancreatic cancer has a poor prognosis with only 16% of patients surviving 
beyond 1 year and only 0.2% - 3% beyond 5 years.274-275 The late presentation of 
this aggressive tumour accounts for the low number of patients who are suitable for 
potentially curative surgery (10-15%).285 The mortality to incidence ratio for 
pancreatic cancer did not improve significantly between the years 1971-2000, 
whilst stomach cancer mortality dropped significantly (Figure 19).518 Following 
radical resection, the 5-year survival from pancreatic cancer is only 10% with most 
patients developing metastatic disease.519 Of those patients receiving chemotherapy 
(30-40%) the median survival time is 6-7 months 500, 506 and for patients not fit for 
chemotherapy (40-50%) it is lower at 3-4 months.520 These poor survival times for 
all stages of the disease emphasize the need for early appropriate supportive and 
palliative therapy in patients to prevent a deteriorating quality of life. Certain 
histological variants of ductal adenocarcinoma (10% of all exocrine tumours) have 
a worse prognosis than typical ductal adenocarcinoma. However, other exocrine 
tumours carry a more favourable prognosis, including mucinous and serous 
cystadenocarcinoma. 
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Figure 19. Mortality to incidence ratio for pancreatic and stomach cancer in men 
and women, 1971-2000 (source; Fitzsimmons et al, Br J Surg 2007518). 
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3. Nutritional aspects in patients with pancreatic cancer 
 
Weight loss 
Weight loss is a common symptom in patients, but often receives less 
attention than the consideration of chemotherapy and relief of jaundice. Weight 
loss is due to a poor nutritional intake, altered metabolism and malabsorption 
which lead to cachexia and a deteriorating quality of life. A nutritional assessment 
and provision of dietary supplementation may not always be a clinical priority, 
although it is beneficial in terms of decreasing morbidity and mortality. Disease 
progression in pancreatic cancer leads to severe anorexia and weight loss, with up 
to 90% of patients having significant weight loss at the time of diagnosis.491-492 
Patients have lost an average of 15% of their pre-illness weight at the time of 
diagnosis and up to 25% 6 months after diagnosis (Figure 20).491  
Weight loss in pancreatic cancer is not only due to a reduced calorie intake 
but also alterations in metabolism. Patients are hypermetabolic, with a raised 
resting energy expenditure (REE) 521-522. Although the metabolic mechanism of 
weight loss is not fully understood, it is thought to be induced by pro-inflammatory 
cytokines (such as interleukin (IL)-1beta, IL-6, IL-8 and tumour necrosis factor-
alpha) derived from the tumour.523 The host’s systemic inflammatory response 
leads to a reprioritisation of protein metabolism with breakdown of this 
macronutrient.524 Activation of neuroendocrine stress hormones and tumour 
specific factors contribute to hypermetabolism. The rise in REE accelerates weight 
loss and muscle wasting, leading to reduced physical activity. 
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Figure 20. Weight loss as a percentage of pre-illness stable weight in 20 patients 
with unresectable pancreatic cancer (source; Wigmore SJ et al Br J of Cancer 
1997491). 
 
The percentage weight loss between onset of weight loss and the time of diagnosis 
(time 0 months) is indicated by the broken line. 
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The clinical significance of weight loss is its impact on survival, tolerance 
of chemotherapy and quality of life. In patients with cancer of any type, weight loss 
is an independent predictor of survival.525 Achieving weight stabilisation following 
the diagnosis of pancreatic cancer is associated with an improved median survival 
which was demonstrated in a study of 109 patients with unresectable pancreatic 
cancer, who all received oral nutritional supplementation. Eight weeks after 
diagnosis, patients who were weight stable (<1kg weight loss) had improved 
survival times compared to those who had lost weight (>1kg) (median survival of 
259 days vs 164 days, p=0.019) (Figure 21).526 Weight stabilisation was also 
associated with improved quality of life scores (global quality of life scores at 8 
weeks of 55 vs 47, p=0.037). To assess the impact of weight loss on chemotherapy 
dosing, The Royal Marsden Hospital recorded the presence or absence of weight 
loss in 1 555 patients with advanced oesophageal (179 patients), gastric (433), 
colorectal (781) or pancreatic (162) cancer.527 In patients receiving chemotherapy 
who had weight loss at presentation, the average duration of therapy was 30 days 
less (120.3 days vs 150.5 days, p=<0.0001). The authors equated this to an average 
reduction of 18% in chemotherapy received. There were also increased 
complications in patients with weight loss undergoing chemotherapy with higher 
rates of stomatitis and plantar-palmar syndrome with 7% of patients with weight 
loss vs 1% without weight loss experiencing increased grade 3-4 plantar-palmar 
syndrome (p<0.0001) (Table 47).527 The plantar-palmar or hand foot syndrome is 
characterised by red and tender palms and soles of the feet which look and feel like 
sunburn (Figure 22). Although these results are not solely applicable to patients 
with pancreatic cancer, they emphasize the potential role weight loss may have 
influencing survival, treatment schedules and side-effects of treatment. 
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Figure 21. Comparison of survival from baseline for both weight losing 
(n=44) and weight stable (n=63) pancreatic cancer patients (source; Davidson W et 
al, Clin Nutr 2004526).  
 
Kaplan-Meier log rank statistic 5.53, p=0.019 
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Figure 22.  Plantar-palmar syndrome induced by chemotherapy (source; 
http://www.flickr.com/photos/sketchesbymez/2681808756/). 
 
  
 
 
 
 
 
Table 47. Plantar-palmar syndrome induced by chemotherapy and its relationship 
to weight loss at presentation in different tumour types (source; Andreyev HJ et al,  
Eur J Cancer 1998527). 
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Oral nutritional supplementation 
An adequate calorie intake is required to slow or arrest the weight loss in 
pancreatic cancer. The British Society of Gastroenterology (BSG)528 and the 
American Gastroenterogical Association (AGA)529 currently advise that dietary 
supplementation should be considered in patients with pancreatic cancer, although 
the specific dosing and timing is not given. The BSG states “attention to dietary 
intake, and the use of specific nutritional supplements, may improve well being”. 
No randomised trials have specifically assessed whether this approach is beneficial 
in patients with pancreatic cancer probably due to logistical and ethical constraints. 
However, a follow-up study of 200 patients with unresectable pancreatic cancer, 
who had lost at least 5% of body weight, were all prescribed 2 cans of oral 
nutritional supplementation per day (one can=237ml, 310kcal, 16g protein, 6g fat) 
and then randomised patients “to receive” or “not to receive” an additional n-3 
polyunsaturated fatty acid supplement of 1.1 grams of eicosapentaenoic acid (EPA) 
plus antioxidants in each carton. The rate of weight change in both groups prior to 
diagnosis was -3.3kg/month which slowed to an average of -0.3kg/month in both 
groups after 8 weeks of oral supplemental feeding.530 This compared to an 
observational study of 20 patients with unresectable pancreatic cancer who did not 
receive routine oral supplementary feeds. Here patients lost 3kg/month prior to 
diagnosis and continued to lose weight at a rate of 1.2kg/month following 
diagnosis491 suggesting the rate of weight loss post-diagnosis is reduced in 
patients receiving oral supplemental feeds compared to patients receiving standard 
care (  
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Figure 23). Although there are limitations in comparing two different 
studies, the reduced rate of weight loss those receiving oral supplementary feeds 
supports their use in attenuating weight loss. In participants randomised to receive 
EPA and antioxidant supplements, who remained fully compliant, gained lean body 
mass and recorded an improved quality of life suggesting there may be a role for 
supplemental n-3 fatty acids in patients. The n-3 fatty acids, eicosapentaenoic acid 
is derived from fish oils, has been shown experimentally to have anti-inflammatory 
and anti-tumour properties. The n-3 fatty acids EPA and DHA have inhibitory 
effects on the growth of human pancreatic cancer cell lines in vitro,412, 414, 417 and 
induce apoptosis in a dose-dependent manner.419 N-3 fatty acids inhibit the 
activation of NF-kB in cancer cells lines. NF-kB is associated with resistance to 
gemcitabine due to the production of anti-apoptotic proteins.531 The inhibition of 
NK-kB facilitates apoptosis and may have the ability to improve gemcitabine 
sensitivity. Overall, prescribing oral nutritional supplements, based on the 
limitations of the current evidence available, appears to be appropriate in patients 
with unresectable pancreatic cancer. 
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Figure 23. The rate of weight loss in patients with pancreatic cancer, pre and post-
diagnosis, receiving either no dietary intervention or a twice daily oral nutritional 
feed of 237ml (1.5kcal/ml) (sources; Wigmore SJ et al, Br J Cancer1997 486 and 
Fearon KC et al, Gut 2003491, 530). 
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Pancreatic enzyme replacement therapy 
Pancreatic enzyme replacement therapy (PERT) is licensed for use in 
patients with evidence of pancreatic exocrine deficiency, although this can be 
difficult to diagnose. Once clinical signs of steatorrhoea and weight loss have 
developed, approximately 90% of exocrine function has been lost.532 The gold 
standard for assessing pancreatic exocrine function is the cholecystokinin 
(CCK)/secretin pancreatic function test, although this is invasive, time consuming, 
costly and only available in specialised centres. In-direct (tubeless) tests of 
pancreatic function, such as faecal elastase-1, are useful in diagnosing severe 
exocrine deficiency.533-534 However, these have limited sensitivity and specificity in 
diagnosing mild to moderate disease. Hence there is no non-invasive test available 
which reliably diagnoses mild exocrine deficiency. Once clinical symptoms are 
evident, the patient is likely to have severe exocrine deficiency and have already 
lost weight. 
Patients with pancreatic cancer often have exocrine deficiency, with a 
study of 25 patients without overt clinical signs of malabsorption, reporting 
biochemical evidence of exocrine deficiency in 80% of patients.535 The BSG and 
AGA both recommend the use of PERT in patients with pancreatic cancer with the 
BSG stating that “compared with untreated patients, patients with advanced 
pancreatic cancer who are given pancreatic enzyme supplements enjoy a better 
quality of life and improved symptoms score”. This recommendation was based on 
two clinical investigations which evaluated the effects of PERT on patients with 
pancreatic cancer.536-537  The first assessed the biochemical effects PERT therapy in 
12 patients with biopsy proven advanced pancreatic cancer. The study found that 
patients with significant fat malabsorption (6 of 12 patients with coefficient of 
absorption <85%) benefitted from the introduction of PERT, with the average 
coefficients of fat absorption improving by over 20%, although those with mild 
malabsorption (coefficient of absorption >85%) did not benefit.536 The second 
study was a randomised controlled trial of PERT in patients with unresectable 
pancreatic cancer, who had recently undergone biliary stent insertion to relieve 
obstructive jaundice. The 21 patients were randomised to receive either PERT (50 
000 lipase units with meals, 25 000 lipase units with snacks) or placebo. Those 
receiving PERT had a significant improvement in the percentage body weight 
change (placebo= -3.7% vs +1.2%, p=0.02) and calorie intake (placebo=6.66MJ vs 
8.42MJ, p=0.04) compared to those in the placebo group (Figure 24).537 Neither 
study included patients undergoing chemotherapy, although they may gain 
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particular benefit by maintaining an anabolic state and a reduction in 
complications. Some medical oncologists already advocate the routine prescription 
of PERT to all patients at the time of diagnosis of pancreatic cancer to prevent the 
development or progression of weight loss.538  
The current but limited evidence supports the use of pancreatic enzyme 
replacement and nutritional supplements in patients with pancreatic cancer, 
although it is unclear which groups would benefit as well as the timing and dosing 
of prescription. More work is needed to investigate whether the routine nutritional 
assessment of patients and potential early prescription of PERT leads to an 
improvement in outcomes. Such investigations should include an assessment of the 
doses, frequency of prescription and their impact on survival as well as clinical 
parameters such as weight change and side-effects from chemotherapy. 
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Figure 24. A randomised controlled trial investigating the effect of pancreatic 
enzyme replacement therapy on weight change in patients with pancreatic cancer 
(source; Bruno MJ et al, GUT 2005537). 
 
*significant difference, p<0.05 
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4. Depression 
 
Depression is a common symptom in patients with pancreatic cancer, 
caused by both biological mechanisms and the psychological consequences of the 
diagnosis. This review will discuss the frequency and impact of depression and 
whether it can be managed if identified and treated early.  
 
Prevalence 
 Depression is commoner in patients with pancreatic cancer than other 
malignancies, with a prevalence of between 33%-50%.539-540 The relationship with 
depression was originally described in the 1930’s by Yaskin 541 who reported the 
symptoms of depression, anxiety and feelings of premonition of serious illness as 
the earliest manifestations of pancreatic cancer. In the 1960’s, Fras et al formalised 
this work by evaluating patients prior to the diagnosis of different cancers.542 They 
found that patients diagnosed with pancreatic cancer were more likely to have 
experienced psychiatric symptoms, especially depression, than patients diagnosed 
with colon cancer (76% vs 20%, p value not calculated). Furthermore, nearly half 
experienced psychiatric symptoms as their earliest manifestation of disease. A US 
study evaluated the prevalence of depression in 130 patients with newly diagnosed 
pancreatic cancer. Using the Beck depression inventory to screen for depression 
they reported 38% had a score (≥15) that suggests high levels of depressive 
symptoms.543 The largest study to evaluate the presence of depression in 
gastrointestinal cancer patients was conducted in 262 Chinese inpatients, which 
reported depression was higher in pancreatic cancer than in other cancers; 78% of 
pancreatic cancer patients; 60% of hepatocellular carcinoma patients; 36% of 
gastric patients; 24% gastric patients; 19% of colon patients.544 However, to assess 
the presence of depression, they solely used the Hamilton Rating Scale for 
Depression-24 (HAMD-24) questionnaire which was developed to screen for 
depression symptoms rather than to diagnose depression.545 Furthermore, the 
HAMD-24 creates a score from 24 stem questions which places participants in one 
of four categories; severe depression (score >35), mild to moderate depression 
(score >20), suspected depression (score 8-20) and no depression (<8). In the 
Chinese study, any participant with suspected depression (score>8) was classified 
as having cancer-related depression when normally a clinical assessment would be 
required to confirm the diagnosis. The HAMD-24 has four stem questions which 
assesses symptoms that are common in pancreatic cancer, with two questions 
260 
 
concerning weight loss and one each on fatigue and loss of appetite. Therefore, it is 
not surprising that the authors reported a high rate of depressive symptoms in such 
patients. The prevalence of depression in pancreatic cancer has been evaluated in 
several studies though the diversity of findings can be attributed to the low sample 
size, the definition depressive symptoms, and varied demographics. 539-540 
 
Biological mechanism 
Pancreatic cancer may lead to depressive symptoms either due to the 
psychological aspects of the diagnosis, or via biochemical mechanisms including 
immunological, hormonal, paraneoplastic and biochemical changes.546 The 
immunological effects can be mediated by proteins released from tumours 
stimulating the production of antibodies that block serotonin receptors, which can 
induce depressive symptoms.547 Solid tumour malignancies can be associated with 
serotonin depletion induced via increased urinary excretion of this hormon.548. 
Biochemical changes of cancer including anaemia, hypercalcaemia, and acid-base 
abnormalities, as well as the production of biogenic amines or neuropeptides can 
also alter the psychological state.540 
 
Diagnosis of depression and screening tools 
Although depression in pancreatic cancer is a relatively common, the first 
challenge is to recognise the condition, which can be complicated in such patients 
as depressive symptoms, such as anorexia and weight loss, are also symptoms of 
the cancer. The reliability of any data on the incidence of depression is dependent 
on the appropriate choice of assessment tool in defining depression, and the varied 
rates, as discussed in the previous section, are likely to relate to the different 
methods of diagnosis. The most robust definition of depression is taken from the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and requires a 
structured clinical interview by skilled trained staff.549 The advantage to structured 
clinical interviews are the robustness of the definition of depression, although they 
require considerable resources and therefore are usually used to confirm the 
diagnosis of depression rather than as a screening tool.550 Self-report screening 
tools are useful in routine practice and can identify significant functional 
impairment during follow up.551 Therefore, it is recommended that self-reported 
screening tools are used as a first step to identify depression followed by a more 
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detailed structured interview, if required, to confirm the diagnosis.552 One such 
screening tool is the Hospital Anxiety and Depression Scale (HADS), used to 
identify patients who may benefit from clinical assessment of their mood and 
which has been validated in patients with terminal cancer.553 This focuses on the 
loss of pleasure response (anhedonia) rather than the somatic symptoms that may 
be found in both cancer and depression (i.e. anorexia, weight loss). The loss of the 
pleasure response is considered to be a disturbance of neurotransmitter function 
and more responsive to antidepressant medication.554 
 
Impact 
Depression does not affect survival in pancreatic cancer 555 but has a 
significant impact upon morbidity. There is worsened pain, anorexia and anxiety 
which compound weight loss with an associated low quality of life scores.544 
Depression in the terminally ill should not be considered normal, as articulated by 
the quote “when depression is considered a normal phenomenon in cancer patients, 
its impact on the quality of life is trivialised”.546 The early recognition and 
treatment of depression can lead to an improvement in function and a sense of well 
being.549 
 
Treatment of depression 
Once depression is diagnosed in patients with pancreatic cancer, organic 
causes of depressive symptoms should be excluded and if found treated 
appropriately. These include metabolic abnormalities (i.e., hypercalcaemia), 
anaemia, nutritional deficiencies (i.e., iron or vitamin B12 deficiency) and drug 
side-effects particularly chemotherapy induced depression.556 If no reversible 
causes of depression are found the patient should be considered for counselling and 
support, which can be accessed via palliative support teams. Pharmacological 
therapy can also be offered with the choice of medication dependent of the side 
effect profile, with the literature suggesting tricyclic antidepressants are commonly 
used,546 although local expertise has found mirtazapine to be useful as its side-
effect profile includes appetite stimulation and weight gain which could have 
obvious benefits.557 A systematic review in 2006 found limited evidence to guide 
the choice management of depression in cancer patients, largely due to a lack of 
adequately powered studies of pharmacological or psychotherapeutic interventions 
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targeted at cancer patients with depression.558 The lack of studies was addressed by 
a Scottish investigation in 2008, conducted in 200 outpatients diagnosed with both 
depression and cancer who were randomised to either standard care or to a 
combination of pharmacological and psychotherapy delivered by a cancer nurse 
over an average of seven sessions. This reported that the intervention improved 
depression scores after a period of three months (p<0.05) although the findings 
may not be generalizable to all cancer patients, including pancreatic cancer 
patients, as those with a prognosis of less than 6months were excluded.559 
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5. Aims of this research 
 
Nutritional depletion and depression are common in patients with 
pancreatic cancer, although the prevalence in many UK hospitals, including ours 
has not been previously assessed. Additionally there is little work on the most 
appropriate clinical service for identifying these factors in clinical practice so that 
treatment could be instituted. Furthermore, such a service needs to be assessed for 
its potential effects on survival and clinical outcomes. The aim of this clinical 
survey was to have a dedicated clinician in place to screen for these conditions, 
describe their prevalence and initiate any relevant treatments. Preliminary data on 
its potential value could be assessed by measuring survival and clinical outcomes 
in patients before and after the commencement of this service. 
The primary outcomes chosen to evaluate the effectiveness of PASS were 
comparison of survival rates as well as the number of chemotherapy doses received 
since this reflects the physical well being of the patient.527 The secondary outcomes 
were hospital admission rates, weight change over time, use of oral supplement and 
pancreatic enzyme replacement therapy and finally evidence of psychological 
assessment and treatment. Hospital admission rates are of importance to both the 
patient and health care provider as reduced hospital admission rates reflect a 
reduction in complications of disease and lead to reduction in total costs of 
providing care. Weight change over time was assessed as weight loss is associated 
with complications and a deteriorating quality of life.527 The use of oral 
supplements and pancreatic enzyme supplements were compared to assess if the 
introduction of PASS lead to an increased use of these therapies. Evidence of 
psychological assessment and treatment was made to verify whether the routine 
screening for symptoms lead to an increase in treatment. Identification of any 
benefits would suggest that a pancreatic support service (PASS) should be assessed 
in larger studies and considered in the routine management of patients with 
pancreatic cancer. 
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Methodology 
 
1. Overview of the study design 
 
 This study compared patients receiving one or more doses of palliative 
chemotherapy for suspected exocrine pancreatic cancer in 2009 against patients 
treated in 2010, who in addition to their standard care, were also seen by PASS. 
Patient baseline data was collected on age at diagnosis, initial staging of pancreatic 
cancer and the type of chemotherapy treatment given. The data collected for the 
primary outcomes were survival rates and the number of chemotherapy doses 
received. The secondary outcomes were the number of hospital admissions in 
patients who died within 12 months, weight change, nutritional and depression 
assessment and treatment. Data was collected in the prospective survey on 
depression screening scores and the frequency of depression treatment. 
 
Study protocol 
Patients receiving chemotherapy for pancreatic exocrine cancer at the 
Norfolk & Norwich University Hospital NHS Trust during 2009 had data collected 
retrospectively concerning their management and clinical outcomes. These 
outcomes were then compared against those collected prospectively in patients 
treated in 2010, who in addition to their standard care, were also seen a PAncreatic 
Support Service (PASS). The clinician in PASS assessed nutritional status, medical 
and psychological symptoms and implemented appropriate treatments if required. 
The ideal study design to evaluate the effect of such a new clinical service would 
be a randomised controlled trial. However, randomising patients to receive or not 
receive this clinical support service was deemed to be unethical as the management 
was already stipulated by national societies of gastroenterology in the UK and 
US.528-529 Consequently, in a pragmatic approach, we surveyed and compared 
outcomes in patients treated prior to and after the implementation of PASS. 
Demonstrating a beneficial outcome of PASS would support its wider use.  
This cross-sectional survey documented the nutritional status and screen 
for depression and in the comparative analysis provide a crude assessment of the 
value of PASS. Patients treated with chemotherapy were chosen to assess the 
efficacy of PASS as they could be reviewed during their chemotherapy 
appointments and hence not require additional hospital attendances. Also, as they 
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were fit enough to undergo chemotherapy, they were likely to have reasonable 
survival times where a potential benefit of PASS may be demonstrated. Those 
receiving palliative measures were judged to have very short survival times where 
nutritional and psychological intervention may be inappropriate. Patients 
undergoing chemotherapy were either treated with gemcitabine monotherapy, 
gemcitabine and capecitabine, or entered into the Telovac trial. This randomised 
patients to either  
a) gemcitabine & capecitabine over a total of 8 weeks;  
b) gemcitabine and capecitabine together, over a period of 8 weeks and 
then a course of Telovac injections;  
c) Gemcitabine and capecitabine (as A & B) but start Telovac in first week. 
 All patients receiving chemotherapy were aiming to receive at least eight doses of 
gemcitabine, regardless of which treatment group they were in, with those on 
gemcitabine monotherapy expected to receive three weekly doses of gemcitabine 
(one cycle of treatment), a week off, and then repeated three weekly doses for six 
cycles. However, it was expected that most patients would stop therapy before this 
although occasionally some patients are considered for longer courses. There were 
no age limitations for patients in the survey although patients undergoing adjuvant 
chemotherapy were not included in the study and as well as those with pancreatic 
endocrine cancer. 
 
Retrospective survey 
 The retrospective survey was of patients diagnosed with in-operable 
pancreatic cancer who received chemotherapy at The Norfolk & Norwich 
University Hospital NHS Trust during the year 2009. Potential patients were 
identified from the pancreatic multi-disciplinary meeting records of that year. The 
oncology computer database and medical records of each patient who had received 
chemotherapy in 2009 were reviewed using a data collection sheet (appendix 1). 
 
Prospective survey  
 All new patients with pancreatic cancer receiving palliative chemotherapy 
during the year 2010 were identified at the pancreatic multi-disciplinary meeting. 
The PASS reviews were undertaken by either a pancreatic cancer nurse specialist 
or specialist registrar in gastroenterology, Dr Paul Banim. The initial PASS review 
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aimed to be completed during the first or second visit for chemotherapy, with 
subsequent monitoring at 4 weekly intervals during attendance for chemotherapy. 
At the initial meeting, details of the PASS service were discussed with the patient, 
who was also give an information leaflet on PASS (appendix 2). At each review an 
assessment of physical symptoms was performed (appendix 3). If new clinical 
problems or diagnoses were identified, appropriate management plans were 
instigated. More specifically, to assess a patient’s nutritional status, they were 
weighed and questioned on appetite, dietary intake and malabsorption symptoms. 
Following the protocol listed below, if nutritional deficiencies were identified, 
advice was given, referral to a dietician was made and when appropriate, oral 
nutritional supplementation or pancreatic enzyme replacement therapy prescribed. 
An additional leaflet was given to patients commenced on PERT with advice on 
dosing (appendix 4). To assess for psychological symptoms the patients were given 
a HAD Scale (appendix 5) to complete in their own time at home and return at their 
next hospital visit. 
 
The protocol followed at each PASS review was as follows; 
i. A record was made of medical symptoms including weight, abdominal 
pain, steatorrhoea, nausea, vomiting and jaundice. If symptoms were 
present, appropriate therapy was implemented via the general practitioner 
or secondary care specialist. 
ii. PERT was considered if was history of weight loss of >2% body weight or 
1kg. Creon 25 000 units to 40 000 units was prescribed, two with each 
meal and one with snacks. The dose was increased further if clinically 
indicated. 
iii. If there was ongoing weight loss or poor appetite, nutritional advice was 
given and oral nutritional supplementation and dietetic review considered. 
The oral nutritional supplement supplied was Ensure Plus twice daily with 
meals. This is a 220ml milk or yogurt style drink which has a high 
nutritional content containing protein 6.3g, fat 4.9g, carbohydrate 20.2g, 
vitamins, minerals and trace elements. The energy value is 1 
390KJ/cartoon (330 kcal = 1.5kcal/ml) and patients will have a choice of 
16 flavours. 
iv. Assessment of mood was made using the Hospital Anxiety and Depression 
Scale (HADS). Patients were scored out of 21 for each of anxiety and 
depression. A score in either category of 0 to 7 was considered normal, a 
score of 8 to 10 suggestive of disease and a score of 11 or more indicated a 
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probable mood disorder.554 Those scoring 8 or more were advised to see 
their GP to discuss implementation of treatment. Patients scoring ≥ 25/42 
in total or ≥ 14/21 for either depression or anxiety were referred to 
palliative care for further assessment. 
v. At follow-up reviews compliance was checked with nutritional therapy and 
PERT. 
 
Patients continued to undergo PASS review until chemotherapy was stopped (and 
hence routine hospital attendance ceased). Information on survival and hospital 
admission was obtained from hospital records and computer databases. 
 
2. Analysis 
 
The primary and secondary outcomes were compared between the 
retrospective and prospective groups using t-tests for normally distributed 
continuous variables, Mann-Whitney U tests for non-parametrically distributed 
continuous variables and chi-squared tests for categorical variables. The precise 
definitions of the outcomes to be assessed were as follow; 
 
Primary outcomes  
1) Patient survival rates at  
a) 6 months 
I b) 12 months 
Survival was defined as that from the 1st investigation suggesting pancreatic 
cancer until death. Data was also available on average survival times, although the 
follow-up times for each group were different and hence cannot be compared. 
2) Number of chemotherapy doses administered 
Defined as the number of gemcitabine doses received by the patient. 
 
Secondary outcomes 
3) Hospital admissions. To allow a direct comparison between the two groups, the 
numbers of hospital admissions were assessed in those whose survival time was 
less than 12 months. 
 a) median number of admissions following 1st dose of chemotherapy 
 b) median number of hospital inpatient days 
4) Weight change during follow-up  
a) weight (kilograms) change per week 
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b) percent weight change per week 
Weight change per week was defined as weight recorded at the booking clinic 
subtracted by the last recorded weight for each patient and then divided by the 
number of weeks between the two. 
5) Use of oral supplements and pancreatic enzyme replacement therapy 
 a) Comparison of documented use of any oral supplements used 
 b) Comparison of documented use of PERT being used 
 c) Comparison of the total daily dose of PERT 
6) Depression screening and treatment 
a) Comparison of documented evidence of a psychological assessment 
being made. 
b) Comparison of the proportion of patients receiving treatment for a 
psychological disorder. 
 
Non-comparative data 
Non-comparative data was available for the use of the HAD scale. 
7) HAD Scale 
  Description of patient scores to detect depression 
 
Approval of the study 
The study was designed by members of the pancreatic multi-disciplinary 
team. This included medical, surgical, oncological, palliative care consultants as 
well as dieticians and cancer specialist nurses. All parties were in agreement with 
the final study design. An ethical submission was not made as the assessments and 
intervention were those recommended by national societies of gastroenterology. 
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Results 
 
 
The number of patients with pancreatic cancer who received chemotherapy 
during 2009 was 16 (9 females) and in 2010 was 19 (9 females), with no statistical 
differences between the age, gender and clinical characteristics of the groups 
(Table 48). In the retrospective group, the median interval between first the 
investigation and initial chemotherapy dose 1.9 months (range 0.9 to 12.7 months) 
with one case of suspected pancreatic tumour taking nearly a year to confirm 
diagnosis. In the prospective group, the interval was 1.8 months (range 1.2 to 4.2 
months). The retrospective group tended to have more advanced disease (56% with 
distant metastases vs 37% in the prospective group) and a higher proportion 
entered into the Telovac trial (50% vs 32%), although, both the differences were 
not statistically significant. In the prospective group, 16 (84%) of the 19 patients 
underwent the first PASS review, with 11 (57%) patients seen at the second 
review, 6 (32%) at the third, 4 (21%) at the fourth and 2 (11%) at the fifth PASS 
review. 
Descriptive data, which cannot be compared due to differing lengths of 
follow-up, shows that all retrospective patients had died after a within a follow-up 
period of 25 months with a mean survival time (from first investigation to death) of 
10.1 months (SD=5.1 months) and a median survival of 10.5 months (2.4 to 23.3 
months). In the prospective group, on October 2nd 2011, 2 of the 19 patients 
remained alive, after 15 and 13 months follow-up. The median survival the group 
was 9.5 months (range 2.5 to unknown). Of the 17 who had died, the mean survival 
was 9.4 months, although inclusion of the two patients still alive improves it to 
10.0 months. 
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Table 48. Comparison of the baseline characteristics between the retrospective and 
prospective groups. 
Descriptor Retrospective Prospective 
    Year 2009 Year 2010 
Number of participants 16 19 
Age at 1st investigation (years, mean 
(SD)) 65.7 (11.3) 68.9 (6.9) 
Interval between 1st investigation  
and 1st chemotherapy dose, (months) 
mean (SD) 2.8 (2.9) 2.1 (0.9) 
median (range) 1.9 (0.9-12.7) 1.8 (1.2-4.2) 
Gender, n (%) 
Male 7 (44) 10 (53) 
Female 9 (56) 9  (47) 
Stage of disease , n (%) 
Locally invasive 0  (0) 3 (16) 
Locally advanced 7 (44) 9 (47) 
Distant metastases 9 (56) 7 (37) 
Oncological treatment, n (%) 
Gemcitabine 8 (50) 12 (63) 
Gemitabine and Capecitabine 0  (0) 1  (5) 
Telovac trial 8 (50) 6 (32) 
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3. Primary outcomes 
 
Survival rate and number of chemotherapy doses 
There were no differences in the survival rates after 6 months 
(retrospective group (RG) 75% vs 68% prospective group (PG), p=0.67) and 12 
months (RG 31% vs 42% PG, p=0.51) (Table 49). The median number of 
chemotherapy doses administered was 9 RG (range 2 to 24 doses) vs 6 PG (1 to 18 
doses) (p=0.19).  
 
4. Secondary outcomes 
 
Hospital admissions 
Hospital admissions were compared in all those who survived less than 12 
months. The median number of admissions was higher in the RG vs PG (2, (range 
of 0 to 5) vs 1 (0 to 4), p=0.034) and they also had a longer median duration of 
admission (11 days, (0 to 75) vs 4 days (0 to 11), p=0.017) (Table 50).These results 
were skewed in the retrospective group by one patient requiring a prolonged period 
of hospital stay during the terminal stages of disease and accrued a 75 day inpatient 
stay.  
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Table 49. Primary outcomes; survival rate and chemotherapy doses. 
Descriptor Retrospective Prospective 
    (n=16) (n=19) 
Survival after 1st investigation 
Alive after 6 months, n (%) 12 (75%) 13 (68%) 
Alive after 12 months, n (%)  5 (31%) 8 (42%) 
Chemotherapy doses 
Doses given, median, n (range) 9 (2-24) 6 (1-18) 
        
 
 
 
 
 
 
 
 
Table 50. Comparison of hospital admissions in those surviving less than 12 
months. 
Descriptor Retrospective Prospective 
    (n=11) (n=11) 
Hospital admissions, n, median (range) 2 (0-5) 1 (0-4)* 
Duration of admissions, days, median 
(range) 11 (0-75) 4 (0-11)** 
        
*p=0.034, **p=0.017 
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Weight change during follow-up 
At the initial booking visit, patients in the retrospective group were slightly 
heavier than those in the prospective group at the initial booking visit (mean = 68.9 
kg vs 63.8 kg, p=0.29) (Table 51). There were 11 (69%) patients with follow-up 
weights in the retrospective group and 15 (79%) patients in the prospective group, 
and these were used to calculate the total weight change and rate of weight change 
in each patient. None of the data related to changes in weight between groups were 
statistically significant. The median total weight change in the RG= -1.15kg (-9.3 
to 16.8 kg) vs -1.5 kg (-9.6 to 13.0 kg) in PG (p=0.98). The median weight change 
per week in RG= -0.18 kg (-0.56 kg/wk to 0.33 kg/wk) vs -0.05 kg/wk (-1.0 kg/wk 
to 0.73 kg/wk) in PG (p=0.74). The median total percentage weight change in the 
RG= -7.2% (-23.1% to 11.4%) vs -2.9% (-10.3 to 16.6) in PG (p=0.38). The 
median weekly change in the RG= -0.42% (-0.77% to 0.45%) vs 0.03% (-1.15% to 
1.68%) in the PG (p=0.32).  
 
Use of oral nutritional supplements and pancreatic enzyme 
replacement 
 In the retrospective group, 5 (31%) patients were documented in the 
clinical notes to have used oral nutritional supplementation, e.g. Ensure plus, 
compared to 11 (58%) (p=0.29) in the prospective group (Table 52). PERT was 
prescribed less frequently in the retrospective group (50% vs 79%, p=0.072), 
although there were no differences between groups for the total mean daily dose 
(RG=95 000 units vs PG=88 700, p=0.73).   
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Table 51. Comparison of weight change between groups. 
Descriptor Retrospective Prospective 
    (n=16) (n=19) 
Booking weight, kg, mean (SD) 68.9 (14.5) 63.8 (13.1) 
Follow-up weight available, n (%) 11 (69) 14 (74) 
Total weight change, kg, median -1.15 (-9.3 to 16.8) -1.5 (-9.6 to 13.0) 
Weight change/week, kg, median -0.18 (-0.56 to 0.33) -0.05 (-1.0 to 0.73) 
Total % weight change (range) -7.2 (-23.1 to 11.4) -2.9 (-10.3 to 16.6) 
Total % weight change/week (range) -0.42 (-0.77 to 0.45) -0.03 (-1.15 to 1.68) 
        
kg=kilograms 
 
 
 
 
Table 52. The comparison of oral nutritional supplements and pancreatic enzyme 
replacement therapy (PERT) use between groups. 
Descriptor Retrospective Prospective 
    (n=16) (n=19) 
Use of oral supplements, n (%) 5 (31) 11 (58) 
Use of PERT, n (%) 8 (50) 15 (79)* 
PERT dose, units/day, mean (SD) 95 000 (36 645) 88 667 (42 655) 
        
*p=0.072 
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Depression screening 
 In the retrospective group, fewer patients had documented evidence of a 
psychological assessment (44% vs 74%, p=0.072), although a higher proportion 
were treated for psychological symptoms (5 patients vs 1 patients, p=0.042) (Table 
53). The hospital anxiety and depression scores were completed by 15 of the 19 
(79%) patients in the prospective group. Here a total of 6 patients (43% of those 
returning the questionnaire) had scores indicating a possible or probable anxiety (3 
patients) or depressive disorder (5 patients), with two patients scoring highly in 
both the categories. Following the second PASS review, seven patients returned a 
completed questionnaire (two failed to return) with one patient scoring in the 
“probable” anxiety and depression category and two in the “possible” depression 
category. 
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Table 53. Comparison of evidence of depression screening and treatment between 
groups as well as outcome of hospital anxiety and depression (HAD) scores in the 
prospective group. 
Descriptor Retrospective Prospective 
    (n=16) (n=19) 
Patients with documented evidence of 
psychological assessment, n (%) 7 (44) 15 (79)* 
Patients treated for depression, n (%) 5 (31) 1 (5)** 
1st HAD score (completed, n=14) 
Anxiety, n (% of completed) 
normal = score ≤7,  N/A 11 (79) 
possible = 8 to 10 3 (21) 
probable = ≥11 0 
Depression, n (% of completed) 
normal = score ≤7 N/A 9 (64) 
possible = 8 to 10 3 (21) 
probable =≥11 2 (14) 
2st HAD score (completed=7) 
Anxiety, n (% of completed) 
normal N/A 6 (86) 
possible 0  (0) 
probable 1 (14) 
Depression 
normal N/A 4 (57) 
possible 2 (29) 
  probable   1 (14) 
*p=0.032, **p=0.042 
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5. Summary 
 
 This survey of patients with pancreatic cancer receiving chemotherapy, 
found that after the implementation of PASS, a higher proportion of patients were 
prescribed PERT (p=0.072), underwent psychological assessment (p=0.032), and 
in those surviving less than 12 months, hospital admission were fewer (p=0.034) 
and shorter (p=0.017). However, there were no differences in the primary outcome 
measures of survival rates at 6 months and 12 month or in the number of 
chemotherapy doses administered. In the secondary outcomes, despite the 
retrospective group undergoing psychological assessment less frequently (44% vs 
79%, p=0.032), there was a significantly higher proportion of patients receiving 
treatment (31% retrospective group vs 5% prospective, p=0.042). Using the self-
administered HAD Scale highlighted that 43% of patients warranted further 
evaluation for psychological symptoms. There were no statistically significant 
differences in the use of oral supplements, dosing of PERT or weight change. 
Although the differences were not statistically significant, patients in the 
prospective group did loose less weight and larger numbers may be needed to 
evaluate if there is a real effect. 
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Discussion 
 
This study reported that over one third of patients with pancreatic cancer, 
when screened for psychological symptoms, had possible clinical anxiety or 
depression. They continued to lose weight after diagnosis, although there is some 
suggestive evidence this may be reduced by pancreatic enzyme replacement 
therapy. The results justify national guidelines which advise screening for 
depression and weight loss. The implementation of PASS, a new clinical support 
service, was associated with some improved measures of clinical care, e.g. 
reduction in the number and duration of hospital admission. However, it did not 
significantly influence the primary outcome measures, namely rates of survival and 
number of chemotherapy doses. The findings of this study should be interpreted 
with caution due to the limitations of the study design, particularly the small 
number of patients enrolled and the inability to directly compare patient groups and 
hence the study should be regarded as a feasibility study, furthermore no 
assessment was made of the cost effectiveness, although if these deficiencies are 
rectified in future work, the benefits of a clinical service such as PASS could 
justify its broader use. The outcomes and limitations of this study as well as areas 
of future work are now discussed in greater detail. 
 Implementing PASS did not change patient survival rates, with survival 
after 12 months in the retrospective group (RG) 31%, vs 42% (p=0.51) in the 
prospective group (PG). The median survival time after the first investigation in the 
retrospective group was 10.5 months and in the prospective one 9.5 months, with 
no differences in median survival times after the 1st dose of chemotherapy. These 
figures are similar to those in the original trial of gemcitabine monotherapy, which 
reported an overall median survival of 5.0 to 7.2 months.560 With extended follow-
up of the prospective group, where 2 of the 19 patients remain alive after 15 
months follow-up, it is possible that the mean survival time will improve. An 
improvement in survival times could occur in patients who are reviewed by PASS 
due to the increased prescription of PERT preventing malnutrition and the early 
identification of medical complications of disease. However, PASS may not be 
responsible for prolonging survival, with evaluation of the seven patients who 
survived over 12 months, revealing only two patients were seen on three or more 
occasions by PASS, with two patients never actually reviewed by PASS as their 
chemotherapy was stopped after a single dose. The lack of any benefit in survival 
implies focusing on nutritional aspects is not sufficient to help mitigate the effects 
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of the cancer. Although survival time was unaffected, future work should look at 
other areas such as quality of life.  
The other primary outcome was the number of doses of gemcitabine 
administered, which did not differ between groups. The clinical aim is give patients 
to 18 doses of gemcitabine in 6 cycles over 6 months, although most stopped 
chemotherapy early. We chose to evaluate the number of chemotherapy doses 
given as weight loss is predictive of shorter chemotherapy courses and increased 
side-effects.527 Less chemotherapy doses often indicates poor survival time, 
although three patients in the prospective group received 4 or less doses of 
chemotherapy and were still alive after one year of follow-up. Again, the lack of 
effect of PASS suggests evaluating aspects of care, such as nutrition, is unable to 
affect the clinical status in the patient given chemotherapy. 
A secondary outcome that was measured was weight loss following 
diagnosis, which was less than expected in both the groups. A probable explanation 
for this was identified during the clinical review the prospective group, where three 
patients developed ascites or peripheral oedema which was accompanied by 
marked weight gain. In future work a reliable assessment of nutritional status 
would need to be used as patients with pancreatic cancer are likely to develop fluid 
retention due the associated catabolism and low serum albumin. There are 
alternative and more reliable assessments of nutritional status. These include mid-
arm muscle circumference measurements that estimate changes in muscle 
volume561 and laboratory assessments which assess body composition change. 
These include bioimpedance analysis, which estimates body fluid volumes, 
although it has not been validated in those who retain fluid secondary to a disease 
state. Dual-energy X-ray absorptiometry (DEXA), which can be used to measure 
total body composition and fat content is another potential method. We 
hypothesised that the assessment of nutritional status would maintain patients’ 
weight due to the early prescription of PERT and oral nutritional supplements. 
Although the changes in percent of body weight per week between the two groups 
were not statistically significant (RG= -0.42 vs -0.03 PG, p=0.32) the differences 
would support further investigation in a larger study. These should include 
alternative assessments of nutritional status to more reliably clarify if these 
interventions are associated with improved outcomes. 
In the PG, 80% of patients screened for ongoing weight loss or symptoms 
of malabsorption may require PERT, compared to 50% in the RG (p=0.072). The 
higher prescription rates in the PG may have occurred due to the existence of 
PASS, or bias, if patients in the retrospective group were more likely to be 
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misclassified as non-users. This bias could occur if general practitioners (GPs) 
prescribed PERT but was not documented in hospital records. To prevent the delay 
in the use of PERT all patients with pancreatic cancer should be prescribed these 
agents at the time of diagnosis538  at an appropriate dose of PERT of at least 40 
000-50 000 units with each meal and 10 000-25 000 units with each to avoid sub-
therapeutic dosing.562 In summary, the results suggest that PERT was not 
prescribed as frequently in the retrospective group, although it is recommended in 
national guidelines. In future work, the impact of early PERT prescription needs to 
assess quality of life in addition to clinical outcomes. 
A further secondary outcome we assessed was depression, which has a 
high incidence in patients with pancreatic cancer. We screened for this in the 
prospective group using the HAD Scale which identified 43% of patients with a 
potential mood disorder. Ideally these patients would have undergone a structured 
interview with a specialist in psychiatric health to determine the presence or 
absence of a mood disorder. The patient with the highest HADS score, of 21 
points, had already been identified with a mood disorder prior to PASS assessment. 
They were already under review by the palliative care team and being treated with 
counselling and medications (mirtazapine and nozinan). Another patient who 
scored 21 points declined the offer for further assessment, although his GP was 
notified. The completion of the HAD scale was initially undertaken by the PASS 
clinician. However, after interviewing a patient with known depression with his 
wife, it became apparent that his responses were unreliable in the structured 
interview setting. Subsequently, patients were asked to complete the questionnaire 
at home and return it at their subsequent hospital attendances to hopefully achieve 
more representative answers. The manner of delivering the HAD Scale needs to be 
more formally assessed in future work. Furthermore, as depression is common in 
pancreatic cancer, there needs to be the appropriate psychological services 
available to manage the mood disorders diagnosed. 
Surveying anti-depressive use, found that despite lower rates of screening 
for depressive symptoms, the retrospective group had a higher rate of prescriptions. 
However, the timing of introduction of these medications was not verified, and 
hence it is uncertain whether these medications had been introduced following the 
diagnosis of cancer, or if the patients were on long-term prescriptions. To improve 
future work, the timing and indication for the anti-depressive medication should be 
determined at the time of note review. 
The study’s intention had been for all patients receiving chemotherapy to 
be reviewed by PASS every four weeks. This was rarely achieved primarily due to 
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a lack of availability of a PASS member during the patients’ visit for 
chemotherapy. Other PASS reviews did not occur due to altered chemotherapy 
appointment times, if review was deemed clinically inappropriate or if the patient 
was too unwell. Future work in this area would need a more robust method to 
ensure all patients are reviewed in a timely fashion, which ultimately would require 
more than one PASS reviewer. 
There were several limitations, including a small sample size with 
heterogeneous groups and several extraneous variables which could affect 
outcomes. These variables included patients receiving different chemotherapy 
regimes, were treated by different clinical teams and during the development of the 
study protocol awareness of PERT and the prevalence of depression in pancreatic 
cancer may have altered clinicians’ practice. Furthermore, although all patients 
with pancreatic exocrine cancer were included, some had less aggressive 
histological types of carcinoma such as mucinous adenocarcinoma. Bias could 
have occurred due to the methods used to collect data in the two groups. In the 
retrospective group, patients receiving PERT, oral supplements or depression 
screening may not have been identified if the data was not recorded in the medical 
notes or if the information was missed upon review of the notes. This 
misclassification was less likely to occur in the group where the data was collected 
prospectively. These limitations could be rectified in future work including the 
assessment of quality of life in patients reviewed in PASS. This was considered 
during the development of the study protocol and the intention was to measure the 
quality of life using the ETORC-30 in patients at 3 months, however, relatively few 
patients reached this stage. To clarify whether PASS leads to an alteration in the 
quality of life of patients, patients could undergo QOL screening routinely and it 
could repeated again after the reintroduction of PASS. The cost effectiveness of 
PASS was not assessed in this study which should be addressed in future work. In 
this work the time required in supplying the clinical PASS was not measured and 
was given without cost. Future work should evaluate the time and cost of supplying 
and managing the PASS service as well as additional costs from the increased use 
of therapies. However, these may be offset by a reduction in clinical complications 
and hospital admissions, which would need to be accounted, as well as ultimately 
improving the care and quality of life of patients with pancreatic cancer. 
In conclusion, this survey identified several aspects about the clinical 
management and delivery of care for patients with pancreatic cancer; 
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• Screening for anxiety and depression identified symptoms in over one third 
of patients. Emphasis should be placed in the clinical management of 
screening for this condition. 
• There was no impact on the primary outcomes of survival and doses of 
chemotherapy with PASS. Future work should assess if such a service 
could affect quality of life outcomes. 
• PASS was associated with a reduced the number and duration of hospital 
admissions and the reasons for this should be explored. Such a benefit 
would be of importance to the patient. 
• Weight loss is common in patients with pancreatic cancer. PASS did 
appear to improve this parameter although the differences were not 
statistically significant. Future larger studies are required to see assess in a 
significant improvement can be achieved. The PASS service did lead to a 
greater number of PERT prescriptions.  
• The work undertaken so far will help provide clinicians with standards 
against which to audit the care of patients with pancreatic cancer. 
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Appendices 
 
Appendix 1. The EPIC physical activity questionnaire from which the 4 level physical activity index was 
derived.  
 
1. We would like to know the type and amount of physical activity involved in your work. Please tick what best 
corresponds to your present activities from the four possibilities 
• Sedentary occupation _____ 
You spend most of your time sitting (such as in an office) 
 
• or Standing occupation 
You spend most of your time standing or walking. However, your work does not require intense physical 
effort (e.g. shop assistant, hairdresser, guard, etc.) 
 
• or Physical work 
This involves some physical effort including handling of heavy objects and use of tools (e.g.plumber, 
cleaner, nurse, sports instructor, electrician, carpenter, etc.) 
 
• or Heavy manual work 
This involves very vigorous physical activity including handling of very heavy objects (e.g. docker, miner, 
bricklayer, construction worker,etc.) 
 
2. In a typical week during the past 12 months, how many hours did you spend on each of the following 
activities? (Put ‘0’ if none) 
• Walking, including walking to work, shopping and leisure  
 _____ hours per week 
 
• Cycling, including cycling to work and during leisure time 
 _____hours per week 
 
• Gardening 
 _____ hours per week 
 
• Housework such as cleaning, washing, cooking, childcare 
______hours per week 
 
• Do-it-yourself 
______hours per week 
 
• Other physical exercise such as keep fit, aerobics, swimming, jogging 
 _____ hours per week 
 
3. In a typical week during the past year did you practise any of these activities vigorously enough to cause 
sweating or a faster heartbeat? 
Yes ____ No ____Don’t know ____ 
 
• If yes, for how many hours per week in total did you practise such vigorous physical activity? (Put ‘0’ 
if none) 
______hours per week 
 
4. In a typical day during the past 12 months, how many floors of stairs did you climb up? (Put ‘0’ if none) 
______floors per day. 
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Pancreatic Support Service 
PASS 
 
 
 
A support service for patients 
receiving chemotherapy for pancreatic 
cancer 
 
 
 
 
 
 
 
Norfolk and Norwich University Hospital 
What is PASS? 
The PAncreatic Support Service, PASS, is for patients with pancreatic cancer 
who are having chemotherapy. If you are agreeable, we aim to meet you 
regularly (usually every 4 weeks) during your attendance for chemotherapy.  
We will focus on maintaining your weight and controlling symptoms. PASS is 
run by a doctor and nurse. 
 
About your pancreas. 
Your pancreas is a gland located high in your abdomen. The pancreas produces 
a liquid containing enzymes. Enzymes are proteins which break down food into 
small fragments which are then absorbed into your body. 
 
What is pancreatic cancer? 
In pancreatic cancer there is a growth within the pancreas reducing the amount 
of these enzymes. This means food is not well absorbed and you can lose 
weight. 
 
Treatments for cancer of the pancreas. 
Treatments are used to slow the growth of the tumour and to improve your 
symptoms. These include chemotherapy, offered by your oncology doctors, as 
well as nutritional treatments, medicines and other methods to control your 
symptoms. 
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What may PASS do for me? 
We aim to meet you during your planned clinic or chemotherapy appointments 
at the hospital. Our aims are to: 
1. Help to explain your diagnosis and answer questions you may have. 
2. Monitor your weight. 
3. If you lose weight offer capsules containing pancreatic enzymes and 
nutritional drinks to help reverse this. 
4. Assess any symptoms you may have and how you are feeling. Further 
treatments will be suggested to you if required. 
 
What are nutritional drinks? 
If you lose weight we will offer you high energy drinks to prevent further 
weight loss. These contain all the major food groups, minerals and vitamins. 
These should be taken between your normal meals. Maintaining your weight 
will help you feel better and stay healthier. 
 
What are pancreatic enzyme capsules? 
These capsules replace the loss of your own pancreas enzymes and help digest 
your food. Using these capsules can help prevent pain and weight loss. The 
capsules are taken with meals and snacks. 
 
 
 
 
Follow-up 
PASS aims to meet you every 4 weeks to help identify any new symptoms. We 
will also ask how the illness is affecting your quality of life and mood to see if 
there is anything further we can help with. We will review you during your 
planned attendance for treatment or clinics to prevent an extra visit for you. 
 
Summary 
PASS aims to help you and your family with problems that pancreatic cancer 
causes. We aim to identify and manage these issues quickly. The doctors in the 
PASS clinic work closely with your other specialists and your GP is kept 
informed. All recommendations are supported by national guidelines from the 
British Society of Gastroenterology. PASS is optional and we completely 
understand if you prefer not to use it. Please give us any feed back on PASS. 
 
 
Contacts 
If you have any questions please contact either; 
Dr Paul Banim, Registrar in Gastroenterology, on telephone 01603 597191, 
email p.banim@uea.ac.uk 
or Maria Cremin, Cancer Nurse Specialist on telephone 01603 288844, email 
Maria.Cremin@nnuh.nhs.uk. 
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Appendix 2. The data record sheet used in the retrospective survey. 
Demographic data  Study number_____  DOB_______  
 
Baseline data 
Date 1st investigation suggesting pancr cancer ________ Age at diagn ____________ 
Male   Female   
 
Staging 1) within pancreas   2) local spread  3) distal spread 
 
Chemo received 1) Gem_____ 2) Gem & Cap  ________  
3a) Telovac trial  A - gemcitabine & capecitabine over a total of 8 weeks. 
3b) B gemcitabine and capecitabine together, over a period of 8 weeks (the same as A). Then a course of GV1001 vaccine 
injections. 
3c) Gemcitabine and capecitabine (as A & B) & start GV1001 vaccine in first week. 
 
Outcome data Date of death = __________ 
 
1) Survival time post diagnosis, (months) ___________    
 
Outcome 1a) alive six months  1b) alive one year 
 
2) Total hospital readmission rate and duration 
 
Number _____  and total duration days _______ 
No exceptions. Time parameter – from 1st chemo dose until death or over one year period. 
 
3) Chemotherapy tolerance; 
a) Number of cycles received  
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4) Weight change over time  Height       BMI at chemo booking 
 
 Kg date 
Weight at diagnosis   
   
Weight booking 4 chemo   
   
Last recorded weight   
 
 
5) Use of oral nutritional supplements 
Any supplements recorded on computer?   
Any supplements recorded in notes?    
 
Date started? 
 
6) Use of Pancreatic Enzyme Replacement Therapy 
Any PERT recorded on computer? 
Any PERT recorded in notes?     total daily dose 
 
Date started? 
 
7) Psychological health; 
 
Any assessment of psychological health recorded? On computer?  In notes? 
 
Provision of treatment 
 Prescribed pharmacological tx? 
 
 Referral for further assessment? 
 
Additional notes. 
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Appendix 3. The patient history and data collection sheet used during each PASS review. 
PASS Name ___________________Age ____   Date of birth___________ date of review ________ 
Hospital no.__________     Tel number _______________ Chemo cycle  
 
Weight (kg)   date    Height  BMI 
          
Booking visit pre chemo wt _____________ TNM staging _______  
Diagnoses 
 
DH         allergies 
       Eats pork? 
       Social history 
 
1) Symptoms – score 0=not present, 1=mild, 2=moderate, 3=severe 
Anorexia   Nausea    Vomiting 
Abdo pain   weight loss   Bowels freq (x/day) 
Loose stool   Fatigue    Jaundice  
 
2) Nutrition 
Supplemental drink  Y / N   date started  dose    
Compliance 1)  nil or poor  2) partial   3) complete  
PERT  Y / N  date started  dose   
Compliance 1)  nil or poor  2) partial   3) complete 
 
3) HADS score _________ 4) Complications , hospital admissions, chemo SEs? 
 
5) Notes /outcome 
 
 
Guidance on Supplements 
1) Lost weight or poor appetite, give nutritional advice (including diet sheet). 
2) Consider nutritional supplementation if despite advice struggling to maintain good oral intake. 
3) If patient is having difficulties with food intake despite advice consider dietetic review. 
PERT If history of weight loss or recorded weight loss >2% or 1kg start PERT. See PERT prescribing 
sheet. 
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Appendix 4. The information leaflet given to patients started on pancreatic enzyme replacement. 
Guidance for patients on Creon 
Your pancreas is a gland located high in your abdomen that produces a liquid containing enzymes. 
Enzymes are proteins which break down food into small fragments which are then absorbed into your 
body. In pancreatic cancer there is often a reduction in these enzymes – this causes food to be poorly 
digested and can lead to diarrhoea and weight loss. 
 
Creon helps to replace the loss of your normal pancreatic enzymes. 
 
Creon capsule sizes available are Creon 10 000, 25 000 & 40 000 units 
 
The capsule can be taken whole or opened and mixed with food i.e. jam or honey. 
The capsule should not be chewed or crushed. 
The dosing can be split – i.e. capsules can be taken before and after a meal. 
 
No Creon is required when eating foods low in fat ie fruit, fizzy drinks, boiled sweets  
 
 
Guide for dosing of Creon 
Meal grams of fat Dose of Creon (lipase units) 
ie fruit and non-milk drinks < 2g fat 0 
Small snack/biscuit 3-5g 10,000 
Snack, milk based ensure 5 -10g 20,000 – 30,000 
Main meal 10 – 20g 40,000 – 50,000 
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Appendix 5. The Hospital Anxiety and Depression Scale given to patients to complete. 
 
H.A.D. SCALE 
 
NAME: ……………………………………………..………………. DATE:  
Doctors are aware that emotions play an important part in most illnesses.  This questionnaire is designed to help 
your doctor to know how you feel.  Read each item and place a firm tick in the box opposite the reply, which 
comes closest to how you have been feeling in the past week. Don’t take too long over your replies; your 
immediate reaction to each item will probably be more accurate than a long thought-out response. 
 
Tick only one box in each section 
 
I feel tense or “wound up”     I feel as if I am slowed down: 
Most of the time    Nearly all the time   
A lot of the time    Very often   
Occasionally    Sometimes   
Not at all    Not at all   
 
       I get a sort of frightened feeling like 
I still enjoy the things I used to enjoy   “butterflies” in the stomach: 
Definitely as much    Not at all   
Not quite so much    Occasionally   
Only a little    Quite often   
Hardly at all    Very often   
 
I get a sort of frightened feeling as if 
something awful is about to happen    I have lost interest in my appearance: 
Very definitely and quite badly    Definitely   
Yes, but not too badly    I don’t take so much care as I should   
A little, but it doesn’t worry me    I may not take quite as much care   
Not at all    I take just as much care as ever   
 
I can laugh and see the funny    I feel restless as if I have to be on 
side of things:      the move: 
As much as I always could    Very much indeed   
Not quite so much now    Quite a lot   
Definitely not so much now    Not very much   
Not at all    Not at all   
 
Worrying thoughts go through 
my mind:      I look forward with enjoyment to things 
A great deal of the time    As much as I ever did   
A lot of the time    Rather less than I used to   
From time to time but not too often    Definitely less than I used to   
Only occasionally    Hardly at all   
 
I feel cheerful:      I get sudden feelings of panic: 
Not at all    Very often indeed   
Not often    Quite often   
Sometimes    Not very often   
Most of the time    Not at all   
 
I can sit at ease and feel relaxed:  I can enjoy a good book or radio/TV programme: 
Definitely    Often   
Usually    Sometimes   
Not often    Not often   
Not at all    Very seldom   
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“Dietary n-3 fatty acids in the aetiology of pancreatic cancer. Data from a UK 
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Digestive Diseases Week, Chicago, May 2011. 
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“Dietary deficiencies of iron and niacin in the aetiology of symptomatic 
gallstones – Data from a UK prospective cohort study using 7-day food 
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“Caffeinated coffee is associated with a reduction of symptomatic gallstones 
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“The role of dietary cholesterol and transfatty acids in the aetiology of 
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